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Breast cancer is the most common female malignancy in the western world. 
Currently, tamoxifen remains the gold standard anti-hormone for ER+ breast 
cancer. However de novo resistance to tamoxifen is a huge clinical problem. 
What is more, as many as 50% of initial responders develop acquired 
resistance to tamoxifen and relapse.
Aberrant growth factor signalling has been linked to the resistant phenotype, in 
particular EGFR and IGF-IR signalling and often gives a more aggressive 
disease type and poorer patient outlook.
There is a substantial clinical need for new anti-breast cancer therapeutics that 
target the resistant phenotype or prevent this from occurring. One hypothesis 
is to combine both anti-hormonal therapies with anti-EGFR therapies, in hope 
of preventing resistant growth.
Many downstream pathways of EGFR have been targeted to develop novel 
therapeutics against; however, these compounds are almost certain to give 
severe adverse reactions, furthermore a complex tablet regime or IV injections 
have a negative effect on patient compliance. A novel transcutaneous delivery 
system would give a more patient friendly alternative, with patients re-applying 
a patch or cream once a day, with rapid termination of dosing in the event of 
adverse event This would also go some way to prevent endometrial 
complications associated with tamoxifen use.
The in vitro simultaneous delivery of 4-hydroxytamoxifen and signal 
transduction inhibitors LY294002 and PD98059 along with EPA determined 
that all compounds were capable o f permeating porcine skin and nipple.
Masses able to permeate were; 5.14 ± 0.93,6.97 ± 0.99, 5.06 ± 0.93 and 1121.6 
± 143 pgcm"2 across skin respectively and 21.14 ± 2.75,18.2 ± 2.55,25.1 ±
6.89 and 3081.2 ± 252.7 pgcm'2 across porcine nipple. These compounds were 
formulated with 2.5% v/v DMSO and ethanol and 4% w/v Cab-o-sil.
Fish oil was shown to be a skin friendly vehicle. Ki-67 assays confirmed that 
incubation with fish oil maintained skin viability and H & E staining confirmed 
no obvious histological effects.
Growth Studies were performed on MCF-7 and TamR cells and showed that 
the combination of these compounds was able to reduce cell growth to 4.04 ±
0.15 and 2.47 ± 1.4 % of control growth when incubated at 25pM PD98059,5 
pM LY294002,1 x 10’7M 4-hydroytamoxifen and 1 pLmL'1 fish oil.
This combination of compounds, without 4-hydroxytamoxifen, was able to 
reduce the migratory capacity of TamR cells (P = < 0.005).
Results confirmed that the simultaneous transcutaneous delivery of multiple 
anti-breast cancer agents is possible and that these show promising anti- 
tumorogenic actions post skin.
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1.1 Breast cancer overview
Cancer is commonly (and erroneously) thought of as one single disease, 
whereas it is in fact a group of diseases. At least 100 different types of cancer 
have currently been identified, generally sub-grouped due to the tissue in which 
they originate and also the cell type in which they originate. Cancer is 
characterized by several criteria, including unregulated cell growth and 
invasion of cells into other sites of the body from the site of origin (Pecorino, 
L. 2005). Ceil proliferation and cell cycle are tightly controlled in healthy 
cells, although DNA damage, which escapes cellular repair, leads to 
uncontrolled cell growth and proliferation, thus leading to tumorogenesis. 
Breast cancer is a cancer that starts in the cells of the breast in men and 
women.
As will become clear in the following pages, there is a substantial clinical 
requirement for new anti-breast cancer systems. This thesis was concerned 
with the development of a strategy involving the simultaneous transcutaneous 
delivery of a cocktail of a mitogen-activated protein kinase inhibitor, a 
phosphotidylinositol 3 kinase inhibitor, tamoxifen and eicosapentaenoic acid. 
This system was designed as an adjuvant to surgery and/or a prophylactic for 
individuals with increased risk (family history, genetic predisposition). This 
novel multi-pronged to combating breast cancer would be expected to confer 
significant advantages over single treatments, and delay or prevent 
chemotherapy resistance.
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1.1.1 Statistics and incidence rates
Breast cancer is now the most common cancer in the UK, with around 44, 000 
new cases diagnosed each year, 1% of which are in males. One in four of all 
cancers in females are accounted for by breast cancer, with an estimated 1 in 9 
women, in the western world, developing breast cancer at some stage in their 
life (Ali, S. & Coombes, R.C. 2002). Although breast cancer has around the 
same incidence rates as large bowel cancer and lung cancer, the mortality rate 
is 50% of these cancers. It is estimated that 77% of woman who are diagnosed 
with breast cancer live for above 5 years. This lower mortality rate is partly 
due to the widespread screening, which leads to early detection and so better 
patient prognosis, along with better treatments, both pre and post operation.
Age is the biggest, but by no means sole, risk factor associated with breast 
cancer, the risk factor sharply increases after 50 years. The UK has the largest 
incidence of breast cancer in the world, and so much work is being and still 
needs to be done to discover any reasons for this trend.
1.1.2 Stages of disease
The breast is composed of glandular, fatty and fibrous tissues, which are 
positioned over the pectoral muscles and adjoined to the chest wall via 
Coopers’ ligaments (fibrous strands). Each breast is a tear shaped gland 
composed of between 15-20 lobes, which are arranged in a circular fashion and 
covered by, and so held in place by a layer of subcutaneous adipose tissue or 
fat, which extends through the breast (figure 1.1).
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lymph vessels 
lobules
fatty tissue
ducts
Figure 1.1 Anatomy o f  the human breast (from www.ribbonofpink.com)
M any bu lb -like  lobules make up each lobe and ducts connect the lobes and 
lobule. These ducts are narrow  at the lobules, however, d iverge and w iden at 
the nipple.
There are m any types o f  breast cancer, w h ich  are termed by the location (in  the 
breast) in  w h ich  the cancer cells begin to grow . For example, ductal carcinoma 
(the most com m on fo rm  o f  breast cancer) is called so because it  begins w ith in  
the cells o f  the ducts. Breast cancers, w h ich  rem ain in  the lobule or duct are 
termed carcinom a in situ , however tum ors that spread outside these are termed 
invasive o r in filtra tin g  carcinoma.
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Breast cancer is also diagnosed according to which ‘stage’ it is at. The stages 
(0 to IV) reflect the tumor size, nodal status and metastasis. Stage 0 signifies 
very early breast cancer, where the tumor is very small and has not spread 
outside the duct or lobule. Stage I classifies tumors that are no bigger than 2cm 
and have not spread outside the breast but cancer cells have spread to other 
parts of the breast Stage II is used to describe either tumors that are between 2 
and 5 cm with no lymph node involvement or tumors that have spread to 
auxiliary lymph nodes (on the same side of the body). However, these lymph 
nodes have not stuck down to surrounding tissue or to each other. Stage III 
includes two sub-stages: stage Ilia and IHb. Cancers in stage Ilia either have 
strong lymph node involvement, where lymph nodes have now adhered to 
surrounding tissue or to other lymph nodes or measure larger than 5 cm. 
Cancers classed as stage IHb are invasive cancers, which have spread to 
internal mammary lymph nodes, the breast skin or the chest wall. Stage IV, the 
most advanced breast cancer, describes tumors that have spread to other organs 
within the body. These commonly include bones, the lungs, the liver or the 
brain.
1.13 Risk factors
Despite many advances in breast cancer research over die last few decades the 
incidence rate and mortality, among females have remained largely unchanged 
for some time now (Russo, J. et al 2000). There have been many risk factors 
identified, which include genetic, hormonal and environmental.
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Age remains of the most significant risk factors related to breast cancer. There 
has also been a strong relationship recognized between breast cancer risk and 
weight, however, this is again dependent on age. There has been no evidence 
that excessive weight alters risk under the age of 50, however at 60+ with each 
10kg increase in weight there has been shown to be an 80% in breast cancer 
risk (Harris, J.R. et al 1995). Other risk factors include diet, cigarette intake 
and alcohol intake.
U  Estrogen signalling
Estrogens (Oestrogens) are hormones involved in the female menstrual cycle, 
of which three exist; estradiol E2, oesterone and oestriol. They are synthesised 
from cholesterol in a complex biosynthetic pathway. Aromatase, a cytochrome 
P450 enzyme, catalyses the final reactions that see testosterone converted to 
estradiol and androstendione to oesterone. Estrogen is released from the 
Graafian follicle and controls the proliferative stage of the endometrium. 
Estrogen not only acts on estrogen receptors in the uterus but also in the 
vagina, anterior pituitary and mammary gland during the menstrual cycle 
(Rang, H.P. et al 2001).
12.1 Estrogen and breast cancer
It has long been known that steroid hormones such as estrogen and progestins 
are involved in breast cell proliferation, however it wasn’t until the late 1800s 
until these steroid hormones were linked to the development of estrogen 
positive breast tumors (Jordan V.C. et al 2001). Sir George Thomas Beatson
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first suggested a link, between the breast and ovaries in the 1890s. He noticed 
that the removal of the ovaries had effects on lactation of sows. Fundamental 
research by Beatson and colleagues then revealed that by removing the ovaries, 
metastatic breast cancer was forced into remission. This groundbreaking work 
uncovered a link between breast cancer progression and tumour growth with 
estrogens in endocrine responsive tumours (Beatson, G.T. 1898). In fact, it is 
now established that estrogens drive the growth of these tumours (Levine, M. 
et al 2001). However, it was this breakthrough, linking cancer progression 
with estrogens that uncovered many problems with resistance that are still 
perplexing to date. Beatson showed that only 25% of patients were sensitive to 
oopherectomy and that many of these responders eventually relapsed and the 
tumors again progressed. Many more patients did not respond to 
oopherectomy and were insensitive. This phenomenon is seen today in the 
clinic with both acquired and de novo (from the beginning) resistance to 
endocrine therapy (Robertson, J.F.R, et al. 2002). With this link between 
ovaries and breast cancer established, anti-estrogen therapies were developed 
to either deplete the production of estrogen, for example aromatase inhibitors, 
or to block the estrogen receptor and so oppose the effect of estrogens, such as 
tamoxifen.
1.2.2 Estrogen receptor
The estrogen receptor (ER) is an important mediator of breast cancer growth 
and progression and is also an important prognostic and chemotherapeutic 
target in breast cancer care. Although it is only expressed in 6-10% of normal
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breast epithelial cells, over 60% of primary breast cancers express it (Hanstein, 
B. et al 2004).
There are two identified ERs; Era and Er0. These receptors belong to a super­
family known as the nuclear hormone receptors. They are hormone activated 
transcription factors and so are responsible for the transcription of genes 
containing a hormone response element (ERE) (Macgregor, J.I. & Jordan, V.C.
1998). The ER has 6 main functional domains. The E region confers to the 
steroid-binding domain. This domain undergoes a conformation change upon 
E2 binding, which locks this hormone in place in the hydrophobic pocket. The 
conformational change allows binding of co-activator proteins to the activating 
function regions 1 and 2 (AF 1 and 2). It also facilitates the interaction of ER 
with DNA through the DNA binding region (Jordan, V.C. & Morrow, M.
1999). The DNA binding region contains two zinc fingers that facilitate the 
receptor binding to hormone response elements in the promoter region of 
hormone responsive genes. ER can alter gene expression in a hormone 
dependent way (Harris Wooge, C. et al 1992). ERs possess both estrogen 
independent (AF-1) and estrogen dependant (AF-2) domains. They use these 
domains to recruit co-activator proteins and to interfere with the transcription 
process (Campbell, R.A et al 2001).
1.23 Estrogen receptor signalling
There are now several mechanisms understood by which estrogen and ER 
influence tumorogenesis. The classical mechanism involves estrogen binding
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to nuclear ERa at the ligand-b ind ing  dom ain; it  is then sealed in  th is position 
by he lix  12 o f  the ER. T h is  b ind ing  induces receptor hom odim erization that 
leads to a conform ationa l change in the ligand-b ind ing  dom ain o f  the receptor. 
Th is a llow s the recru itm ent o f  co-activator proteins to the A F-2  region. A  
transcription com plex is then form ed at an ERE, located in  the prom oter region 
o f  estrogen responsive genes and gene transcription can occur, figure 1.2 
shows the suggested mechanism (Jordan, V .C  2001).
DNA
AP-1 ERE
Gene
transcription
Gene
transcription
fosjun
SERMs
Estrogen
Figure 1.2 Nuclear ER signalling. ERE -  estrogen response element. CoA- co-activator. CoR 
-  co-repressor. AP-1 -  activating protein 1. SERM -  selective estrogen receptor modulator.
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Genetic studies revealed that over a third of genes that are regulated by ERs but 
do not contain EREs (O’Lone, R. et al 2004). This new evidence has 
suggested that this mechanism is not the sole way that ER can regulate gene 
expression.
ER can regulate gene transcription without binding directly to DNA. Through 
protein-protein interactions within die nucleus ER can modulate the function of 
other transcription factors (Gottlicher, M. et al 1996). The interaction of ER 
and the Jun or Fos proteins at AP-1 binding sites leads to the transcription of 
genes that produce proteins such as ovalbumin and collagenase (BjOmstrOm, L. 
& SjOberg, M. 2006).
Some actions mediated by ER occur extremely rapidly, therefore eliminating 
effects on RNA as a plausible mechanism. These actions occur through 
activation of cell membrane ER and are non-genomic actions of estrogens. 
Cell membrane ERs remain quiescent in mammary tissue until stimulation by 
steroid hormones. This stimulation induces the production of growth factors in 
ER+ cells, which act on neighbouring ER- cells in a paracrine fashion to 
stimulate growth (Song, X-D. & Santen, R J. 2006). However, in neoplasia the 
growth factors predominantly stimulate the growth of the ER+ cells in an 
autocrine fashion (Streuli, C.H. & Haslam, S.Z. 1998). The membrane 
receptor has not been fully characterised and its exact role in breast cancer 
tumorogenesis has not been defined. It is known that the receptor is a G- 
protein coupled receptor capable of induction of signalling pathways upon
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activation by E2 (Razandi, M. et al 1999). Protein kinase signalling pathways 
are activated in this way, which leads to altered cytoplasmic proteins such as 
upregulation of eNOS (BjdrnstrOm, L. & Sjdberg, M. 2006). The membrane 
ER can also directly interact with and/or activate IGF-IR, PI3K, Src and EGFR 
(Osbourne, C.K. et al 2005).
Activation of the membrane ER can, in turn, also affect gene transcription. 
Many transcription factors are regulated by protein kinases, which 
phosphorylate and thus activate them. These actions are termed nongenomic- 
to-genomic signalling (BjdrnstrOm, L. & Sjdberg, M. 2006).
13 Endocrine therapy
13.1 Tamoxifen
For some time now tamoxifen has remained the gold standard treatment for 
hormone sensitive or ER+ breast cancer.
Tamoxifen is an anti-estrogen and exerts its anti-estrogenic effect by 
competitively blocking the ER within mammary tissue. Tamoxifen also blocks 
the transcription of ERE containing genes, thus it has been termed a selective 
estrogen receptor modulator or SERM (Levine, M et al 2001). SERMs show 
both estrogenic and anti-estrogenic activities at various sites of the body.
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SERMs bind to nuclear ERs and alter the conformational shape of these 
receptors. Tamoxifen binds to ERa at the ligand-binding site. It suppresses 
AF-2 fully, therefore stopping co-activator molecules from binding and thus 
giving anti-estrogenic activity (Jordan, V.C 2001). However tamoxifen 
binding does not silence the charge on a specific amino acid that is important in 
co-activator binding. This means that binding of few co-activators is still 
possible in certain cell types, thus suggesting why tamoxifen is estrogenic in 
certain cell types (Barkhem, T. et al 1998).
It has been shown, in clinical trials, that tamoxifen significantly increases 
survival rate and inhibits the development of metastatic spread compared to 
placebo. In 1989 the B-14 clinical trial was launched, which was a part of the 
National Surgical Adjuvant Breast and Bowel Project This trial studied the 
benefit of tamoxifen treatment on survival rates, tumor recurrence and second 
primary tumor development. The B-14 trial randomly assigned post operated 
patients whom had just had ER+ breast cancer tumors with no auxiliary lymph 
node involvement removed to either tamoxifen treated (20 mg day-1) or 
placebo group for 5 years. After 5 years disease free patients from the 
tamoxifen treated group were then reassigned to new groups and either 
received tamoxifen for a further 5 years or placebo for the remaining five 
years. It was demonstrated, through the B-14 clinical trial, that survival rate 
increased with the length of tamoxifen treatment up to 5 years, however the 
trial also showed there were no survival benefits of tamoxifen treatment for 
more than 5 years compared to 5 years only (Fisher, B. et al 1996).
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Although tamoxifen has been very successful in treating metastatic, ER+ breast 
cancer, it can give rise to severe, although rare, adverse effects such as 
endometrial cancer and thromboembolic events and, more commonly, nausea 
and vomiting. There has been much speculation as to whether tamoxifen 
administration leads to an increased risk in developing second primary tumors 
excluding those of the breast, in particular the development of endometrial 
cancer. The aforementioned B-14 trial monitored closely the incidence of 
endometrial cancer development after tamoxifen treatment This trial showed 
that tamoxifen treatment significantly increased the risk of developing 
endometrial cancer when compared to placebo (Fisher, B. et al 1994). 
However, there are conflicting and controversial results regarding this issue in 
the scientific literature. One trial, which took place in Manchester, showed no 
difference in the risk of developing endometrial cancer between tamoxifen 
treated and placebo groups. Cases of endometrial cancer were detected in the 
placebo group, however these were only discovered when the patient had 
commenced tamoxifen treatment for second primary tumors (Ribeiro, G. & 
Swindell, R. 1992). So it is questionable whether the data from this trial was 
accurate. Another trial, which took place in Scotland, also showed that there 
was no statistically significant link between tamoxifen treatment and 
endometrial cancer development, when compared to control (Stewart, H.J 
1992). These conflicting results highlight the need for a more planned and 
prepared trial. The trials mentioned above did not follow a standard protocol; 
in fact they all had differences in treatment time, follow-up time, patient 
population, group size and doses. So it is not entirely surprising that no
13
Chapter 1 General Introduction
reproducible results have been detected from them. Although there is a need to 
undertake more trials to ascertain whether or not there is a link between 
tamoxifen and endometrial cancer, it has to be taken into account whether such 
a trial is still ethical. We now know the value of tamoxifen in treating all 
stages of breast cancer. The question is would it be ethical to withhold a 
beneficial treatment from a patient?
Tamoxifen treatment does not give rise only to unwanted effects, it is 
suggested that it is cardio-protective. A study by Love, R.R and colleagues in 
1994 showed that after 2 or more years of tamoxifen treatment, the risk of 
cardiovascular disease decreased significantly in post-menopausal women. 
Tamoxifen was shown to lower total cholesterol (lipoprotein a) and fibrogen 
and it is this that is thought to contribute to a decreased risk of cardiovascular 
disease. However, more work is needed to look into the effect on both HDL 
levels and blood pressure.
Experimental models of breast cancer have shown that the ER can be activated 
in a ligand-independent manner. It has been suggested that it is this switch to 
ligand-independent activation of the ER that is a key mechanism that underlies 
altered ER activity and anti-estrogen resistance (Adeyinka, A. et al 2002). 
However, it is not yet fully understood what causes this switch to occur.
The development of tamoxifen resistance has also brought limitations to the 
use of long-term tamoxifen treatment. This is thought to affect around 50% of
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patients and leads to a more aggressive phenotype and poorer patient outlook 
(deGraffenried, L.A 2003). The problems associated with tamoxifen 
mentioned above have highlighted the need for new treatments to be found.
13.2 Aromatase inhibitors
Aromatase inhibitors (AIs) inhibit the conversion of testosterone and 
androstenedione to estradiol and estrone respectively in peripheral and breast 
tumor tissues. They exert this effect by inhibiting the cytochrome P450 
aromatase enzyme (Nicholson, R.I. et al 2004). There are two types of Al: 
irreversible AIs such as exemestane, which bond and degrade the aromatase 
enzyme rendering it non-usable. There are also reversible AIs such as 
anastrozole, which inhibit the aromatase enzyme in a competitive manner 
allowing re-use of the enzyme.
1 3 3  Fulvestrant
Fulvestrant or faslodex is a non-steroidal, pure anti-estrogen developed to 
overcome the estrogenic actions seen in tamoxifen treatment. It has a binding 
efficiency of ~100 times that of tamoxifen (Robertson, J.F. et al 2001). It is 
thought to exert anti-estrogenic actions by downregulating ER and by 
inhibiting the nuclear/cytoplasm shuttling of the ER and by inhibiting receptor 
dimerization and DNA binding (McClelland, R.A. et al 2001). It is also 
suggested the faslodex may modulate the recruitment and interaction of co­
regulators.
15
Chapter 1 General Introduction
1.4 A n ti-h o rm o n e  re s is ta n c e  a n d  E G F R  s ig n a llin g
The mechanisms by w h ich  both prim ary and acquired resistance occur are only 
vaguely understood and, so more w ork needs to be done in this area i f  new 
therapies to overcome this obstacle are to be developed. I t  is now  accepted, 
however, that g row th factor s ignalling is a key, but not sole, factor invo lved in  
anti-estrogen resistance. Th is has led to down stream mediators o f  these 
pathways becoming new targets fo r breast cancer therapy. Increased epidermal 
growth factor receptor (EG FR) signalling  is com m only seen both c lin ica lly  and 
in breast cancer ce ll lines that have developed endocrine resistance (N icholson, 
R .I et al 2004).
Gives docking 
Sites for adaptor 
Proteins and 
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Link upstream 
MRK ’s to 
Downstream 
IPK ’s
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Cell proliferation 
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Angiogenesis
Figure 1.3 A flow chart to show EGFR signalling. TK - tyrosine kinase, MRK - membrane 
receptor kinase, IPK -  intracellular protein kinase.
Epidermal g row th factor receptors are a fa m ily  o f  4 protein tyrosine kinase 
receptors, named EGFR or H ER -1, H ER -2, HER-3 and HER-4 (A ta lay, G. et 
al 2003). They possess both a ligand b ind ing domain (except H ER -3) and a
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tyrosine kinase domain (except HER-2). Figure 1.3 shows a much simplified 
flow chart-type representation of EGFR signalling.
Taking into consideration that there are 10 known ligands, several dimer 
variations and many downstream effectors, the EGFR signalling network is 
complex and diverse and not fully understood (Atalay, G. et al 2003).
Activation of downstream EGFR mediators such as phosphatidylinositol-3- 
kinase (PI3K) and mitogen activated protein kinase (MAPK) can lead to 
ligand-independent activation of the estrogen receptor. PI3K and MAPK can 
phosphorylate key serine residues, serine 118 and 167 respectively on the 
estrogen receptor within the AF-1 domain. This phosphorylation activates the 
estrogen receptor in the absence of estrogen. In this instance, if tamoxifen is 
present the tamoxifen/ER complex is enhanced and results in tamoxifen 
displaying an estrogenic effect on breast cancer cells, (Nicholson, R.I. et al 
2004). This highlights the attractiveness and benefit of targeting such kinase 
pathways in the fight against tamoxifen resistant breast cancer.
1.4.1 Phosphatidylinositol 3 kinase
Phosphatidylinositol 3-kinases are a sub-class of the lipid kinase superfamily 
that catalyse the addition of phosphates to position 3 of the inositol ring of 
phosphoinositides. However, 3’ phosphorylated phosphoinositides only 
account for 0.025% of all inositol-containing lipids, suggesting that they are 
not ubiquitous or homeostatic lipids, but play an important role in cell 
regulation (Ramelh, L.E. & Cantley, L.C. 1999).
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PI3K is heterodimer of two subunits; p85, which is a regulatory subunit and 
pi 10, a catalytic subunit. An inter SH (iSH) sequence separates the two SH2 
domains of the p85 subunit and links this subunit to the catalytic subunit. The 
two SH2 domains provide binding sites for tyrosine kinases (TKs). The pi 10 
subunit is also a dual specificity kinase that can phosphorylate serine and 
threonine residues in addition to phosphoinositides lipids. The regulatory 
subunit can interact with both the pi 10 subunit and TKs. This is proposed as 
the reason behind the membrane targeting of pi 10 and its subsequent 
complexation with lipid substrates (Krasilnikov, M.A. 2000). The PI3K 
enzymes can be activated in a number of ways, by G-protein coupled receptors, 
proteins with tyrosine kinase activity or by tyrosine-phosphorylated proteins. 
PI3 kinase signalling revolves around the presence of lipid recognition modules 
found in target proteins. Two key recognition domains have been described to 
date; these are the pleckstrin homology (PH) domain and the FYVE domain 
(Vanhaesebroeck, B.et al 1999). 3-phosphorylated inositol lipids are produced 
in the target membrane upon activation of an appropriate PI3 kinase. This 
results in the recruitment of proteins containing high affinity binding sites for 
these lipids, such as Akt (Fry, M.J. 2001). Upon activation, these kinases 
phosphorylate inositol lipids at the ‘3 position. The PI3 kinase generated 
phosphoinositides recruit Akt to the plasma membrane through their affinity 
for the PH domain of Akt (Scheid, M. et al 2002) where it undergoes 
independent phosphorylation at two residues, a threonine present in the 
activation loop and a serine at the carboxyl terminus. Once activated, Akt is
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capable o f  phosphorylating a number o f  proteins invo lved in metabolism, 
translational contro l, contro l o f  ce ll cycle by a ffecting cyc lin  D i and cell 
survival by a ffecting  forkhead fam ily  transcrip tion factors, B A D  and caspase- 
9. (Cam pbell, R .A  et al 2001) The P I3K  pathway is one o f  the pathways over­
activated in  tam oxifen resistance. Figure 1.4 is a cartoon representation o f  the 
PI3 kinase pathway.
H I
PI3K PDK1 AKT / 
PKB
P21, CIP1 AKT/
PKB
eNOS
Proliferation
Survival
MDM2 FKHR
TSC2 AFX
GSK3 BAD
Growth
Glycogen synthesis Survival
Increased NO 
synthesis
Figure 1.4 The P13K pathway.
It  can be seen from  figure  1.4 that activation o f  PI3 kinase leads to  the 
transcription o f  many tum or prom oting  proteins such as B A D , CIP1 and 
FKH R , w h ich  leads to  increased ce ll p ro life ra tion , grow th and surviva l and 
increased glycogen synthesis.
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1.4.2 M ito g e n -a c tiv a te d  p ro te in  k in ase
M itogen-activated prote in kinases (M A P K ), are proline-directed 
serine/threonine kinases that are w ide ly  expressed in tracellu lar s ignalling 
molecules invo lved in  m itosis and meiosis and many other facets o f  ce llu lar 
regulation (Chang, L . et al 2001). Figure 1.5 shows the m itogen-activated 
protein (M A P ) kinase pathway.
Stress / Cytokines
Hormones, Growth Factors Mid 
Neurotransmitters
Cell Membrane
PKC
PLCMEKK Rafs
MEK 1/2MAPKK4/7
ERK 1/2
Elk-1
AFT2
Elk-1
c-Myc
Nuclear Membrane
Figure 1.5 MAPK pathway.
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They are activated as a result of numerous stimuli and mediate signal 
transduction from the cell surface to the nucleus (Choi, K-C. et al 2003). 
When activated they catalyse the transfer of the terminal phosphate of ATP 
onto their target proteins (Choi, K-C. et al. 2003). There are three subsets of 
this family, ERK 1/2, p38MAPK and the c-Jun N terminal kinase/stress 
activated kinase (JNK/SAPK).
They are organised into three kinase modules consisting of a MAP kinase, an 
activator of this (MEK or MAP kinase kinase) and a MAP kinase kinase kinase 
(MEKK or MEK kinase). Figure 1.5 shows that activation of these pathways 
leads to the transcription of many tumour-promoting proteins.
In the anti-estrogen resistant phenotype, the activation of the MAPK pathway 
is enhanced, and so inhibition of this pathway could be beneficial in treating 
tamoxifen resistant breast cancer.
1.5 Inflammation and breast cancer
1.5.1 Inflammation
Inflammation is a tightly controlled process, which occurs in response to tissue 
damage. The main purpose of this process is to contain and/or destroy the 
pathogen, repair damaged tissue and remove tissue debris. The following 
sections will describe how this process may be implicated in malignancies.
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1.5.2 Cyclooxygenase
The prostaglandin-endoperoxide synthase (PTGS), cyclooxygenase (COX), is 
an enzyme that can oxygenate, with varying efficacy, 18-22 carbon 
polyunsaturated fatty acids (PUFAs), such as arachadonic acid (AA), 
eicosapentaenoic acid (EPA) and dihomo-y-linolenic acid (DGLA) 
(Malkowski, M.G., et al. 2001). Physiologically, the pivotal role of these 
enzymes is to catalyse the conversion of, primarily, AA into a range of 
biological mediators termed prostanoids. These prostanoids include 
prostaglandins, prostacyclin and thromboxane (Lee, J.L., et al 2003).
The COX enzymes are dimeric, with each monomer containing three folding 
units. The first folding unit displays heavy sequence homology to that of the 
EGFR and is thought to be responsible for protein-protein interactions. The 
second folding unit is responsible for insertion and anchoring into the lipid 
bilayers. It contains four right-handed helices, which form a motif that allows 
this insertion to occur. The third folding unit is the catalytic domain and is the 
largest of the three units. It contains two active sites and so displays two 
distinct enzymatic activities. The cyclooxygenase enzymes possess both a 
cyclooxygenase and peroxidase activity. In step 1, shown in figure 1.6, the 
cyclooxygenase site facilitates the conversion of AA to an intermediate 
prostaglandin (PG) termed hydroperoxy endoperoxide prostaglandin G2 
(PGG2).
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In this step the peroxidase active site generates a tyrosine radical, which 
abstracts hydrogen atoms from  A A . The tyrosine radical then interacts w ith  
two oxygen molecules to form  PGG 2 . The second step a llow s the reduction o f  
PGG2 to PG H 2 v ia  peroxidase ac tiv ity  (S ilva, P.J., et al 2003). The specific 
prostaglandins, prostacyclins and thromboxanes are then synthesised v ia  
specific enzymes, shown in  step 3.
C aa
I COX
(cyclooxygenase)
COX
(peroxidase)
PGH
\ r
Figure 1.6 Flow chart diagram to show prostanoid biosynthesis (Dubois, R.N., et al. 1998).
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There are currently 3 identified isoforms of the COX enzymes, namely COX-1, 
COX-2 and COX-3. COX-1 was first cloned in 1988 and is now known to be a 
‘housekeeping’ enzyme. It is constitutively expressed in most tissues and cell 
types and is responsible for the management of homeostatic physiological 
processes including ovulation, bone metabolism and platelet aggregation 
(Dubois, R.N. et al 1998). COX-1 mediated production of PGs occurs via 
hormone stimulation (Malkowski, M.G., et al. 2001).
COX-2, on the other hand, is normally undetectable in most tissues but is 
induced by a variety of stimuli such as growth factors, tumor promoters and 
pro-inflammatory cytokines (M6ric, J-B. et al. 2006). COX-3, the most 
recently identified form, is now thought to be a splice variant of COX-1 and so 
is sometimes referred to as COX-lb. It is formed by intron retention, a 
complex form of alternative splicing (Xie, W. et al. 1991).
1.53 Prostanoids
Prostanoids are potent and bioactive lipid messengers (Simmons, D.L. et al.
2004). There are currently 3 classes of prostanoid identified; prostaglandins 
(PGs), thromboxanes (Txs) and prostacyclins (PGIs). Each of these classes 
consists of several different series of prostanoid, depending on the precursor 
fatty acid.
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Precuroor Fatty 
Acid
Series of PG, 
PGI and TX
Series of LK Inflammatory potency
AA 2 4 Potent pro-inflammatory
EPA 3 5 Weak pro or sometimes 
anti-inflammatory
DGLA 1 3 Weak pro or sometimes 
anti-inflammatory
Table 1.1 Table to show die series o f prostanoid and leukotriene (LK) generated from die 3 
PUFA pre-cursors and the potency o f the inflammatory response produced by the creation of 
each.
Within each series of prostanoids many of the same class of prostanoid exist, 
which are distinguished with ABC after their class (e.g. PGE2, TXA3). Table
1.1 shows the classes and series of prostanoid and the fatty acid they were 
derived from.
1.5.4 COX, PGE2 and breast cancer
It has become evident that the cyclooxygenase enzyme group is involved in 
many tumors such as prostate, colorectal and breast. A strong correlation 
between regular non-steroidal anti-inflammatory drug (NSAID) use, which 
inhibit the cyclooxygenase enzymes, and a reduced risk of colorectal, breast 
and lung cancer development has also been noted (Liu, C.H., et al. 2001).
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Both COX-1 and COX-2 isoforms of the enzyme have been found to be 
expressed in solid tumors, however, addition of selective inhibitors of the two 
isoforms suggested that only COX-2 contributes to malignant behaviour, as 
selective COX-1 inhibitors gave no effect on tumor size and grade (Kundu, N. 
& Fulton, A.M. 2002). It has been widely reported that COX-2 is over­
expressed in tumors of the breast, prostate and GIT; this over expression is 
associated with high tumor grade (Larkins, T.L., et al. 2006). The over 
expression of COX-2 and thus accumulating concentrations of prostaglandins 
have been suggested to mediate many tumorogenic mechanisms, such as 
proliferation, angiogenesis and avoidance of apoptosis (Costa, C. et al. 2002). 
In fact, it is now understood that COX-2 overexpression in tumors plays an 
important role in metastasis and the development of resistance (Dandekar, D.S. 
& Lokeshwar, B.L. 2004). Various studies have shown this link between up- 
regulated COX-2 and tumorigenesis. Soslow et a l (2000) investigated the 
expression of COX-2 in ductal carcinomas in situ (DICS), a precursor to 
invasive breast cancer and compared this to adjacent non-neoplastic breast 
tissue. They showed that no COX-2 expression was detected in non-neoplastic 
lesions; although there was a 56% increase in expression found in the DCIS 
lesion.
There is also evidence suggesting that COX-2 upregulation is not only 
involved in metastasis and resistance but is enough solely to induce 
tumorigenesis. Studies using transgenic mice that over-expressed COX-2 by 
using the mouse mammary tumor virus (MMTV) long terminal repeat
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promoter showed that COX-2 was sufficient to induce breast tumorogenesis. 
This process led to the over-expression of COX-2 in mammary tissue alone and 
to 85% of mice developing tumors (Liu, C.H. et al 2001).
1.6 Metastasis
1.6.1 Extracellular matrix and cellular adhesion
The cells of most tissues remain resident within their tissue and do not possess 
the ability to spread to other tissues and locations within the body. Metastasis 
is a multi-step process by which cancer cells spread throughout the body. The 
process involves a large number of molecules such as growth factors, their 
receptors and angiogenic factors (Davidson, B. et al 2004). This ability of cells 
to migrate is the fundamental difference between benign and malignant tumors, 
with only the malignant variant possessing this capacity. Metastasis is the 
most deadly aspect of cancer and, regrettably, over 50% of malignant tumors 
have already metastasised at the time of diagnosis (Pecorino, L. 2005).
Malignant tumors contain both neoplastic (cancer) cells and non-neoplastic 
cellular components, which include macrophages, lymphocytes, fibroblasts and 
endothelial cells (Hagemann, T. et al 2004). The cellular elements of the 
tumor are surrounded by an extracellular matrix (ECM), and it is the 
interactions between the cellular and extracellular components that are 
fundamental in tumorogenesis (Hiscox, S. et al 2006).
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In order to understand the mechanisms and steps o f  metastasis, it  is firs t 
important to understand the typ ica l ce llu la r adhesion mechanisms, w h ich  
cancer cells must overcome in  order to m igrate and spread to distant sites.
1.6.1.1 C ell A d h esio n  m olecu les a n d  c a d h e r in s
C ellu la r interactions w ith  the cytoskeleton are im perative fo r normal cell 
adhesion. T w o  m ain fam ilies o f  proteins are responsible fo r both same cell 
type (hom otyp ic) and d iffe ren t ce ll type (heterotypic) recognition; these are the 
cell adhesion m olecules (C A M s) and cadherins.
Figure 1.7 Illustration o f  cell anchorage to the cytoskeleton. a nucleus, b catenins, c and c’ 
different subunits o f  integrin receptors, d, cadherins, e cytoskeleton, f  collagen, g fibronectin.
Figure 1.7 shows the typ ica l method and molecules invo lved  in  cell adhesion 
and anchoring to the cytoskeleton. Cadherins are ca lcium  dependant 
glycoproteins that traverse the ce ll membrane. They form  ‘ hooks’ by w h ich
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cells link together. These proteins interact with catenins, also shown in figure 
1.7, which, in turn interact with the cytoskeleton (Pecorino, L 2005).
1.6.1.2 Laminin
Laminin is a component of the ECM and the major non-collagen element of the 
basal lamina. Laminin molecules have high affinity for other laminin 
molecules, forming the sheet structure of the basement membrane on which 
epithelial cells sit (Haralson, M.A. & Hassell, J.R. 1995). Cellular attachment 
to laminin is a crucial step involved in local and vascular invasion (Davidson, 
B. et al 2004). Laminin receptors can be divided into two distinct categories: 
integrin and non-integrin receptors.
Integrin receptors, shown in figure 1.7, are responsible for interactions between 
the cell and the ECM. They also mediate intracellular signal transduction. 
They are a family of heterodimers made up of a variety of a and p subunits, the 
assembly of which allows for the recognition of different components of the 
ECM including fibronectin, collagen and laminin. Upon ligand binding, these 
integrin receptors cluster and allow actin binding proteins and kinases such as 
focal adhesion kinase to interact with the cytoskeleton. Several studies have 
shown that focal adhesion kinase may affect motility of cells by recruiting Src 
and activating the RAS signalling pathway. Altered integrin receptor 
expression may promote metastasis by allowing adherence to different ECMs 
or by modifying the distribution of the receptors. However, in most cancers,
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the precise role of integrins in metastasis is still unclear, with the receptors 
being up regulated in some cases and down regulated in others.
Non-integrin receptors mature from the homodimerisation of two molecules 
and or the heterodimerisation with an unknown protein to yield a 67KDa 
receptor (Menard, S. et al 1997). The non-integrin lamanin receptor is 
upregulated by cytokines, and ECM proteins such as fibronectin and laminin 
and is expressed in a wide array of malignancies (Menard, S. et al 1998).
1.6.2 Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) are a family of zinc dependent 
metalloendopeptidases that are secreted or membrane bound proteins that are 
involved in the majority of ECM turn over (Birkedal-Hansen, H. et al 1993). 
They are responsible for cleaving many ECM components such as gelatin, 
fibronectin, elastin, collagen and laminin (Low, J.A. et al 1996). MMPs are 
normally regulated tightly due to being synthesised as latent enzymes and 
needing proteolytic cleavage to become activated. Endogenous tissue 
inhibitors (TIMPs) also regulate the function of these proteases (Pecorino, L.
2005). EMMPIN (extracellular matrix metalloproteinase inducer) also regulate 
MMP expression. Stimulation by EMMPIN is known to upregulate MMP-1, 
MMP-2 and MMP-3 (Kataoka, K. et al 1993). EMMPIN is also capable of 
binding MMP-1 to the tumor cell surface and is known to co-localise with 
integrin receptors at the cell membrane (Guo, H. et al 2000, Berditchevski, F. 
et al 1997). MMPs are often over activated in tumor cells or in surrounding
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stromal cells, enabling breakdown of ECM components and of the basement 
membrane (Hagemann, T. et al 2004). It is understood that MMP-2 and MMP- 
9 are the key proteases involved in this process (Reich, R. et al 1995).
1.63 Steps In metastasis
1.63.1 Intravasation
As suggested before, the process of metastasis is a multi-step one, illustrated in 
figure 1.8. Intravasation is the process by which tumor cells attach to the 
stromal side of the blood or lymphatic vessel, degrade the basement membrane 
(only present in blood vessels) migrate transendothelially into the blood stream 
or lymph.
1.633 Cell transport
The tumor cells are then transported to distant body sites via these two systems. 
In the blood, they can travel as lone cells or as emboli (groups of cells) in one 
direction only i.e. the direction of the blood. The specificity of metastatic site 
is not only due to cell surface receptors, which are specific to some organs and 
are responsible for the seed and soil theory. A phenomenon called first pass 
organ also influences the site of metastatic spread. In breast cancer blood 
flows through the superior vena cava to the lung, therefore the lung is often a 
site for metastasis in breast cancer. The lung also receives lymphatic drainage 
from the breast, which also enhances the potential of metastasis to this site 
(Pecorino, L. 2005).
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M igration ( ^ )  Intravasation^  ( ^ )  Transport
Metastatic
colonisation
Figure 1.8 A flow chart-type diagram to show the stages o f metastatic spread o f  cancer cells. 
Adapted from Pecorino, L. 2005.
1.6.3.3 Extravasation
Extravasation is, in  effect, intravasation in  reverse. I t  invo lves the tum or cells 
attaching to the endothelia l side o f  the vessel, insert through the basement 
membrane and m igrate in to  the surrounding stromal environment. Calcium  
dependant specialised adhesion molecules are present on the endothelial cells, 
w h ich  aid the process o f  extravasation by cancer cells. These molecules are 
called Selectins and are thought to be, in  part, responsible fo r the seed and soil 
theory mentioned previously.
1.6.3.4 Metastatic colonisation
Metastatic co lonisation goes hand in  hand w ith  angiogenesis, w ithou t 
continuous expansion o f  a cap illa ry  netw ork to supply oxygen and nutrients to
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the cancer cells; the secondary tumor would not grow. In this instance 
proliferation and apoptosis would balance out and the secondary tumor or 
micrometastasis may lay dormant for many years.
A new class of genes have been discovered that encode metastasis suppressors. 
These suppressors are expressed at an alarmingly low level in metastatic tumor 
cells when compared with non-metastatic tumor cells and so their loss of 
function may be key in the induction of metastasis (Pecorino, L. 2005).
1.63.5 Angiogenesis
A crucial step in metastasis is the formation of new blood capillary networks to 
provide tumor cells with oxygen and nutrients, a process called angiogenesis. 
If the rate of blood vessel formation is not sufficient, distant metastasis cannot 
grow and so remain a micrometastasis. Angiogenesis hinges on a balance 
between pro- and anti-angiogenic factors such as proteolytic factors, growth 
factors, cytokines and chemokines. An increase in inducers or decrease in 
inhibitors could tip the balance and turn on angiogenesis.
1.63.6 c-Src
This protein belongs to the Src family of non-receptor protein tyrosine kinases, 
which play a variety of critical roles in cell physiology including proliferation, 
adhesion, angiogenesis and survival (Gonz&lez, L. et al 2006). There are 
eleven members of the Src kinase family; Fyn, Yes, Lck, Hck, Blk, Lyn, Src, 
Fgr, Bik, Frk and Yrk (Roskoski, R. 2004). Their structures are highly
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conserved, with family members containing SH4, SH3, SH2 and SHI regions 
along with a short C-terminal tail, which is important for activation (Baggon, 
T.J. & Eck, M.J. 2004).
All Src family members have a unique SH4 domain and N-terminus that is 
myristoylated. The SH3 domain is the ligand-binding domain, while the SH2 
domain contains protein recognition sites. The arginine at 175 is highly 
conserved among Src family members and confers to a phosphotyrosyl 
recognition pocket. The SH2 and SH3 domains are responsible for 
protein/protein interactions. The SHI domain is the tyrosine kinase domain 
and contains the ATP binding site at Lysine 295. The tyrosine residue at 416 is 
an autophosphorylation site (Gonzdlez, L. et al 2006). The C-terminus 
contains a tyrosine at residue 527, which regulates Src kinase activity. 
Phosphorylation of the residue gives an intramolecular interaction with the 
SH2 domain of Src leading to its inactivation via a conformational change 
(Thomas, S.M. & Brugge, J.S. 1997). Activation of Src family members can 
occur by receptor tyrosine kinases such as the EGFR. Activation and thus 
autophosphorylation of the EGFR allows the receptor to interact with the SH2 
domain of the Src family member and disrupts the inactive conformation, 
allowing activation of Src. Activated Src can then phosphorylate a number of 
target proteins, such as transcription factors, adaptor proteins and focal 
adhesion proteins such as focal adhesion kinase (Pecorino, L. 2005).
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Cell culture and in vivo data has shown that it is not only the enzymatic 
activity of the Src kinases that exerts their cellular functions. It has been 
demonstrated that, through the SH2 and SH3 domains, these kinases can 
generate complexes of signalling molecules that are involved in a diverse array 
of signal transduction pathways (Brunton, V.G. 2005).
1.7 Targeting tamoxifen resistant growth
Targeting downstream EGFR mediators supposes beneficial clinical results for 
de novo resistance to endocrine therapy. It may also prevent or somewhat 
delay the onset of acquired resistance as both of these phenotypes display 
elevated EGFR, HER2, IGF-IR and downstream signalling.
Quercetin and LY294002, shown in figure 1.9, are selective PI3k pathway 
inhibitors. Quercetin is a naturally occurring bioflavonoid found in red wine, 
fruit and vegetables and is especially abundant in onions (Formica, J.V. & 
Regelson, W. 1995). Flavonoids share a common structure of two phenol 
rings, which are linked by three carbons (Nanua, S. et al 2006). The anti­
oxidant properties of bioflavanoids, such as quercetin have long been known 
and these properties offer cardiovascular protection by preventing low-density 
lipoprotein oxidation (Moon, J-H. et al 2000). Quercetin is known to inhibit 
several serine/threonine, lipid and protein tyrosine kinases including PI3 kinase 
(Nanua, S. et al 2006).
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Figure 1.9 Chemical structures o f PD98059 (A), LY294002 (B), SL327 (C) and quercetin (D).
LY294002 was developed from the naturally occurring bioflavanoid quercetin, 
which is known to inhibit PI3 kinase. LY294002 acts by competitively 
inhibiting the ATP binding site of PI3K, therefore preventing the transfer of the 
terminal phosphate of ATP to phosphoinositol and so inhibiting the formation 
of PIP’s (Vlahos, C.J. et al 1994).
PD98059 and SL327, shown in figure 1.9 are flavonoid-based compounds that 
possess the ability to inhibit the MAPK pathway. PD98059 exerts its MAPK
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inhibitory effects without directly acting on MAPK. It gives these effects by 
binding to and preventing phosphorylation of MEK by cRAF or MEK kinase 
(Dudley, D.T. et al 1995). MEK is directly upstream of MAPK, thus this 
impedes the phosphorylation and activation of this mediator (Alessi, D.R. et al 
1995).
SL327 also binds to and prevents the activation of MEK, thus inhibiting 
MAPK, however it has the ability to penetrate the blood brain barrier and 
reduce cortical phospho-MAPK levels (Dash, P.K. et al 2002). It shows 
selectivity for MEK, without any effects on CaMKI, PKC or PKA (Atkins, 
C.M. et al 1998). Davis, S. and colleges (2000) also reported that SL327 
prevented Elk-1 phosphorylation.
Figure 1.10 summarizes the pathways targeted by the multi-pronged 
transcutaneous device and shows how the pathways crosstalk and overlap in 
tamoxifen resistance. This cross talk will be discussed later in relevant 
chapters.
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Figure 1.10 Pathways and mediators targeted in the transcutaneous device.
Oral ingestion or IV  adm inistration o f  such compounds is assumed to be 
problem atic due to  the ir non-specific nature fo r cancer cells and other bod ily  
cells. This, coupled w ith  know n adverse events associated oral tam oxifen has 
lead to the idea o f  a lternative de livery  o f  cockta ils o f  these compounds.
Transcutaneous (permeation across fu ll thickness skin and d iffus ion  to 
underly ing tissue) o ffers such an alternative de livery route. The benefits o f  
w hich shall be discussed in  detail in  the fo llo w in g  sections.
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1.8 T he  physiology o f skin
The skin is the largest organ o f  the body, m aking up 12-16 %  o f  tota l body 
mass. It presents as a com plex organ and has a range o f  b io log ica l functions 
inc lud ing  a barrier to contro l o r prevent the entry o f  chemical or 
m icroorganism s into, and water and heat loss from  the body (W illia m s , A .C . 
2003). The skin is under constant regeneration and is m etabo lica lly active. It 
comprises o f  three discrete layers, as displayed in  figure 1.11. These w il l  be 
discussed in  the fo llo w in g  sections from  the outer most to the innerm ost layer.
sebaceous
stratum
corneum
sensory I blood ,ending II vessels
EPIDERMIS
DERMIS
hair'  \® ollicl<  
muscle \ l l \
SU6CUTA
NEOUS
LAYER
Figure 1.11 Cartoon diagram o f the structure o f  skin (www.natural-skin-health.com).
1.8.1 Stratum corneum
The stratum corneum (SC), (figu re  1.12 A ), is the outermost structure o f  the 
skin and is the end result o f  epidermal d iffe rentia tion . This layer comprises o f  
10-30 cell layers and is on ly  30-40pm  th ick  when dry, although it  can swell,
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sometimes to 3 times th is thickness when hydrated (G oldsm ith , L .A . 1991). It 
is comprised o f  comeocytes, w h ich  are dead com ified  keratinocytes and devoid 
o f  a ll organelles. These largely impenetrable cells have been flattened and 
keratinised and are tig h tly  and embedded in an in terlock ing  lip id  m atrix 
comprised o f  cholesterol, sphingolip ids, fa tty  acids and ceramides 
(Charalambopoulou, G .C. et al 2004) however, phospholip ids are m ostly 
absent. The arrangement o f  the comeocytes w ith in  the lip id  m atrix  is referred 
to as a w a ll o f  bricks, where the comeocytes represent the bricks and the lip id  
m atrix represents the cement (E lias, P.M . 1983). The lip ids  o f  the SC are the 
exocytotic products o f  lam ella r bodies and are suggested to give rise to the SCs 
remarkable barrier characteristics (E lias, P. 1988, Grubauer, G. et al 1989).
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Figure 1.12 Haematoxylin staining o f  a cross section o f freshly excised porcine ear skin using 
immunocytochemistry. Left is at x20 resolution and right is at x40 resolution using a Olympus 
BH-2 phase microscope and photographed using an integrated Olympus DP-12 digital camera 
system (Olympus, Oxford, UK). A. Stratum corneum (SC). B. Epidermis. C. Dermis. D. 
Keratinocytes.
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1.8.2 The viable epidermis
The epidermis (figure 1.12 B) consists of four distinct layers: the stratum 
germinativum, stratum spinosum, stratum granulosum and the aforementioned 
stratum corneum, however the stratum corneum is often thought of as a 
discrete layer. The remaining 3 sub-layers make up the viable epidermis and 
contain the live epithelial tissue.
The viable epidermis varies in thickness at different parts of the body, with 
around a 10- fold variation between the thickest and thinnest It is at its 
thinnest at the eyelids, where it measures around 0.06mm and it is thickest at 
the palms and soles, where it is 0.8mm thick. The main cell type within the 
viable epidermis is keratinocytes, which are produced at the stratum basale and 
differentiate as they migrate towards the SC, where they are continually 
sloughed and replaced.
This layer is enzymatically active, containing phosphatases, proteases, lipases 
and hydrolases (Patil, S. et al 1996). However this is only at around 10% of 
the enzymatic activity seen in the liver (Hotchkiss, S.A.M. 1998). This may 
seem minimal and somewhat irrelevant, although several studies have shown 
significant bioconversion of drugs within the skin. A study by Thomas, C.P et 
al. (2007) revealed that eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA) were significantly metabolised within the epidermis. The 
bioavailability of nitroglycerin post topical application was shown to be just
56.6 ± 5.8 when compared to IV administration (this event should be borne in
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mind when considering transdermal or transcutaneous delivery). The dermis is 
devoid of blood supply therefore nutrients and waste must pass either to the 
cells or from them from the dermal vasculature by passive diffusion through 
the dermo-epidermal layer. The same phenomenon is observed with 
permeating compounds.
1.8.2.1 Stratum lucidum
The cells within this layer continue to flatten and start to keratinise. The nuclei 
of the cells also start to degrade in this layer. It is not known for certain to date 
whether this is in fact a separate membrane, or whether it is just the lower part 
of the stratum corneum.
1.8.2.2 Stratum granulosum
This layer is termed the granular layer as the cells change and take on granular 
features. The cells within this layer also continue to differentiate and become 
flattened; they also start the process of organelle degradation. Membrane 
coating granules are synthesised in these cells and as the cells migrate towards 
the surface, these granules begin to extrude and contain the precursor for the 
stratum corneum lipid lamellae.
1.8.23 Stratum spinosum
This layer is also known as the spinous layer. The keratinocytes within this 
layer change morphologically from those of the stratum germinativum. They 
become polygonal rather than columnar and begin to differentiate. The cells
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within this layer also produce tonofilaments, which condense and make up the 
desmosomes. It is the role of the desmosome to maintain an equal distance of 
around 20nm between each keratinocyte.
1.8.2.4 Stratum germinativum/basale
The cells within this layer are metabolically active (germinative) and are 
histologically similar to cells in other tissues, in that they contain all the normal 
organelles such as mitochondria and a nucleus. These cells have been shown 
to produce pro-inflammatory cytokines (Barker, J.N.W.N. et al 1991).
The keratinocytes are anchored to the basement membrane or basale lamina by 
specialised proteinaceous structures termed hemidesmosomes. The cells 
within the stratum basale are the only cells within the epidermis, which are 
under constant mitosis, and, in fact, only half of these cells progress onto 
differentiation, while the other half remain intact to the basement membrane 
and continue mitosis. Melanocytes are also present within the stratum basale. 
These are specific cells that synthesise the pigment melanin. Melanin is passed 
from melanocytes to keratinocytes via dendritic connections. Situated on the 
dermal side of the basement membrane, there is another specialised cell type, 
termed the Merkel cell. This cell is fairly specific to the touch-sensitive parts 
of the body and so is thought to be involved in cutaneous sensation. 
Langerhans cells, which are the major antigen presenting cells of the skin and 
also free radical scavengers, are also found in the stratum basale. They are 
dendritic structures, which are connected to keratinocytes via these processes.
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1.83 Dermis
The dermis, shown in figure 1.12 C is the major component of the skin in terms 
of size, measuring between 3 and 5 mm thick. The main structural component 
of the dermis is a connective tissue network consisting mainly of collagen 
fibrils and elastic tissue, which provide support and flexibility respectively. 
These are embedded in a mucopolysaccharide gel, which collectively provides 
this component of the skin with a hydrophilic nature; this provides an 
environment more suitable to the permeation of hydrophilic molecules and may 
hinder the permeation of lipophilic permeants. The dermis is also infiltrated 
with blood and lymphatic vessels, along with nerve endings. There are also 
appendageal structures within the dermis, such as hair follicles, sebaceous 
glands, sweat glands, nerve endings as well as blood and lymphatic vessels, 
shown in figure 1.11.
1.8.4 Hypodermis
The hypodermis, shown in figure 1.11, is an adipose layer, which acts as a 
connection between the dermis and underlying body organs and tissues. The 
main role is to act as a biological shock absorber to protect the organs from 
physical impact and to insulate the inner constituents of the body from extreme 
temperature changes. The hypodermis also contains the primary blood vessels 
and nwypi qf pkin. The layer of adipose provides the body with energy 
providing molecules, which are readily available when the body requires them.
44
Chapter 1 General Introduction
1.9 Routes of drug delivery
The most common types of drug administration are oral (p.o) intravenous (i.v). 
Administration via these two routes means that the drugs either enter directly 
into the systemic circulation or high quantities of the administered dose diffuse 
into it via the GI tract.
Topical administration, whereby drugs or other products are applied to the SC 
surface, can have the benefit of being applied directly to the ‘site of action9. 
An example of this is NSAID formulations for muscle pain, which prove to be 
a competitive alternative to oral preparations. Also topical drug delivery 
avoids the 1st pass effect, which can hugely reduce bioavailability of orally 
administered drugs that undergo extensive and somewhat unwanted 
metabolism by the liver. Thus lower dosages can be given, which in turn 
means that any coinciding toxicity could be reduced. Thirdly, topical 
administration overcomes the problem of pulse dosing, ensuring that the 
concentration of drug at the site of action lies steadily in the therapeutic 
window. This again reduces the chances of toxicity associated with overdose 
and ensures that therapeutically active concentrations remain at the site of 
action.
When discussing drug administration via the skin, 3 main routes should be 
considered. Conditions requiring the drug to remain on the skin surface or 
within the skin itself require minimal permeation through the skin to 
underlying tissues, whereas condition requiring the drug to diffuse through the
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skin and either enter the systemic circulation or pass through to underlying 
tissues should be formulated in such a way to allow maximum penetration of 
the skin, including passage through the SC. All three methods of drug 
administration will be discussed in detail in the following sections; however, 
all three require successful partition of drug into and passage through the SC. 
With this in mind, the routes of entry into and channel through the SC shall be 
discussed first.
1.9.1 Passage through the stratum corneum
There is no evidence of active transport within the skin, therefore entry to 
compounds must be passive. Permeants may enter via the appendages of the 
skin; the hair follicle channel or sweat gland. These routes are termed shunt 
routes. There is still much debate in skin and drug delivery research as to the 
extent that these two routes contribute to total permeation. This is suggested to 
be due to the relatively sparse occurrences of these openings in human skin 
compared many animal counterparts (Roberts, M.S. 2002).
Conflicting reports are found in the literature. One study shows that 
radiolabelled pesticides were more significantly recovered in the urine of 
humans when the application site was the head rather than the less hairy 
forearm (Maibach et al 1971). However, another study showed that this route 
was significant for the permeation of mannitol, a hydrophilic compound but 
had negligible contributions to the permeation of estradiol, a lipophilic 
compound (Essa, E.A. et al 2002).
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Figure 1.13 Routes o f  permeation (Moghimi HR Williams AC and Barry BW. Stratum 
comeum and barrier performance; a model lamellar structural approach. In: Bronaugh RL and 
Maibach HI. (Eds.) Percutaneous Absorption. Marcel Dekker, New York (1999) 515-553)
The fina l tw o  routes o f  permeation through the SC are shown in  figure 1.13 
and described in  the next sections.
1.9.1.1 Intercellular Route
The in terce llu lar route is now  accepted as the m ain route o f  SC penetration fo r 
most small non-charged molecules. The lip o p h ilic  nature o f  this region allows 
m oderately lip o p h ilic  permeants to penetrate most readily compared to h igh ly  
lip o ph ilic  o r hyd roph ilic  molecules. The lip id  bilayers w ith in  the SC are 
unique to this site o f  the body and are present in  several states ranging from  
flu id  to solid. It  has been suggested that the more flu id ic  areas a llo w  passage 
o f  permeants (Forslind, B. 1994).
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1.9.1.2 Transcellular Route
This route provides the most direct route across the SC. However, this route 
provides multiple obstacles for the permeant in the form of partitioning through 
lipid bilayers, followed by diffusion through hydrated keratin, followed by 
partitioning through lipid bilayer once more. This process would be repeated 
in great succession and so it has been accepted that this route is not followed 
by most compounds (Lee, A.J. et al 1996).
1.9.2 Dermatological formulations
Such formulations are focused on retaining the drug(s) in question within the 
layers of the skin where they exert a local effect on or in the skin. In many 
conditions requiring such formulations, such as psoriasis, athletes foot, eczema 
and bums the SC is compromised and so it becomes difficult to maintain the 
drug in the desired location, without permeation through and into the systemic 
circulation. Many mechanisms have been explored to avoid this behaviour; 
one successful method is the use liposomes. Liposomes are defined in the 
oxford medical dictionary as ‘an artificial vesicle composed of one or more 
concentric phospholipid bilayers and used especially to deliver microscopic 
substances to body cells. As the name suggests, the lipophilic liposomes can 
overcome the SC barrier with relative ease, however cannot partition into the 
more hydrophilic viable epidermis with such ease. This means that the 
liposomes accumulate in the SC where they release their encapsulated drug.
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Due to the penetration enhancing effects of alcohols and other solvents, 
dermatological formulations often avoid such ingredients to minimise 
permeation through the skin.
1.93 Transdermal delivery
Transdermal delivery necessitates the permeation of the drug in question 
through the SC and epidermis into the dermis where it can diffuse into the 
projecting blood vessels and enter the systemic circulation. From here it can 
circulate to the site of action. An example of such a preparation is the nicotine 
patch, where formulated nicotine enters the circulation at the site of application 
of the patch (usually the arm) and exerts its pleasure-inducing effect in the 
brain.
1.9.4 T ranscutaneous delivery
The aim of transcutaneous delivery is for the drug(s) in question to permeate 
the lipophilic SC, the more hydrophilic viable epidermis and then partition into 
the dermis, where it by-passes uptake into blood vessels and so into the 
systemic circulation and passes into underlying tissues. There are two causes 
for concern, which may limit transcutaneous delivery; firstly, the drug must be 
formulated in such a way so that it can permeate both lipophilic and 
hydrophilic environments, and secondly, the rate of permeation must exceed 
the rate of clearance by the dermal vasculature to ensure that a certain 
proportion of the drug reaches underlying tissues.
49
Chapter 1 General Introduction
1.9.5 Permeation enhancement strategies
Often, the desired permeant does not permeate the skin at a sufficiently high 
rate to be therapeutically useful. Therefore, permeation enhancement strategies 
are employed to increase the amount of compound able to penetrate the SC. 
Enhancement may be by either chemical means, by which solvents or other 
chemicals can be included into the formulation to disrupt the barrier function or 
by physical means, such as iontophoresis or ultrasound or by bypassing the SC 
completely via the use of microneedles. Chemical permeation enhancers 
(CPEs) are added to a drug formulation to increase flux.
I.9.5.I. Sulfoxides
Sulfoxides are a much-studied group of CPEs of which dimethyl sulfoxide 
(DMSO) is most well known. DMSO is a widely used and studied aprotic 
industrial solvent. Upon its introduction by Dr Stanley Jacobs in 1963 it was 
hailed as super solvent, having many pharmacological and therapeutic 
characteristics (Schaffer, T.E & Pruitt, A.W. 1983). It was envisaged that due 
to the ability of DMSO to penetrate intact skin, the ‘dragging’ of a variety of 
chemicals would replace injections. It was also imagined that its ability to 
inhibit prostaglandins would lead to an anti-inflammatory treatment. However 
clinical research was suspended in 1965 due to lens damage seen in animal 
studies and since this date the use of DMSO has mainly been restricted to use 
as a scientific tool and industrial solvent. DMSO is now widely established as 
a CPE and is an effective enhancer for both lipophilic and hydrophilic 
compounds. It partitions into the stratum comeum and disrupts its barrier
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properties, which at low concentrations is said to be a reversible event 
(Williams, A.C 2003). Fourier transform (FT) Raman spectroscopy has shown 
that DMSO is capable of transforming stratum comeum keratin to P sheet 
conformation from an a helical structure. Solutions of 60% and above DMSO 
enhance permeation by not only protein alterations but by changing SC lipid 
organization and affecting partitioning of compounds, effects which are not 
reversible (Anigbogu, A.N.C. et al 1995).
1.9.5.2 Terpenes
Terpenes, exemplified by 1,8-cineole have been accepted as permeation 
enhancers and as fragrances for topical formulations. They enhance 
permeation by affecting SC lipids. They have been shown to alter transition 
temperatures of SC lipids, rendering more areas fluidic in state (Narishetty, 
S.T. & Panchagnula, R. 2005). It is also suggested that hydrocarbon terpenes 
increase permeation by increasing the diffusivity of the SC lipids, whereas 
cyclic terpenes act by increasing the partitioning of solute into the skin.
1.9.53 Alcohols
Alcohols, such as methanol and ethanol can increase the solubility of solute so 
increase its partitioning into the skin. They can also affect the skins 
permeability to the solute irreversibly due to its entry and passage through the 
skin by extracting lipids from the stratum comeum membrane and so 
increasing the passage of the permeant through this barrier (Oh, S.Y. et al 
2003).
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1.9.5.4 Fatty acids
Fatty acids can enhance the permeation of both lipophilic and hydrophilic 
compounds. They are thought to intercalate with the lipid bilayers and exist in 
separate phases or pools within this. These pools are thought to provide a 
permeability route for compounds.
1.9.5.5 The Pull or Drag effect
Recent attention has been focused on the pull effect as a viable explanation of 
the enhancing properties of solvents or fatty acids. It is suggested that the 
close relationship between the permeation of mefenamic acid and ethanol/1,8- 
cineole was attributed to the pull effect and not the effect on the SC (Heard, 
C.M., et al 2006). Studies using heat separated membranes devoid of SC saw 
ethanol giving the same permeation enhancement as seen with full thickness 
skin, thus suggesting effects on SC lipids was not the reason for permeation 
enhancement (Heard, C.M., et al 2007). Fish oil has also been shown to 
increase the permeation of ketoprofen in a similar manner (Thomas, C.P. et al 
2007).
1.10 In-vitro models of topical drug delivery
The Franz diffusion cell is the standard method for determining permeation or 
penetration across a skin membrane, and so all permeation studies throughout 
this thesis were carried out using all glass Franz diffusion cells.
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Figure 1.14 An all glass Franz diffusion cell.
These are displayed in  figure  1.14 and consist o f  2 separate chambers, a 
receptor (low er) compartment, on w h ich  the skin membrane sits stratum 
comeum up and the donor (upper) compartment. M a ting  flanges o f  the tw o 
compartments were lined w ith  h igh vacuum s ilicon grease (D ow  C om ing, U K ) 
and the tw o compartments clamped to m in im ise leakage.
1.10.1 Choice of skin membrane
Fu ll thickness excised porcine ear skin was used throughout th is thesis due to 
the lack o f  a va ilab ility  o f  human skin samples. Porcine skin th is provides the 
most comparable model o f  human skin (Sekkat, N . et al 2002). A  noted 
difference between fresh porcine skin and frozen skin has been established; 
therefore, fresh skin was used throughout a ll permeation studies.
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1.10.2 Receptor solution
The choice of receptor phase is of utmost importance when designing in vitro 
permeation studies. It must provide a suitable sink in which permeants should 
be soluble, without modulating the barrier function. To ensure that no 
retardation of the flux occurs due to an imbalance of the concentration 
gradient, the permeating species should not exceed 20% of its solubility in the 
receptor phase. A micro stirrer bar is included to constantly agitate the 
receptor phase and to mimic the effect of dermal clearance. The receptor phase 
should exert no effect on the membrane, which would alter the permeation of 
the permeants in question and should, as much as possible, mimic the in vivo 
situation. Many different solutions have been used as receptor solutions, 
including ethanol, bovine serum albumin (BSA) and cetrimide. The use of 
BSA as a receptor phase is currently being scrutinized due to its keratinocyte 
toxicity (Haberland, A. et al 2006).
A recent study has shown that cetrimide does not give rise to any adverse 
effects on the skin membrane and does not affect the flux of permeants 
(Morris, A.P. 2003). This receptor phase has also been shown to behave in a 
similar way to the traditional octanol/water receptor phase (Heard, C.M. et al 
2002).
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1.103 Measurements of flux, lag time and kp
1.103.1 Flux
The flux of a permeant is a measure of the mass of a compound permeating per 
unit area per unit time. It is calculated as the gradient of the linear portion of 
the permeation profile and is typically measured in pg cm'2 h*1.
1.1033 Lag time
Lag time is a measure of length of time taken to reach steady state flux. The 
linear portion of the permeation profile is extrapolated to the x axis in order 
achieve this value. Lag time is usually measured in hours.
1.1033 Permeability coefficient, kp
Kp is the permeability coefficient and is derived from using the flux and 
concentration in the donor phase by using Ficks first law equation 1.1
Kp = flux (ug cm'2 h"1)
Concentration in donor phase (pg)
Equation 1.1
0 1The Kp thus has units of cm* h~ and is a measure of the conductance of skin to 
a particular permeant (Degim, I.T. 2005).
1.11 Topical delivery of breast cancer therapeutics
Currently, chemotherapy for ER+ breast cancer relies on oral or iv 
administration of compounds. Complex tablet regimes are often given, which
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include; tamoxifen, an aromatase inhibitor and fulfestrant. A transcutaneous 
device that could deliver combinations of these compounds would provide 
benefit to the patient, allowing dosing every 1-2 days, with minimal 
discomfort.
1.12 Aims and objectives
The objectives of this thesis was to test the hypothesis that the combination of 
tamoxifen and two signal transduction inhibitors downstream of the EGFR 
could be delivered across skin and be efficacious in the transcutaneous 
treatment of both tamoxifen sensitive and resistant breast cancer.
Associated aims of this project were:
1. To select signal transduction inhibitors based on their skin permeation 
and anti-breast cancer activities.
2. To formulate these with tamoxifen or its metabolite to give maximal 
skin penetration.
3. To investigate the simultaneous effects and biological efficacy of these 
compounds on breast cancer cell lines
4. To examine the possibility of trans-mammary papilla delivery
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The following sections describe all the general materials and methods; 
however, the details involved in each method are expanded upon in each 
chapter where necessary.
2.1 Materials
PD98059 and LY294002 (99.8% HPLC) were purchased from Promega UK, 
Southampton, UK. Super-strength fish oil capsules were purchased from a 
local Boots store.
Hanks balanced buffered salt solution (HBBSS), HEPEs, gentamycin sulphate, 
sodium bicarbonate PBS, PBS + 0.02% TWEEN, sodium citrate, citric acid, 
methyl green, copper sulphate, paraffin wax pellets, 30% hydrogen peroxide 
solution, sodium hydroxide, hydrogen chloride, acrylamide/bis-acrylamide 
29:1 (30% v/v solution), activated charcoal, ammonium persulphate (APS), 
ampicillin, aprotinin, bovine serum albumen (BSA), crystal violet, di- 
thiothreitol (DTT), ethylene diamine tetraacetic acid (EDTA), ethylene glycol- 
bis(2-amino-ethylether)-N,N,N’ ,-tetraacetic acid (EGTA), fibronectin, glycine, 
leupeptin, N,N,N’ ,N’ -tetramethylene-diamine (TEMED),phenylarsine oxide, 
phenylmethyl sulphonyl fluoride (PMSF), polyoxyethylene-sorbitan 
monolaurate (Tween 20), ponceau S solution (0.1% w/v in 5% acetic acid, 
sodium azide, sodium chloride (NaCl), sodium dodecyl sulphate (SDS), 
sodium fluoride, sodium molybdate, Tris HC1, triton X-100, 17p estradiol 
(98% HPLC), tamoxifen (99% HPLC), 4-hydroxytamoxifen (98% HPLC), 
SL327 (98% HPLC), quercetin (98% HPLC), fulvestrant/faslodex (98%
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HPLC), 1,8-cineole and cetrimide were from Sigma-Aldrich Company Ltd, 
Poole, England.
Total and phospho-ERK 1/2 primary antibody, total and phospho-Akt primary 
antibodies, rabbit total COX-2 primary antibody, mouse phospho-ER 118 
monoclonal antibody total and phospho Src antibodies and activated ERa 167 
antibody were from Cell Signalling Technology, New England Biolabs, 
Hitchin, UK.
NeoMarkers total EGFR primary antibody was from LabVision products, 
Chesire, UK.
HRP labelled anti-rabbit and anti-mouse EnVision™+ system, peroxidase 
(DAB kits, normal goat serum, liquid DAB+ substrate chromagen system, Ki- 
67 primary antibody, normal goat serum, normal rabbit serum, total ER clone 
ID5 mouse antibody and delimiting pen were from Dako UK, Ely, England.
Ethanol, xylene, Whatman filter papers (45 p), Whatman parafilm, high 
vacuum silicon grease, Coming Standard Transwell inserts 6.5 diameter and 
8pm pore size, disposable plastic cuvettes, glycerol, sucrose and chloroform 
were from Fisher Scientific UK, Loughborough, England.
BioSource phospho-EGFR 1068 primary antibody, amphoteracin B 
(fungizone), antibiotics (streptomycin and penicillin), RPMI 1640, phenol free
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RPMI, L-glutamine, trypsin/EDTA xlO solution and FCS were from Invitrogen 
Life Technologies, Paisley, UK. Tissue culture plasticware was from Nalge 
Nunc International, Roskilde, Denmark. Bio-Rad protein assay reagents, lower 
buffer for SDS-PAGE (tris 1.5M pH 8.8) and upper buffer for SDS-page (tris 
0.5M pH 6.8) were from Bio-Rad Laboratories LTD, Hemel Hempstead, UK.
Bromophenol blue and glass coverslips (thickness no2 22mm2) were from 
BDH Chemicals LTD, Poole, UK. Cell scrappers and universal containers 
were from Greiner Bio-One LTD, Gloucestershire, UK.
Chemiluminescent Supersignal® West HRP substrate (pico, dura and femto) 
were from Pierce and Warriner LTD, Cheshire, UK.
Coulter counter counting cups and lids and sterile, disposable serological 
pipettes (5, 10 and 25 mL) were from Sarstedt AG and Co, NOmbrecht, 
Germany. Nitrocellulose transfer membrane (Protran® BA85; 0.45pm pore 
size was from Schleicher and Schuell, Dassel, Germany. Syringe needles were 
from Sherwood-Davies and Geek, Gosport, Hampshire, UK.
Syringes were from Becton Dickinson (BD) UK LTD, Oxford, UK. X-ray film 
developer and film fixative solutions were from X-O-graph Imaging System, 
Tetbury, UK. Kodak MXB autoradiography film (blue sensitive) was from 
Genetic Research Instrumentation (GRI), Rayne, UK. Di-butylpthalatexylene 
(DPX) was from Raymond A Lamb LTD, Eastbourne, UK.
60
Chapter 2 Materials and methods
Parental MCF-7 cells were a gift from AstraZeneca, Macclesfield, UK. 
Porcine skin was obtained from a local abattoir.
2.2 Methods
2.2.1 In-Vitro permeation studies
22.1.1 Preparation of ex-vivo porcine skin membrane
Porcine ears were excised from freshly slaughtered animals and, as soon as 
practicable, immersed in iced HEPES modified Hanks balanced buffered salt 
solution (HHBBSS) during transportation to the laboratory to maintain 
viability (Morris, A.P. 2003, Thomas, C.P. et al 2007). On arrival to the 
laboratory (usually < 1 h post excision) the ears were washed under running 
water to remove dirt The epidermal membranes were then liberated from 
subcutaneous material and cartilage by blunt dissection whilst being 
continually bathed in HHBBSS. Skin was patted dry and hairs were removed 
using electric clippers. The skin was cut into 2 cm2 samples and used 
immediately.
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2.2.1.2 Preparation of receptor phase for in vitro permeation studies
To provide an adequate sink for the lipophilic permeants in this work a 
receptor phase of 30mgml'1 cetrimide solution was used. This was made up in 
de-ionised water was used for all in vitro permeation studies throughout the 
work in this thesis.
2.2.13 In-vitro transcutaneous delivery
The volume of the receptor phase and the diffusional area were pre-determined 
in order to calculate accurate permeation measurements. The chosen receptor 
phase was degassed prior to use to minimize air bubbles, which would have a 
detrimental effect on the flux of the permeants due to changes between liquid 
air phases. This was subsequently injected into the receptor compartment via 
the sampling arm. The complete Franz cell was placed onto a Variomag 
submersible stirrer plate (Thermo Fisher Scientific, MA, USA) and set in a 
Clifton unstirred water bath (Nickel Electronics LTD, Weston-super-Mare, 
UK). This was set to 37 °C to give a skin surface temperature of 32 °C 
(Bronaugh, R.L et al 1982) and the Franz cells were left for 30 minutes prior to 
dosing to equilibrate at the aforementioned set temperature. A constant 
concentration gradient was maintained and stagnant diffusion layers were 
overcome with the addition of a micro stirrer bar.
The Franz cells were dosed after equilibration with the test or control permeant 
and this time was so called time 0. The donor phase was occluded with 
Whatman Parafilm to mimic a transdermal patch system. At times 3, 6, 12, 24
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and 48 h whole receptor compartment samples were taken and analyzed for 
permeants via reverse phase HPLC. The receptor compartment was then re­
filled with fresh pre-warmed cetrimide solution (30 mg mL*1) until the next 
sample time.
2.2.1.4 HPLC - Mobile Phase Development
Standards of known concentrations of tamoxifen, PD98059, LY294002, 
quercetin and SL327 were dissolved in DMSO and analysed using reverse 
phase HPLC. All analysis was carried out using an Agilent 1100 series 
automated system with Chemstation software. Samples were separated using a 
Luna C l8 ODS 150 x 4.6 mm, 5 pm column (Phenomenex, Hurdsfield, UK).
A gradient mobile phase of 80:20 methanol:water to 70:30 methanol:water 
over a time of 20 minutes and detection at 254nm proved successful for the 
analysis of these two structurally similar compound as it gave good separation 
of PD98059 and LY294002. Under these conditions the retention times of 
PD98059 and LY294002 were 14.5 and 16.5 minutes respectively. The mobile 
phase described for the analysis of PD98059 and LY294002 was used for the 
analysis of quercetin, which, under these conditions had a retention time of 6.7 
minutes. This method did not give adequate separation of SL327. The 
analysis of SL327 used a mobile phase of 90:10 methanol:water with 0.1% 
acetic acid, where SL327 had a retention time of 7 minutes. A mobile phase of 
80:20 methanol:water with 0.02% v/v TFA was used for the analysis of 
tamoxifen and 4-hydroxytamoxifen. Run time was 10 min and detection was
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at 240 nm. Under these conditions tamoxifen and 4-hydroxytamoxifen had 
retention times of 6.9 and 4.7 min respectively. Standard solutions (prepared 
in receptor phase) provided linear responses with r2 = 1.000.
2.2.2 Cell culture
2.2.2.1 Routine cell culture/maintenance
All cell culture procedures were performed in a MDH class II laminar-flow 
safety cabinet (BIOQUELL UK LTD, Andover, UK). MCF-7 cells are 
adherent epithelial breast cancer cell line, which have been derived from a 
pleural effusion adenocarcinoma (Knowlden, J.M. et al 2004). Cells were 
routinely cultured in RPMI-1640, which was supplemented with 5% FCS (v/v), 
lOU/ml and 10 pg mL'1 penicillin/streptomycin and 2.5 pg mL'1 fungizone. 
Cells were grown as a monolayer in T-75 cm2 sterile plastic flasks and medium 
was changed every 3-4 days. Cells were maintained in a Sanyo MCO-17AIC 
incubator (Sanyo, E&E Europe BV, Loughborough, UK) at 37 °C in a 
humidified atmosphere of 5% CO2 in air. At 80-90% confluency, culture 
media was removed by aspiration and 10ml trypsin/EDTA was added to detach 
and disperse cells. The flask was returned to 37 °C for 3-5 minutes. The 
detached cells were then transferred to a 25 mL Universal tube and any 
remaining cells within the flask were recovered with a lOmL wash with routine 
culture media. This was, again, transferred to the Universal tube and was 
centrifuged at lOOOrpm for 5 minutes using a Jouan C312 centrifuge (Thermo 
Fisher Scientific, MA, USA). The supernatant was discarded and residual
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pellet was re-suspended in fresh routine culture media and added to a sterile T- 
75 cm2 flask at a ratio of 1:10 with culture media.
TamR cells were developed in-house at the Tenovus Research Center. MCF-7 
cells were routinely cultured in phenol-free RPMI-1640 (wRPMI), to remove 
the estrogen-like effect of phenol. The wRPMI-1640 was again supplemented 
with 10 U mL*1 and 10 pg mL'1 penicillin/streptomycin and 2.5 pg mL*1 
fungizone. Serum was also included at 5%; however, this was charcoal 
stripped, SFCS (see appendix 3 for stripping protocol) prior to use to remove 
any steroid hormones from the serum. The cells were also cultured in the 
presence of 1 x 10‘7 M 4-hydroxytamoxifen, the more potent metabolite of the 
parent compound tamoxifen. The normal metabolism takes place within the 
liver by the cytochrome P450 enzymes (Dehal, S.S. & Kupfer, D. 1997) 
whereby this active metabolite is derived. This process would not occur in the 
in vitro cell culture model, for this reason it was deemed necessary to challenge 
the cells with the metabolite rather than the parent compound. All cell culture 
experiments throughout this thesis use the potent metabolite (4- 
hydroxytamoxifen) rather than the parent compound (tamoxifen). After 6 
months of culture in the presence of 4-hydroxytamoxifen the MCF-7 cells took 
on a new phenotype and became resistant to and began to grow in the presence 
of 4-hydroxytamoxifen. It has been demonstrated that this resistant growth is 
driven by extreme growth factor signaling, particularly through the EGFR. 
The cells also take on a new morphology, displaying a spikier structure than 
their parental MCF-7’s and become more aggressive in growth rates and
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metastatic potential (Hiscox, S. et al 2004). Routine media change and 
passaging, were as stated for MCF-7 cells.
2.2.2.2 Dose response curves
MCF-7 were grown to ~70% confluency in a T-75 cm2 sterile plastic flask and 
then trypsinised as described previously and set up in wRPMI plus 5% SFCS, 
lOU/ml and 10 pg mL'1 penicillin/streptomycin and 2.5 pg mL'1 fungizone at 
1.5 million cells per plate in a 24 well plate. The cells were left overnight to 
attach to the wells. After this 24 h equilibration, 3 wells were counted to act as 
base counts and this time point was day 1. In order to count, cells were 
trypsinised to detach them from the well bottom. The lmL of cells in trypsin 
were then separated into a single cell suspension using a 5mL syringe and a 
25mm 23 gauge sterile needle. Stabilization of the tryspinisation was ensured 
with three successive 1ml additions of isoton X-100 solution (see appendix 3) 
into the well, which was subsequently drawn into the syringe. The 4ml of cells 
were then syringed into a further 6mL of isoton X-100 contained in a coulter 
counter counting cup. The lid of which was firmly closed and the contents of 
the cup were agitated gently to disperse the cells throughout the solution. The 
cells were counted using the Coulter Multisizer II counter, Beckman Coulter 
UK Ltd, High Wycombe, UK. Counts were made for lOOpL of the cell 
suspension and were subsequently modified for 1ml. After base counts were 
completed cells were then treated with each compound or control (vehicle in 
which compounds were diluted alone). Treatments were repeated in triplicate.
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Cells were re-treated on day 4 and counted on day 7 using the same method as 
for base counts.
This was repeated using TamR cells, however, these cells were also in the 
continuous presence of lxlO’7 M 4-hydroxytamoxifen. TamR cells were 
counted following the same time schedule and also re-treated on day 4.
2 2 2 3  Growth Inhibition studies
MCF-7 cells, in log phase growth, were passaged and seeded into 24 well 
plates, at a density of 1.5 million per plate, on day 0. The cells were left to 
settle and attach to the wells overnight. On day 1 base counts were taken. 
Cells were counted as described in section 22.22. Cells were then treated (9x 
wells per treatment) with IC50 concentrations of test compounds or with control 
(0.025 % v/v vehicle in media) also on day 1. Cells were subsequently counted 
on days 3, 5 and 8 and re-treated on day 4. Media was removed on re­
treatment, which mimicked dermal clearance.
This was repeated using TamR cells; however, these cells were also in the 
presence of 1x10" M 4-hydroxytamoxifen. TamR cells were counted 
following the same time schedule and also re-treated on day 4.
1
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2.2.2.4 Cell migration assays
For migration assays, a modified 24-well plate was used to assess the 
migratory potential of cells. The wells of aforementioned plates were similar 
to those of the normal plates; however, these wells had removable Coming 
Standard Transwell® inserts with an 8pm pore size. On the start of each 
migration assay, the bottom-facing surface of the insert was coated with 
fibronectin (from human plasma: lmg mL'1 in 0.05 M TBS pH 7.5) in PBS 
(1:1000). This was incubated at 37 °C for 2 h. After 2 hours incubation the 
inserts were allowed to air dry. This was added to mimic the normal 
composition of the extracellular matrix (Hiscox, S. et al 2005).
MCF-7, TamR and FasR cells (80-90% confluency) were passaged using the 
protocol outlined previously. Fresh culture media (600 pL) was applied to the 
underside of the coated inserts. Passaged cells were seeded into the insert onto 
the upper surface of the membrane at a density of 80,000 cells per well. These 
were then incubated at 37 °C in a humidified atmosphere of 5 % CO2 in air for 
2 days. After 2 day, media was removed from the insert and cells migrated 
through the membrane to the bottom surface were fixed in 3.7 % formaldehyde 
(in PBS) for 15 min. Cells were then washed in PBS for 5 min. The inserts 
were then placed into a 0.5% w/v solution of crystal violet for 15-30 min to 
stain migrated cells. Inserts were then washed in PBS to remove excess stain, 
non migrated cells were removed fro the upper surface of the membrane using 
a fresh cotton bud and the inserts were then left in a dust free environment to 
dry. Migrating cells were then counted in 7 random fields of view using and
68
Chapter 2 Materials and methods
Olympus BH-2 phase microscope integrated with an Olympus DP-12 digital 
camera system (Olympus, Oxford, UK).
This procedure was then repeated using TamR cells in the presence of 1 pL 
mL1 fish oil, 25 nM PD98059, and 5 jiM LY294002.
2.23 Immunocytochemistry (ICC)
233.1  Paraffin embedded porcine skin sections
2.23.1.1 Preparation of HEPES modified Hanks balanced buffered salt 
solution (HHBBSS)
In order to maintain tissue viability, a suitable physiological media had to be 
found to bathe the tissue in. It has been shown previously that HHBBSS 
maintained tissue viability for up to 24 h (Thomas, C.P. et al 2007). Hanks 
balanced buffered salt solution was made up in 1L of de-ionised water. It was 
then filtered using a vacuum filter and 45pm Whatman filter papers. 
Furthermore it was modified with the addition of 25 pM HEPES and adjusted 
to pH 7 with 1M HCL or NaOH. Sodium bicarbonate (0.35 gL'1) and 
gentamicin sulphate (50 pg mL'1) were also included. The HHBBSS was 
made up fresh for each experiment and was stored at 2-8 °C until required.
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2.23.1.2 Preparation of porcine skin membrane
Full thickness excised porcine ear skin was used throughout this thesis for 
immunocytochemical analysis, as this provides the most comparable model of 
enzymatic activity of human skin (Middelkoop, E. et al 2004). Tissue viability 
is of utmost importance when studying immunocytochemistry within the 
tissue, and so tissue preparation was as in 2.2.1.2.
2.23.13 Diffusion cell set-up and dosing of skin
Franz diffusion cells were set up as stated in section 2.2.1.3. An equimolar 
(2.54 x IV4 M) solution of test compounds in vehicle or vehicle alone was 
dosed onto the surface of the stratum comeum. At 3, 6, 10 and 24 h 
formulations were removed using a glass pipette and the skin was cleaned to 
remove residual formulation with a clean cotton bud. Skin was then removed 
from the diffusion cell apparatus and the area in which the formulation was 
applied was cut into 2 x 1  mm pieces and placed into labeled white fixation 
cassettes.
233.1.4 Fixing and embedding the skin
The white cassettes containing dosed skin were placed in 4% formaldehyde 
and left to fix for 24 h. Table 2.1 shows the timetable for dehydration of the 
skin. The skin was put through a series of 70 % to 90 % to 100 % ethanol 
baths to displace all the water in the skin. The skin was then put through a 
series of 4 xylene baths to displace all alcohol.
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Solvent Length of Time Skin left in
Formaldehyde 24 h
1“ 70% ethanol Overnight
2“  70% ethanol 30 min
90% ethanol 2 x 30 min
100% ethanol 2 x 30 min
1“ xylene 60 min
Xylene 3x 30 min
Table 2.1 Timetable for the dehydration and alcohol displacing processes.
Post-dehydration and the ethanol displacement the pre-treated skin was 
subjected to a series of 3 molten wax baths. The first wax step involved the 
skin sitting in molten wax for 15 min; a vacuum was then applied for 10 min to 
remove the xylene from the skin. The skin then was left for a further 5 min 
without the vacuum on. The skin was then transferred to the second wax bath, 
where the skin was left in the wax for 10 min, the vacuum was turned on for 
fifteen minutes and then turned off for a further 5 min. The skin was then 
transferred into the third bath, where it was left in the wax for 10 min, the 
vacuum was then turned on for 15 min, finally the vacuum was turned off and 
the skin was left in the molten wax for 25 min. The lid of the white cassette 
case was then removed and the skin was embedded in a paraffin wax block.
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2.23.13 Sectioning
The embedded skin was cut using a Shandon Finesse microtome and sections 
were transferred onto 1” x 3” x 1mm Surgipath pre-cleaned microslides. 
Sectioned skin was dried overnight at 40 °C.
2.23.1.6 Hematoxylin and Eosin staining of excised porcine ear skin
Pre-dried sections were de-waxed and re-hydrated through a series of xylene, 
ethanol and water baths, as shown in table 2.2.
Solvent Length of Time Skin left in
Xylene 2 x 7  min
100 % ethanol 2 x 3  min
90% ethanol 2 x3  min
70% ethanol 2 x 3  min
Water 1x5 min
PBS 1x5 min
Table 2.2 Timetable for the re-hydration process.
The sections were then incubated with a 10 % (w/v) haematoxylin solution, 
made up in de-ionised water for 10 min. Sections were the placed under 
running tap water for 5 minutes and subsequently incubated with a 1% (w/v) 
eosin solution, made up in de-ionised water for 10 min. The sections were
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rinsed in de-ionised water to remove excess dye, air dried and sealed with a 
coverslip.
2.23.1.7 Detection of pMAPK, pAkt, pER, total ER, pEGFR, total EGFR, 
total COX-2 and ki-67 in excised porcine ear skin
Pre-dried sectioned skin was de-waxed and hydrated as shown in table 2.2. 
Endogenous peroxidases were subsequently blocked using a 3% hydrogen 
peroxide solution for 5 min. Excess solution was removed by 2 x 3 min 
washes in PBS. A heat source was then applied to unmask the antigens present 
within the skin. This process was specific to the detection of each protein, as 
shown in table 2.3.
73
Chapter 2 Materials and methods
Protein
Detecting
Unmasking Process Non-specific Protein 
Block
1* Antibody
p-ERKl/2 Microwaved in 1L 
0.01M citrate buffer 
pH 6* for 30 minutes 
at 560 Watts. Cooled 
for ten minutes under 
running tap water
20% Normal Human 
Serum in PBS solution 
for fifteen minutes
CST rabbit polyclonal 
phospho-ERK 1 !2 
kinase antibody at 1/20 
in 20% Normal Human 
Serum in PBS 
overnight
p-Akt Microwaved in 1L 
0.01M sodium citrate 
buffer pH 6* for 1 
minute at power level 
10 and 9 minutes at 
power level 6. Cooled 
for ten minutes under 
running tap water
5% Normal Goat 
Serum in PBS for 5 
minutes
CST rabbit anti-Akt 
(activated) polyclonal 
abtibody at 1/30 in PBS 
overnight
Total-ER Pressure cooked in 2L 
o f 0.01M sodium 
citrate buffer pH 6* for 
2 minutes at full 
pressure. Cooled for 
10 minutes under 
running tap water
20% Normal Human 
Serum in PBS for 10 
minutes
DAKO total ER clone 
ID5 mouse antibody at 
1/100 in PBS for 60 
minutes
p-EGFR 1068 Microwaved in 1L 
EDTA lOmM pH8 for 
1 minute power 9 and 
9 minutes power level 
1. Slides were left to 
cool for 20 minutes
PBS-Tween for 5 
minutes
Biosource pEGFR 
1068 rabbit primary 
antibody at 1/25 
overnight
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Total-EGFR Enzymatic retrieval: 
slides warmed in 37°C 
in PBS for 10 minutes. 
Transfer into Sigma 
Protease P6911 (0.02% 
in PBS) at 37°C for 20 
minutes. Reaction was 
stopped by running 
under tap water for 10 
minutes. Slides were 
then transferred into 
PBS.
5% BSA in PBS for 
ten minutes
NeoMarkers EGFR 
mouse monoclonal 
antibody at 1/20 in PBS 
overnight
Total COX-2 Microwaved in sodium 
citrate buffer pH 6* for 
30 minutes at 590W. 
Slides cooled in 
running tap water for 
10 minutes
PBS-Tween for 10 
minutes
NEB total COX-2 
rabbit primary antibody 
at 1/25 in PBS 
overnight
Ki-67 (MIB) Microwaved in 1L 
0.01M citrate buffer 
pH 6* for 30 minutes 
at 560 Watts. Cooled 
for ten minutes under 
running tap water
10% Normal Rabbit 
Serum in 0.1% 
BSA/PBS for 20 
minutes
DAKO Ki-67 (MIB) 
mouse Primary 
antibody at 1/50 in 
0.1% BSA/PBS for 2 
hours
Table 23  Table to show the unmasking process and 1° antibody type and concentration used in 
the detection o f each protein in excised porcine skin. *For buffer recipes see appendix 1.
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The sections were then washed in PBS twice for 3 min. Slides were then 
wiped dry, retaining moisture on the skin sections, and sections were encircled 
with delimiting pen to retain solution around the section. Once the waxy seal 
had been applied non-specific proteins were blocked as stated in table 2.3. 
Excess block was removed before application of the primary antibody, which 
was applied as stated in table2.3. The length of application of primary 
antibody was dependant on the protein being detected, however, incubation 
with 1° antibody was always at 25 °C.
The sections were then washed once in PBS for three minutes and twice in 
PBS-Tween for 5 min. Horseradish peroxidase (HRP) labeled secondary 
antibody was then applied for 2 h and was incubated at 25 °C, after which, 
DAB chromagen was applied for 10 min and subsequently washed off in de­
ionised water. The sections were then counter-stained with a 0.5% w/v methyl 
green solution in de-ionised water for 5 min and washed with de-ionised water. 
The sections were then dried at 37 °C for 24 h and coverslips mounted using 
di-butylpthalatexylene (DPX), a xylene based mountant.
After sufficient time for the DPX to dry, sections were inspected on an 
Olympus BH-2 phase microscope and photographed using an integrated 
Olympus DP-12 digital camera system (Olympus, Oxford, UK).
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2.23.2 ICC of breast cancer cells
2.23.2.1 Cell culture
Prior to culture, sterile TESPA coated glass coverslips were placed into 60 mm 
sterile plastic dishes. MCF-7 and Tam-R cells, at log phase growth, were 
passaged and seeded onto the coverslips at a density of 5 x 105 cells per dish. 
Cells were grown as a monolayer and upon reaching 60-70 % confluency cells 
were treated with control or test compounds for 3 h. The cells were then fixed 
according to the protein to be detected (as developed in house by the Tenovus 
Research Group). Table 2.4 shows the particular fixation protocol for each 
protein.
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Protein Detecting Fixation M ethod Is Antibody 2* Antibody
p-ERKl/2 Formal Saline CST phospho- 
ERK1/2 polyclonal 
at 1/20 in PBS for 60 
minutes
DAKO rabbit 
EnVision HRP 
labeled polymer 
antibody for 60 
minutes
p-Akt ER-ICA CST phospbo-Akt 
polyclonal at 1 /100 
in PBS for 2 hours
DAKO rabbit 
EnVision HRP 
labeled polymer 
antibody for 2.5 
hours
p-ER 118 2% paraformaldehyde NEB phospho-ER 
118 monoclonal 
antibody at 1/500 in 
PBS overnight
DAKO mouse 
EnVision HRP 
labeled polymer 
antibody for 60 
minutes
p-ER 167 ER-ICA CST phospho-ER 
167 antibody at 1/25 
in PBS overnight
DAKO rabbit 
EnVision HRP 
labeled polymer 
antibody for 2 hours
Total-ER ER-ICA DAKO total ER 
clone ID5 mouse 
antibody at 1/100 in 
PBS for 90 minutes
DAKO mouse 
EnVision HRP 
labeled polymer 
antibody for 75 
minutes
p-EGFR 1068 2.5% Phenol-Formal 
Saline
Biosource pEGFR 
1068 rabbit primary 
antibody at 1/75 
overnight at 37°C
DAKO Rabbit 
EnVision HRP 
labeled polymer 
antibody for 1 hour
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Total-EGFR 2.5% Phenol-Formal 
Saline
NeoMarkers EGFR 
mouse monoclonal 
antibody at 1/20 in 
PBS overnight
DAKO mouse 
EnVision HRP 
labeled polymer 
antibody for 2.5 
hours
Total COX-2 Formal Saline NEB total COX2 
rabbit primary 
antibody 
1/40 1.5 hours
DAKO Rabbit 
EnVision peroxidase 
labeled polymer 
antibody for 1.5 
hours
Total-Src Formal Saline CST total Src mouse 
polyclonal primary 
antibody at 1/1000 in 
1% w/v dried milk in 
TBS-Tween with 
0.05% sodium azide
EnVision mouse 
HRP labelled 
polymer at 1/100000 
in 1% w/v dried milk 
in TBS-Tween
Phospho-Src Formal Saline CST p-Src Tyr 414 
rabbit polyclonal 
primary antibody at 
1/1000 in 1% w/v 
dried milk in TBS- 
Tween with 0.05% 
sodium azide
EnVision rabbit HRP 
labelled polymer at 
1/100000 in 1% w/v 
dried milk in TBS- 
Tween
Table 2.4 Table to show die fixation method, 1° antibody concentration and incubation times, 
2° antibody incubation times.
Once fixed, the cells were stored in sucrose storage media (SSM, see appendix 
for recipe) and were kept at -20 °C until required.
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2J23.2J2 Detection of pMAPK, pAkt, pER, total ER, phospho-EGFR, total 
EGFR, total COX-2 and pSrc in fixed MCF-7 and Tam-R cells grown on 
coverslips
The coverslips bearing the fixed cells were removed from storage at -20 °C and 
washed in PBS until residual SSM was washed away. The coverslips were 
subsequently washed twice in PBS-TWEEN for 5 min. After adequate 
washing, primary antibody was applied as stated in table 2.4. Coverslips were 
incubated for the stated time in a humidity chamber at 25 °C. After sufficient 
incubation with the primary antibody, this was washed off with one 3-minute 
wash in PBS and two 5 min washes in PBS-TWEEN. These washes were 
followed by application of HRP labeled secondary antibody. The coverslips 
were incubated in the presence of the secondary antibody for the stated times at 
25 °C in a humidity chamber.
Subsequent to ample incubation with secondary antibody, the coverslips were 
washed once in PBS for 3 min and twice in PBS-TWEEN for 5 min. After 
these washes the coverslips were incubated with DAB chromagen for ten 
minutes, washed with de-ionised water and then counterstained with a 10% 
methyl green solution. Excess methyl green solution was removed with de­
ionised water washes and then coverslips were dried at 40 °C for 24 h. The 
coverslips were then mounted onto Surgipath pre-cleaned microscope slides 
with DPX mountant. Once DPX had dried, the coverslips were observed and 
photographed as in 2.2.3.1.7.
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2.2.4 Western blot protein analysis 
2.2.4.1 Cell culture and preparation of whole cell lysates
MCF-7 and Tam-R cells in log phase growth were passaged and seeded into 
90mm dishes at a density of 1.5 x 106 cells per dish. Cells were grown in a 
monolayer to between 60 and 70% confluency with media replenishment every
3 day, at which point they were treated with control or test compounds for 3 h. 
The cells were then washed 3 times with pre-warmed PBS. Cells were then 
subjected to 200 pL ice-cold lysis buffer (see appendix for recipe) and kept on 
ice for 5 min then scraped from the bottom of the dish using a cell scraper and 
transferred into 1.5 mL Eppendorf tubes and kept on ice for 15 min. After this 
incubation, cell dispersions were subjected to centrifugation at 13000 rpm and
4 °C. Supernatants were then transferred, in aliquots of 50 pL, to fresh 
Eppendorf tubes and stored at -20 °C until required.
2.2.4.2 Protein quantification and standard curve
A Bio-rad protein assay was used to construct a standard curve of known 
concentrations of bovine serum albumin (BSA) made up in de-ionised water, 
from a starting concentration of lmgmL'1. All concentrations were made in 
duplicate to minimise error.
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Protein concentration 
(mgmL1)
Volume of water (pL) Volume of BSA (pL)
0 1000 0
5 995 5
10 990 10
15 985 15
20 980 20
25 975 25
Table 2.5 Table to show the preparation o f protein standard concentrations for the BioRad 
protein assay.
Protein concentrations were made as outlined in table 2.5. These were made 
up in 1.5 mL Eppendorf tubes and vortex-mixed 5 s to ensure even dispersion 
of protein. An 800 pL aliquot was removed from the eppendorf and transferred 
to a 2 mL plastic spectrophotometer cuvette. To this, 200 pL of Bio-Rad 
reagent was added and the solution was agitated gently. The solution was 
allowed to develop for 15 min and was subsequently analysed for optical 
density using a Cecil CE2041 2000 series spectrophotometer, set at 595 nm.
Once a standard curve of known protein concentrations had been constructed, 
this was used to determine the amount of protein in whole lysate samples. 
Protein samples were allowed to thaw gently, then vortexed for 5 s to ensure 
even dispersion of the protein. To a 5 pL aliquot of protein sample 995 pL of
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de-ionised was added and this solution was again vortex-mixed to ensure 
thorough distribution of the protein into the water. An 800 pL aliquot of this 
solution was then transferred into 2 ml plastic spectrophotometer cuvette. To 
this, 200 pL of Bio-Rad reagent was added and the solution was agitated 
gently. The solution was allowed to develop for 15 min and the amount of 
protein was determined using a Cecil CE2041 2000 series spectrophotometer 
(Cecil Instruments, Cambridge, UK), set at 595 nm. The amount of protein in 
each sample was then calculated to ensure that 50 pg mL'1 of protein was 
loaded in each lane of the SDS-PAGE.
2.2.43 Sodium dodecyl sulphate poly acrylamide gel electrophoresis (SDS 
PAGE)
Gel electrophoresis was completed using a Mini-Protein Slab II 
Electrophoresis Cell (Bio-Rad Laboratories LTD). Separating and loading gels 
were prepared as explained in the appendix and set between freshly cleaned 
glass plates. Once set the electrophoresis apparatus was assembled as 
described in the manufacturers guidelines and the running buffer (see appendix 
1 for recipe) was poured into the electrophoresis cell.
Protein samples were allowed to thaw gently at 4 °C. To each sample lOpl of 
loading buffer (see appendix 1) was added and samples were subsequently 
spun down for 10 s in an IEC Micromax RF microcentrifuge (Thermo Electron 
Corporation, Hampshire, UK) at 1000 rpm. Samples were then heated in a 
Thermo Scientific (Fisher Scientific UK, Loughborough, England), heating
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b lock set at 100 °C fo r 10 m in  to  denature the proteins. N ext, a ra inbow  
prote in m arker and the p ro te in  samples were loaded in to  the w e lls  o f the 
loading gel and the electrophoresis ce ll was subjected to 200V  fo r around 45 
m in  or u n til the pro te in  samples had reached the bottom  o f the gel.
2.2.4.4 Transfer of proteins
F o llow ing  separation o f the p ro te in  samples the gels were rem oved from  the 
glass plates in  w h ich  they were set and assembled in  p lastic transfer cassettes 
as shown in  figu re  2.1, to  make a transfer ‘ sandw ich’ .
Nitrocellulose membrane 
Gel
Sponge
Paper
Paper
Sponge
Figure 2.1 Diagram to show the assembly o f the blotting sandwich
The sandw ich was assembled such that the gel was nearer to  the b lack side o f 
the cassette (cathode) to  ensure that the proteins trave lled  from  the gel to  the 
n itroce llu lose  membrane, w h ich  was at the anode side o f  the cassette. I t  was 
then placed in  the electrophoresis ce ll. A n  ice pack was included to  ensure the 
electrophoresis ce ll d id  not overheat. The ce ll was fille d  w ith  transfer b u ffe r 
(see appendix 1) and a m agnetic s tirre r was added to guarantee adequate 
c ircu la tion  o f transfer b u ffe r and to  m aintain a constant tem perature. The
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electrophoresis cell was then subjected to 100 V for 1 h to transfer the protein 
from the gel to the nitrocellulose membrane.
The membrane was then incubated with Ponceau S solution to ensure transfer 
success, which was subsequently washed off with TBS-Tween washes (see 
appendix 1 for recipes).
2.2.4.S Application of primary and secondary antibodies
Subject to transfer success, the membrane was then blocked with a 5 % w/v 
dried milk solution made up in TBS-Tween for 1 h. Whilst blocking, the 
membrane and block were rocked gently on a Stuart rocker (Bibby Scientific 
Ltd, Staffordshire, UK). After blocking, the membrane was incubated with 
primary antibody (see table 2.6) overnight at 4 °C on a Stuart roller (Bibby 
Scientific Ltd, Staffordshire, UK).
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Protein detected 1* antibody concentration 2° antibody concentration
p-MAPK CST p-MAPk polyclonal at 
1/1000 in 1% w/v dried milk in 
TBS-Tween with 0.05% SA 
overnight at 4°C
EnVision rabbit HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
p-Akt CST p-Akt polyclonal at 
1/1000 in 1% w/v dried milk in 
TBS-Tween with 0.05% SA 
overnight at 4°C
EnVision rabbit HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
p-ER 118 NEB p-ER 118 monoclonal 
antibody at 1/1000 in 0.05% 
POD v/v in TBS-Tween 
overnight at 4°C
EnVision rabbit HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
p-ER 167 CST p-ER 167 antibody at 
1/1000 in 1% dried milk w/v in 
TBS-Tween overnight at 4°C
EnVision rabbit HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
Total-ER DAKO total ER clone ID5 
mouse antibody at 1/1000 in 
0.05% v/v POD in TBS-Tween 
overnight at 4°C
EnVision mouse HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
p-EGFR Biosource pEGFR 1068 rabbit 
primary antibody at 1/1000 in 
1% w/v dried milk in TBS- 
Tween with 0.05% SA 
overnight at 4°C
EnVision rabbit HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
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Total-EGFR NeoMarkers EGFR mouse 
monoclonal antibody at 1/1000 
in 1% w/v dried milk in TBS- 
Tween with 0.05% SA 
overnight at 4°C
EnVision mouse HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
Total COX-2 NEB total COX2 rabbit 
polyclonal primary antibody 
1/1000 in 1% w/v dried milk in 
TBS-Tween with 0.05% 
sodium azide overnight at 4°C
EnVision rabbit HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
Total Src CST total Src mouse 
polyclonal primary antibody at 
1/1000 in 1% w/v dried milk in 
TBS-Tween with 0.05% SA 
overnight at 4°C.
EnVision mouse HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
p-Src CST p-Src Tyr 414 rabbit 
polyclonal primary antibody at 
1/1000 in 1% w/v dried milk in 
TBS-Tween with 0.05% SA 
overnight at 4°C.
EnVision rabbit HRP labelled 
polymer at 1/100000 in 1% 
w/v dried milk in TBS-Tween
Table 2.6 Table to show the concentrations o f l°and 2° antibody for each protein detected.
After sufficient incubation with the primary antibody, the membrane was 
rocked gently for 3 x 5 min washes in TBS-Tween. The membrane was 
incubated in the presence of the secondary antibody (as shown in table 2.6) for 
75 min.
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2.2.4.6 Visualisation of proteins by chemiluminescence
The membranes were washed three times in TBS-Tween for 10 min. The 
membranes were then placed into a clean plastic folder and were treated with 
luminol/peroxide based enhanced chemiluminescence (ECL) reagent (Pico, 
Dura or Femto). The luminol present within this reagent is oxidised by 
horseradish peroxidase to produce an excited state product, which emits 
photons of light as it decays to a lower energy state. Kodak autoradiography 
film was then placed over the membranes and the film was developed using a 
X-O-graph Compact X2 X-ray developer (X-O-graph Imaging System, 
Tetbury, UK) in a dark room.
2.2.5 Statistical Analysis
All statistics throughout this thesis were carried out on Minitab for Windows. 
Confidence intervals were set at 95% and significance was defined as p=<0.05.
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3.1 Introduction
Over recent years attention paid to topical drug delivery has increased greatly. 
The primary benefit of topical delivery is local targeting, which could much 
reduce quantities of drug administered and thus circulating in the blood stream 
(and non-target tissues). Other benefits include the elimination of 1st pass 
hepatic metabolism, controllable 0-order rates of delivery, and rapid 
termination of dose in event of adverse reaction (Williams, A.C. 2003). 
Furthermore, skin patches are generally well accepted and tolerated, thus 
aiding patient compliance.
The FDA approved the first topical preparations in 1981 for the treatment of 
angina pectoris and motion sickness; however, it took many years to prove the 
clinical efficacy of these and for researchers to believe that molecules could 
overcome the physicochemical barrier properties of the skin and reach post 
skin targets at therapeutic levels.
Early studies had strict exclusion criteria when selecting candidates to deliver 
across the skin including size and lipophilicity. Compounds above 500 Da and 
without adequate lipophilicity were not considered for topical delivery. 
However, the development of chemical and physical enhancers and the 
manipulation of formulations to increase the thermodynamic activities of 
compounds have increased the number of products available for topical 
delivery.
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Transcutaneous delivery of compounds involves the permeation of compounds 
across full thickness skin and diffusion to underlying tissues. The compounds 
must permeate at a sufficiently high rate to evade clearance by the 
microvasculature in order to reach their final target destination. Numerous 
transcutaneous products are now commercially available, such as topical 
NSAIDs for pain relief.
The breast represents a reasonably accessible target for topical administration, 
where the drugs can be delivered transcutaneously using a semi-solid 
formulation or device, which then undergo passive diffusion to the underlying 
tissues.
Several studies have demonstrated the possibility of percutaneously delivering 
tamoxifen and 4-hydroxytamoxifen to the breast. Mauvais-Jarvis (1986) and 
colleagues showed that radio-labelled tamoxifen and 4-hydroxytamoxifen, 
when formulated in a 60% alcoholic solution, were detected in breast tissue 
after topical application. Furthermore, these two compounds were retained in 
the breast tissue significantly when compared to their application to the 
abdomen. Another study showed that 4-hydroxytamoxifen could permeate the 
skin sufficiently as to affect tumor proliferation when formulated as a simple 
gel (Rouanet, P. et al 2005). A previous study demonstrated in vitro 
transcutaneous delivery of tamoxifen and y linolenic acid from a borage oil 
formulation containing ethanol and 1,8-cineole Ho, S. et al 2004).
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The aims of this chapter were to incorporate 1 MAPK inhibitor and 1 PI3K 
inhibitor into a transcutaneous formulation and assess their singular and 
simultaneous permeation through full thickness porcine skin when combined 
with tamoxifen.
3.2 Materials and Methods
3.2.1 Materials
The materials for this study were outlined in chapter 2 (section 2.2.1).
3.2.2 Tamoxifen metabolism
It is widely documented that it is the metabolite 4-hydroxytamoxifen that is the 
potent SERM, rather than the parent compound tamoxifen. In fact, it has been 
noted that this metabolite is 100 times more efficacious than tamoxifen in 
inhibiting the ER signalling (Borgna, J-L. & Rochefort, H. 1981). The 
metabolite exists in two isoforms, with the trans isomer being far more potent 
than the cis isomer (Robertson, D.W. et al 1982). The purchased 4- 
hydroxytamoxifen exists as transrcis at 70:30 and remains at this ratio as it 
enters and penetrates the skin (Malet, C. et al 2002). For this reason, only the 
trans isomer was analysed and quantified by HPLC. 4-hydroxytamoxifen was 
analysed using the method described in section 3.2.4 for tamoxifen; however, 
the trans isomer had a retention time of 4.7 minutes.
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3.2.2.1 Skin homogenisation
Freshly excised porcine ears were maintained in HHBBSS during 
transportation from a local abattoir. The ears were then washed in tepid tap 
water to remove excess surface dirt and the subcutaneous material was 
removed by blunt dissection. The ears were then cut into small pieces and 
weighed to provide 2grams of skin per sample. These samples were then 
transferred to 5mL PBS and homogenised using a Silverson homogeniser 
(Silverson Machines Ltd, UK) for 3 x 30 seconds.
3.2.2.2 Tamoxifen metabolism study
Tamoxifen was dissolved in 7.5mL PBS to provide a lmgmL'1 solution. PBS 
has been previously shown to maintain viability of skin enzymes for the 
duration of metabolism studies (Rittirod, T. et al 1998). From this solution 
lmL was transferred to 14mL of fresh PBS, which was subsequently 
transferred to the 5mL of PBS containing the homogenised skin, thus giving 
20mL of PBS in total (n=5). A further 2 vials contained only tamoxifen (lmL 
of lmgmL"1 tamoxifen in 19mL PBS), while a further 2 vials included only 
homogenised skin in 20mL PBS. Vials were incubated at 37°C and rotated on 
a Stuart blood rotator (Barloworld Scientific, Staffordshire, UK) throughout the 
experiment. Samples were taken at 1,2,5,10 and 24 hours. Vials were mixed 
thoroughly using a vortex mixer at the stated sample times and 1 mL was 
removed from the vial and analysed using the HPLC method stated in section 
3.2.4. The removed lmL was not replenished with fresh PBS so as to not 
unbalance the concentration of tamoxifen and metabolites.
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3.2.23 Prediction of Log P values
The prediction of LogP was a valuable tool when assessing the potential of 
compounds to permeate full thickness skin. From this prediction, it was 
possible to determine whether the compounds were lipophilic or hydrophilic 
and an estimated Log Kp could be calculated using equation 3.1 and from this 
an estimated flux could be calculated using equation 3.2.
Log Kp = -6.3 + 0.71 log octanol/water -0.0061 mol wt 
Equation 3.1
Log flux = log Kp + solubility 
Equation 3.2
Using a virtual computational chemistry laboratory website it was possible to 
estimate the LogP and solubility of the 5 compounds based on their chemical 
structure. This website was: http://l46.107.217.178/lab/ and the program was 
ALOGPS.
3.2.2.4 Solubility in DMSO and cetrimide solution
It was important to assess the solubility of the 4 signal transduction inhibitors 
(STIs) and 4, hydroxytamoxifen in both the donor solution and the receptor 
solution. The compounds should all be soluble in DMSO to provide a high 
chemical potential between the compounds and vehicle. The receptor solution 
should provide adequate sink conditions for permeants.
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The solubility of PD98059, LY294002, quercetin, SL327 and 4, 
hydroxytamoxifen was assessed in DMSO and cetrimide solution (SOmgmL'1). 
Compounds were added to 200pi of solution and spun on a Stuart blood rotator 
(Barloworld Scientific, Staffordshire, UK) at 32°C until excess compound 
remained. Samples were then centrifuged using a Heraeus (Thermo Scientific, 
Northumberland, UK) instrument at 1000 rpm for 1 minute to separate the 
excess drug. Samples of supernatant were then diluted 20-fold and analysed by 
reverse phase HPLC.
3.2.2.5 Stability in DMSO and cetrimide solution
The stability of the compounds was assessed to ensure that the compounds 
were stable throughout the time course of the experiment. Poor stability could 
give misleading results in the permeation experiments.
Compounds were prepared at lmg mL"1 in DMSO or SOmgmL"1 cetrimide 
solution. These were then analysed immediately and then after 1, 5, 12, 24, 48 
and 168 hours using reverse phase HPLC.
3.2.2.6 Preparation of porcine skin membranes
The method outlined in chapter 2, section 2.2.1.2 was followed for all skin 
preparation throughout this chapter.
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3.2.2.7 The in vitro transcutaneous delivery of PD98059, LY294002, 
quercetin and SL327
The transcutaneous delivery of 4 compounds was assessed to determine the 
two compounds with the greatest permeability to take forward and formulate 
with tamoxifen. Transcutaneous delivery (i.e. across both full thickness 
porcine skin) was modelled using glass Franz-type diffusion cells in which skin 
samples were mounted between the greased flanges. A receptor phase of 
cetrimide 30mg/mL was added, along with a magnetic stirrer bar, to the 
receptor compartment. The cells were placed in a submersible stirrer plate set 
up in a water bath and maintained at 37°C. After a 30-minute equilibration 
period the cells were dosed with 200 pi of PD98059, LY294002, quercetin or 
SL327 made up in DMSO, previously prepared to provide equimolar aliquots 
of 2.54 x 10*4 mol. The donor phase compartments were occluded and at 3, 6, 
12,24 and 48 hours the entire contents of the receptor phases were removed for 
analysis, and replenished with fresh solution.
3.2.2.8 The in vitro transcutaneous delivery of PD98059, LY294002, 
formulated with and without 4-hydroxytamoxifen
The method outlined in section 3.2.7 was repeated, however PD98059 and 
LY294002 were formulated together and their simultaneous delivery was 
determined across excised full thickness porcine skin both with and without 4- 
hydroxytamoxifen present in the formulation. The cells were dosed with 200 
pi of PD98059 plus LY294002, with and without tamoxifen made up in 
DMSO, previously prepared to provide equimolar aliquots of 2.54 x 10*4 mol.
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3.2.2.9 Immunocytochemical analysis to determine potential inflammatory 
activity of DMSO on porcine skin
Immunocytochemistry was performed to detect any potential toxicity of the 
DMSO vehicle on porcine skin. An assay to detect ki-67, a proliferation 
marker, was conducted to represent skin viability. Haematoxylin and eosin 
staining was also carried out to observe the histology of the skin.
Skin was prepared and set up as mentioned in chapter 2, section 2.2.3, but in 
this case the skin having been dosed with treatments as shown in table 3.1. 
Treatments were removed and skin samples were processed at the stated times. 
The skin was processed, embedded and microtomed as in section 2.2.3. Once 
dried, H&E staining and a ki-67 assay were performed on the sections.
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Cell numbers Treated with Sample time (hour)
1-3 Water 0
4-6 DMSO 0
7-9 Water 8
10-12 DMSO 8
13-15 Water 24
16-18 DMSO 24
19-21 Water 48
22-24 DMSO 48
Table 3.1. Franz diffusion cells 1-24 treated with either 200pl water or 200pl DMSO. 
Receptor phase was HHBBSS and skin was maintained at 32°C.
3.23 Statistical analysis
Unpaired t-tests were used to compare the permeation of each compound when 
applied to the skin individually, simultaneously and then together with 
tamoxifen. T-tests were also used to compare the concentration of tamoxifen 
present with and without homogenised skin to assess the levels of tamoxifen 
metabolism. All statistics were performed using Minitab for Windows.
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3.3 Results
3.3.1 Tamoxifen metabolism
Tam oxifen is metabolised in  the live r by cytochrome P450 enzymes to, among 
other metabolites, 4 -hydroxytam oxifen. Potential metabolism w ith in  the skin 
has not been investigated o r reported. Understanding that 4-hydroxytam oxifen 
is s ign ifican tly  more potent at inh ib iting  ER signalling, this small study was 
aimed at determ ining the extent, i f  any, o f  tam oxifen metabolism to its more 
active m etabolite w ith in  the skin. Figure 3.1 shows the concentration o f  
tam oxifen throughout the metabolism study.
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Figure 3.1 Tamoxifen metabolism assay. Concentration o f tamoxifen (m gm L1) with 
increased incubation with 2g homogenised porcine skin in PBS. Starting concentration was 
0.05mgmL'V Samples were maintained at 37°C and agitated on a blood rotator throughout the 
experiment (n=15 ± SD).
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The metabolism study shows no significant decrease in the concentration of 
tamoxifen when the homogenised skin was present compared to when the skin 
was absent (P = 0.184). No HPLC peaks were detected at 4.7 or 6.1, using the 
previously described method, suggesting the absence of trans- or cis-4- 
hydroxytamoxifen in each sample. Analysis of samples containing only 
homogenised skin showed no peaks at 6.9 minutes or at 4.7 or 6.1 minutes. 
This ensured that that peaks quantified as tamoxifen in the test samples were 
true peaks and not homogenised skin material. No metabolism of tamoxifen 
was detected in the presence of the homogenised skin.
33.2 Predicted log P
The predicted log P of PD98059, LY294002, quercetin. SL327 and 4- 
hydroxytamoxifen using the ALOGPs software package were 2.89, 3.46, 0.95,
3.7 and 5.44 respectively. The ALOGSs using the same software were 
predicted as -3.99, -3.38, -2.42, -4.82, and -5.11 respectively. Therefore 
predicted solubilities were 0.102, 0.42, 0.38, 0.015 and 0.007mgmL l. The 
predicted flux values of the compounds were 129, 899,95, 36.7 and 172 pgcm'
V.
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3 3 3  Solubility of PD98059, LY294002, quercetin SL327 and 4, 
hydroxytamoxifen in DMSO and cetrimide solution at 32°C
The solubility of PD98059, LY294002, quercetin, SL327, 4-hydroxytamoxifen 
in DMSO was 6.98 ± 0.34,14.76 ± 1.08,12.54 ± 1.68, 6.57 ± 0.86 and 21.03 ± 
3.22 mgmL'1 respectively. Solubility of PD98059, LY294002, quercetin, 
SL327, 4-hydroxytamoxifen in cetrimide was 4.57 ± 0.76, 9.42 ± 0.9841, 6.43 
± 0.11,2.87 ± 0.34 and 16.23 ±1.13 mgmL'1 respectively.
33.4 Stability of PD98059, LY294002, quercetin SL327 and 4, 
hydroxy tamoxifen in DMSO and cetrimide solution
Table 3.2 and 3.3 show the stability of all 5 compounds in DMSO and 
cetrimide solution respectively by presenting the percentage of degradation of 
each compound over 168 hours.
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Time (hours) PD LY Q SL 40HTam
0 0 0 0 0 0
5 0 0 0 0 0
12 0 0 0 0 0
24 0.21 0.39 0.99 1.01 1.54
±0.011 ±0.04 ±0.13 ±0.22 ±0.067
48 1.96 2.27 3.22 2.74 2.88
±0.24 ±0.23 ±0.015 ±0.24 ±0.19
168 5.27 6.11 7.93 5.48 4.72
±0.47 ±0.82 ±0.43 ±0.47 ±0.66
Table 3.2 Table to show the percentage degradation of PD98059, LY294002, SL327, quercetin 
and 4-hydroxytamoxifen in DMSO over 1 week. Solutions were made at lmgmL'1 and left on 
the bench top. Samples were taken at the stated times (n=3 ± SD).
All 5 compounds show good stability in DMSO up to 48 hours, with 4, 
hydroxytamoxifen showing the worst stability after 48 hours. 
4,hydroxytamoxifen degraded by 2.88 ± 0.19%. After 168 hours, however, 
considerable degradation was seen with all 5 compounds, with quercetin 
showing the most degradation (7.93 ± 0.43%).
Each compound showed reduced stability in cetrimide when compared to 
DMSO. Up to 24 hours all compounds showed negligible degradation when 
dissolved in cetrimide solution, with the highest degradation being seen with
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LY294002, which degraded by 2.76 percent. However, at 48 and 168 hours 
degradation was as high as 10.6 % for PD98059.
Time (hours) PD LY Q SL 40HTam
0 0 0 0 0 0
5 0 0 0 0 0
12 0.1 0.248 0.13 0.054 0
±0.005 ±0.026 ±0.011 ±0.0018
24 2.44 2.76 2.276 1.242 0.98
±0.35 ±0.048 ± 0.022 ± 0.089 ± 0.025
48 4.872 5.12 3.891 3.987 2.795
±0.63 ±0.78 ±0.55 ±0.27 ±0.77
168 10.576 9.598 9.154 6.905 7.58
± 1.28 ±0.92 ± 1.73 ±0.88 ±0.32
Table 3 3  Table to show the percentage o f degradation of PD98059, LY294002, SL327, 
quercetin and 4-hydroxytamoxifen in cetrimide over 1 week. Solutions were made at lmgmL'1 
and left on die bench top. Samples were taken at the stated times (n=3± SD).
It was important for the compounds to be stable in DMSO for 48 hours because 
the compounds are applied to the skin and remain dissolved in this solvent 
throughout the skin permeation experiment, which is over a 48 hour time 
period. Samples taken from the receptor phase were frozen and analysed over
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12 hours, and so it was important that the compounds showed negligible 
degradation over 12 hours.
33.5 Permeation studies for PD98059, LY294002, quercetin and SL327 
The permeation of the 4 compounds when dosed at equimolar concentrations 
(2.54 x lO^mol) individually to excised, full thickness porcine skin in DMSO 
is shown in figure 3.2. This figure shows typical 0-order permeation profiles 
for all 4 compounds. LY294002 permeated significantly more readily than 
quercetin (P = 0.001) and PD98059 permeated more readily than SL327 (P = 
0.012). These conditions allowed 3.81 ± 0.62, 5.38± 0.78, 1.15 ± 0.37 and 2.3 
± 0.48 pgcm'2 of PD98059, LY294002, quercetin and SL327 to permeate after 
48 hours respectively. Steady state flux was seen between 6 and 12 hours for 
PD98059 and SL327 and between 12 and 24 hours for LY294002 and 
quercetin. These were 0.09 ± 0.08, 0.14 ± 0.015, 0.03 ± 0.009 and 0.066 ± 
0.01 pgcm'2h_1 for PD98059, LY294002, quercetin and SL327 respectively. 
Lag times varied between the 4 compounds, with PD98059 having the shortest 
lag time of 2.73 ± 0.66 hours, while quercetin showed the longest lag time of 
6.17 ± 0.499 hours.
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Figure 3.2 Permeation profiles for PD98059, LY294002, quercetin and SL327. Excised 
porcine skin was maintained at 32°C. Receptor phase was 30mgmL'1 cetrimide solution, 
which was agitated with a micro-stirrer. Donor phase was 2.54 x 10-4 mol PD98059, 
LY294002, quercetin or SL327 in DMSO (n=6 ± SD)
The lag times o f  LY294002 and SL327 were 4.84 ±  0.84 and 6.01 ±  0.01 hours 
respectively. The K p  o f  the fou r compounds was 1.06 x 10'3 ±  1.5 x 10-4, 9.28 
x 10"4 ±  9.8 x 10'5, 2.68 x 10-4 ±  7.9 x 10‘5 and 4.65 x 10A ± 7.04 x 10’5 cm 'V  
respectively fo r PD98059, LY294002, quercetin and SL327.
3.3.6 Permeation studies for PD98059 and LY294002 with and without 4- 
hydroxytamoxifen
The permeation o f  in d iv id u a lly  dosed PD98059 and LY294002 was described 
in section 3.3.3. Th is study was aimed at concluding whether simultaneous
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dosing o f  PD98059 and LY294002 changed the permeation o f  the tw o 
compounds compared to separate dosing. It also determined i f  the inclusion o f  
4-hydroxytam oxifen altered the permeation o f  the 2 compounds.
The permeation pro files detailed in figure 3.3 show typical 0-order permeation 
profiles. Surpris ingly the permeation o f  both compounds increased 
s ign ificantly  (P =  0.018 and 0.006) when applied to the skin simultaneously. 
Table 3.5 compares the mass and number o f  moles permeated after 24 and 48 
hours, the steady state flu x , lag tim e and K p o f  the tw o compounds when 
applied to the skin in d iv idua lly  and simultaneously.
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Figure 3.3 Permeation profiles for simultaneously dosed PD98059 and LY294002. Excised 
porcine skin was maintained at 32°C. Receptor phase was 30mgmL'1 cetrimide solution, 
which was agitated with a micro-stirrer. Donor phase was 2.54 x 10-4 mol PD98059 plus 
LY294002 in DMSO (n=6 ± SD).
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Dosed individually Dosed simultaneously Simultaneously with 4-OHT
PD98059 LY294002 PD98059 LY294002 PD98059 LY294002
J . 0.09 ±0.008 0.14 ±0.015 0.24 ±0.045 0.49 ±0.051 0.38 ±0.098 0.61 ±0.081
(Mg cm'2 h'1) (@6-12h) (@12-24h) (@6-12h) (@24-48h) (@6-12h) (@12-24h)
Lag time (h) 2.73 ± 0.66 4.84 ±0.84 4.31 ±0.62 11.1 ±1.22 5.24 ±0.87 7.14 ±1.42
Q24 (Mg cm'2) 1.8 ±0.26 2.74 ±0.46 4.59 ±0.88 6.28 ±1.04 5.64 ±0.98 10.99 ±1.39
Q48 (Mg cm'2) 3.81 ±0.62 5.38± 0.78 9 ±1.77 17.95 ±1.30 10.51 ±1.81 23.31 ±2.83
Q24 (pmol cm'2) 0.007 ±0.001 0.009 ±0.001 0.017 ±0.004 0.02 ± 0.003 0.021 ± 0.004 0.036 ±0.005
Q48 (Mmolcm*2) 0.014 ±0.002 0.018 ±0.003 0.034 ±0.008 0.058 ±0.09 0.04 ±0.007 0.076 ±0.006
Kp (cm h'1) 1.06 x 10'* ± 1.5 9.28 x 10*4 ± 9.8 1.25 x 103± 1.77 2.99 x l0 '3± 2.65 3.28 x lO 3 ±8.92 3.995 x 10* ±
xlO"4 x 10'5 xlO -4 xlO-4 x 10"4 6.21 x 10-4
Table 3.4 Steady state flux (JjJ, cumulative permeation at 24 hours (Q24) and at 48 hours (Q48) and permeability coefficient (Kp) data for the delivery of PD98059 and LY 
294002 across excised full thickness porcine skin when applied separately or simultaneously. Simultaneous delivery includes both data with and without the addition of 4- 
hydroxytamoxifen (n=6, ± SD)
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Table 3.4 clearly reveals that the mass and number o f  moles o f  both 
compounds permeating after 48 hours increased s ign ifican tly  when the 
compounds were dosed together, w ith  enhancement ratios (EnRs) o f  2.36 and 
3.71 fo r PD98059 and LY294002 respectively.
Interestingly the steady state flu x  (P =  0.004, 0.001 PD and L Y ) and lag times 
(P =  0.05, 0004 PD and L Y ) o f  both compounds were also s ign ificantly  
increased when the tw o compounds were dosed simultaneously.
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Figure 3.4 Permeation profiles for PD98059, LY294002 and 4-hydroxytamoxifen (40htam) 
when dosed simultaneously. Excised porcine skin was maintained at 32°C. Receptor phase 
was 30mgmL'1 cetrimide solution, which was agitated with a micro-stirrer. Donor phase was 
2.54 x 10-4 mol PD98059, LY294002 or 4- hydroxytamoxifen in DMSO (n=6 ± SD).
Figure 3.4 shows the permeation o f  PD98059, LY294002 and 4- 
hydroxytam oxifen when form ulated and dosed together in  D M SO . The data
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show typical 0-order permeation profiles for all 3 compounds. The addition of 
4-hydroxytamoxifen did not significantly alter the mass permeated, flux or lag 
time of PD98059 (P = 0.961, 0.116 and 0.301). No significant difference in 
mass permeated and flux of LY294002 was seen with the inclusion of 
tamoxifen compared to the when PD98059 and LY294002 were dosed 
simultaneously without 4-hydroxytamoxifen (P = 0.367 and 0.08 respectively). 
However the lag time of LY294002 was significantly reduced (P -  0.018) 
when 4-hydroxytamoxifen was included in the formulation.
Figure 3.4 demonstrates the permeation of 4-hydroxytamoxifen, showing that
18.5 ± 2.52 pgcm'2 permeated into the receptor compartment after 48 hours. 
Steady state flux was detected between 12 and 24 hours and was determined as 
0.47 ± 0.045pgcm'2h'1. The lag time of 4-hydroxytmoxifen, under these 
conditions, was 5.72 ± 0.86 hours and the kp was 3.87 x 10‘3 ± 3.68 x 10*4 cm"
V 1.
33.7 Immunocytochemical analysis of the effect of DMSO on porcine skin
33.7.1 H & E staining
The anatomy of the skin was examined using a standard haematoxylin and 
eosin assay, where cell nuclei stain blue and the cytoplasm stains pink. The 
effect of DMSO compared to water control on the structure of the skin using 
this assay, as skin toxicity in response to DMSO administration has previously 
been reported when DMSO is over 60%.
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Figure 3.5 shows the result of the H & E assay, showing clearly the dermis, 
epidermis and stratum comeum. Figure 3.5 A-B show H & E staining of skin 
freshly dissected and fixed. The staining shows healthy epidermal 
keratinocytes and shows the stratum comeum still attached to the epidermis.
Figure 3.5 C-D shows H & E staining on excised porcine skin of which the SC 
was incubated with water for 3 hours. Viability was maintained by using a 
receptor phase of HHBBSS.
The H & E assay revealed that incubation with water gave no observable 
changes in the structure of the skin, suggesting that no skin toxicity was 
caused.
Figure 3.5 E-F, however did show considerable structural changes. This skin 
was incubated with DMSO for 3 hours and seemed to cause detachment of the 
stratum comeum and some evidence of keratinocyte damage, which has been 
highlighted with an arrow.
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Figure 3.5 A-F H & E staining o f freshly excised porcine skin, immediately post dissection (A 
xlO, B x20), incubated with 200pl water for 3 hours (C x20, D x40) and with 200pl DMSO for 
3 hours (E x 20, F x 40). Skin was fixed in formaldehyde, dehydrated and embedded in wax. 
Sections (5pm) were then cut using a Shandon microtome and placed onto Surgipath pre­
cleaned microscope slides and dried at 37°C. A standard H & E assay was performed and 
slides were dried at 37°C and images were viewed and recorded using an Olympus BH-2 phase 
microscope and photographed using an integrated Olympus DP-12 digital camera system 
(Olympus, Oxford, UK).
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33.7.2 Ki 67 assay
The ki-67 assay was performed to examine the effect of DMSO on skin 
viability. Figure 3.6 shows the ki-67 assay performed on excised porcine skin 
when treated with either water or DMSO. Figure 3.6 A-B shows skin assayed 
immediately post dissection. It shows significant ki-67 staining within the 
lower stratums of the epidermis, which is localised to the nuclei of these cells. 
Figure 3.6 C-D shows the results of the ki-67 assay completed on skin 
incubated with water for 3 hours. Again, ki-67 was found predominantly 
within the lower layers of the epidermis and was confined to the nuclei of these 
cells. Comparing ki-67 staining in both time 0 and after 3 hours incubation 
with water, showed no visible differences in extent of ki-67 presence.
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Figure 3.6 A-F Ki-67 assay on freshly excised porcine skin, immediately post dissection (A 
x20, B x40), incubated with 200pl water for 3 hours (C x40, D x20) and with 200pl DMSO for 
3 hours (E x 20, F x 20). Sections (5 pm) were then cut using a Shandon microtome and placed 
onto Surgipath pre-cleaned microscope slides and dried at 37°C. A DAKO corporation ki-67 
mouse monoclonal primary antibody was used at 1/50 in 1% BSA in PBS for two hours and a 
DAKO EnVision detection system was applied for 2 hours. Counter stain was with methyl 
blue. Slides were dried at 37°C and images were viewed and recorded using an Olympus BH-2 
phase microscope and photographed using an integrated Olympus DP-12 digital camera system 
(Olympus, Oxford, UK).
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Figure 3.6 E-F shows the outcome of the ki-67 assay on skin incubated with 
DMSO. The red arrow highlights stratum comeum damage, where this stratum 
is almost completely missing from the section of skin. The blue arrow shows 
keratinocyte nuclei damage. These nuclei, as with those in the respective H & 
E staining did not appear to take up any stain and appear as holes.
There was also a significant loss in ki-67 staining.
3.4 Discussion
This study was aimed at selecting 2 signal transduction inhibitors, one MAPK 
pathway inhibitor and one PI3K pathway inhibitor according to their skin 
permeability properties, to incorporate with tamoxifen into a cocktail 
transcutaneous patch. The in-vitro transcutaneous delivery of two MAPK 
pathway inhibitors; PD98059 and SL327 and two PI3K pathway inhibitors; 
LY294002 and quercetin revealed that PD98059 and LY294002 permeated the 
skin most effectively allowing 4.23 ± 0.69 and 4.68 ± 0.68 percent of the 
applied dose to permeate after 48 hours.
The predicted flux values of all compounds were significantly greater than the 
flux values seen in the permeation experiments. This could be due to the donor 
phase containing sub-saturated concentrations of all compounds due to cost 
limitations; however, the average permeation of active ingredients of 
commercially available transdermal and transcutaneous formulations is around
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ten percent. Considering that this simple drug in vehicle delivered 5% of 
applied dose and that manipulation with chemical penetration enhancers could 
improve these results, the preliminary results appeared promising.
The permeation of PD98059 through skin has had little attention paid to it, 
however, it has been previously described that a 5-10mM dose of PD98059 
permeated the stratum comeum and entered the viable epidermis of mouse ears 
sufficiently after 30 minutes to affect CCL2, CXCL8, CCL5 and CXCL10 
expression (Pastore, S. et al 2005). The permeation of LY294002 across or 
into skin has received more consideration. Bedogni, B et al (2004) described 
how LY294002 was able to permeate the skin and inhibited the growth of 
TPras transgenic melanomas, their invasive behaviour and angiogenesis in 
mice. They also showed that the invasion inhibitory effects seen with topical 
administration of LY294002 or U0126 (a MAPK inhibitor) correlated with a 
reduction in MMP expression. It has also been shown that 5 pmol solution of 
LY294002 was able to permeate the skin and inhibit TPA-induced p-Akt 
expression (Hwang, D-M. et al 2006). However, the two remaining STIs; 
SL327 and quercetin, did not permeate full thickness porcine skin with such 
ease. In fact, only 0.87 ± 0.2 percent of the applied dose of quercetin 
permeated the skin membrane after 48 hours. The skin permeation of quercetin 
has been investigated intensively due to its poor oral bioavailability. 
Casagrande, R. et a l (2007) reported similar observations as seen in the 
present transcutaneous permeation study. Quercetin showed very poor 
permeation through porcine skin, even though release studies showed that
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quercetin was released from each formulation sufficiently. However, this 
investigation revealed that topical quercetin could inhibit oxidative stress and 
inflammation within the skin caused by UVB damage, suggesting that 
quercetin was capable of partitioning into the stratum comeum and viable 
epidermis to inflict these effects and was retained in this location (Casagrande, 
R. et al 2007). It has also been shown that without the presence of either a 
fatty acid or fatty alcohol enhancer present, quercetin did not permeate into the 
receptor phase. This study also concluded that without the presence of an anti­
oxidant such as BHA, quercetin degraded rapidly in the donor phase (Kim, 
H.W. et al 2004). This oxidation of quercetin would offer an explanation on 
the poor permeation seen in this chapter; however, the stability of quercetin 
was measured in both these experiments and those in the study conducted by 
Casagrande, suggesting this was not the reason for poor permeation in both of 
these cases. Saija, A. and co-workers (1998) investigated the permeation of 
three flavanoids; quercetin, hesperetin and naringenin. They discovered that 
while hesperetin and naringenin permeated the skin sufficiently, quercetin, 
which is not structurally unlike these two compounds, did not permeate the 
skin. The skin has both lipophilic and hydrophilic stratums and so compounds 
that are either highly lipophilic or hydrophilic often have inferior permeation 
properties (Williams, A.C, 2003). The poor water solubility of quercetin has 
been suggested as another possible reason for the absence of skin permeability 
properties (Bonina, F.P. et al 1996).
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SL327 permeated slightly more readily, with 2.42 ± 0.5 percent of the applied 
dose permeating after 48 hours. The topical administration of SL327 has not 
been previously described.
DMSO proved a successful vehicle for the delivery of PD98059, LY294002 
and, to some extent, SL327. The permeation enhancing properties of DMSO 
are widespread throughout the topical drug delivery literature, with increasing 
bodies of evidence suggesting that at concentrations above 60% particularly 
DMSO increases the permeation of a wide variety of compounds by altering 
SC protein conformation and lipid organization (Anigbogu, A.N.C. et al 1995). 
Several studies have demonstrated the value of DMSO in aiding the 
permeation of a variety of compounds. It was shown that where PEG, a known 
permeation enhancer, failed to deliver acyclovir through human skin, 5% 
acyclovir in a 95% DMSO solution improved the permeation of the compound 
significantly. A subsequent study by the same authors showed that a 95% 
solution of DMSO had the same penetration enhancing effect on another anti­
viral compound; indoxuridine. A study by Bugaj and co-workers in 2006 
illustrated that DMSO gave rise to the most significant increase in the 
permeation of the methyl ester of 5 -aminolevulinic acid measured by the 
formation of porphyrins in mouse skin. In this study the authors suggest that 
DMSO acts as a stratum comeum emollient DMSO does not always improve 
permeation, however. Jantharapprapap, R. & Stagni, G. (2007) showed that 
neither DMSO nor Tween 20 enhanced the permeation of meloxicam gels 
through human cadaver skin, although DMSO was only included at 1, 5 and
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10% compared to 100% in this chapter. The extent of permeation enhancing 
effects related to the concentration of DMSO has already been discussed, 
which may explain the results obtained by Jantharapprapap, R. & Stagni, G. 
(2007).
The permeation rates of the two STIs increased when applied together 
compared to when they were applied individually. This is could be a 
consequence of the increased thermodynamic activity when both compounds 
were present in the vehicle; alternatively, it could have been due to a 
complexation effect.
This chapter has also illustrated that tamoxifen cannot be metabolised within 
the skin. Tamoxifen, when administered orally, is readily metabolised in the 
liver and small intestine by the cytochrome P450 (CYP450) enzymes, 
particularly the CYP4503A subfamily (Tucker, A.N. et al 2005). CYP4502D 
and CYP4502C have also been linked to the formation of N- 
desmethyltamoxifen (N-DMT), 4-hydroxytamoxifen (4-OHT), and 4-hydroxy- 
N-desmethyl-tamoxifen (40HNDMT) (Gallicchio, L. et al 2004). The skin 
does not contain CYP450 enzymes, and so it was necessary to examine if 
epidermal enzymes, including esterases, were capable of metabolizing 
tamoxifen into identified or novel metabolites. The presence of homogenized 
skin, and so liberated epidermal enzymes did not affect the concentration of 
tamoxifen, suggesting that tamoxifen metabolism is a CYP450 specific 
process.
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Several studies, including the aforementioned study by Mauvais-Jarvis have 
demonstrated that 4-hydroxytamoxifen readily permeates breast skin in vivo. 
A further study compared gel formulations with increasing 4- 
hydroxytamoxifen concentrations to oral tamoxifen on several breast cancer 
markers. The authors reported that the topical formulations were capable of 
significantly reducing tumor tissue proliferation indexes, such as ki-67 and 
PCNA and that this reduction was comparable to that seen with oral tamoxifen 
administration, however, no benefit was seen with increased 4- 
hydroxytamoxifen concentrations. The 4-hydroxytamoxifen gels did not effect 
the expression of the apoptotic marker BCL-2. Although plasma levels of 4- 
hydroxytamoxifen was consistently higher when tamoxifen was administered 
orally and although the topical 4-hydroxytamoxifen gels were generally well 
tolerated, hot flushes were as common in the higher gel doses as with oral 
tamoxifen (Rouanet, P. et al 2005).
Immunocytochemical assessment of DMSO treated skin revealed alarming 
toxicological effects. H&E analysis showed that DMSO caused the stratum 
comeum to separate from the underlying epidermis and keratinocyte nuclei loss 
after just 3 hours incubation with DMSO. Smith, E.R. et al (1966) 
demonstrated that repeated exposure of up to 80% DMSO gave rise to punctate 
ulcerative lesions on the skin.
i
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3.5 Conclusions
These studies have demonstrated several things. Firstly, preliminary 
permeation studies revealed that compounds only differing in structure slightly 
can have drastically different skin permeating capabilities. LY294002, a 
compound developed from quercetin showed a significantly superior ability to 
permeate full thickness porcine skin. These permeation studies highlighted 
PD98059 and LY294002 as the best candidates to take forward to develop into 
a transcutaneous formulation based on their permeating capabilities compared 
to SL327 and quercetin.
It was also noted that epidermal enzymes were not capable of metabolising 
tamoxifen to its more potent metabolite 4, hydroxytamoxifen.
These studies also showed that when PD98059 and LY294002 were formulated 
together in DMSO, the permeation of both compounds was significantly 
enhanced, in-fact, each compound seemed to enhance the permeation of the 
other synergistically. However, the addition of 4-hydroxytamoxifen did not 
affect the permeation of the two compounds further. 4-hydroxytamoxifen was 
capable of permeating full thickness porcine skin when formulated with 
PD98059 and LY294002.
Upon assessment of DMSO as a clinically suitable vehicle, it soon became 
clear that the pure DMSO solution gave rise to skin toxicity by damaging the 
stratum comeum and keratinocytes. This observation on the skin toxicity
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eliminated DMSO as a possible vehicle for further development, and so 
another ‘skin friendly9 vehicle must be found.
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Chapter 4 Transcutaneous delivery of PD98059, LY294002 and 4-hydroxytamoxifen from a
fish oil vehicle
4.1 Introduction
Chapter 3 demonstrates the plausibility of delivering 4-hydroxytamoxifen, 
PD98059 and LY294002 across excised porcine skin. However, the use of 
ICC revealed that DMSO inflicted severe skin toxicity. This analysis showed 
stratum comeum toxicity and keratinocyte nuclei loss, thus keratinocyte 
toxicity. At high concentrations, above 60%, DMSO can cause delamination 
of the stratum comeum and protein denaturing. Moreover these effects are not 
reversible which limits the usefulness of DMSO as a vehicle (Williams, A.C. 
2003). The issue regarding skin toxicity eliminated DMSO as a viable vehicle 
to develop an anti-breast cancer formulation and so an alternative vehicle had 
to be found.
Fatty acids are widely established as being successful topical penetration 
enhancers. Green, P.G. and colleagues (1988) suggested that fatty acids 
achieve this enhancing quality by having a kinked structure due to their double 
bond. As the kinked fatty acid enters the straight chain structured stratum 
comeum lipid environment they intercalate and cause perturbation of the 
ordered lipid array (Walker, R.B. & Smith, E.W. 1995). It has also been 
proposed that oleic acid may increase the fluidity of the stratum comeum lipids 
by decreasing the phase transition temperatures of these lipids, therefore, 
simplifying the permeation of many compounds of differing polarities (Golden, 
G.M., et al 1987). It has also been demonstrated that the combination of fatty 
acids with polar solvents such as propylene glycol augments permeation of 
many compounds. It is postulated that this combination may reduce the
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resistance of the stratum comeum or the diffusional path length by making the 
route of administration less tortuous. The authors suggest that the combination 
achieves this by stimulating severe alterations in the membrane lipid structure, 
which causes faults between solid and liquid phases (Ongpipattanakul, B. et al 
1991).
It has been previously reported that fish oil provides a useful vehicle for 
several non-steroidal anti-inflammatory drugs (NSAIDs) including ketoprofen 
(Thomas, C.P. & Heard, C.M. 2004). It has also been suggested that 
thermodynamic activity is not responsible for the penetration of these NSAIDs 
into the skin, rather, the permeants enter the skin bound to the fish oil vehicle 
and permeate via a ‘pull effect9 phenomenon. This phenomenon involves the 
binding of compound and vehicle in a solvation cage (Heard, C.M. et al 2003). 
Indeed it was later proposed, through the use of NMR studies, that ketoprofen 
bound to EPA as it permeated the skin and that EPA along with DHA were 
quantitively detected in the receptor phase of diffusion cell studies (Thomas, 
C.P. et al 2007).
Other oils and fatty acids have also been shown to permeate the skin and act as 
permeation enhancers. Topically applied safflower oil was shown to be 
absorbed and provide nutritional benefits (Solanki, K. et al 2005). The 
permeation of tamoxifen has also been shown when formulated in borage oil, 
this formulation allowed the simultaneous delivery of tamoxifen and gamma 
linolenic acid. (Karia, C. et al 2003). Later, permeation studies and HNMR
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spectral data revealed that complexation occurred between polyunsaturated 
constituents of borage oil (eg y linolenic acid) and tamoxifen and that these 
complexes permeated intact (Heard, C.M. et al 2005).
The use of fish oil would provide a superior vehicle in which to formulate 
tamoxifen and the two STIs; however, to develop this into a clinically 
acceptable formulation it would need to be thickened to produce a more 
viscous gel, cream or paste. HPC has previously been investigated as a 
thickening agent for fish oil based formulations. It was shown that while this 
formulation did not affect the permeation of ketoprofen, the permeation of the 
constituents of fish oil, such as EPA and DHA were retarded significantly.
Cab-o-sil® is an amorphous, synthetic and untreated fumed silicon dioxide. It 
is an inert thickening agent, which is used to thicken many liquids including 
tomato ketchup. Omran, M.O. and colleges (1996) used cab-o-sil to thicken 
oily suspensions for the oral delivery of sodium salicylate. Here they show that 
up to 0.3% Cab-o-sil allows adequate release of the active ingredient into the 
blood, however, at 1% and above strong H-bonds between the cab-o-sil silanol 
groups and sodium salicylate prevent its release. Previously, Cab-o-sil was 
also employed to increase the viscosity of topical preparations containing 
NSAIDs. (Gallagher, S.J. et al 2003).
The utilisation of fish oil as a vehicle, and the subsequent permeation of EPA, 
an n-3 fatty acid, would provide a possible additional therapeutic benefit to the
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formulation. Many studies have investigated the role of inflammation, in 
particular the role of the cyclooxygenase enzymes, in cancer. These studies 
link it to breast cancer tumor initiation, progression and metastatic spread. 
With this in mind, the inclusion of an inhibitor of these cyclooxygenase 
enzymes seems attractive.
As 4-hydroytamoxifen, PD98059 and LY294002 are lipophilic compounds; the 
aims of this work were to incorporate fish oil as an alternative vehicle to 
DMSO and to probe the effect of chemical permeation enhancers and Cab-o- 
sil® on the transcutaneous delivery of 4-hydroxytamoxifen, PD98059 and 
LY294002.
4.2 Materials and Methods
4.2.1 Materials
The materials used in this chapter have been discussed in chapter 2.
4.2.2 Methods
4.2.2.1 Solubility and stability of 4-hydroxytamoxifen, PD98059 and 
LY294002 in fish oil
Solubility and stability of 4-hydroxytamoxifen, PD98059 and LY294002 in 
fish oil was performed as described for their solubility and stability in DMSO 
in chapter 3.
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Samples were diluted 1/20 in methanol before analysis.
4.2.2.2 Preparation of porcine skin membrane
Skin membranes were prepared as previously stated in chapter 2.
4.2.23 In vitro transcutaneous delivery of 4-hydroxytamoxifen, PD98059 
and LY294002 in a fish oil vehicle
Transcutaneous delivery (i.e. across hill thickness skin) was modelled using 
glass Franz-type diffusion cells as described in chapter 2. A receptor phase of 
cetrimide 30mgmL_1 plus 0.05% butylated hydroxyanisole (BHA) to prevent 
oxidation of any permeating polyunsaturated fatty acid (Howard, F.A. & 
Henderson, C. 1999) was added along with a magnetic stirrer bar. The cells 
were dosed with 200pl of 4-hydroytamoxifen, PD98059 or LY294002 made up 
in fish oil, previously prepared to provide equimolar aliquots of 2.54 x 10*4 
mol. The donor phase compartments were occluded with Whatman Parafilm 
and at 3, 6, 12, 24 and 48 hours the entire contents of the receptor phases 
removed for analysis, and replenished with fresh solution. Removed receptor 
phase was separated into 3 x lmL aliquots and stored at -20°C until required.
4.2.2.4 Probing the effect of permeation enhancers on the permeation of 4- 
hydroxytamoxifen, PD98059 and LY294002
The addition of various chemical penetration enhancers was assessed for their 
ability to improve the permeation of 4-hydroxytamoxifen, PD98059 and
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LY294002. The in vitro transcutaneous delivery protocol as stated in 4.2.2.4 
was followed; however, the cells were dosed as shown in table 4.1.
Cell numbers Vehicle Enhancer
1-5 Fish oil 5% DMSO
6-10 Fish oil 5% Ethanol
11-15 Fish oil 5% 1,8-cineole
16-20 Fish oil 2.5% DMSO / 2.5% ethanol
21-25 Fish oil 2.5% DMSO / 2.5% 1,8-cineole
26-30 Fish oil 2.5% ethanol / 2.5% 1,8-cineole
Table 4.1 Table to show die vehicle and enhancer combinations used.
Donor phases were dosed with 200pi of each formulation, with each dose 
containing equimolar concentrations of 4-hydroxytamoxifen, PD98059 and 
LY294002 at 2.54 x 10"4 mol. Enhancers were tested firstly alone and then in 
combination to establish whether synergy or additive benefit could be 
achieved.
4.2.2.5 Probing the effect of Cab-o-sil® on the permeation of tamoxifen, 
PD98059 and LY294002
The effect of the addition of the thickening agent Cab-o-sil on the permeation 
of all 3 compounds and EPA was assessed to evaluate the possibility of 
creating a viscous gel formulation. The in vitro transcutaneous delivery
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protocol as stated in 4.2.2.4 was followed; however, the cells were dosed as 
shown in table 4.2.
Cell numbers %  Cabosil
1-5 0
6-10 4
11-15 4.5
16-20 5
21-25 5.5
26-30 6
Table 4.2 Table to show the percentage o f Cab-o-sil used in die fish oil and enhancer 
formulations. This was repeated for formulations containing 2.5% DMSO/ethanol, DMSO/1,8 
cineole and 1,8 cineole/ethanol n=5.
The donor phase of each diffusion cell was dosed with 200pl of each 
formulation containing equimolar concentrations of each compound (2. 5 x 10"4 
mol). The compounds were formulated in a fish oil vehicle and various 
concentrations of Cab-o-sil were added.
4.2.2.6. HPLC analysis
Samples were analysed using methods stated in chapter 2. Samples were also 
analysed for EPA. Again, samples were separated on a Phenomenex Luna C l8 
column (150 x 4.6 mm, 5pm). However an isocratic mobile phase of 20:80
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methanol:water with 2.5% acetic acid was employed and detection was at 
21 Onm. EPA, under these conditions, had a retention time of 6.5 minutes.
4.2.2.7 Immunohistological analysis of porcine skin
4.2.2.7.1 Haematoxylin assay to reveal the histological effects of fish oil on 
porcine skin
The immunohistological procedure as outlined in chapter 3 was followed. 
However, in this case, freshly excised and HHBBSS maintained porcine skin 
was dosed with the following treatments, shown in table 4.3. The fish oil 
formulation included 0.05% v/v BHA to prevent the oxidation of the fish oil 
constituents. At the times stated within table 4.3 the skin to which the 
treatments were applied was cut into 3 x 1  mm pieces and transferred to 3.7% 
formaldehyde solution.
Processing of the skin tissue, embedding and microtoming was followed as 
stated in chapter 3.
Cell number Treatment Time Processed at (hour)
1-3 Water 0
7-9 Water 5
10-12 Fish oil 5
13-15 Water 12
16-18 Fish oil 12
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Table 43  Table to show the treatment and processing regime prior to H&E staining and ki67 
assay.
4.2.2.8 Immunocytochemical analysis of porcine skin
The immunocytochemical procedure as outlined in chapter 2 was followed, 
however freshly excised and HHBBSS maintained porcine skin was dosed with 
the following treatments, shown in table 4.4. The fish oil formulation included 
0.05% v/v BHA, 2.5% v/v DMSO/etOH and 4% w/v cab-o-sil. At the times 
stated within table 4.4 the skin to which the treatments were applied was cut 
into 3 x 1 mm pieces and transferred to 3.7% formaldehyde solution.
4.2.2.8.1 Ki-67 assay
ICC was performed as outlined in chapter 3, however freshly excised and 
HHBBSS maintained porcine skin was dosed with the following treatments, 
shown in table 4.3. . The fish oil formulation included 0.05% v/v BHA0.05% 
v/v BHA, 2.5% v/v DMSO/etOH and 4% w/v cab-o-sil. At the times stated 
within table 4.3 the skin to which the treatments were applied was cut into 3 x 
1 mm pieces and transferred to 3.7% formaldehyde solution. Processing of 
skin tissue, embedding, microtoming and Ki-67 assay were performed as stated 
in chapter 2.
4.2.2.8.2 pERKl/2, pAkt, pEGFR1068 and total COX-2
To examine the effects of the cocktail formulation on pERKl/2, pAkt, 
pEGFR1068 and COX-2 in the skin ICC analysis of skin treated with either 
water, fish oil (plus 2.5% v/v DMSO/etOH and 4% w/v cab-o-sil) or fish oil,
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and 2.54 x lO^M PD98059, LY294002, 4-hydroxytamoxifen (plus 2.5% v/v 
DMSO/etOH and 4% w/v cab-o-sil) was determined. Skin was dosed with 
formulations as stated in table 4.4 and fixed at the stated times.
Cell number Treatment Time Processed at (hour)
1-3 Water 0
4-6 Water 3
7-9 Fish oil 3
10-12 PD LY 40HTam fish oil 3
13-15 Water 6
16-18 Fish oil 6
19-21 PDLY40HTam fish oil 6
22-24 Water 12
25-27 Fish oil 12
28-30 PDLY4QHTam fish oil 12
Table 4.4 Table to show the treatment and processing regime prior to ICC analysis. PD = 
25pM PD98059, LY = 5pM LY294002,40HTam = 1 x 10 7 M 4-hydroxytamoxifen.
Processing of skin tissue, embedding and microtoming protocol was followed 
as stated in chapter 2. The skin sections were then assayed for pERKl/2, pAkt, 
pEGFR1068 and total COX-2 as stated in chapter 2.
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4.2.3 Statistical analysis
Com parison between the mass permeated, flu x  and lag tim es o f compounds 
were compared between each fo rm u la tion  using un-paired t-tests. A ll 
statistica l analysis was perform ed using M in ita b  fo r W indows.
4.3 Results
4.3.1 The effect of fish oil on excised porcine skin
4.3.1.1 H & E staining
H aem atoxylin  and eosin staining revealed a clear h is to logy o f the porcine skin 
and showed that it  was very s im ila r in  appearance to human skin. F igure 4.1 
shows the H  &  E sta in ing o f fish  o il treated skin compared to skin  treated w ith  
water. F igure 4.1 A  shows haem atoxylin  and eosin staining on excised porcine 
skin  at 0 hours post-dissection.
Figure 4.1 A H & E assay on paraffin embedded excised porcine skin after 0 hours. Sections 
were cut at 5pm on a Shandon Finesse 325 microtome. A- x 20
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Figure 4.1 C-J. H & E assay on paraffin embedded excised porcine skin after 5 hours (B-E) and 12 hours (F-I) incubation with water control (B-C, F-G) or 200pl fish oil 
(D-E, H-I). Sections were cut at 5pm on a Shandon Finesse 325 microtome. F, H x 10, B, D- x 20 C, E, F, I- x 40.
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4.3.1.2 Ki-67 assay
A  k i-67  assay was used to  determ ine the v ia b ility  o f fish  o il treated skin 
compared to w ater contro ls. Th is assay is displayed in  figure  4.2. F igure 4.2A  
shows a negative con tro l, in  w h ich  PBS was applied to the section instead o f 
p rim ary antibody. This demonstrates that any stain ing seen in  figu re  4.2B is 
specific k i-67 . Figure 4.2B shows a section o f sk in  at 0 hours. This displays 
the tim e p o in t where the skin is m ost viab le  and so was used as a reference fo r 
the other tim e points.
'■if
Figure 4.2 A-B. ICC assay to detect ki-67 in excised porcine skin after 0 hours incubation 
with water control A - ICC negative control. PBS applied instead o f primary antibody. B - 
ICC positive control. Primary antibody was DAKO MIB made up in 0.1% BSA in PBS at 
1/50. Sections were cut at 5pm on a Shandon Finesse 325 microtome. A- x 20 B- x 10.
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Figure 4.2 C-F. ICC assay to detect ki-67 in excised porcine skin after 5 hours (C-F) and 12 hours (G-J) incubation with water control (C-D, G-H) or fish oil (E-F, I-J). 
Receptor phase was HHBBSS and skin was maintained at 32°C. Primary antibody was DAKO MIB made up in 0.1% BSA in PBS at 1/50. Sections were cut at 5pm on a 
Shandon Finesse 325 microtome microtome. C, E, G, I- x 20, D, F- x 40.
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Figure 4.2 C-F shows sections of skin left in the presence of either water or fish 
oil for five hours. C-D shows water treated skin, which shows positive ki-67 
staining of the same degree as seen in E-F, which was treated with fish oil. In 
figure 4.2 C and D it is clear that the stratum comeum has detached from the 
underlying epidermis, whereas, the fish oil formulation does not cause this 
detachment to occur.
Figure 4.2 G-J shows sections of porcine skin after incubation for 12 hours. 
Again, both water and fish oil treated sections are positive for ki-67. In these 
sections, however, it is predominantly seen within the basal layer of the 
epidermis compared to staining throughout the epidermis that was seen at 5 
hours. Stratum comeum damage is seen with both treatments at this time 
point, although is much less severe than that seen with DMSO treated skin.
4.3.2 Suitability of fish oil as vehicle for the permeation of 4- 
hydroxytamoxifen, PD98059 and LY294002
4.3.2.1 Solubility and Stability of 4-hydroxytamoxifen, PD98059 and 
LY294002 in fish oil
The solubility of PD98059 LY294002 and 4-hydroxytamoxifen in fish oil was 
2.47 ± 0.13mgmL_1, 5.16 ± O^lmgmL'1 and 3.83 ± O.HrngmL'1 respectively 
when assessed separately. The solubility of all 3 compounds did not change 
significantly when determined within the same solution. These were 2.21 ± 
O.lmgmL'1, 5.48 ± 0.62mgmL’1 and 4.12 ± 0.46 mgmL'1 respectively.
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Table 4.5 displays the stability and degree of degradation of 
4,hydroxytamoxifen, PD98059 and LY294002 singly and together.
Time
(hours)
%  Degradation
PD LY Tam PD + LY All 3
PD LY PD LY Tam
0 0 0 0 0 0 0 0 0
5 0 0 0 0 0 0 0 0
12 0.1 0.248 0.13 0.035 0.165 0.054 0.065 0
24 1.44 0.76 1.276 1.87 1.487 1.242 1.232 0.98
48 1.872 2.12 1.891 2.18 1.845 1.987 2.141 2.795
168 10.576 9.598 9.154 7.15 8.186 6.905 7.86 7.58
Table 4.5 Table to show the degree o f degradation of PD98059 and LY294002, both singly 
and together in a fish oil vehicle.
This degradation data suggests that all 3 compounds can be left at room 
temperature for 48 hours and overnight analysis can be performed without 
causing errors in results obtained. It can also be seen that the combination of 
compounds seems to slightly reduce the amount of degradation of all 3 
compounds.
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43.2.2 In vitro transcutaneous delivery of PD98059, LY294002 and 4- 
hydroxy tamoxifen
As stated in chapter 3, the mass of PD98059, LY294002 and 4- 
hydroxytamoxifen that permeated after 48 hours when applied simultaneously 
in a DMSO vehicle was 9.1 pgcm'2 ±2.19,20.18pgcm*2 ± 2.83 and 15.99pgcm‘ 
2 ± 0.963 respectively. However, a replacement vehicle had to be found due to 
the skin toxicity of DMSO. Fish oil was chosen to replace DMSO and 
assessed as a vehicle for the delivery of both PD9805 and LY294002. Figure
4.3 shows the cumulative mass of PD98059, LY294002 and 4- 
hydroxytamoxifen that permeated across excised porcine skin after 48 hours 
when applied simultaneously in a fish oil vehicle.
Figure 4.3 shows that the order of permeation of the two compounds changed 
from 0-order when combined in a DMSO vehicle to first order when 
formulated in a fish oil vehicle.
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Figure 4.3 Permeation profile to compare the mass (pgcm'2) o f  simultaneously applied 
PD98059, LY294002 and 4-hydroxytamoxifen across excised porcine skin. Donor phase was 
2.54 x lO^mol PD98059, LY294002 and 4-hydroxytamoxifen in 200pl fish oil with 0.05% 
BHA. Receptor phase was 30mgmL~' cetrimide solution, it was stirred continuously and 
maintained in a water bath set to maintain a skin surface temperature o f 32°C (n=6 ± SD).
Perm eation data fo r PD98059, LY294002 and 4 -hydroxytam oxifen  when 
applied to the skin  sim ultaneously in  fish  are displayed in  table 4.6. Th is table 
also compares perm eation th is  data to that obtained in  chapter 3, when 
compounds were form ulated in  a D M SO . Th is com parison h igh ligh ts  many 
in teresting data. The extent o f the reduction in  perm eation when form ulated in  
fish  o il compared to  D M SO  is clear and was s ign ifican t fo r a ll compounds (P = 
0.006, 0.001 and 0.0005 fo r PD98059, LY294002 and 4-hydroxytam oxifen 
respective ly).
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DMSO Fish oil
PD LY 40HTam PD LY 40HTam
Mass
(pgcnf2)
9.1 ±2.19 20.18 ± 
2.83
16.0 ±0.7 1.269 ± 
0.26
3.8 ± 
0.039
2.13 ± 
0.45
Flux
(pgcm'2h~
*)
0.38 ± 
0.12
0.61 ± 
0.09
0.468 ± 
0.05
0.067 ± 
0.01
0.197 ± 
0.025
0.105 ± 
0.016
Lag time
(h)
5.24 ± 
0.87
7.42 ± 1.4 5.72 ± 
0.86
7.83 ± 
0.96
3.558 ± 
0.23
7.65 ± 
1.15
Kp (cm2h‘
i)
1.96 x 10‘
2 ± 6.2 x 
10*3
1.993 x 
IO2 ± 2.9 
x 10‘3
1.93 x 10z 
± 2.1 x 10-
3
3.45 x 10* 
3 ± 5.2 x
io-4
6.44 x 10- 
3 ± 8.2 x
io-4
4.34 x 10'3 
± 6.6 x 10-
4
Table 4.6 Table to show the mass o f PD98059, LY294002 and 4-hydroxytamoxifen 
permeated, flux, lag time and Kp when formulated in DMSO and fish oil vehicle.
The table also shows that the flux of all 3 compounds was reduced significantly 
(P = 0.014, 0.003 and 0.001) for PD98059, LY294002 and 4- 
hydroxytamoxifen respectively.
Lag times did not follow this pattern. The lag time of PD98059 was 
significantly increased when formulated with fish oil (P = 0.039), whereas the 
lag time of LY294002 was significantly reduced (P = 0.02) while there was no 
significant effect on the lag time of 4-hydroxytamoxifen (P = 0.263). Overall,
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it is obvious that the use of fish oil as a vehicle limits the permeation of all 3 
compounds significantly compared to when applied in DMSO.
However, formulation into a fish oil vehicle gave a fourth prong to this cocktail 
therapeutic with the delivery of COX inhibitors. One such inhibitor found in 
fish oil is eicosapentaenoic acid (EPA). The mass of EPA permeating the skin, 
therefore, was calculated.
Figure 4.4 shows the mass (pgcm ) of EPA that permeated the skin from the 
fish oil vehicle when formulated with PD98059, LY294002 and 4- 
hydroxytamoxifen. In these conditions 266.95 ± 31.18pgcm‘2 of EPA 
permeated excised porcine skin after 48 hours. However, when applied to the 
skin in the absence of the two signal transduction inhibitors and 40H 
tamoxifen, no EPA permeation was detected.
Compared to the permeation of PD98059, LY294002 and 40H tamoxifen, a 
large amount of EPA seemed to permeate, however, when converted into the 
percentage of applied dose permeated it was obvious that a huge concentration 
gradient existed between the dosed mass and that within and permeating the 
skin.
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Figure 4.4 Permeation profile showing the mass (pgcm'2) o f  EPA permeated from the fish oil 
vehicle, through excised porcine skin. Donor phase was 2.54 x lO^mol PD98059 and 
LY294002 in 200pl fish oil with 0.05% BHA. Receptor phase was 30mgmL'' cetrimide 
solution, it was stirred continuously and maintained in a water bath set to maintain a skin 
surface temperature o f 32°C (n=6 ± SD).
Steady state flu x  o f EPA was reached a fte r 6 hours. The flu x  o f EPA under 
these conditions was 7.798 ±  lJ lp g c m "2! ! '1 and the lag tim e was 3.744 ±  0.31 
hours. The perm eability coe ffic ie n t was determ ined as 1.2 x  10 ±  1.98 x 10'
5cm V .
4.3.3 The effect of chemical penetration enhancers and their combinations 
on the permeation of 4-hydroxytamoxifen, PD98059 and LY294002
Due to the poor perm eation o f a ll 3 compounds in  fish  o il, th is section aimed to 
im prove perm eation w ith  the add ition  o f three w e ll know n CPEs and
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com binations o f these. D M SO , ethanol and 1,8-cineol were the chosen as 
CPEs and were used at 5% (v /v ) when assessing th e ir e ffect separately and at 
2.5%  (v /v ) when com bining CPEs.
F igure 4.5 shows the perm eation o f PD98059 when form ulated w ith  the three 
CPEs and com binations o f enhancers.
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Figure 4.5 Permeation profile showing the mass (pgcm*2) o f PD98059 permeating from the 
fish oil vehicle, combined with various enhancers and enhancer combinations. Donor phase 
was 2.54 x lO^mol PD98059 and LY294002 in 200pl fish oil with 0.05% BHA. Receptor 
phase was SOmgmL'1 cetrimide solution, it was stirred continuously and maintained in a water 
bath set to maintain a skin surface temperature o f 32°C (n=6 ± SD).
Figure 4.5 shows that the mass o f PD98059 permeated could be m anipulated 
w ith  add ition  o f various enhancers. A ll enhancers and enhancer com binations 
increased the perm eation o f PD98059 when compared to the perm eation seen 
w ith  fish  o il alone. The highest mass permeated was seen when fish  o il was
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formulated with a combination of 2.5% DMSO/ethanol. This formulation 
allowed 6.31 ± 0.95 p.gcm'2 of PD98059 to permeate after 48 hours, which was 
significantly greater than from fish oil alone (P = 0.01). This was statistically 
indistinguishable from the mass permeating from a DMSO vehicle (P = 0.092). 
PD98059 permeated with a flux of 0.195 ± 0.02 pgcm^h'1 and the lag time was 
2.39 ± 0.5 hours when formulated with these two CPEs. Steady-state flux was 
statistically greater with the presence of 2.5% DMSO/ethanol (P = 0.016) and 
lag time was significantly shorter (P = 0.003). The permeation coefficient of 
PD98059 in this formulation was 1.02 x 10'2 ± 3.09 x 10-3 cm2^ 1, which was 
higher than that seen when PD98059 was formulated with fish oil alone.
Table 4.7 shows the enhancement ratio (EnR) of the mass permeated of 
PD98059 with the various CPEs and combinations. It shows that the 
combinations of CPEs enhance the permeation of PD98059 greater than when 
included individually. The EnR data also highlights that the combination of 
DMSO and ethanol (both at 2.5% v/v) gave the greatest enhancement.
The inclusion of the enhancers also affected the permeation of LY294002 
through excised porcine skin. Figure 4.6 shows permeation profiles for 
LY294002 when formulated with the various enhancers (PD98059 and 4- 
hydroxytamoxifen also present in formulation).
Again, as with the permeation of PD98059, the combination of DMSO and 
ethanol gave maximal permeation of LY294002. This formulation allowed 9.4
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±  0.95 p g cn f2 o f LY294002 to permeate a fte r 48 hours. This was s ig n ifican tly  
greater than the mass that permeated when LY294002 was form ulated in  fish  
o il alone (P =  0.003). However, th is  was s till s ig n ifica n tly  less than that seen 
w ith  a pure D M SO  vehicle  (P =  0.0026).
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Figure 4.6 Permeation profile showing the mass (pgcnf2) o f  LY294002 permeating from the 
fish oil vehicle, combined with various enhancers and enhancer combinations. Donor phase 
was 2.54 x IO"4 mol PD98059 and LY294002 in 200pl fish oil with 0.05% BHA. Receptor 
phase was 30mgmL'1 cetrimide solution, it was stirred continuously and maintained in a water 
bath set to maintain a skin surface temperature o f  32°C (n=6 ± SD).
LY294002 permeated w ith  a flu x  o f 0.6 ±  0.08 pgcm ‘2h_1, w hich was 
s ig n ifica n tly  greater than from  fish  o il alone (P =  0.001) and the lag tim e was
3.03 ±  0.54 hours, w h ich  was not s ig n ifica n tly  changed by the add ition  o f 
DSM O /ethanol to  the fo rm u la tion  (P =  0.145). The perm eation coe ffic ien t o f
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LY294002 in this formulation was 2.0 x 10'2 ± 2.26 x 10‘3 cm2h_1, which was 
greater than that seen when LY294002 was formulated in fish oil alone.
CPE(s) EnRPD EnRLY EnR 40HTam EnR EPA
DMSO 2.8 1.3 1.53 4.4
etOH 2.76 1.7 1.22 2.4
1,8-cineole 2.5 1.76 1.28 3.5
DMSO/etOH 5.0 2.5 2.5 5.0
DMSO/1,8-cineole 3.6 1.78 1.96 4.1
1,8-cineole/etOH 3.9 1.55 1.96 3.4
Table 4.7 Table to show the enhancement ratio (EnR) in the mass permeated o f PD98059 
(PD), LY294002 (LY), 4-hydroxytamoxifen and EPA when formulated in a fish oil vehicle 
with various enhancers present compared to fish oil alone.
Table 4.7 shows that the addition of ethanol, 1,8-cineole, DMSO/l,8-cineole or 
1,8-cineole/ethanol all gave rise to similar EnRs for the mass of LY294002 
permeating after 48 hours. The EnR data also confirms that the formulation 
containing the combination of DMSO and ethanol gave m ax im al enhancement 
of LY294002.
The permeation of 4-hydroxytamoxifen was also assessed in the presence of 
the CPEs.
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Figure 4.7 Permeation profile showing the mass (pgcm'2) o f 4-hydroxytamoxifen permeating 
from the fish oil vehicle, combined with various enhancers and enhancer combinations. Donor 
phase was 2.54 x KT4 mol PD98059 and LY294002 in 200pl fish oil with 0.05% BHA. 
Receptor phase was 30mgmL‘' cetrimide solution, it was stirred continuously and maintained 
in a water bath set to maintain a skin surface temperature o f 32°C (n=6 ± SD).
F igure 4.7 shows perm eation p ro files  fo r 4 -hydroxytam oxifen  when form ulated 
w ith  the various enhancers. A gain , the com bination o f D M S O  and ethanol 
gave m axim al perm eation o f 4 -hydroxytam oxifen . Th is fo rm u la tion  allow ed 
7.19 ±  0.13 pgcm '2 o f 4 -hydroxytam oxifen  to  permeate a fte r 48 hours, w hich 
was s ig n ifica n tly  greater that that perm eation seen w ith o u t CPEs present (P =  <  
0.001), how ever was s till s ig n ifica n tly  less than that perm eating when 4- 
hydroxytam oxifen  was form ulated in  D M SO  (P =  0.001). Th is was a 
s ign ifican t increase from  2.13 ±  0.45 pgcm '2 that permeated when 4- 
hydroxytam oxifen  was form ulated w ith ou t CPEs present.
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4-hydroxytamoxifen permeated with a flux of 0.27 ± 0.02 jigcm^h'1, which 
was significantly greater than the flux seen when 4-hydroxytamoxifen was 
applied in fish oil alone (P = 0.002). Lag time was 3.61 ± 0.66 hours, which 
was significantly shorter than when CPEs were absent (0.012). The 
permeation coefficient of 4-hydroxytamoxifen in this formulation was 1.12 x 
10'2 ± 8.26 x 10‘3 cm2h_1, which was greater than that seen when 4- 
hydroxytamoxifen was formulated in fish oil alone.
Figure 4.8 shows permeation profiles for EPA when formulated with the 
various enhancers.
149
Chapter 4 Transcutaneous delivery o f PD98059, LY294002 and 4-hydroxytamoxifen from a
fish oil vehicle
1500
1250
^  1000
500
250
20 350 5 10 15 25 30 40 45 50
Time (hours)
fish oil plus 5% DMSO
fish oil plus 5% ethanol
Fish oil plus 2.5% DMSO/Cineole
fish oil
fish oil plus 5% cineole 
■ Fish oil plus 2.5% DMSO/ethanol 
• Fish oil plus 2.5% Cineole/ethanol
Figure 4.8 Permeation profile showing the mass (pgcm'2) o f  EPA permeating from the fish oil 
vehicle, combined with various enhancers and enhancer combinations. Donor phase was 2.54 
x 10-4 mol PD98059 and LY294002 in 200pl fish oil with 0.05% BHA. Receptor phase was 
SOmgmL1 cetrimide solution, it was stirred continuously and maintained in a water bath set to 
maintain a skin surface temperature o f 32°C (n=6 ± SD).
A ll fo rm u la tions increased the perm eation o f EPA. H ow ever, fo rm u la tions 
conta in ing D M SO  seemed to o ffe r the m ost bene fit. A ga in , the com bination o f 
D M SO  and ethanol gave m axim al perm eation o f EPA. T h is mass o f EPA able 
to  permeate when 2.5% D M SO /ethanol was added was s ig n ifica n tly  greater 
than when no CPEs were present (P =  0.006). The mass able to permeate from  
th is  fo rm u la tio n  was 1329 ± 1 4 2  pgcm '2 a fte r 48 hours. Steady-state flu x  was 
seen between 6 and 12 hours and was 67.67 ±  10.8 pgcm*2h_1 and the lag tim e  
was 3.01 ±  0.44 hours. The flu x  increased s ig n ifican tly  (P =  0.011) but lag 
tim e rem ained s ta tis tica lly  unchanged (P =  0.1). The perm eation co e ffic ie n t o f
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EPA seen in the presence of the DMSO/ethanol combination was 1.03 x 10'3 ± 
1.6 x 10*4 cmV1, which was 10 fold greater than that seen with fish oil alone.
Table 4.7 shows the enhancement ratio of each CPE or CPE combination on 
the permeation of EPA compared to data obtained when compounds were 
dosed in fish oil alone. It is clear that all enhancers give rise to significant 
increases in the permeation of EPA, especially the formulation containing both 
DMSO and ethanol.
The permeation studies probing the effect of CPEs on the permeation of 
PD98059, LY294002, 4-hydroxytamoxifen and EPA revealed that the 
formulation containing 2.5% (v/v) DMSO/ethanol gave maximal enhancement 
of all 4 actives.
43.4 Probing the suitability of Cab-o-sil ® as a thickening agent
Cab-o-sil ® was assessed as a thickening agent for the fish oil based 
formulation containing 2.54x10*4 mol PD98059, LY294002 and 4- 
hydroxytamoxifen, along with 2.5% v/v DMSO and ethanol and 0.05% v/v 
BHA.
Cab-o-sil, at various percentages, was added to the liquid formulation to 
produce a series of oleo gels, as described in section 4.2.2.6.
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Therm odynam ically stable oleo gels were generated from  the add ition  o f the 
various percentages o f cab-o-sil, shown in  figure  4.9.
Figure 4.9 Photo o f a fish oil oleo gel containing 2.5% v/v DMSO and ethanol, 0.05% v/v 
BHA, 2.54X 10"4 mol PD98059, LY294002 and 4-hydroxytamoxifen. This gel contained 4% 
Cab-o-sil®. Gels were prepared and maintained at 32° C until required.
The viscosity  o f these gels increased as the percentage o f C ab-o-sil added 
increased, however, th is  percentage range yie lded gels that could s till be 
measured and dosed using a G ilson lm L  pipette.
Permeation data revealed a ll three compounds were released from  a ll 
percentage C ab-o-sil o leo gels. The add ition o f C ab-o-sil d id  not a ffect the 
cum ulative mass o f PD98059, LY294002 or 4 -hydroxytam oxifen  perm eating 
excised porcine skin  a fter 48 hours when com pared to  un-thickened 
fo rm u la tion  (P =  0.111, 0.091 and 0.366 respective ly).
152
Chapter 4 Transcutaneous delivery of PD98059, LY294002 and 4-hydroxytamoxifen from a
fish oil vehicle
%  Cab-o-sil 0 4 4.5 5 5.5 6
Mass 
permeated 
after 48 h
EPA 1660.9
±98.1
1420.12 
± 119
541.89
±88.7
417.56 
± 56.34
16.26 ± 
3.22
8.99 ± 
0.76
(pgcm 1)
40Htam 8.09 ± 
0.67
8.25 ± 
0.36
7.44 ± 
0.81
7.28 ± 
0.69
7.99 ± 
0.84
8.27 ± 
0.53
LY294002 8.21 ± 
0.47
9.17 ± 
0.77
8.03 ± 
0.82
7.86 ± 
0.46
7.92 ± 
0.53
9.01±
0.64
PD90859 6.56 ± 
0.24
6.92 ± 
0.55
5.57 ± 
0.68
5.71 ± 
0.33
5.97 ± 
0.81
6.18±
0.7
Table 4.8 Table to show the mass (pgcm*1) of PD98059, LY294002, 4-hydroxytamoxifen and 
EPA permeated excised porcine skin after 48 hours when formulated with 2.5% DMSO/etOH 
and various % ’s of Cab-o-sil.
The addition of Cab-o-sil did affect the release of EPA. At percentages of 
4.5% and above the mass of EPA that permeated after 48 hours was 
significantly lower than the mass that permeated from the un-thickened 
formulation (P = 0.001 for 0% cab-o-sil vs 4.5% and less than 0.001 for other 
percentages of Cab-o-sil). At 4% Cab-o-sil, however, there was no statistical 
difference in the mass of EPA permeating after 48 hours compared to when the 
formulation was absent of Cab-o-sil (P = 0.075).
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Figure 4.10 Permeation profile showing the mass (pgcm'2) o f PD98059, LY294002 and 4- 
hydroxytamoxifen permeating from the fish oil vehicle, when formulated with 2.5% v/v 
DMSO/ethanol, 0.05% v/v BHA and 4.0 %  w/v Cab-o-sil. Donor phase was 2.54 x lC 4 mol 
PD98059 and LY294002 in 200pl fish oil with 0.05% BHA. Receptor phase was SOmgmL’1 
cetrimide solution, it was stirred continuously and maintained in a water bath set to maintain a 
skin surface temperature o f 32°C (n=6 ± SD).
Figure 4.10 shows perm eation p ro files  fo r PD98059, LY294002 and 4- 
hydroxytam oxifen  when 4.0%  cab-o-sil was incorporated. Due to  the 
retardation in  release o f EPA beyond th is percentage o f  cab-o-sil, th is 
fo rm u la tion  was deemed the m ost e ffective.
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Figure 4.11 Permeation profile showing the mass (pgcm'2) o f EPA permeating from the fish 
oil vehicle, when formulated with 2.5% v/v DMSO/ethanol, 0.05% v/v BHA and 4.0 % w/v 
Cab-o-sil. Donor phase was 2.54 x 10"* mol PD98059 and LY294002 in 200pl fish oil with 
0.05% BHA. Receptor phase was SOmgmL'1 cetrimide solution, it was stirred continuously 
and maintained in a water bath set to maintain a skin surface temperature o f  32°C (n=6 ± SD).
The steady state fluxes fo r the three actives were seen at 12-24 hours, w h ich  
was la ter than seen w ith  the absence o f 4%  C ab-o-sil. The steady-state flu x  o f 
PD98059, LY294002 and 4 -hydroxytam oxifen  when 4.0%  C ab-o-sil was 
incorporated was not s ig n ifica n tly  d iffe re n t from  when cab-o-sil was absent 
from  the fo rm u la tion  (P =  0.122, 0.72, 0.993 respective ly). These were 0.25 ±  
0 .034pgcm '2h_1, 0.529 ±  O .O TSpgcm 'Vand 0.35 ±  0.056pgcm '2h '1
respective ly. The lag tim es were 7.2 ±  0.98, 8.15 ±  0.76 and 9.2 ±  0.93 hours 
and were s ig n ifica n tly  longer than those seen when cab-o-sil was not included
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(P = < 0.001 for each compound). The permeability coefficients for PD98059, 
LY294002 and 4-hydroxytamoxifen under these conditions were 2.58 x 10'3 ± 
3.51 x 10"4 pgcm‘2, 2.8 x 10‘3 ± 5.1 x 10*4 pgcm'2 and 2.9 x 10’3 ± 4.63 x 10"4 
pgcm'2.
Figure 4.11 shows the permeation profile for EPA with the inclusion of 4% 
Cab-o-sil. Steady state flux was again seen later at 12-24 hours. Under these 
conditions the flux of EPA was statistically unchanged from that seen in the 
absence of Cab-o-sil (P = 0.692) however, was still significantly greater than 
the flux of EPA seen from fish oil vehicle without enhancers or Cab-o-sil 
present (P = 0.01). The lag time followed the same pattern. Flux of EPA with 
4% Cab-o-sil present was 63.967 ± 9.93 pgcm'2h_1. Lag time was statistically 
longer than in formulations of fish oil alone and with 2.5%DMSO/ethanol (P = 
0.023 and 0.017). With the inclusion of 4% Cab-o-sil the lag time of EPA was 
7.29 ± 0.89 hours respectively. The permeability coefficient for EPA was 9.7 x 
10-4 ± 1.5 x 10"4 ngcm"2.
43.5 The effect of Cab-o-sil ® on the viability of porcine skin
43.5.1 H & E staining
The H&E assay as used in section 4.3.2.1 was followed, however, skin was 
dosed with either water, which acted as control, or fish oil with 2.5% (v/v) of 
both DMSO and ethanol and with 4.0% (w/v) Cab-o-sil. Figure 4.12 shows the 
sections of skin from each treatment and reveals that the inclusion of the two
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enhancers and C ab-o-sil causes no obvious h is to log ica l changes to the porcine 
skin  when compared to skin incubated w ith  fish  o il alone.
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Figure 4.12. A- H & E assay on paraffin embedded excised porcine skin at 0 hours. Sections 
were cut at 5 pm on a Shandon Finesse 325 microtome. A- x 20
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Figure 4.12 B-l. H & E assay on paraffin embedded excised porcine skin after 5 hours (B-E) and 12 hours (F-I) incubation with water control (B-C, F-G) or 200pl fish oil 
plus 2.5% v/w DMSO/ethanol and 4% w/v Cab-osil (D-E, H-I). Sections were cut at 5pm on a Shandon Finesse 325 microtome. F x 10, B, D, H- x 20 C, E, G, I- x 40.
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4.3.5.2 Ki-67 assay
I t w a s  o f  p a ra m o u n t  im p o r ta n c e  to  m a k e  s u re  th a t  f is h  o il  p lu s  2 .5 %  (v /v )  o f  
b o th  D M S O  a n d  e th a n o l a n d  a ls o  w ith  4 .0 %  (w /v )  C a b -o -s i l  w a s  a b le  to  
m a in ta in  s k in  v ia b i l i ty
F ig u re  4 .1 3  sh o w s  th e  k i-6 7  a s s a y  c a r r ie d  o u t  s k in  in c u b a te d  w ith  e a c h  
fo rm u la t io n . T h e  a s s a y  s h o w s  K i-6 7  s ta in in g  w a s  m a in ta in e d  th ro u g h o u t  th e  
d u ra t io n  o f  th e  12 h o u r  e x p e r im e n t  w h e n  s k in  w a s  in c u b a te d  w ith  e a c h  
f o rm u la t io n , s u g g e s t in g  th a t  f is h  o il  p lu s  2 .5 %  (v /v )  o f  b o th  D M S O  a n d  e th a n o l 
a n d  a ls o  w i th  4 .0 %  (w /v )  C a b -o -s i l  d id  n o t  a f fe c t  s k in  v ia b i l i ty .
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Figure 4.13 ICC assay to detect ki-67 in excised porcine skin (x40) after 0 (A, D), 5(B, E) and 12 (C, F) hours incubation with water (A-C) or fish oil (D-F). Primary 
antibody was DAKO MIB made up in 0.1% BSA in PBS at 1/50. Sections were cut at 5pm on a Shandon Finesse 325 microtome.
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4.3.5.3 pERKl/2
Figure 4.14 displays porcine skin im m ediately post dissection. Figure 4.15A 
represents a negative contro l, where the p E R K l/2  prim ary antibody was replaced w ith  
PBS. Figure 4.14 shows porcine skin assayed fo r the detection o f p E R K l/2  after 0 
hours. The negative contro l displays no staining; suggesting that staining seen in  
figure 4.14B and the sections throughout th is experim ent was specific fo r p E R K l/2 .
Figure 4.14 ICC assay to detect pERKl/2 in excised porcine skin immediately post dissection (A= 
negative control x 20, B = 0 hours control x 10) Primary antibody was a CST rabbit polyclonal 
phospho-ERKl/2 kinase antibody at 1/20 in 20% Normal Human Serum in PBS overnight. Sections 
were cut at 5pm on a Shandon Finesse microtome.
Figure 4.15 displays sections o f porcine skin assayed fo r the detection o f p E R K l/2  
over 12 hours. The assayed revealed that p E R K l/2  was localised to the nucleus o f 
epiderm al keratinocytes, although some cytoplasm ic staining was seen. Figure 4.15 
A -C  shows that water has no effect on p E R K l/2  levels, w ith  staining rem aining at a 
constant level from  the 0 hour contro l and throughout the 12 hours when the skin was 
incubated w ith  water.
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Figure 4.15 ICC assay to detect pERKl/2 in excised porcine skin (x40) after 3 (A, D, G), 6 (B, E, H) and 12 (C, F, I) hours incubation with water (A-C), fish oil (0.05% v/v 
BHA) (D-E) or fish oil plus 2.54 x lO^M PD98059, LY294002, 4-hydroxytamoxifen (plus 0.05 v/v BHA 2.5% v/v DMSO/ethanol and 4% w/v Cab-o-sil). Primary antibody 
was a CST rabbit polyclonal phospho-ERKl/2 kinase antibody at 1/20 in 20% Normal Human Serum in PBS overnight. Sections were cut at 5pm on a Shandon Finesse 
microtome
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4.3.5.4 pAkt
F ig u re  4 .1 6  d is p la y s  p o rc in e  s k in  im m e d ia te ly  p o s t  d is s e c tio n . I t  r e v e a le d  th a t  
p A k t  w a s  lo c a l is e d  to  th e  c y to p la s m  o f  th e  e p id e rm is .  F ig u re  4 .1 6 A  re p re s e n ts  
a  n e g a t iv e  c o n tro l ,  w h e re  th e  p A k t  p r im a ry  a n t ib o d y  w a s  re p la c e d  w ith  P B S . 
F ig u re  4 .1 6 B  s h o w s  p o rc in e  s k in  a s s a y e d  fo r  th e  d e te c t io n  o f  p A k t  a f te r  0  
h o u rs . T h e  n e g a t iv e  c o n tro l  d is p la y s  n o  s ta in in g ;  s u g g e s t in g  th a t  s ta in in g  s e e n  
in  f ig u re  4 .1 6 B  a n d  th e  s e c tio n s  th ro u g h o u t  th is  e x p e r im e n t  w a s  s p e c if ic  fo r  
p A k t.
Figure 4.16 ICC assay to detect pAkt in excised porcine skin immediately post dissection (A= 
negative control xlO, B = 0 hours control x40) Primary antibody was CST rabbit anti-Akt 
(activated) polyclonal antibody at 1/30 in PBS overnight Sections were cut at 5pm on a 
Shandon Finesse microtome
F ig u re  4 .1 7  d e m o n s tra te s  e x c is e d  p o rc in e  s k in  a s s a y e d  to  d e te c t  p A k t  o v e r  12 
h o u r s  w h e n  t r e a te d  w i th  w a te r ,  f i s h  o i l  o r  f is h  o il a n d  2 .5 4  x  lO ^ M  P D 9 8 0 5 9 , 
L Y 2 9 4 0 0 2 , 4 - h y d ro x y ta m o x if e n  (p lu s  2 .5 %  v /v  D M S O /e th a n o l a n d  4 %  w /v  
C a b -o -s i l) .
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Figure 4.17 ICC assay to detect pAkt in excised porcine skin (x40) after 3 (A, D, G), 6 (B, E, H) and 12 (C, F, I) hours incubation with water (A-C), fish oil (0.05% v/v 
BHA) (D-E) or fish oil plus 0.05% v/v BHA, 2.54 x 10'4M PD98059, LY294002, 4-hydroxytamoxifen (plus 2.5% v/v DMSO/ethanol and 4% w/v Cab-o-sil). Primary 
antibody was CST rabbit anti-Akt (activated) polyclonal antibody at 1/30 in PBS overnight. Sections were cut at 5pm on a Shandon Finesse microtome
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F igure 4.17 shows tha t epiderm al p A k t expression was not a ffected when w ater 
was applied to  the stratum  com eum  (fig u re  4.17 A -C ). The app lica tion  o f fish  
o il (p lus 2.5%  v /v  D M S O /ethanol and 4%  w /v  C ab -o-s il) d id  no t a ffec t the 
p ro te in  expression o f p A k t throughout the 12 hour experim ent (4.17 D -F ). The 
app lica tion  o f fis h  o il (p lus 2.5%  v /v  D M S O /ethano l and 4%  w /v  C ab-o-sil 
,2.54 x  lO ^M  PD98059, LY 294002, 4 -hyd roxytam oxifen ) to  the surface o f the 
sk in  was capable o f in h ib itin g  p A k t w ith in  the epiderm is a fte r 3 hours (4.17G ), 
furtherm ore, th is  in h ib itio n  was m aintained fo r the 12 hour experim ent
4.3.5.5phospho EGFR
F igure 4.18 disp lays porcine  sk in  im m ed ia te ly  post d issection. The assay 
revealed th a t pEG FR1068 was o n ly  found w ith in  the epiderm is and was 
loca lised to  the cytoplasm . F igure 4 .18A  represents a negative con tro l, where 
the pEG FR1068 p rim ary antibody was replaced w ith  PBS. F igure 4.18B 
shows porcine skin  assayed fo r the detection o f pEG FR1068 a fte r 0 hours. The 
negative co n tro l displays no sta in ing ; suggesting tha t s ta in ing  seen throughout 
th is  assay was pEG FR  specific.
F igure 4.19 displays the pEG FR1068 assay perform ed on porcine skin  treated 
w ith  w ater, fis h  o il o r fis h  o il p lus 2.54 x  lO ^M  PD98059, LY 294002, 4- 
hyd roxytam ox ifen  (p lus 2.5%  v /v  D M S O /ethanol and 4%  w /v  C ab-o-sil). I t  
revealed tha t pEG FR  p ro te in  expression rem ained constant throughout the 12 
hour experim ent w hen w ater was applied to  the SC surface (4.19 A -C ).
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A pp lica tion  o f both the fish  o il vehicle  and the cockta il o f compounds reduced 
pEGFR1068 w ith in  porcine skin a fter 3 hours (4.19 D  &  G). A t 12 hours (4.20 
F &  I), however, pEGFR specific staining was elevated compared to at 3 hours.
Figure 4.18 ICC assay to detect pEGFR 1068 in excised porcine skin immediately post 
dissection (A= negative control x40, B = 0 hours control x40) Primary antibody was Biosource 
pEGFR 1068 rabbit primary antibody at 1/25 overnight. Sections were cut at 5 pm on a 
Shandon Finesse microtome.
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Figure 4.19 ICC assay to detect pEGFR1068 in excised porcine skin (A, B, x20 C-I x40) after 3 (A, D, G), 6 (B, E, H) and 12 (C, F, I) hours incubation with water (A-C), 
fish oil (0.05% v/v BHA) (D-E) or fish oil plus 0.05% v/v BHA, 2.54 x 10‘4M PD98059, LY294002, 4-hydroxytamoxifen (plus 2.5% v/v DMSO/etOH and 4% w/v cab-o- 
sil). Primary antibody was Biosource pEGFR 1068 rabbit primary antibody at 1/25 overnight. Sections were cut at 5pm on a Shandon Finesse microtome
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4.3.5.6 T o ta l C O X -2
Figure 4.20 displays porcine skin im m ediately post dissection. The assay 
revealed that to ta l CO X-2 prote in was on ly  found w ith in  the epiderm is 
and was cytoplasm ic and nuclear. F igure 4.20A  represents a negative 
contro l, where the tota l CO X-2 prim ary antibody was replaced w ith  PBS. 
Figure 4.20B shows porcine skin assayed fo r the detection o f to ta l CO X- 
2 after 0 hours. The negative contro l displays no staining; suggesting 
that staining seen throughout th is assay was to ta l CO X-2 specific.
Figure 4.20 ICC assay to detect total COX-2 in excised porcine skin immediately post 
dissection (A= negative control xlO, B = 0 hours control x40) Primary antibody was 
New England Biolabs total COX-2 primary antibody at 1/25 overnight. Sections were 
cut at 5 pm on a Shandon Finesse microtome.
Figure 4.21 displays the to ta l CO X-2 assay perform ed on porcine skin 
treated w ith  water, fish  o il or fish  o il plus 2.54 x  lO ^M  PD98059, 
LY294002, 4-hydroxytam oxifen (plus 2.5%  v /v  DM SO /ethanol and 4% 
w /v  cab-o-sil). I t  revealed that to ta l CO X-2 protein expression remained 
constant up to 6 hours when water was applied to the SC surface. A t 12 
hours, however, to ta l C O X-2 staining was greater than that at 3 and 6 
hours.
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Application of fish oil knocked down total COX-2 protein expression within 
the epidermis after 3 hours (figure 4.2ID). Total COX-2 staining increased in 
intensity at 6 hours (4.2IE) and again at 12 hours (4.2IF) post fish oil 
application. Application of fish oil plus PD98059, LY294002 and 4- 
hydroxytamoxifen gave a continual knockdown in total COX-2 protein 
throughout the 12 hour experiment (4.21 G-I).
4.4 Discussion
The aims of this study were to investigate the plausibility of fish oil as an 
efficacious replacement for the DMSO vehicle and to probe whether it offered 
a skin friendly alternative.
Immunohistological and immunocytochemical data suggested that fish oil met 
the first criterion of the aims. H&E staining showed no obvious detrimental 
effects of fish oil, after 12 hours treatment, on the structure of the skin and 
showed no obvious keratinocyte toxicity, as observed with only 3 hours 
incubation with DMSO. It is widely documented that the mechanism by which 
DMSO exerts its permeation enhancement is by modifying the structure of the 
SC by removing the lipid content of it (Williams, A.C 2003) which is thought 
to be the reason that skin toxicity was seen.
The ki-67 assay determined that fish oil could be superior to water at 
maintaining the viability of excised porcine skin, possibly due to incorporation 
of fatty acids into cell membranes (Walker, R.B. & Smith, E.W. 1995). The
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staining was seen throughout the 12-hour timescale of the study, localised 
mainly to the lower layers of the epidermis.
The epidermis is the main enzymatic site within the skin, with most phase 1 
and phase 2 catalytic reactions occurring here, however only at a much reduced 
level (~10%) compared to that seen in the liver (Williams, A.C. 2003). The 
main sub-layer of the epidermis actively proliferating is the stratum basale, 
which explains the localisation of the ki-67 staining to this layer.
After the successful determination of fish oil as a non-toxic vehicle, it was then 
assessed for its’ ability to enhance the permeation of PD98059, LY294002 and 
4-hydroxytamoxifen. Permeation data and steady state flux of both PD98059 
and LY294002 with and without 4-hydroxytamoxifen present was vastly 
reduced compared to that seen with DMSO. The mechanism by which the 
PUFAs within the fish oil enhance permeation is different to that seen with 
DMSO. PUFAs are known to intercalate into the lipid domain of the stratum 
comeum, where the kink in their structures disrupts the linear array of lipids. 
DMSO at percentages over 60% is thought to cause an irreversible effect on 
the skin, causing loss of SC lipids and, in effect, forming a hole in the barrier. 
Taking the mechanisms into account, the severity in the permeation enhancing 
mechanism of DMSO compared to the more subtle mechanism of the PUFAs 
may be a plausible explanation for the results. Another theory, involving the 
pull effect, may explain the retardation in the permeation of all 3 compounds 
when formulated with fish oil. NSAIDs formulated within a fish oil vehicle
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have been shown to permeate proportionally to EPA and DHA, two PUFAs 
present within the fish oil. The permeation of ketoprofen and ibuprofen were 
assessed when both were formulated in fish oil. Interestingly the flux of EPA 
and DHA were greater when formulated with the fastest permeating NSAID. 
The authors suggest that this could be explained by the solute permeating in its 
solvent cage (Heard, C.M et al 2003). Later the permeation of ketoprofen and 
EPA was probed using NMR studies. Here it was discovered that ketoprofen 
and EPA permeated the skin whilst bound together (Thomas, C.P. et al 2007). 
With this in mind, possible binding complexes between PD98059, LY294002 
and 4-hydroxytamoxifen with EPA were studied.
Complexation between PUFAs and tamoxifen have already been shown, where 
HNMR showed that tamoxifen and y linolenic acid permeated full thickness 
skin bound together.
Figure 4.23 shows the most likely bonding complexes of PD98059/EPA and 
LY294002/EPA.
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Figure 4.23 Bonding complexes formed between PD98059 and EPA (left) and LY294002 
(right).
H -bonding interactions between the acid group o f EPA and the rin g  carbonyl 
group o f each o f the compounds are responsible fo r the com plexes and the 
s im ila r b ind ing  energies produced. These were 98.7K J/m ol and lO l.O K J/m ol 
fo r PD98059 and LY294002 respectively.
Th is b in d ing  could be responsible fo r the retardation o f perm eation o f a ll 3 
com pounds i f  the mechanism by w h ich  PUFAs com prom ise the barrie r 
properties o f sk in  is exam ined. I f  the PUFAs b ind the three compounds and 
then are in tercalated w ith in  the skin, unless the b ind ing  is overcom e, the 
compounds m ay be retained w ith in  the skin. Th is is also supported by the fact
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that EPA did not permeate the skin in the absence of the three compounds, 
suggesting that all permeating EPA was intercalated into the lipid environment 
of the SC. Incorporation of the compounds allowed small amounts of EPA to 
permeate via the pull effect.
The addition of the three permeation enhancers and combinations of these was 
aimed at improving the permeation of PD98059, LY294002 and 4- 
hydroxytamoxifen. The inclusion of all enhancers and enhancer combinations 
increased the permeation and steady state flux of all 4 actives. The method of 
enhancement caused by DMSO has been mentioned. The addition of ethanol 
may have enhanced the permeation of all 3 compounds in a wide range of 
ways. Ethanol can increase the solubility of solute so increase its partitioning 
into the skin. It can also affect the skins permeability to the solute irreversibly 
due to its entry and passage through the skin (Oh, S.Y. et al 2003). It has also 
been suggested by Liu, H. and colleagues (2006) that ethanol can extract lipids 
from the stratum comeum membrane and so increase the passage of the 
permeant through this barrier. Recent attention has been focused on the pull 
effect as a viable explanation of the enhancing properties of ethanol. It is 
suggested that the close relationship between the permeation of mefenamic 
acid and ethanol or 1,8-cineole was attributed to the pull effect and not the 
effect on the SC (Heard, C.M., et al 2005). Indeed, it was later established that 
ethanol gave rise to the same permeation enhancement in both full thickness 
skin and in heat separated dermal membranes. The absence of the SC in these
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membranes eliminates effects on the SC lipid content as a mechanism of 
permeation enhancement (Heard, C.M., et al 2007).
Terpenes, such as 1,8-cineole, have been widely used as penetration enhancers 
and have GRAS (generally regarded as safe) status (Narishetty, S.T.K. & 
Panchagnula, R. 2004). They are used to increase the permeation of 
compounds such as estradiol, ketoprofen and haloperidol (Monti, D. et al 2002, 
Rhee, Y.S. et al 2001, Vaddi, H.K. et al 2002). It has also previously been 
demonstrated that terpenes can enhance the permeation of tamoxifen (Gao, S. 
& Singh, J. 1998). The addition of 1,8-cineole may have enhanced the 
permeation of PD98059, LY294002 and 4-hydroxytamoxifen by disrupting 
stratum comeum lipid bilayers. Narishetty and co-workers (2004) showed, by 
differential scanning calorimetry, that terpenes caused a shift in endothermic 
transition temperature of SC lipids and suggested this was the main mechanism 
of their penetration enhancing actions. Moghimi, H.R. and colleagues, (1996- 
1997) throughout many short studies, concluded that hydrocarbon terpenes 
increase permeation by increasing the diffusivity of the SC lipids, whereas 
cyclic terpenes act by increasing the partitioning of solute into the skin.
Investigations looking at the effect of combination of two or more CPEs on 
permeation have received little attention in the literature, mainly due to the 
enormous quantity of combinations that exist. The combination of DMSO and 
ethanol gave an additive increase in permeation compared to the enhancement 
seen with the individual CPEs. Synergy was not seen with any combinations,
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which was similar to results seen by Karande, P. and colleagues (2006). This 
group showed, using a high through-put screening of CPE combinations that 
combinations of two or more CPEs very rarely displayed synergy and more 
often show additive benefit. Additive interactions may have caused an increase 
in permeation due to the different mechanisms of permeation enhancement of 
each individual CPE. However, as the definitive permeation enhancement 
mechanism of each CPE has not been elucidated, this can only be speculated.
Cab-o-sil forms gels due to its fumed silica network forming H-bonds with 
either solvents or with actives within the formulation. The inclusion of each 
percentage of cab-o-sil did not significantly alter the mass permeated or steady 
state flux of PD98059, LY294002 or 4-hydroxytamoxifen. This result suggests 
that each compound was released from the thickener sufficiently to allow 
maximal flux. However, the lag time of each compound was increased 
significantly, suggesting that cab-o-sil did slow down the initial release of the 
compounds. Interestingly, studies by Gallagher, S.J. and colleagues (2003) 
revealed that even the inclusion of 0.5% cab-o-sil retarded the permeation of 
ketoprofen and ibuprofen significantly. The inclusion of cab-o-sil above 4.0% 
(w/v) significantly impeded the permeation of EPA, suggesting that cab-o-sil 
formed H-bonds preferentially with constituents of the fish oil rather than with 
the active compounds.
The inclusion of the two enhancers and 4% cab-o-sil showed no obvious 
detrimental effects on the skin. Cab-o-sil is commonly used commercially as a
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non-matrix forming thickening (Gallagher, S.J. et al 2003). It is even used to 
thicken tomato ketchup so it is not surprising that this did not exert any toxicity 
on the skin. What was surprising, however, was evidence suggesting that the 
two enhancers (DMSO and etOH) did not display any skin toxicity when both 
were included at 2.5%. Common sense would dictate that if these two 
enhancers enhanced the permeation of PD98059, LY294002 and 4- 
hydroxytamoxifen in the classical method (by removing SC lipids and 
elevating SC lipid fluidity then some SC damage would be expected. This was 
not seen, either in H&E staining or with the ki-67 assay. These data may 
provide support that the enhancement seen is due to the pull effect rather than 
severe SC structural alterations. One other explanation could be that the 
percentages of each CPE used were enough to cause permeation enhancement 
by the classical mechanism but the alterations seen in the SC were too subtle to 
be seen in the ICC and IHC.
ICC detection of pERKl/2, pAkt, pEGFR and total COX-2 demonstrated, 
qualitatively, that the active constituents permeated through into the epidermis, 
where they inhibited the target molecules. After 3 hours the formulation 
containing fish oil plus PD98059, LY294002 and 4-hydroxytamoxifen was 
capable of inhibiting these mediators within the epidermis, compared to water 
control. This inhibition was maintained during the 12 hour experiment. 
Interestingly, COX-2 expression seemed to increase with time when skin was 
treated with water and increased after 3 hours incubation with fish oil. This 
suggests that the inflammatory response invoked by amputation and dissection
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of the ear caused a sustained induction of COX-2 protein, which overcame the 
concentrations of EPA and DHA within the epidermis. The cocktail 
formulation, however, maintained COX-2 knockdown throughout the 12 hour 
experiment, suggesting that PD98059, LY294002 or 4-hydroxytamoxifen 
affected total COX-2. A recent study supports this and linked the regulation of 
COX-2 expression in HT29 colon cancer cell lines to pERKl/2 activity, 
showing that PD98059 (20pmol/L) inhibited serum-induced COX-2 expression 
(Tominga, K. et al 2004). The pull effect could be another plausible 
explanation as to the maintained knockdown of COX-2. The permeation of 
EPA and DHA are significantly increased when compounds such as ketoprofen 
and ibuprofen were applied simultaneously (Thomas, C.P. & Heard, C.M. 
2004). This result was observed in this chapter, where EPA was only detected 
in the receptor fluid when PD98059, LY294002 and 4-hydroxytamoxifen were 
included. This increased permeation suggests that there would be more EPA 
and DHA within the epidermis to act on COX-2 localised there.
This limited investigation has shown that choice of vehicle and exipients is of 
paramount importance in the development of topical formulations. Even the 
replacement of one enhancer for another can, and has had significant effects on 
the permeation of different compounds. It has been very fortunate that the 
combination of DMSO and ethanol gave maximal enhancement of all 3 
compounds and EPA.
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4.5 Conclusions
Fish oil has been demonstrated as a potentially skin friendly vehicle, and with 
the correct mixture of enhancers and the optimum percentage of thickener can 
provide a suitable vehicle for the permeation of PD98059, LY294002 and 4- 
hydroxytamoxifen.
Although the permeation seen with the addition of CPEs was still not to the 
magnitude observed with the pure DMSO vehicle, a compromise must be made 
between safety and efficacy. Permeation studies and ICC have shown 
quantitatively and qualitatively that the constituents of the cocktail formulation 
permeate frill thickness skin at potentially useful rates.
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5.1 Introduction
The work in the earlier chapters detailed the development of an anti-breast 
cancer therapeutic system comprised of a MAPK inhibitor, a PI3K inhibitor 
and 4-hydroxytamoxifen and EPA (fish oil vehicle). This combination was 
derived primarily based upon their skin permeation characteristics, although 
assessment of their effects on human breast cancer cells is of key importance.
Two human breast cancer cell lines were used in this chapter to represent two 
phenotypes of the disease. MCF-7 cells are an adherent epithelial breast cancer 
cell line, derived from a pleural effusion adenocarcinoma. They are ER 
positive (ER+) and are steroid hormone sensitive (Hiscox, S. et al 2006), 
representing the ER+ phenotype that responds to tamoxifen (figure 5.1). TamR 
cells were developed ‘in house’ at the Tenovus Cancer Research Centre, 
Cardiff University. The cells were developed from parental MCF-7 cells that 
were grown in the presence of 4-hydroxytamoxifen until normal growth was 
restored (Knowlden, J.M. et al 2003). These cells were used to represent the 
patient population that develop acquired resistance to tamoxifen. The cells 
have lost sensitivity to E2 and tamoxifen but still have a growth inhibitory 
response to the pure anti-estrogen Faslodex (figure 5.2).
The use of fish oil not only provided a beneficial effect on the delivery of both 
PD98059 and LY294002 but research has shown that EPA, contained in fish 
oil, could provide an additional prong to the transcutaneous anti-breast cancer 
cocktail.
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It has been widely documented that many breast tumors overexpress COX-2, 
the inducible isoform of the cyclooxygenase enzyme (Davis, G. et al 2002). 
However the exact role for COX-2 in tumorogenesis is still unclear. Wild, P.J. 
and colleagues (2004) conducted a high throughput tissue microarray trial but 
used immunocytochemical techniques to assess the correlation of COX-2 
expression with molecular, clinical and pathologic markers involved in breast 
cancer. This study concluded that strong COX-2 staining was significantly 
correlated with high tumor stage and BRE grade and that there was a strong 
correlation with metastatic status and in hormone-refractory tumors compared 
to those confined to one organ suggesting that COX-2 may play a role in breast 
cancer cell motility and metastasis (Parrott, M.L. et al 1997).
5.1.1 Alms
Using a combination therapy comprising of 4-hydroxytamoxifen, LY294002 
and PD98059 it is postulated that tamoxifen resistance could be largely delayed 
or even eradicated. The aims of this chapter therefore, were to assess the 
effects of the cocktail formulation, developed in chapter 4, on tamoxifen 
sensitive and resistant cell lines. Growth assays were conducted to examine 
the effects of the compounds singly and simultaneously, while ICC analysis 
was employed to visualise the effect of the cocktail of compounds on key 
mediators of tumorogenesis such as COX-2, EGFR, ER, Akt, and ERK 1/2.
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5.2 Materials and Methods
5.2.1 Materials
The materials for this chapter have been outlined in chapter 2 (section 2.1).
5.2.2 Methods
5.2.2.1 Dose response curve for fish oil on growth of MCF-7 and TamR 
cells
The IC50 concentrations of 4-hydroxytamoxifen, PD98059 and LY294002 had 
already been determined in house on MCF-7 and TamR cells as 1 x 10'7 M, 25 
x 10"6 M and 5 x 10*6 M respectively, however the optimum volume of fish oil 
to deliver the optimum concentration of EPA on these cell lines had not been 
explored.
MCF-7 and TamR cells were grown to —70 % confluency, trypsinised and 
seeded into 24 well plates at a density of 1.5 x 106 per plate on day 0. Dose 
response assays were carried out as stated in chapter 2. Cells were dosed with 
volumes of filter sterilised fish oil made up in 2 :1  with ethanol to give final 
concentration of 0.1, 0.5, 1, 2 and 5 pi mL' 1 on days 1 and 4 and counted on 
day 7.
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5.2.2.2 Growth assays
Growth assays were performed as stated in section 2.2.2.3. Firstly the 
phenotype of both MCF-7 and TamR cells were checked to ensure the cells 
were behaving characteristically. Cells were seeded on day 0 and on days 1 
and 4 treated with compounds as shown in table 5.1.
Cell Line Treatment
MCF-7
0.1 pL mL'1 DMSO (Control)
1 x 10'7M Faslodex
1 x 10*7 M 40HTam
lx 10^ M E 2
TamR
0.1 pL mL'1 DMSO (Control)
1 x 10'7M Faslodex
lxlO'^MEz
Table 5.1 Dosing concentrations o f compounds for phenotypic analysis o f MCF-7 and TamR 
cells.
Secondly, MCF-7 and TamR cells were seeded on day 0. On day 1 base counts 
were taken and cells were dosed with IC50 and secondly permeated 
concentrations of 4-hydroxytamoxifen, PD98059, LY294002 and EPA as 
shown in table 5.2.
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Cell Line ICso Treatment
MCF-7
0.1 pL mL'1 DMSO (Control)
lpLmL'1 Fish oil
1 x 10*7M 40HTam
25 pM PD98059
5pM LY294002
1 x 10*7M 40HTam, 25 pM PD98059, 5pM LY294002
lpL mL*1 Fish oil,l x 10*7M 40HTam, 25pM PD98059,5pM 
LY294002
lx lO '^MEz
TamR
. 0.1 pL mL'1 DMSO (Control)
lpL mL'1 Fish oil
25 pM PD98059
5pM LY294002
1 x 10'7M Faslodex
25pM PD98059, 5pM LY294002
lpL mL'1 Fish oil, 25pM PD98059, 5pM LY294002
1 x 10'vME2
Table 5.2 Dosing concentrations of 4-hydroxytamoxifen, PD98059, LY294002 and EPA for 
growth assays.
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Concentrations were taken from the in vitro permeation studies (0.65 pM 
PD98059, 0.8 pM LY294002 and 0.41 pM 4-hydroxytamoxifen). The studies 
were conducted as above, except that cells were treated 0.65 pM PD98059, 0.8 
pM LY294002 and 0.41 pM 4-hydroxytamoxifen on day 1 and then with the 
concentration permeated after 24 h, each day thereafter (0.325 x 10"6 M 
PD98059,0.4 10"6 M LY294002 and 0.205 pM 4-hydroxytamoxifen).
The effect of permeated concentration of EPA was also assessed on the growth 
of MCF-7 cells. Cells were set up as in previous growth studies. Cells were 
dosed with 4pl of fish oil per 1ml of media to deliver the accurate permeated 
amount of EPA to the cells on days 1 and 4. Fish oil was dissolved 2:1 with 
ethanol. Counts were taken on days 1,3, 5 and 8 .
5.2.23 ICC of cell lines
Cells were grown to -70% confluency on TESPA coated glass coverslips 
placed at the bottom of sterile petri dishes. The cells were then treated as 
described in table 3 for 3 h. Cells were then fixed post treatment according to 
the assay to be performed (chapter 2). Coverslips were then frozen at -20 °C 
until required.
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Cell Line IC30 Treatment
MCF-7
O.lplml1 DMSO (Control)
lplmT1 Fish oil
1 x 10’7M4OHTam
25pM PD98059
5jiM LY294002
lplmT1 Fish oil, 1 x 10‘7M 40HTam, 25pM PD98059, 5\iM 
LY294002
TamR
O.lplmT1 DMSO (Control)
lplml' 1 Fish oil
25 pM PD98059
5pM LY294002
lplml1 Fish oil, 25pM PD98059, 5pM LY294002
Table 5.3 Treatments for ICC analysis
ICC assays to detect, total ER, pER 118, pER 167, EGFR, pEGFR 1068, pAkt 
and pERKl/2 were performed; coverslips were then dried and mounted onto 
glass microscope slides using DPX.
H-score was used as a semi-quantitative method of measuring specific staining. 
It was determined by equation 5.1 (McClelland, R. et al 2001).
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H-score = £ (% of cells very weakly stained cells x 0.5) + (% weakly stained 
cells x 1) + (% of moderately stained cells x 2) + (% strongly stained cells x 3) 
Equation 5.1
This analysis gives H Scores of between 0-300, where 0 is no staining seen and 
300 is the strongest staining possible.
S.2.2.4 Western blot
Western blot analysis was carried out as described in chapter 2. Cells were 
grown to -70% confluency, at which point they were dosed with either control 
(O.lplmT1 DMSO) or test (1 pL mL' 1 Fish oil,l x 10'7 M 40HTam, 25 pM 
PD98059, 5 pM LY294002 for MCF-7 cells and 1 pL mL' 1 Fish oil, 25 pM 
PD98059, 5pM LY294002 for TamR cells) treatments. These were incubated 
for 3 h, after which protein was extracted and frozen at -20 °C until required. 
Samples were probed for protein concentrations of total ER, pER 118, pER 
167, EGFR, pEGFR 1068, pAkt and pERKl/2.
Western blot analysis of P-actin using a CST p-actin was used as an internal 
control to ensure equal protein loading between lanes was achieved. P-actin is 
a ubiquitous protein and a major component of the cytoskeleton and has been 
proved as a positive control for protein loading (Grande, M. et al 2002, 
Suliburk, J. et al 2005).
188
Chapter 5 Probing the effect o f  PD98059, LY294002, 4-hydroxytamoxifen and fish oil on
human breast cancer cells
5.3 Results
5.3.1 Phenotypic analysis of cell lines
Before any experim entation in  th is  chapter both ce ll lines were analysed fo r 
typ ica l phenotypic behaviour. M C F -7  ce lls  were chosen to  represent hormone 
responsive breast cancer ce lls , w h ile  Tam R  ce lls were chosen to  represent the 
c lin ica l p rob lem atic s itua tion  o f  tam ox ife n  resistance. Therefore, it  was o f 
param ount im portance tha t the ce lls  behaved as expected.
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Figure 5.1 Growth assays to detect the effects o f  1 x 10'7M Faslodex, 1 x 10‘9M E2 and 1 x 10'7 
M 4-hydroxytamoxifen on MCF-7 cell growth. Cells were maintained in wRPMI + 5% SFCS 
for the duration o f  the experiment and were incubated at 37°C with 5%  C 0 2. Cells were dosed 
on days 1 and 4 and media replenished on doing. Passage numbers used were 25, 26 and 28 
(n=3 ±  SD).
189
Chapter 5 Probing the effect o f  PD98059, LY294002, 4-hydroxytamoxifen and fish oil on
human breast cancer cells
Figure 5.1 shows g row th  assays fo r M C F -7 ce lls treated w ith  0.1 p L  m L '1
D M SO  (co n tro l), 1 x  10'7 M  Faslodex, 1 x  10'9 M  E2 and 1 x  10‘7 M  4-
hydroxytam oxifen . I t  shows tha t the M C F-7 ce lls behaved as expected w ith  
Faslodex and 4 -h yd roxytam ox ifen  reducing ce ll g row th  to  64.3 ±  7.2 and 72.4 
±  10.1 %  o f con tro l g row th  a fte r 8 days. Treatm ent w ith  1 x  10'9 M  E2
elevated g row th  to 143 ±  12.7 %  o f co n tro l g row th  a fte r 8 days.
Figure 5.2 shows g row th  assays fo r Tam R  ce lls  when incubated w ith  0.1 pL  
m L '1 D M S O  (co n tro l), 1 x  10'7M  Faslodex and 1 x  10'9M  E 2 .
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Figure 5.2 Growth assays to detect the effects o f  1 x 10’7M Faslodex and 1 x 10'7M E2 on 
TamR cell growth. Cells were maintained in wRPMI + 5%  SFCS (with 1 x 10'9 M 4- 
hydroxytamoxifen present in the media) for the duration o f  the experiment and were incubated 
at 37°C with 5% C 0 2. Cells were dosed on days 1 and 4 and media replenished on day 4. 
Passage numbers used were 13, 15 and 18 (n=3 ± SD).
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The ce lls behaved characteristic  o f  tam oxifen  resistant ce lls, show ing
in se n s itiv ity  to  E 2 but s till d isp lay ing  a g row th  in h ib itio n  in  response to
incubation w ith  the true anti-estrogen Faslodex. G row th  was 69.9 ±  9.97 and
97.19 ±  12.5 %  o f  co n tro l ce ll g row th  when Tam R  ce lls  were incubated w ith  1
x  10*7M  Faslodex and 1 x  10'9M  E 2 respective ly.
5.3.2 Dose response for fish oil on the growth of MCF-7 and TamR cells
Before g row th  assays show ing the e ffe c t o f  fis h  o il over 8 days could  be 
achieved, the I C 5 0  o f fish  o il needed to  be discovered.
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Figure 5.3 Dose responses o f  MCF-7 and TamR cells to increasing volumes o f  fish oil. Cells 
were maintained in wRPMI + 5%  SFCS (with 1 x 10‘9 M 4-hydroxytamoxifen present in the 
media for TamR cells) for the duration o f  the experiment and were incubated at 37°C with 5% 
C 0 2. Cells were dosed on days 1 and 4 and media replenished on day 4. Passage numbers 
used were 18, 19 and 23 for MCF-7 cells and 20, 22 and 23 for TamR cells (n=3 ± SD).
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Figure 5.3 demonstrates that there was an inverse relationship between 
increased fish oil and cell count, suggesting that fish oil inhibited MCF-7 and 
TamR cell growth in a dose dependant manner. Interestingly, both cell lines 
gave the same IC50 concentration of 1 pL mL"1.
5 3 3  Growth assays
533.1 IC50 concentrations
The growth of MCF-7 and TamR cells were measured when insulted with 
PD98059, LY294002, 4-hydroxytamoxifen and fish oil. Figure 5.4 shows 
growth assays performed on MCF-7 cells.
Again the assay showed that the MCF-7 cells were hormone sensitive as they 
showed growth acceleration in response to estradiol and growth inhibition in 
response to 4-hydroxytamoxifen. These treatments altered growth rates to 
130.9 ±11.9 and 65.6 ± 5.8 % of control growth respectively. The incubation 
of MCF-7 cells with PD98059, LY294002, fish oil and combinations of 
compounds all reduced cell growth as displayed in table 5.4
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Figure 5.4 Growth assays to detect the effects o f  25pM PD98059, 5pM LY294002, 1 x 10'7 M 
4-hydroxytamoxifen and 1 pi ml'1 fish oil on MCF-7 cell growth. Cells were maintained in 
wRPMI + 5%  SFCS for the duration o f the experiment and were incubated at 37°C with 5% 
C 0 2. Cells were dosed on days 1 and 4 and media replenished on day 4. Cell passage numbers 
were 14, 16 and 17 n=3 ± SD).
F igure 5.4 shows the effects o f in su lt w ith  25 PD98059, 5 [iM LY294002
and 1 |xL m L -1 fish  o il (in d iv id u a lly  and sim ultaneously) on Tam R ce ll grow th.
The g row th  assays fo r Tam R  ce lls, again, show that th is  ce ll lin e  has lost 
se n s itiv ity  to  E2, how ever, PD98059, LY 294002, Faslodex and fish  o il gave 
grow th  in h ib ito ry  results.
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Figure 5.5 Growth assays to detect the effects o f 25pM PD98059, 5pM LY294002 and lplml' 
1 fish oil on TamR cell growth. Cells were maintained in wRPMI + 5% SFCS for the duration 
o f the experiment and were incubated at 37°C with 5% C 02. Cells were dosed on days 1 and 4 
and media replenished on day 4. Cell passage numbers were 12, 14 and 17 (n=3 ± SD).
As w ith  M C F-7 cells, the sim ultaneous incubation o f PD98059 plus 
LY294002, w ith  and w ithou t fish  o il present, gave s ig n ifican tly  greater ce ll 
grow th in h ib itio n  than incubation o f these compounds in d iv id u a lly . 
Percentage grow th compared to contro l when incubated w ith  these compounds 
can be seen in  table 5.4
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Cell Line Treatment %  growth compared to control
lplm l'1 Fish oil 65.56 ± 15.9§
1 x 10'7M 40HTam 65.55 ± 5.8*
25 pM PD98059 86.2 ± 4.95§
5pM LY294002 81.8 ± 5.78§
MCF-7 1 x 10'7M 40HTam, 25 pM 
PD98059, 5pM LY294002
8.84 ± 0.2** §
lplml"1 Fish oil, 1 x 10'7M 
40HTam, 25pM PD98059, 5pM 
LY294002
4.04 ±0.15** §
l x l O ^ M E 2 130.9 ± 11.9* §
lplm l'1 Fish oil 65.1 ± 16.8*
25pM PD98059 66.4 ±15.3*
5pM LY294002 55.7 ± 14.5*
TamR 1 x 10'7M Faslodex 59.7 ± 16.3*
25pM PD98059, 5pM LY294002 3.7 ± 0.9**
lp lm l1 Fish oil, 25pM PD98059, 
5pM LY294002
2.47 ± 1.4**
1 x 10^ M E2 98.7 ± 14.5
Table 5.4 Percentage cell growth compared to control when MCF-7 and TamR cells were 
incubated with 25pM PD98059, 5pM LY294002, 1 x 10'7M 4-hydroxytamoxifen and lplmT1 
fish oil (and combinations o f these). * p = <0.05 compared to control growth, ** p = < 0.004 
compared to control growth, § p = < 0.05 compared to same treatment between cell lines.
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5.33.2 Effect of levels of drug found to permeate full thickness skin
Although IC50 concentrations of the compound in the formulation gave 
significant reductions of MCF-7 and TamR cell growth, this does not 
necessarily extrapolate to the concentrations likely to reach breast cancer tissue 
when delivered transcutaneously. A more realistic assessment could be made 
by calculating the concentrations found in earlier chapters to permeate skin 
(4.3.4), correct for a 25 cm2 patch and apply to the cells.
The cells were dosed with concentrations permeated after 48 h (from the 
formulation consisting of 4 % cab-o-sil and 2.5 % DMSO ethanol) on day 1 
(0.65 pM PD98059,0.8 pM LY294002 and 0.41 pM 4-hydroxytamoxifen) and 
then with concentrations permeated after 24 h each day thereafter (half of those 
stated above).
Figure 5.6 shows the effects of the permeated doses of compounds on MCF-7 
cells. Permeated concentrations of compounds were able to inhibit the growth 
of MCF-7 cells, as shown in figure 5.6. PD98059 and LY294002 were able to 
reduce growth to 71.6 ± 9.98 and 72.1 ± 10.2 % of control growth (P = 0.024, 
0.026). The addition of permeated concentrations of 4-hydroxytamoxifen, 
which was more than the IC50 concentration, reduced cell growth to 62.2 ± 5.08 
% of control growth (P = 0.004).
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Figure 5.6 Growth assays to detect the effects o f  permeated concentrations o f PD98059, 
LY294002, 4-hydroxytamoxifen and lplm l'1 fish oil on MCF-7 cell growth. Cells were 
maintained in wRPMI + 5% SFCS for the duration o f the experiment and were incubated at 
37°C with 5% C 0 2. Cells were dosed on day 1 with permeated concentrations after 48 hours 
and with permeated concentrations after 24 hours on each day thereafter. Media was 
replenished on re-treatment. Cell passage numbers were 22, 24 and 29 (n=3 ± SD).
The sim ultaneous incuba tion  o f  these three com pounds was able to  reduce ce ll 
g row th  s ig n ific a n tly  to  17.27 ±  1.56 %  o f con tro l g row th  (P =  0.002). The 
add ition  o f  lp L  m L "1 fis h  o il to  these 3 com pounds reduced ce ll g row th  again, 
to  9.3 ± 2 .1  %  o f  co n tro l g row th  (P =  0.0018).
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Figure 5.7 Growth assays to detect the effects o f  permeated concentrations o f PD98059, 
LY294002 and lplml'1 fish oil on TamR cell growth. Cells were maintained in wRPMI + 5% 
SFCS for the duration o f the experiment and were incubated at 37°C with 5% C 02. Cells were 
dosed on day 1 with permeated concentrations after 48 hours and with permeated 
concentrations after 24 hours on each day thereafter. Media was replenished on re-treatment. 
Cell passage numbers were 19, 22 and 26 (n=3 ± SD).
Figure 5.7 demonstrates that when incubated sim ultaneously PD98059 and 
LY294002 reduced Tam R ce ll grow th s ig n ifican tly  compared to contro l 
grow th (P =  0.001). The com bination reduced ce ll grow th to 25.4 ± 3 . 9  and
6.4 ±  1.6 %  o f contro l grow th when incubated w ith o u t and w ith  1 pL  m L*1 fish  
o il.
Permeated concentrations o f PD98059 and LY294002 when incubated sing ly 
were also capable o f g iv ing  a modest reduction in  ce ll grow th; 87.5 ± 1 3 .9  and 
83.5 ±  11.3 %  o f contro l grow th respectively, however, th is was not a
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significant observation. No significant difference was seen in the ability of 
each compound and mixture of compounds to inhibit cell growth of MCF-7 or 
TamR cells (P > 0.08)
53.4 ICC of MCF-7 and TamR cells
53.4.1 Total ERa
MCF-7 and TamR cells were assessed for total ERa protein using ICC 
detection. Figure 5.8 demonstrates that ERa is localised to the nucleus of the 
MCF-7 and TamR cells. The assay also highlights that total ERa is expressed 
at a higher level in MCF-7 cells than TamR cells. This is reiterated in the H- 
score analysis, shown in table 5.4, where ERa has a H-score of 213 ± 31 in 
MCF-7 cells and 122 ± 27 shows that expression of total ERa is significantly 
reduced in TamR cells compared to MCF-7 cells (P = 0.034).
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Figure 5.14 A-F MCF-7 cells assayed for pEGFR 1068 (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with 
O.lplml'1 DMSO (A), 25p PD98059 (B), 5pM LY294002 (C) 1 x 10'7M 40HTam (D), lp lm f1 fish oil (E) and combination of PD, LY, 40HTam and fish oil (F) for 3 
hours. Fixation was 2.5% Phenol-Formal Saline. Primary antibody was Biosource pEGFR 1068 rabbit primary antibody at 1/75 overnight at 37°C.
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Figure 5.14 G-K TamR cells assayed for pEGFR 1068 (x20). Cells were grown to ~70% confluency on a TESPA coated coverslip. They were then treated with 
O.lplml'1 DMSO (G), 25p PD98059 (H), 5pM LY294002 (I), Iplml'1 fish oil (J) and combination o f PD, LY and fish oil (K) for 3 hours. Fixation was 2.5% Phenol- 
Formal Saline. Primary antibody was Biosource pEGFR 1068 rabbit primary antibody at 1/75 overnight at 37°C
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Figure 5.8 A-F MCF-7 cells assayed for total ER (x20). Cells were grown to -70%  confluency on a TESPA coated coverslip. They were then treated with O.lglml"1
DMSO (A), 25g PD98059 (B), 5pM LY294002 (C) 1 x 10'7M 40HTam (D), lglm l'1 fish oil (E) and combination o f PD, LY, 40HTam  and fish oil (F) for 3 hours.
Fixation was ER-ICA. Primary antibody was DAKO total ER clone IDS mouse antibody at 1/100 in PBS and was incubated for 60 minutes.
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Figure 5.8 G-K TamR cells assayed for total ER (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with O.lplml'1 
DMSO (G), 25p PD98059 (H), 5pM LY294002 (I), liilm f1 fish oil (J) and combination of PD, LY and fish oil (K) for 3 hours. Fixation was ER-ICA. Primary 
antibody was DAKO total ER clone ID5 mouse antibody at 1/100 in PBS and was incubated for 60 minutes
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F ig u re  5 .8  s h o w s  to ta l  E R  s ta in in g  w a s  n u c le a r ,  w i th  n o  c y to p la s m ic  E R  
s ta in in g  se e n . 4 - h y d r o x y ta m o x i f e n  (D )  a n d  th e  c o c k ta i l  f o r m u la t io n  (F )  b o th  
g a v e  th e  m o s t  o b v io u s  r e d u c t io n  in  to ta l  E R  s ta in in g  in  M C F - 7  c e l ls ,  r e d u c in g  
th e  H -s c o re  f ro m  2 1 3  ±  31 s e e n  in  c o n tro l ,  to  81 ±  11 a n d  7 5  ±  7 , w h ic h  w e re  
s ig n if ic a n t  r e d u c t io n s  in  p E R 1 1 8  p r o te in  (P  =  0 .0 2 2  a n d  0 .0 1 9  r e s p e c t iv e ly ) .  
P D 9 8 0 5 9  (B )  a n d  L Y 2 9 4 0 0 2  (C )  b o th  g iv e  a  m u c h  le s s  p r o m in e n t  a n d  a lm o s t  
u n n o t ic e a b le  r e d u c t io n  in  to ta l  E R  s ta in in g .  F i s h  o i l  (E )  g a v e  n o  r e d u c t io n  in  
to ta l  E R  p ro te in .
F ig u re  5 .8  a ls o  s h o w s  T a m R  c e l l s  s ta in e d  f o r  to ta l  E R . I t  is  o b v io u s  b y  
c o m p a r in g  f ig u re s  5 .8  (A )  a n d  (G )  t h a t  to ta l  E R  p r o te in  is  v a s t ly  r e d u c e d  in  
T a m R  c e l ls  c o m p a r e d  to  M C F - 7  c e l l s .  E x p r e s s io n  o f  to ta l  E R  in  T a m R  c e l ls  is  
s im i la r  to  e x p r e s s io n  in  4 - h y d r o x y ta m o x i f e n  t r e a te d  M C F - 7  c e l l s  (D ) . F ig u re  
5 .8  s h o w s  th a t  P D 9 8 0 5 9  (H )  a n d  L Y 2 9 4 0 0 2  ( I )  b o th  r e d u c e d  to ta l  E R  p r o te in  
in  T a m R  c e lls ,  to  a  s im i la r  d e g r e e .  H o w e v e r ,  f i s h  o i l  d id  n o t  h a v e  a n y  e f f e c t  
o n  to ta l  E R  p r o te in  le v e ls  ( J ) .  T h e  c o c k ta i l  o f  c o m p o u n d s  p r o v e d  to  g iv e  th e  
m o s t  s ig n if ic a n t  (P  =  0 .0 4 6 )  r e d u c t io n  in  to ta l  E R  in  T a m R  c e l l s  (K ) , r e d u c in g  
th e  H -s c o re  f ro m  1 2 2  ±  2 7  s e e n  in  c o n t r o l  T a m R  c e l ls ,  t o  5 1 .3  =t 3 .6 7 .
5.3.4.2 pER118
I t  w a s  a ls o  im p o r ta n t  to  lo o k  a t  a c t iv a te d  E R a  a s  th e  M A P K  a n d  P I3 K  
p a th w a y s  c a n  p h o s p h o r y la te  a n d  th u s  a c t iv a te  E R a  a t  s p e c i f ic  r e s id u e s .  M A P K  
c a n  p h o s p h o r y la te  E R  a t  s e r in e  1 1 8 , th e r e f o r e  p E R  1 1 8  p r o te in  le v e ls  w e re  
a n a ly s e d  in  b o th  c e l l  l in e s .  F ig u r e  5 .9  s h o w s , l ik e  to ta l  E R , p E R 1 1 8  s h o w s
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nuclear sta in ing  in  both  c e ll lin e s  w ith  no cytop lasm ic s ta in ing . Leve ls o f
pER 118 p ro te in  were m uch lo w e r than  to ta l ER a, w ith  pER 118 leve ls being
h ighe r in  M C F -7  ce lls  (A ) than in  Tam R  ce lls  (G ).
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Figure 5.9 A-F MCF-7 cells assayed for pER 118 (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with 0.1 plrnl'1 
DMSO (A), 25p PD98059 (B), 5pM LY294002 (C) 1 x 10'7M 40HTam (D), lplml'1 fish oil (E) and combination of PD, LY, 40HTam and fish oil (F) for 3 hours. 
Fixation was 2% paraformaldehyde. Primary antibody was NEB phospho-ER 118 monoclonal antibody at 1/500 in PBS overnight.
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Figure 5.9 G-K TamR cells assayed for pER 118 (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with 0. lplml'1 
DMSO (G), 25p PD98059 (H), 5pM LY294002 (I), lplml'1 fish oil (J) and combination of PD, LY and fish oil (K) for 3 hours. Fixation was 2% paraformaldehyde. 
Primary antibody was NEB phospho-ER 118 monoclonal antibody at 1/500 in PBS overnight.
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F ig u re  5 .9  s h o w s  th a t  e a c h  c o m p o u n d  s e e m e d  to  r e d u c e  p E R 1 1 8  p r o te in ,  w i th  
th e  c o m b in a t io n  t r e a tm e n t  g iv in g  th e  g r e a te s t  r e d u c t io n  in  p E R l  18  in  b o th  c e l l  
l in e s . H - s c o re  a n a ly s is  ( ta b le  5 .4 )  s h o w e d  th a t  th is  c o m b in a t io n  o f  c o m p o u n d s  
re d u c e d  p E R l  18 s p e c if ic  s ta in in g  in te n s i ty  s ig n i f ic a n t ly  in  b o th  c e l l  l in e s ;  f ro m  
125 ±  18 to  2 0  ±  5 in  (P  =  0 .0 0 0 5 )  M C F - 7  c e l ls  a n d  f r o m  5 9  ±  4  to  1 6 .5  ±  2 .5  
(P  =  0 .0 0 1 )  in  T a m R  c e lls .
5.3.4.3 pER167
A s  w i th  p E R 1 1 8 ,  p E R 1 6 7  is  a  l ig a n d  in d e p e n d e n t  a c t iv a t io n  s ite , w i th  
a c t iv a t io n  o f  th e  P I 3 K  s ig n a l l in g  p a th w a y  p h o s p h o r y la t in g  E R a  a t  th i s  r e s id u e . 
F ig u re  5 .1 0  e x a m in e s  th e  e x te n t  o f  p E R 1 6 7  in  b o th  c e l l  l in e s  a n d  th e  e f f e c t  th a t  
e a c h  c o m p o u n d  a n d  th e  c o c k ta i l  o f  c o m p o u n d s  h a d  o n  p E R  1 6 7  p r o te in  
e x p re s s io n .
F ig u re  5 .1 0  s h o w s  th a t  p E R 1 6 7  w a s  lo c a l i s e d  to  th e  n u c le u s ,  w i th  n o  
c y to p la s m ic  s ta in in g  b e in g  d e te c te d .
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Figure 5.10 A-F MCF-7 cells assayed for pER 167 (x20). Cells were grown to ~70% confluency on a TESPA coated coverslip. They were then treated with 0.1 plml'1 
DM SO (A), 25p PD98059 (B), 5pM LY294002 (C) 1 x 10’7M 40HTam (D), lp lm f1 fish oil (E) and combination of PD, LY, 40HTam and fish oil (F) for 3 hours. 
Fixation was ER-ICA. Primary antibody was CST phospho-ER 167 antibody at 1/25 in PBS overnight.
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Figure 5.10 G-K TamR cells assayed for pER 167 (G x 40 H-K x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated 
with O.lplml'1 DM SO (G), 25 p PD98059 (H), 5pM LY294002 (I), lp lm f1 fish oil (J) and combination of PD, LY and fish oil (K) for 3 hours. Fixation was ER-ICA. 
Primary antibody was CST phospho-ER 167 antibody at 1/25 in PBS overnight.
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U n lik e  to ta l  E R  a n d  p E R 1 1 8 , p E R 1 6 7  p r o te in  e x p r e s s io n  w a s  s ig n i f ic a n t ly  
e le v a te d  (P  =  0 .0 1 1 )  in  T a m R  c e l ls  (5 .1 0  G )  c o m p a r e d  to  M C F - 7  c e l ls  (A ) . H -  
s c o re  w a s  18 ±  3 in  c o n tro l  M C F - 7  c e l l s  a n d  1 8 2  ±  3 0  in  T a m R  c e l ls .  p E R 1 6 7  
s ta in in g  w a s  v e r y  lo w  in  M C F - 7  c e l ls ,  h o w e v e r ,  i t  w a s  p o s s ib le  to  te l l  th a t  
P D 9 8 0 5 9  (B ) , L Y 2 9 4 0 0 2  (C ) ,  4 - h y d r o x y ta m if e n  (D )  a n d  th e  c o c k ta i l  o f  
c o m p o u n d s  (F )  a l l  r e d u c e d  th e  e x p r e s s io n  o f  p E R 1 6 7  in  M C F - 7  c e l ls ,  
H o w e v e r ,  f i s h  o i l  (E )  h a d  n o  e f f e c t ,  q u a n t i f ie d  in  th e  H - s c o r e s  in  ta b le  5 .4 .
S ta in in g  w a s  m u c h  s t r o n g e r  in  c o n t r o l  t r e a te d  T a m R  c e l ls ,  w h ic h  a l lo w e d  
e a s ie r  e x a m in a t io n  o f  th e  e f f e c t s  o f  P D 9 8 0 5 9 ,  L Y 2 9 4 0 0 2 ,  f i s h  o i l  a n d  th e  
c o c k ta i l  o f  c o m p o u n d s . L Y 2 9 4 0 0 2  ( I )  s ig n i f ic a n t ly  r e d u c e d  p E R 1 6 7  s p e c if ic  
s ta in in g  (P  =  0 .0 1 7 ) ,  h o w e v e r  to  a  le s s e r  e x te n t  th a n  th e  c o c k ta i l  o f  c o m p o u n d s  
(K ). In v e r s e ly  to  r e s u l t s  s e e n  in  M C F - 7  c e l l s ,  in  T a m R  c e l ls  f i s h  o i l  ( J )  
s ig n if ic a n t ly  r e d u c e d  p E R 1 6 7  p r o t e in  le v e ls  ( P =  0 .0 2 7 ) .
H -s c o r in g , d is p la y e d  in  ta b le  5 .4 ,  s h o w e d  th a t  th e  c o c k ta i l  f o r m u la t io n  
s ig n if ic a n t ly  r e d u c e d  th e  H - s c o r e  o f  p E R 1 6 7  s ta in in g  c o m p a r e d  to  c o n tro l  in  
b o th  c e l l  l in e s  f r o m  1 8 ± 3 t o 2 ± 2 i n  M C F - 7  c e l ls  (P  =  0 .0 5 )  a n d  f ro m  1 8 2  ±  
3 0  to  11 ±  6  in  T a m R  c e l l s  (P  =  0 .0 1 1 ) .
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H-Score
Cell line Treatment Total ER pER118 pER167 pERKl/2 pAkt Total
EGFR
pEGFR1068
MCF-7
Control 213 ± 31 125 ±18 18 ± 3 105 ±26 121 ±8 52 ±18 34 ±6
PD 183 ±24 61 ±4. 10 ± 2 37 ±5 125 ±7 44.2 ±4 21 ±8
LY 198 ±18 81 ± 9 16 ± 4 96 ±8 45 ±3 36 ±4 12±4
40HTam 81 ± 11 54 ± 6 13 ± 3 108 ±19 111 ± 9 66 ±12 0±0
FO 213 ±34 93 ±13 5 ± 4 64 ±17 77 ± 7.5 32 ± 6 9±4
PD, LY,
40HTam,
FO
75 ±7 20.5 ± 5 2 ± 2 15 ±3 30 ± 5 19 ± 5 0±0
TamR
Control 122 ±27 59 ± 4 182 ±30 210 ± 33 175 ±11 256 ±17 277 ±21
PD 112 ± 14 57 ± 3 141 ± 6 70 ±21 180 ±9 235 ± 27 162 ±22
LY 102 ±10 53 ±7 46 ±7 159 ±18.5 40± 6 253 ± 24 168 ±15
FO 122 ± 17 41 ±6.5 71 ± 11 118 ±22 109 ±12.5 130 ±21 222 ± 33
PD, LY, 
FO
51.3 ±3.67 16.5 ± 2.5 11 ± 6 17 ± 3 15 ± 7 126 ±30 132 ±10
Table 5.4 H-score analysis of MCF-7 and TamR cells when assayed for the immunocytochemical detection of ER, pERl 18, pER167, pERKl/2, pAkt, total EGFR and 
pEGFR1068. Cells were treated with control (O.lplml'1 DMSO), 25pM PD, 5pM LY, 1 x 10'7 M 40HTam, lplml*1 fish oil for 3 hours (n=3 ± SD).
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5.3.4.4 pERK 1/2
T h e  p r o te in  e x p r e s s io n  o f  p E R K l / 2  w a s  a n a ly s e d  in  b o th  c e l l  l in e s  w h e n  
in s u l te d  w i th  th e  c o c k ta i l  f o r m u la t io n  a s  th is  is  th e  t a r g e t  o f  P D 9 8 0 5 9 .  F ig u re  
5 .1 1  s h o w s  th a t  p E R K l / 2  w a s  d e te c te d  in  b o th  th e  c y to p la s m  a n d  n u c le u s .  
M C F -7  c e l ls  (5 .1 1  A )  s h o w e d  s ig n i f ic a n t ly  le s s  p E R K l / 2  p r o te in  e x p r e s s io n  
th a n  T a m R  c e l ls  ( 5 .1 1 G ) d id  (p  =  0 .0 2 2 ) .  P D 9 8 0 5 9  g a v e  a  s ig n i f ic a n t
k n o c k d o w n  in  p E R K l / 2  p r o te in  e x p r e s s io n  in  b o th  c e l l  l in e s  w i th  p  v a lu e s  o f  
0 .0 4 5  a n d  0 .0 0 8  f o r  M C F - 7  a n d  T a m R  c e l l s  r e s p e c t iv e ly  (5 .1  I B  &  H ) . T h is  
w a s  q u a n t i f ie d  b y  th e  H - s c o r e  a n a ly s i s ,  w h e r e  P D 9 8 0 5 9  r e d u c e d  th e  H - s c o r e  o f  
E R K 1 /2  f ro m  105  ±  2 6  to  3 7  ±  5 in  M C F - 7  c e l ls  a n d  f r o m  2 1 0  ±  3 3  to  7 0  ±  21 
in  T a m R  c e lls .  F i s h  o i l  a ls o  g a v e  a  m o d e s t  d e c r e a s e  in  p E R K l / 2  s ta in in g  in  
b o th  c e l l  l in e s  (5 .1  I E  &  J ) . T h e  c o c k ta i l  f o r m u la t io n  o f  P D 9 8 0 5 9 ,  L Y 2 9 4 0 0 2 ,  
4 - h y d r o x y ta m o x if e n  a n d  f i s h  o i l  i n  M C F - 7  c e l l s  a n d  P D 9 8 0 5 9 ,  L Y 2 9 4 0 0 2  a n d  
f is h  o i l  in  T a m R  c e l ls  g a v e  th e  m o s t  s ig n i f i c a n t  k n o c k d o w n  in  p E R K l / 2  
p r o te in  e x p r e s s io n  (p  =  0 .0 2 6  a n d  0 .0 1  r e s p e c t iv e ly ) ,  w h ic h  a lm o s t  s i le n c e d  
p E R K l / 2  e x p r e s s io n  c o m p le te ly .  T h i s  w a s  c o n f i r m e d  in  H - s c o r e  a n a ly s is  
s h o w n  in  ta b le  5 .4 .
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Figure 5.11 A-F MCF-7 cells assayed for pERKl/2 (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with 0.1 plmf 
1 DMSO (A), 25p PD98059 (B), 5pM LY294002 (C) 1 x 10'7M 40HTam (D), lp lm f1 fish oil (E) and combination of PD, LY, 40HTam and fish oil (F) for 3 hours. 
Fixation was formal saline. Primary antibody was CST phospho-ERK. 1/2 antibody at 1/20 in PBS for 1 hour.
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Figure 5.11 G-K TamR cells assayed for pERKl/2 (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with O.lplml'1 
DMSO (G), 25p PD98059 (H), 5pM LY294002 (I), 1 plml'1 fish oil (J) and combination o f PD, LY and fish oil (K) for 3 hours. Fixation was formal saline. Primary 
antibody was CST phospho-ERK 1/2 antibody at 1/20 in PBS for 1 hour.
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L Y 2 9 4 0 0 2  (5 .1 1  C  &  I) d id  n o t  a f fe c t  p E R K l /2  e x p re s s io n  in  e i th e r  c e ll lin e , 
w h ile  in c u b a tio n  o f  M C F -7  c e lls  w ith  4 -h y d ro x y ta m o x ife n  d id  n o t  a f fe c t 
p E R K l /2  p ro te in  e x p re s s io n .
§.3.4.5 pAkt
T h e  p ro te in  e x p re s s io n  o f  p A k t  w a s  a n a ly s e d  in  b o th  c e l l  l in e s  w h e n  in s u lte d  
w ith  th e  c o c k ta i l  fo rm u la tio n  a s  th is  is  th e  ta rg e t  o f  L Y 2 9 4 0 0 2 . F ig u re  5 .1 2  
sh o w s  th a t  p A k t  w a s  m a in ly  lo c a lis e d  to  th e  c y to p la s m  b u t  s o m e  n u c le a r  
s ta in in g  w a s  d e te c te d . M C F -7  c e lls  (5 .1 2 A )  s h o w e d  le s s  p A k t  p ro te in  
e x p re s s io n  th a n  T a m R  c e lls  (5 .1 2 G )  d id , h o w e v e r  th is  w a s  n o t  s ig n if ic a n t  (P  =  
0 .0 7 9 ) . L Y 2 9 4 0 0 2  g a v e  a  s ig n if ic a n t  k n o c k d o w n  (P  =  0 .0 1 3 , 0 .0 0 0 2
re s p e c tiv e ly )  in  p A k t  p ro te in  e x p re s s io n  in  b o th  c e ll  l in e s  (5 .1 2 B  &  H ). F is h  
o il  a lso  h a d  n o  e f fe c t  o n  p A k t  s ta in in g  in  M C F -7  o r  T a m R  c e lls  (5 .1 2 E  &  J). 
T h e  c o c k ta i l  fo rm u la t io n  o f  P D 9 8 0 5 9 , L Y 2 9 4 0 0 2 , 4 -h y d ro x y ta m o x ife n  a n d  
f is h  o il  in  M C F -7  c e l ls  a n d  P D 9 8 0 5 9 , L Y 2 9 4 0 0 2  a n d  f is h  o il  in  T a m R  c e lls  
g a v e  th e  g re a te s t  k n o c k d o w n  in  p A k t  p ro te in  e x p re s s io n  (P  =  0 .0 0 9 , 0 .0 0 0 1  
re s p e c tiv e ly  fo r  M C F -7  a n d  T a m R  c e lls ) .
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Figure 5.12 A-F MCF-7 cells assayed for pAkt (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with O.lplml'1 
DMSO (A), 25p PD98059 (B), 5pM LY294002 (C) 1 x 10‘7M 40HTam (D), lplm!'1 fish oil (E) and combination o f PD, LY, 40HTam and fish oil (F) for 3 hours. 
Fixation was ER-ICA. Primary antibody was CST phospho-Akt antibody at 1/100 in PBS for 2 hours.
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Figure 5.12 G-K TamR cells assayed for pER 167 (G x 40 H-K x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated 
with O.lplml"1 DMSO (G), 25p PD98059 (H), 5pM LY294002 (I), lp lm f1 fish oil (J) and combination of PD, LY and fish oil (K) for 3 hours. Fixation was ER-ICA. 
Primary antibody was CST phospho-Akt antibody at 1/100 in PBS for 2 hours.
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5.3.4.6 Total EGFR
P I3 K  a n d  M A P K  a re  d o w n s tre a m  m e d ia to r s  o f  E G F R . T h e re fo re  to ta l  E G F R  
w a s  m e a s u re d  to  a s s e s s  th e  e x p re s s io n  o f  E G F R  in  b o th  c e ll  l in e s  a n d  to  
e x a m in e  th e  e f fe c ts ,  i f  a n y , o f  P D 9 8 0 5 9 , L Y 2 9 4 0 0 2 , 4 -h y d ro x y ta m o x ife n , f is h  
o il a n d  th e  c o c k ta i l  o f  c o m p o u n d s  o n  th e  e x p re s s io n  o f  to ta l  E G F R .
F ig u re  5 .1 3  s h o w s  e x p re s s io n  o f  to ta l  E G F R  in  M C F -7  a n d  T a m R  c e lls .
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Figure 5.13 A-F MCF-7 cells assayed for total EGFR (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with 
O.lglml'1 DM SO (A), 25 \i PD98059 (B), 5pM LY294002 (C) 1 x 10'7M 40HTam (D), lplml'1 fish oil (E) and combination of PD, LY, 40HTam and fish oil (F) for 3 
hours. Fixation was 2.5% Phenol-Formal Saline. Primary antibody was NeoMarkers EGFR mouse monoclonal antibody at 1/20 in PBS overnight.
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Figure 5.13 G-K TamR cells assayed for total EGFR (x20). Cells were grown to -70% confluency on a TESPA coated coverslip. They were then treated with 
O.lplml'1 DMSO (G), 25p PD98059 (H), 5pM LY294002 (I), 1 plrnl'1 fish oil (J) and combination of PD, LY and fish oil (K) for 3 hours. Fixation was 2.5% Phenol- 
Formal Saline. Primary antibody was NeoMarkers EGFR mouse monoclonal antibody at 1/20 in PBS overnight.
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F ig u re  5 .1 3  sh o w s  th a t  to ta l  E G F R  w a s  e x p re s s e d  a t  s ig n if ic a n tly  h ig h e r  le v e ls  
in  T a m R  c e lls  c o m p a re d  to  M C F -7  c e lls , c o m p a re d  in  f ig u re  5 .1 3  A  a n d  G  (P  =  
0 .0 1 ) . T o ta l  E G F R  d is p la y e d  m e m b ra n e  a n d  c y to p la s m ic  lo c a liz a tio n . 
P D 9 8 0 5 9  (H ) a n d  L Y 2 9 4 0 0 2  (I)  d id  n o t  a f fe c t  to ta l  E G F R  in  T a m R  c e lls , 
h o w e v e r , f is h  o i l  (J )  a n d  th e  c o m b in a tio n  o f  c o m p o u n d s  (K ) g a v e  a  s ig n if ic a n t  
d e c re a s e  in  to ta l  E G F R  s ta in in g  (P  =  0 .0 0 4  a n d  0 .0 0 7  re s p e c tiv e ly ) .
53.4.7 pEGFR 1068
T h e  e x p re s s io n  o f  p E G F R 1 0 6 8  w a s  a lso  e x a m in e d  a s  th is  p h o s p h o ry la t io n  s ite  
is  in v o lv e d  w i th  M A P K  s ig n a llin g . F ig u re  5 .1 4  s h o w s  th e  e x p re s s io n  o f  
p E G F R  1 0 6 8  in  b o th  c e ll  l in e s  w a s  lo c a l is e d  to  th e  c e ll  m e m b ra n e  a n d  
c y to p la s m .
M C F -7  c e l ls  e x p re s s e d  s ig n if ic a n tly  lo w e r  (P  =  0 .0 0 3 )  le v e ls  o f  p E G F R 1 0 6 8  
th a n  T a m R  c e lls ,  d is p la y e d  in  f ig u re  5 .1 4  A  a n d  G .
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P D 9 8 0 5 9  (H ) , L Y 2 9 4 0 0 2  ( I )  a n d  th e  c o c k ta i l  fo rm u la t io n  (K )  a l l  s h o w e d  
s ig n if ic a n t  in h ib i t io n  o f  p E G F R 1 0 6 8  p r o te in  e x p re s s io n  in  T a m R  c e l ls  (P  =  
0 .0 0 7 , 0 .0 0 5 , 0 .0 0 8  re s p e c tiv e ly ) . F is h  o il  ( J )  g a v e  a  m o d e s t  in h ib i t io n  in  
p E G F R  e x p re s s io n  in  T a m R  c e l ls ,  h o w e v e r  th is  w a s  n o t  s ig n if ic a n t  (P  =  
0 .0 9 3 ) .
53.5 Western blot
T o  c o n f i rm  th e  re s u lts  s e e n  in  th e  IC C  a n a ly s is  o f  M C F -7  a n d  T a m R  c e lls ,  
w e s te rn  b lo t  w a s  c a r r ie d  o u t  to  a s s e s s  th e  p r o te in  e x p re s s io n  o f  to ta l  E R , 
p E R 1 1 8 , p E R 1 6 7 ,  p A k t, p E R K l/2 ,  to ta l  E G F R  a n d  p E G F R  w h e n  t r e a te d  w ith  
e i th e r  O . lu lm l '1 D M S O  (c o n tro l)o r  2 5 j i  P D 9 8 0 5 9 , 5 ( iM  L Y 2 9 4 0 0 2 , 1 x  1 0 '7M  
4 0 H T a m , l^ i lm l '1 f i s h  o i l  ( te s t) .
53.5.1 ERa
T h e  c o c k ta i l  fo rm u la t io n  g a v e  a  r e d u c t io n  to ta l ,  p i  18 a n d  p l 6 7  E R a  in  b o th  
c e l l  l in e s .  F ig u re  5 .1 5  sh o w s  w e s te rn  b lo t  a n a ly s is  f o r  to ta l  E R , p E R 1 1 8  a n d  
p E R 1 6 7  in  M C F -7  a n d  T a m R  c e lls .
W e s te rn  b lo t  o f  p  a c t in  re v e a le d  e q u a l  p r o te in  lo a d in g  w a s  a c h ie v e d , a s  s h o w n  
in  f ig u re  5 .1 5 A . A ll  d e n s ito m e try  w a s  n o rm a lis e d  f o r  a c t in .
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Figure 5.15 Western Blot for the levels o f total ERa, pERal 18, pERal67 and p-actin protein. 
MCF-7 and TamR cells were incubated with lplml"1 fish oil, 25 pM PD98059, 5pM LY294002 
and 1 x 10'7M 40HTam (MCF-7 cells only) for three hours. Cells were lysed and protein 
extracted and quantified for equal loading. Protein was separated by SDS-PAGE, immobilised 
on a nitrocellulose membrane and immunoprobed using a total ERa, pERall8 or pERal67 
primary antibody. Passage numbers 37, 29, 31 for MCF-7 cells and 23, 26 and 28 for TamR 
cells. B Densitometry analysis o f total ERa, pERal 18 and pERal67 protein (n=3 ± SEM). 
M7- MCF-7 cells, TR- TamR cells. Densitoetry was normalised to actin. Densitometry was 
performed using Alpha Digi Doc ™ RT camera and image analysis system, Genetic Research 
Instrumentation, Essex, UK.
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Western blot and densitometry analysis showed that total ERa and pERall8 
were expressed at higher levels in MCF-7 cells than in TamR cells (P = 0.011), 
while pERal67 protein was significantly higher in TamR cells compared to 
MCF-7 cells (P = 0.01). The cocktail formulation was able to knockdown total 
ERa in both cell lines, however, this was only significant in MCF-7 cells (P = 
0.026 and 0.079 respectively for MCF-7 and TamR cells) and significantly 
knockdown pERal67 in TamR cells (P = 0.038). A knockdown in pER al67 
was visible from the immunoblot, however, densitometry analysis proved this 
to be an insignificant result (P = 0.5).
53.5.2 ERK1/2
The protein expression of total and phospho-ERKl/2 was assessed by western 
blot, shown in figure 5.16.
Total ERK1/2 protein expression was higher in TamR cells than in MCF-7 
cells; however, densitometry analysis proved that this was not significant (P = 
0.077). Incubation with PD98059, LY294002, 4-hydroxytamoxifen (MCF-7 
cells only) and fish oil did not affect the expression of total ERK1/2 in either 
cell line.
The expression of pERKl/2 was significantly higher in TamR cells than in 
MCF-7 cells (P = 0.025). The cocktail of compounds reduced the expression 
of pERKl/2 significantly in TamR cells only (P = 0.036).
225
Chapter 5 Probing the effect o f PD98059, LY294002,4-hydroxytamoxifen and fish oil on
human breast cancer cells
M C F - 7  T a m R
44 KDa 
42 KDa
44 KDa 
42 KDa
45KDa
T o ta l  E R K  1 /2  
p E R K  1 /2  
P - a c t in
B
M7 control M7 test TR control TR test
Cell line and treatment 
■  Total ERK1/2 ■pERKl/2
Figure 5.16 Western Blot for the levels o f total ERK 1/2, pERKl/2 and p-actin protein protein. 
MCF-7 and TamR cells were incubated with lplml'1 fish oil, 25pM PD98059, 5pM LY294002 
and 1 x 10‘7M 40HTam (MCF-7 cells only) for three hours. Cells were lysed and protein 
extracted and quantified for equal loading. Protein was separated by SDS-PAGE, immobilised 
on a nitrocellulose membrane and immunoprobed with either a CST total ERK 1/2 or pERKl/2 
(Thr202/Tyr204) primary antibody. Passage numbers 37, 29, 31 for MCF-7 cells and 23, 26 
and 28 for TamR cells.B Densitometry (normalise to actin) analysis o f total ERK 1/2 and p- 
ERK1/2 protein (n=3 ± SEM). M7- MCF-7 cells, TR- TamR cells. Densitometry was 
performed using Alpha Digi Doc ™ RT camera and image analysis system, Genetic Research 
Instrumentation, Essex, UK.
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53.53 Akt
The expression of Akt, both activated and non-activated, was assessed in both 
MCF-7 and TamR cells by western blot, displayed in figure 5.17.
Total and phospho-Akt was expressed at a significantly higher level in TamR 
cells than in MCF-7 cells (P = 0014), however, the cocktail of compounds had 
no effect on the expression of total Akt protein in both cell lines. The cocktail 
of compounds reduced p-Akt in both cell lines; however, this reduction was 
only significant TamR cells (P = 0.016).
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Figure 5.17 Western Blot for the levels o f total Akt, phospho-Akt and P-actin protein. MCF-7 
and TamR cells were incubated with lp lm l1 fish oil, 25pM PD98059, 5pM LY294002 and 1 x 
10'7M 40HTam (MCF-7 cells only) for three hours. Cells were lysed and protein extracted 
and quantified for equal loading. Protein was separated by SDS-PAGE, immobilised on a 
nitrocellulose membrane and immunoprobed using a total Akt or pAkt (ser473) primary 
antibody. Passage numbers 37, 29, 31 for MCF-7 cells and 23, 26 and 28 for TamR cells.B 
Densitometry (normalised to actin) analysis o f total Akt or pAkt protein (n=3 ± SEM). M7- 
MCF-7 cells, TR- TamR cells. Densitometry was performed using Alpha Digi Doc ™ RT 
camera and image analysis system, Genetic Research Instrumentation, Essex, UK.
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53.5.4 EGFR
Total EGFR protein was expressed at a significantly higher level in TamR cells 
compared to the parental MCF-7 cells (P = 0.044). The cocktail of compounds 
decreased total EGFR expression modestly in both cells, albeit this was not a 
significant decrease.
Phospho-EGFR1068 was significantly upregulated in TamR cells compared to 
expression in MCF-7 cells (P = 0.005); basal levels of pEGFR protein were 
barely detected in the parental MCF-7 cell line. The combination of PD98059, 
LY294002, 4-hydroxytamoxifen and fish oil almost completely silenced 
pEGFR1068 expression in MCF-7 cells, although this was not a significant 
finding (P = 0.55). This combination (minus 4-hydroxytamoxifen) was 
capable of reducing the expression of EGFR in TamR cells significantly (P = 
0032), levels of pEGFR1068 were around half in TamR cells when incubated 
with this combination of compounds.
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Figure 5.18 Western Blot for the levels o f total EGFR, phospho-EGFR1068 and P-actin 
protein. MCF-7 and TamR cells were incubated with lplml'1 fish oil, 25pM PD98059, 5|iM 
LY294002 and 1 x 10‘7M 40HTam (MCF-7 cells only) for three hours. Cells were lysed and 
protein extracted and quantified for equal loading. Protein was separated by SDS-PAGE, 
immobilised on a nitrocellulose membrane and immunoprobed using a total EGFR or p- 
EGFR1068 primary antibody. Passage numbers 37, 29, 31 for MCF-7 cells and 23, 26 and 28 
for TamR cells.B Densitometry (normalised to actin) analysis o f total EGFR and phospho- 
EGFR1068 protein (n=3 ± SEM). M7- MCF-7 cells, TR- TamR cells. Densitometry was 
performed using Alpha Digi Doc ™ RT camera and image analysis system, Genetic Research 
Instrumentation, Essex, UK.
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5.4 Discussion
This chapter focussed on determining the effects of the cocktail of PD98059, 
LY294002, 4-hydroxytamoxifen (MCF-7 cells only) and fish oil on MCF-7 
and TamR cells.
MCF-7 cell growth was reduced by a similar margin with the addition of 
PD98059, LY294002 and 4-hydroxytamoxifen when applied singly. Fish oil 
also reduced MCF-7 cell growth, albeit to a lesser extent. It has previously 
been demonstrated that significant inhibition of MCF-7 cell growth could be 
achieved with incubation of either 5 pM LY294002 or 15 pM PD98059 
(Zhang, S. et al 2005). It has also been shown that the concentrations of 
LY294002 and PD98059 used within this research were enough to inhibit 
MCF-7X cells (estrogen and growth factor depleted) by 65 and 35 % with 
LY294002 and PD98059 treatment respectively (Staka, C.M. et al 2005).
Greatest inhibition in MCF-7 growth was seen when cells were insulted with 
combinations of 25 pM PD98059, 5 pM LY294002, 1 x 10‘7 M 4- 
hydroxytamoxifen and 25 pM PD98059, 5 pM LY294002, 1 x 10’7 M 4- 
hydroxytamoxifen and 1 pL mL'1 fish oil simultaneously. Staka, C.M. and 
colleagues (2005) also observed the synergistic actions of PD98059 and 
LY294002, reporting that this combination reduced cell growth to 15 % of 
control growth.
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It was interesting to see that PD98059 and LY294002 inhibited MCF-7 cell 
growth to a lesser extent as seen in TamR cells (shown in figure 5.3 and 5.4). 
This may be explained by the knowledge that TamR cells express both 
pERKl/2 and PI3K/pAkt at elevated levels compared to MCF-7 cells as a 
compensatory growth pathway induced by tamoxifen resistance (Nicholson, 
R.I. et al 2005). This was exemplified in this chapter in both ICC of cells 
(figure 5.11 and 5.12) and western blot analysis of MCF-7 and TamR cells 
(figure 5.16 and 5.17), which showed elevated expression of pERKl/2 and 
pAkt in TamR cells compared to the parental MCF-7 cell line. A recent study 
demonstrated similar results by comparing MAPK activity in several breast 
cancer cell lines. Results showed that MAPK activity was increased in cell 
lines overexpressing growth factor signalling mediators, such as MDA-MD- 
231 and BT-474 cells. There was a significant correlation with IGF-IR 
expression and MAPK activity in these cell lines, in which PD98059 showed 
an enhanced sensitivity.
Incubation of MCF-7 and TamR cells with 5 pM LY4002 reduced cell growth 
significantly compared to control growth. PI3 kinase/Akt signalling has 
previously been linked to cell cycle abnormalities in human malignancies, 
driving increased cell proliferation. Akt is a key mediator involved in 
preventing cyclin D1 degradation by its regulation of cyclin D1 kinase 
glycogen synthase kinase 3 p. Overactivation, of Akt, as seen in malignancies 
of the breast, allows accumulation of cyclin D1. LY294002 has been shown to 
greatly decrease the expression of cyclin D1 and induced G1 cell cycle arrest in
232
Chapter 5 Probing the effect of PD98059, LY294002,4-hydroxytamoxifen and fish oil on
human breast cancer cells
ovarian cancer cells (Gao, N. et al 2004). Arrest of cell cycle may have been 
the way in which LY294002 reduced cell proliferation as described in this 
chapter.
Several studies have also shown that MAP kinase activation is critical for 
cancer cell growth. A study assessing the levels of pERKl/2 in MCF-7 and 
T47D compared to non-malignant cell lines revealed that expression of 
pERKl/2 expression was higher in both MCF-7 and T47D compared to non- 
malignant cell lines. The study also showed that PD98059 was capable of 
reducing this expression and the growth of MCF-7 and T47D cells (Hermanto, 
U. et al 2000). Overexpression of MAPK signalling has been shown to alter 
cell cycle progression by deregulating p27kipl, which is a kinase inhibitory 
protein that regulates cell cycle transitions. Overactivation of MAPK 
signalling compromises the inhibitory function of p27 and allows elevated 
growth rate in breast cancer cells; however, MAPK inhibitors were able to 
reduce growth rate. Upon tamoxifen resistance mitogen-activated protein 
kinase phophatase is upregulated (Zhou, B. et al 2001). This has been shown 
to de-activate MAPK activity in normal cells via a negative feedback loop, 
however, in the continued presence of tamoxifen, it is downregulated, which 
leads to accentuated MAPK activity. PD98059 was able to inhibit the growth 
of tamoxifen resistant cells in this study and also increased the phosphorylation 
of c-Jun NH2-terminal kinase, suggesting a role for MAPKP3 in this resistant 
growth (Cui, Y. et al 2006).
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TamR cells were developed in-house to mimic the considerable clinical 
challenge represented by anti-hormone resistance exemplified by that seen with 
tamoxifen treatment. These cells were insensitive to 4-hydroxytamoxifen and 
E2, however still showed growth inhibition when incubated with Faslodex, as 
shown in figure 5.2. Incubation of TamR cells with PD98059 and LY294002 
singly gave similar inhibition in growth, while fish oil only modestly inhibited 
TamR growth. Greatest inhibition was seen when PD98059 and LY294002 
were incubated with TamR cells simultaneously with and without fish oil 
present.
Upon acquisition of tamoxifen resistance, elevated EGFR signalling is detected 
both in vitro and in vivo. This was portrayed in ICC detection and western blot 
analysis of total EGFR and PEGFR1068. Further dissection of the EGFR 
signalling pathway has elucidated that this is, in part, responsible for tamoxifen 
resistant growth. It is also hypothesised that downstream pathways of the 
EGFR, including the MAPK and PI3K pathway are also responsible for many 
aspects of tamoxifen resistant tumorogenesis (Nicholson, R.I. et al 2005). This 
chapter showed that total EGFR, pEGFR1068, pERKl/2 and pAkt were 
upregulated in TamR cells, suggesting that resistant growth was driven by 
these signalling pathways. Interestingly, pER167 was significantly 
upregulated in TamR cells, as displayed in figure 5.10 and 5.15. This could be 
explained by the increased MAPK and PI3K signalling within TamR cells 
compared to MCF-7 cells. Activation of these pathways can result in the 
ligand independent activation of ERa at key serine residues (Sun, M. et al
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2001). Activated PI3K/Akt are known to phosphorylate ERa at serl67. As
this signalling pathway is activated to a greater extent in TamR cells, this may
have lead to an elevation in ligand independent activation of ERa by
phosphorylation at serl67. The significant knockdown in pERal67 signal
when TamR cells were incubated with LY294002 and the cocktail of
compounds may have been mainly due to the inhibition of the PI3K/Akt
pathway by the actions of LY294002 (Campbell, R.A. et al 2001). In fact, a
number of discreet and unrelated observations have led to the understanding
that this signalling pathway confers to tamoxifen resistant cell growth. It was
noticed that patients suffering from Cowdens disease, which presents as a germ
line mutation of PTEN, are more susceptible to breast cancer development.
PTEN is a tumor suppressor that inhibits Akt.
Fish oil was capable of inhibiting the growth of both MCF-7 and TamR cells, 
giving a more exaggerated effect on TamR cells. Many studies have 
investigated the effect of dietary fat on tumor progression and have suggested 
that the anti-tumor properties of PUFAs arise from their ability to inhibit the 
COX enzymes. This chapter, however, revealed that fish oil was capable of 
reducing the expression of EGFR, pEGFR1068, pAkt and pERKl/2, 
suggesting that n-3 PUFAs may also exert anti-tumorogenic via actions on 
these key mediators.
There are 12 different fatty acids that are essential to the body but are not 
endogenous. These can be divided into two main sub-groups dependant on the
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saturation state. N-3 (co-3) PUFAs are unsaturated at the third carbon from the 
methyl terminus, whereas n-6 (©-6) PUFAs are unsaturated at carbon 6. The 
position of this first double bond seems to have significant effects on the 
actions of PUFAs, with n-6 PUFAs, such as AA and GLA being cancer cell 
growth promoting, while n-3 PUFAs, such as EPA and DHA show cell growth 
inhibition (Xia, S. et al 2006).
Investigations into the effects of n-3 PUFAs on tumorogenesis have revealed 
that these fatty acids are potent protein kinase inhibitors at low concentrations. 
EPA (IC50 concentrations of 2-36 pM) was capable of inhibiting the activity of 
protein kinase c (PKC), cyclic AMP dependent protein kinase A and ERK1/2. 
Furthermore, this inhibition was ©-3 specific and was not as a result of 
competitive inhibition of ATP (Mimikjoo, B. et al 2003). This could explain 
the effect that fish oil gave on the expression of pAkt and pERKl/2.
Several studies have proposed that n-3 PUFAs show efficacy as anti-angigenic 
therapeutic by inhibiting microvessel formation in tumor tissues (Mukutmoni- 
Norris, M. et al 2000). Only recently has a mechanism behind this observation 
been proposed, suggesting that n-3 PUFAs inhibit VEGF expression through 
negative regulation of COX-2/ERK1/2 pathways (Calviello, G. et al 2004). 
This study shows that n-3 PUFAs, in particular EPA, were able to inhibit 
COX-2 and the phosphorylation of ERK1/2, which downregulated the 
expression of VEGF.
236
Chapter 5 Probing the effect of PD98059, LY294002,4-hydroxytamoxifen and fish oil on
human breast cancer cells
The n-6 PUFA, AA, was capable of stimulating the activity of PI3K and 
transiently phosphoryladng Akt on Thr-308 and Ser-473 (Hii, C.S.T. et al 
2001). Another notable finding of this study was that AA was capable of 
activating ERK1/2, however, this was independent of PI3K activation.
Conversely, n-3 PUFAs have shown opposite effects on PI3K and Akt 
activation. EPA (and DHA to a less extent) showed a dose-dependent decrease 
in insulin-induced Akt activity and reduced activity by 67% compared to 
control. This effect of EPA and DHA (found at high levels in fish oil) could 
explain the decrease in pAkt in both MCF-7 and TamR cells. It could also 
rationalise that fact that fish oil had a more prominent affect on TamR cells 
compared to MCF-7 cells, since the resistant cell line showed higher basal 
pAkt than MCF-7 cells.
N-3 PUFAs have also displayed EGFR inhibitory effects. Investigations into 
membrane biology have revealed that lipid rafts may play an important role in 
cell signalling by aiding the association of signalling molecules such as the 
EGFR (Brown, D.A. & London, E. 1998). A recent study showed that EPA 
and DHA altered the lipid composition of lipid rafts in MDA-MB-321 cells. 
This study also discovered that EPA and DHA decreased EGFR protein levels 
in lipid rafts, however, the PUFAs increased pEGFR signalling in MDA-MB- 
231 cells (Schley, P.D. et al 2004). The study by Schley and colleagues 
corroborated results found in a previous study suggesting that EPA and DHA 
were the most effective unsaturated fatty acids at inducing EGFR
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autophosphorylation, leading to p38 MAPK activation (Vacaresse, N. et al 
1999). However, PGE2 is known to transactivate EGFR through a Src 
dependent mechanism to facilitate ligand independent EGFR signalling in 
COX-2 over-expressing cells (Buchanan, F.G. et al 2003). N-3 PUFAs such as 
EPA and DHA compete with AA for the COX-2 enzyme and hinder the 
production of series 2 prostanoids, including PGE2 . Instead, series 3 
prostanoids are synthesised offering a much weaker inflammatory mediator 
(Uauy, R. & Valenzuela, A. 2000). The n-3 PUFAs within the fish oil may 
have decreased the levels of PGE2, thus inhibiting the transactivation of EGFR 
induced by this prostanoid.
It was not straightforward to compare the amounts of drug delivered across the 
skin to the amounts used in the cell growth experiments. On the face of it, the 
25 x 10"6 M of PD98059 used to stop the cell proliferation does not compare 
favourably with the maximum delivery of 0.06 pmol cm' after 48 hours - an 
area of application ~ 400 cm2 would be necessary. Even then this does not take 
into consideration the precise location within breast tissue of the cancer to be 
reached via passive diffusion or the proportion of drug cleared by the dermal 
microvasculature (although the amount in the systemic circulation would 
probably be beneficial). Such considerations point to the chemo-prevention of 
breast cancer a more plausible goal for transcutaneous delivery of these agents, 
rather than a cure.
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However, permeated concentrations were applied to MCF-7 cells in a patch 
application model system, by which concentrations permeated after 48 hours 
were first applied and the concentrations permeation after 24 hours were 
applied every 24 hours after this. Although the concentrations that were added 
were significantly lower previously used in the IC50 experiments, cell growth 
was still reduced to 13.78 ± 0.63 % of control when both compounds were 
added together. Although this seems surprising, it could be explained by the 
uptake rates of the compounds into MCF-7 cells. The IC50 value 
concentrations were only dosed twice during the week-long experimentation, 
whereas the permeated concentrations were dosed on a daily basis. If the 
uptake of compounds into cells was less or around equal to the concentrations 
dosed per day in the permeated concentrations investigations then increasing 
the concentration would not improve the growth inhibition seen. However it 
has been reported previously through western blot techniques that lOOnM 
PD98059 was adequate to block ERK1/2 significantly (Lassarre, C. et al 
2003). This concentration is lower than the 0.65pM used in these experiments, 
which suggests that the inhibition was specific to ERK1/2 inhibition.
Conclusions
This work has shown that the levels at which PD98059, LY294002 and 4- 
hydroxytamoxifen permeate the skin, are sufficient to exert substantial growth 
inhibitory effects on MCF 7 and TamR cancer cells in vitro. This work has 
also provided confirmatory evidence that n-3 PUFAs found in fish oil have
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intrinsic anti-tumorogenic properties and that they are capable of inhibiting 
several key tamoxifen-resistant growth mediators.
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Probing the Anti-Metastatic Properties of 
LY294002, PD98059 and fish oil
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6.1 Introduction
6.1.1 COX-2 and Metastasis
An increasing body of evidence supports a role for COX-2 in many 
malignancies, including those of the colon, prostate and breast (Masferrer, J.L. 
et al 2000). A study investigating the relationship between COX-2 and various 
clinical markers involved in breast cancer tumorogenesis revealed that up- 
regulation of COX-2 was significantly correlated with distant metastasis 
(Ranger, G.S. et al 2004). Many authors have reported a link between up- 
regulation of COX-2 and elevated angiogenesis. Davies, G. and colleagues 
(2003) reported the first significant relationship between COX-2 and 
angiogenesis measured by CD31 (platelet -endothelial cell adhesion molecule), 
an immunoglobulin involved in invasion, migration and angiogenesis.
6.1.2 Breast Cancer and Metastasis
Unfortunately, breast cancer shows a high incidence of metasizing, usually via 
the lymphatic system, giving a much poorer patient prognosis (Cunnick, G.H. 
et al 2008). Lymph node metastasis is the most common site of secondary 
colonization of breast cancer cells, with the likelihood of metastatic spread 
increasing with increasing tumor grade and in hormone receptor negative 
cancers. As mentioned previously, metastasis from the point of origin seems to 
be organ of origin specific. It has been established for over a decade that breast 
cancer cells preferentially metastasize to bone and lung (Fidler, I.J. 2003).
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6.13 Aims
It has previously been shown in chapter 5 that PD98059, LY294002 and fish 
oil could suppress the growth o f both MCF-7 and TamR cells. The MAPK and 
PI3K pathways have already been implicated in metastasis (Alfiya, F. et al 
2006, Jia, Y. et al 2004) and so PD98059 and LY294002 are proposed to have 
ant-metastatic properties.
Insights into the mechanisms involved in metastasis o f breast cancer have 
discerned a possible role for COX-2 in both tumorogenesis and metastatic 
spread o f breast cancer. This short study was aimed at determining whether 
COX-2 alone, and in combination with LY294002 and PD98059 had a role in 
TamR cell migration. Also this investigation aimed to see if  the constituents o f 
the developed formulation could curb this migratory potential.
6.2. Materials and Methods
6.2.1 Materials
The materials used within this chapter were detailed in section 2.2.1
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6.2.2 Methods
6.2.2.1 Growth assays
Growth assays were performed as described in chapter 2. Firstly, the growth 
rates o f three in-house cell lines were compared. MCF-7, TamR and FasR 
cells were grown to 70 % confluency as previously described, passaged, and 
seeded into 24 well plates at a density o f 1.5 million cells per plate. Cells were 
trypsinized and counted on days 1 ,4 , 7 and 9.
Secondly, using both MCF-7 and TamR cells, the effect o f the PD98050, 
LY294002 and 4-hydroxitamoxifen (MCF-7 cells only) and fish oil were 
determined on the growth rate o f both cell lines. The treatment strategies were 
as detailed in table 6.1. Cells were seeded (1.5 x 106 per plate) on day 0, 
counted and treated on day 1 and counted on days 2, 4, 7 and 9. Cells were 
retreated on day 4.
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Cell Line Treatments Concentrations
DMSO 0.1 pL mL**
40HTam 1 x 10'^ M
PD98059 25 pM
MCF-7 LY294002 5pM
PD+LY+40HTam As in single treatments
Fish oil 1 pL mL’1
Fish oil+ PD+LY+40HTam As in single treatments
E2 1 x lO'^ M
DMSO 0.1 pLmL'1
PD98059 25 pM
LY294002 5pM
TamR PEH-LY As in single treatments
Fish oil 1 pLmL'1
Fish oil+ PD+LY As in single treatments
E2 1 x 10_yM
Fas 1 x 10'7M
Table 6.1 Table to show the treatments used in growth assays to detect the effects of 
formulation constituents on the growth rate of both MCF-7 cells and TamR cells. Cells were 
seeded at a density of 1.5 million cells per plate on day 0. On day 1 cells were counted and 
then treated. Additional counts were at days 4 ,7  and 9 and treatments replenished on day 4.
6.2.2.2 Migration assays
Migration assays were performed using the method outlined in section 2.2.2.4. 
Initially migration assays were carried out to compare the migratory potential
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o f three breast cancer cell lines; MCF-7, TamR and FasR. Secondly the effects 
o f fish oil and fish oil plus PD98059 and LY294002 on the migration o f TamR 
cells were assessed. The assays were assembled as described previously; 
however, the wells o f the modified plate were filled with wRPMI (SFCS, 
fungicide and antibacterial) with either 0.1 pL mL"1 DMSO (control), 1 pL 
mL'1 fish oil or 1 |xL m l/'fish  oil, 25nM  PD98059 and 5 nM LY294002. 
Detection o f migrated cells was as previously outlined (2.2.2.4).
6.2.23 Western blot analysis for c-Src and COX-2
MCF-7 and TamR cells were cultured for western blot analysis as detailed in 
section 2.2.4. After reaching 70% confluency, the cultured cells were 
incubated, for three hours, with compounds as detailed in table 6.2.
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Cell line Treatment
MCF-7 0.1 pL mL'DMSO (Control)
lplml'1 Fish oil
1 x 104M 40HTam, 25 pM PD98059, 5pM 
LY294002
1 pL mL*1 Fish oil,l x 10-7M 40HTam, 
25pM PD98059, 5pM LY294002
TamR 0.1 pL mL*1 DMSO (Control)
1 pL mL^Fish oil
25pM PD98059, 5pM LY294002
1 pL mL*1 Fish oil, 25pM PD98059, 5pM 
LY294002
Table 6.2 Treatments for MCF-7 and TamR cells prior to Western blot and ICC analysis. 
PD98059 and LY294002 were made up in DMSO, while 40HTam was made up in ethanol. 
Treatments were incubated for 3 hours, after which protein was extracted for western blot 
assays and cells were fixed for ICC assays. Cells were maintained at 37°C with 5% C02.
Compound(s) were incubated with the cells for 3 h as ICC analysis o f porcine 
skin sections revealed knock down o f several markers, including COX-2 after 3 
h (described in chapter 5). Protein was then extracted, quantified and analysed 
via western blot using the methods described in 2.2.4.
Gels were immunoprobed for P-actin as an internal control to ensure equal 
protein loading.
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6.2.2.4 Immunocytochemical detection of c-Src and COX-2 in MCF-7 and 
TamR cells
MCF-7 and TamR cells were cultured and set up for immunocytochemical 
assays as detailed in section 2.2.3.2. On reaching 70 % confluency the cells 
were treated with treatments for 3 hours, as detailed in table 6.2. The fixation 
o f cells for all assays and the detection o f total-Src, phospho-Src and total 
COX2 were conducted as detailed in section 2.2.3.2.
6.3. Results
6.3.1 Growth Assays
Figures 6.1 and 6.2 show repeats o f growth studies performed in chapter 5. 
This repetition was o f paramount importance to ensure that cells were behaving 
phenotypically. Figure 6.1 shows the growth rate o f un-treated MCF-7, TamR 
and FasR cells over 9 days. It is obvious that upon hormone resistance, growth 
rate accelerates, as shown with TamR and FasR cells compared to the parental 
and hormone sensitive MCF-7 cells.
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Figure 6.1 Growth assay to show the growth rates o f MCF-7, TamR and FasR cells. Cells 
were seeded at a density o f 1.5 million cells per plate on day 0. Cells were counted on days 1, 
4, 7 and 9 and media was replenished on day 4. Cells were incubated at 37°C with 5% C 0 2. 
Cell counts represent the mean number per 3 counts (n=3 ± SD). Passage numbers were 12, 
14, 20 for MCF-7 cells, 22 ,25, 30 for TamR cells and 31, 35 and 40 for FasR cells.
The grow th assay shown in  figure  6.1 shows that Tam R ce lls have a faster 
grow th rate than the parental M C F-7 cells, however th is  was not a s ig n ifican t 
observation (P =  0.120). FasR cells showed a s ig n ifica n tly  elevated grow th 
rate compared to  both Tam R and M C F-7 ce lls (P =  0.012 and 0.05 
respectively).
The e ffect o f the active constituents o f the fin a l fo rm u la tion  on the grow th  o f 
both M C F-7 and Tam R cells were then exam ined.
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The M C F-7 cells, shown in  figure  6.2, displayed typ ica l horm one sensitive 
behaviour. Treatm ent w ith  estradiol gave an elevated g row th  rate, w h ils t 4- 
hydroxytam oxifen (1 x 10_/ M ) gave a reduction in  ce ll g row th  to 68.9 ±  13.1 
%  compared to contro l grow th.
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Figure 6.2 Growth assay to show the growth rates o f MCF-7 cells when treated with 4- 
hydroxytamoxifen, PD98059, LY294002 and fish oil (both singly and in combination) and also 
estradiol. Cells were seeded at a density o f  1.5 million cells per plate on day 0. Cells were 
counted on days 1, 2, 4, 7 and 9 and media and treatments were replenished on day 4. Cells 
were incubated at 37°C with 5%  C 02. Cell counts represent the mean number per 3 counts 
(n=3 ± SD). Passage numbers were 19,21,24.
The addition o f 25 tiM  PD98059, 5 |tM  LY292002 and 1 |tL  m L '1 fis h  o il, 
separately, reduced M C F-7 grow th to  81.5 ±  11.4, 66.2 ±  14.5 and 81.7 ±  13.7 
%  o f contro l M C F-7 grow th respectively. The com bination treatm ents o f 1 x
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10’7M  4-hydroxytam oxifen, 25 p M  PD98059, 5pM  LY 292002 and 1 x  10'7M  
4-hydroxytam oxifen, 25 p M  PD98059, 5 p M  LY292002 p lus 1 p L  m L*1 fish  
o il gave, by some m argin, the greatest retardation in  M C F -7  ce ll grow th  by 
reducing it  to 3.2 ± 0 .1 8  and 2.2 ±  0.2 %  o f contro l g row th  respective ly.
F igure 6.3 shows grow th assays perform ed on the tam oxifen  resistant ce ll line : 
TamR. The absence o f an estradiol-induced e levation in  grow th  rate h ig h ligh ts  
the loss o f hormone sensitiv ity.
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Figure 6 3  Growth assay to show the growth rates o f  TamR cells when treated with PD98059, 
LY294002 and fish oil (both singly and in combination) and also faslodex and estradiol. Cells 
were seeded at a density o f  1.5 million cells per plate on day 0. Cells were counted on days 1, 
2, 4, 7 and 9 and media and treatments were replenished on day 4. Cells were incubated at 
37°C with 5%  C 02. Cell counts represent the mean number per 3 counts (n=3 ± SD). Passage 
numbers were 25, 27 and 32.
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Although the TamR cells displayed insensitivity to E2, they were still sensitive 
to the true anti-estrogen Faslodex (Fulvestrant). Incubation with 1 x 10"7 M 
faslodex reduced growth to 58.4 ± 8.3 % of control TamR growth suggesting 
that the cells were still sensitive to anti-estrogen challenge. The addition of 
5pM LY292002 reduced TamR growth to a similar degree, as seen with 
faslodex: 58.3 ± 9.3 % of control growth. Incubation with 25 pM PD98059 or 
lplmT1 fish oil inhibited the growth of TamR cells to similar levels: 68.1 ±8.1 
and 64.9 ± 7.4 % of control TamR growth respectively. It was interesting to 
note that the two STIs and fish oil gave a more profound inhibition of TamR 
cell growth than they did MCF-7 cell growth.
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6 .3 .2  M ig r a t io n  A ssa y s
The m igra tory potentia l o f three in  house ce ll lines was firs tly  assessed. Figure
6.4 shows the number o f M C F-7, TamR and FasR cells m igra ting  after 48 h.
300 t-----------------------------------------------------------------------------------------------------------------------------------------
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Figure 6.4 Migration assay to show the number o f MCF-7, TamR and FasR cells migrating 
after 48 hours. Cells were seeded onto fibronectin coated porous membranes at a density of 
80,000 cells per well, incubated and allowed to migrate for 48 hours at 37°C with 5%  C 02. No 
o f cells migrated represents the mean number o f cells per field o f view (7 fields per insert were 
counted) (n=3 ± SD). Passage numbers were 12, 14, 20 for MCF-7 cells, 22, 25, 30 for TamR 
cells and 31, 35 and 40 for FasR cells.
I t  was obvious that Tam R cells m igrated s ig n ifican tly  more than M CF-7 cells 
(P =  0.004) and FasR cells m igrated s ign ifican tly  more than both M C F-7 and 
TamR cells (P =  0.001 and 0.001). One-way A N O V A  determ ined that there
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was a s ign ifican t difference in  the m ig ra to ry potentia l o f these three ce ll lines 
(P <0.001). A lthough FasR cells displayed the greatest m igra tory potentia l, 
TamR cells have been previously used throughout th is  thesis as a model fo r 
tam oxifen resistance, therefore th is  ce ll line  was chosen to  investigate the anti- 
m igra tory potentia l o f fish  o il and the tw o  signal transduction inh ib ito rs .
120-1------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Figure 6.5 Migration assay to show the number o f  TamR cells migrating after 48 hours, when 
incubated with control, lplml"1 fish oil or lpml'1 fish oil plus 25 pM PD98059 and 5pM 
LY294002 treatments. Cells were seeded at a density o f 80,000 cells per well and incubated at 
37°C with 5% CO2 No o f cells migrated represents the mean number o f cells per field o f view 
(7 fields per insert were counted) (n=3 ± SD). Passage numbers were 23 ,27  and 30.
Figure 6.5 shows the e ffect o f fish  o il alone and in  com bination w ith  PD98059 
and LY294002 on the m ig ra tion  o f Tam R cells. F ish o il gave a s ign ifican t 
reduction in  the num ber o f Tam R ce lls m ig ra ting  a fte r 48 hours (P =  0.05),
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while the addition of the two signal transduction inhibitors decreased the 
migratory potential of TamR cells significantly compared to both control cells 
(P = >0.001) and fish oil treated cells (P = 0.003). One-way ANOVA analysis 
revealed that the migratory potential of control, fish oil treated and fish oil plus 
STIs are significantly different (P<0.001)
63 3  Western blot analysis of c-Src and total COX-2
COX-2 is an intermediate response gene that encodes a 71 KDa protein that is 
induced in response to inflammation (Half, E. et al 2002). Western blot 
analysis of total COX-2 levels in MCF-7 and TamR cells showed that TamR 
cells had an elevated level of total COX-2, as displayed in figure 6.6. Fish oil, 
incubated for 3 hours, reduced total COX-2 protein levels in both cell types. 
The addition of PD98059 and LY294002 to TamR cells and the addition of the 
two STIs and 4-hydroxytamoxifen to MCF-7 cells also reduced the amount of 
total COX-2 proteins, albeit, to a lesser extent than fish oil. The addition of 
fish oil to the two treatments mentioned previously, allowed a further additive 
reduction of the total COX-2 protein in both MCF-7 and TamR cells.
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Figure 6.6 A Western Blot for the levels o f  total COX-2 protein. MCF-7 and TamR cells were 
incubated with FO (lp m f1 fish oil), PD (25 pM PD98059), LY (5pM LY294002) and 1 x 10' 
7M 4-hydroxytamoxifen (MCF-7 cell only) for three hours. Cells were lysed and protein 
extracted and quantified for equal loading. Protein was separated by SDS-PAGE. Proteins 
were immobilised on a nitrocellulose membrane and immunoprobed using a total COX-2 
primary antibody. B Densitometry analysis o f  total COX-2 protein. Densitometry was 
performed using Alpha Digi Doc ™ RT camera and image analysis system, Genetic Research 
Instrumentation, Essex, UK. M7- MCF-7 cells, TR- TamR cells (N=3 ±SD). Results were 
normalised to actin. Passage numbers were 23, 27 and 30.
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The protein expression of total Src and phospho-Src was also investigated in 
both cell lines when incubated with constituents of the transcutaneous 
formulation, as shown in figure 6.7
Western blot analysis of total Src protein revealed that this protein was 
elevated in TamR cells compared to MCF-7 cells. Although the addition of 
PD98059 and LY294002 to TamR cells or the addition of PD98059, 
LY294002 and 4-hydroxytamoxifen to MCF-7 cells did not result in a 
significant decrease in p-Src levels, the addition of fish oil reduced p-Src 
expression markedly in both cells. The incubation of fish oil, PD98059 plus 
LY294002 reduced expression of p-Src in TamR cells to a similar degree as 
fish oil alone. Also the combination of fish oil, PD98059, LY294002 and 4- 
hydroxytamoxifen showed no additional reduction in p-Src expression 
compared to incubation of MCF-7 cells with fish oil alone.
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Figure 6.7 A Western Blot for the levels o f  total Src, and phosphorylated Src (at tyr 416) 
protein. MCF-7 and TamR cells were incubated with FO (ljim f1 fish oil), PD (25 pM 
PD98059), LY (5pM LY294002) and 1 x 10'7M 4-hydroxytamoxifen (MCF-7 cells only) for 
three hours. Cells were lysed and protein extracted and quantified for equal loading. Protein 
was separated by SDS-PAGE. Proteins were immobilised on a nitrocellulose membrane and 
immunoprobed using a cell signalling technology total Src or phospho-Src primary antibody. 
B Densitometry analysis o f total Src, and phosphorylated Src (at tyr 416) protein. M7- MCF-7 
cells, TR- TamR cells. Densitometry was performed using Alpha Digi Doc ™ RT camera and 
image analysis system, Genetic Research Instrumentation, Essex, UK. Results were 
normalised to actin. Passage numbers were 23, 27 and 30
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W estern b lo t o f p-actin, shown in  figure  6.8, confirm ed equal prote in  loading 
due to  the equal band w id th  detected in  each lane.
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Figure 6.8 Western Blot for the levels o f P-actin protein. MCF-7 and TamR cells were 
incubated with DMSO (O.lpml1), FO (lpm l'1 fish oil), PD (25pM PD98059), LY (5pM 
LY294002) and 1 x 10'7M 4-hydroxytamoxifen (MCF-7 cells only) for three hours. Cells were 
lysed and protein extracted and quantified for equal loading. Protein was separated by SDS- 
PAGE. Proteins were immobilised on a nitrocellulose membrane and immunoprobed using a 
cell signalling technology P-actin primary antibody.
6.3.4 Im m u n o cy to ch em ica l de tec tion  o f p -S rc  an d  to ta l C O X -2 in M C F-7  
a n d  T a m R  cells
To v e rify  results seen in  the western b lo t analysis o f p-Src and to ta l C O X-2, 
im m unocytochem ical detection o f these proteins was carried out on both ce ll 
lines.
F igure 6.9 shows the results fo r the detection o f to ta l C O X-2 in  M C F-7 and 
TamR cells. S taining in  both ce ll lines was granular and localised to the
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cytoplasm, similar to previous immunocytochemical analysis for COX-2 
(Davies, G. et al 2003). Figure 6.9A-B shows that small amounts of total 
COX-2 were present in MCF-7 cells without treatment (under basal 
conditions).
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Figure 6.9 A-H ICC detection of total COX-2 in MCF-7 cells incubated with 0.1 plml'1 DMSO (A & B), lplm r1 fish oil (C & D), 1 x 10'7M 4-hydroxytamoxifen, 25pM 
PD98059 and 5pM LY294002 (E & F) or 1 plml'1 fish oil, 1 x 10‘7M 4-hydroxytamoxifen, 25|uM PD98059 and 5|iM LY294002 (G & H) for three hours. Cells were grown 
to 70% confluency on TESPA coated glass coverslips and fixed using formal saline. 10 antibody was NEB total COX-2 rabbit primary at 1/40 for 1.5 hours. Secondary 
antibody was DAKO Rabbit EnVision peroxidase labeled polymer antibody for 1.5 hours. A, C, E, G x 10 and B, D, F, H x 40. Passage numbers were 22, 27 and 33.
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T o ta l C O X -2 p ro te in  was low e r in  M C F -7  ce lls  (6 .9  A -B ) com pared to  Tam R  
ce lls , shown in  fig u re  6.9 I-J. Incuba tion  fo r three hours w ith  fis h  o il reduced 
the leve ls o f C O X -2 p ro te in  in  bo th  M C F -7  ce lls  (6 .9  C -D ) and Tam R  ce lls  
(6 .9  K -L ). Incubation  w ith  lx  10-7 M  4 -h yd ro xy ta m o x ifen , 2 5 p M  PD 98059 
and 5 p M  LY 294002 also reduced to ta l C O X -2  leve ls in  M C F -7  ce lls , show n in  
fig u re  6.9 E -F. The add ition  o f  fis h  o il to  th is  co ck ta il treatm ent seemed to  
com p le te ly  abolish a to ta l C O X -2  p ro te in  s ignal, show n in  fig u re  6.9 G -H .
F igure  6.9 M -N  shows Tam R  ce lls  incubated w ith  the com b ina tion  o f  25 p M  
PD 98059 and 5 p M  LY 294002. I t  dem onstrates tha t a lthough th is  treatm ent 
does knock dow n to ta l C O X -2  p ro te in  expression a fte r 3 hours, it  is  no t as 
great as the knock dow n seen w ith  the incuba tion  o f  1 p L  m L '1 fis h  o il. The 
add itio n  o f  fish  o il to  the tw o  STIs gave a knock dow n o f  to ta l C O X -2  p ro te in  
s im ila r to  tha t seen w ith  fish  o il alone.
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Figure 6.9 I-P Immunocytochemical detection of total COX-2 in TAMR cells. Cells were incubated with O.lfilml'1 DMSO (I & J), lplml'1 fish oil (K & L), 25pM PD98059 
and 5(iM LY294002 (M & N) or 1 plml'1 fish oil, 25pM PD98059 and 5pM LY294002 (O & P) for three hours. Cells were grown to 70% confluency on TESPA coated glass 
coverslips and fixed using formal saline. Primary antibody was NEB total COX-2 rabbit primary antibody at 1/40 for 1.5 hours. Secondary antibody was DAKO Rabbit 
EnVision peroxidase labeled polymer antibody for 1.5 hours. I, K, M, O x 10, L x 20 and J, N, P x 40. Passage numbers were 15,19 and 30.
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B o th  c e ll  l in e s  w e re  a ls o  a n a ly s e d  fo r  p -S rc  le v e ls , a s  d is p la y e d  in  f ig u re  6 .1 0 . T h is  
d a ta  s h o w s  c y to p la s m ic  lo c a l iz a t io n  o f  p -S rc  in  b o th  c e ll  l in e s ;  h o w e v e r ,  a t  h ig h  le v e ls  
o f  s ta in in g  s o m e  n u c le a r  p -S rc  w a s  d e te c te d . F ig u re  6 .1 0  A -B  s h o w s  th a t  M C F -7  
c e l ls  e x p re s s e d  m o d e ra te d  le v e ls  o f  p -S rc , h o w e v e r ,  a s  w i th  to ta l  C O X -2  le v e ls ;  p - S r c  
p ro te in  w a s  e x p re s s e d  a t  a  h ig h e r  le v e l in  T a m R  c e l ls  ( f ig u re  6 .1 0  I -J ) . A d d i t io n  o f  
f is h  o il (1 p L  m L '1) fo r  3 h  g a v e  a  d ra m a tic  r e d u c t io n  in  p - S r c  p r o te in  s ta in in g  in  
M C F -7  c e l ls  ( f ig  6 .1 0  C -D )  a n d  in  T A M R  c e l ls  (6 .1 0  K -L ) . I n c u b a t io n  o f  M C F -7  
c e lls  w i th  l x  10-7 M  4 ,h y d ro x y ta m o x ife n , 2 5  p M  P D 9 8 0 5 9  a n d  5 p M  L Y 2 9 4 0 0 2  a ls o  
re d u c e d  th e  in te n s i ty  o f  p -S rc  s ta in in g , h o w e v e r ,  th is  w a s  a  m u c h  m o re  s u b t le  
d e c re a s e  in  p -S rc  th a n  th a t  s e e n  w h e n  c e l ls  w e re  in c u b a te d  w i th  f is h  o il . A  s im i la r  
p a t te rn  w a s  o b s e rv e d  w ith  th e  in c u b a tio n  o f  T a m R  c e l ls  w i th  2 5  p M  P D 9 8 0 5 9  a n d  5 
p M  L Y 2 9 4 0 0 2  ( f ig  6 .1 0  M -N ). A  m o d e ra te  r e d u c t io n  w a s  o b s e r v e d ,  h o w e v e r ,  w a s  
n o t  a s  p ro fo u n d  a s  th e  k n o c k d o w n  s e e n  w ith  th e  a d d i t io n  o f  f is h  o il.
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Figure 6.10 A-H Immunocytochemical detection o f phospho-Src in MCF-7 cells. Cells were incubated with O.lplmf1 DMSO (A & B), lplml'1 fish oil (C & D), 1 x 10'7M 
4-hydroxytamoxifen, 25pM PD98059 and 5pM LY294002 (E & F) or lplml'1 fish oil, 1 x 10'7M 4-hydroxytamoxifen, 25pM PD98059 and 5pM LY294002 (G & H) for 
three hours. Cell were grown to 70% confluency on TESPA coated glass coverslips and fixed using formal saline. Primary antibody was Cell Signal Technology phoshpo- 
Src rabbit primary antibody at 1/40 for 2 hours. Secondary antibody was DAKO Rabbit EnVision peroxidase labeled polymer antibody for 2 hours. A, C, E, G x 10 and B, 
D, F, H x 40. Passage numbers were 22, 27 and 33.
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U pon incubation  o f M C F -7  ce lls w ith  the com b ina tion  o f  4 -h yd ro xy ta m o x ifen , 
PD98059, LY 294002 and fish  o il (fig u re  6.10 G -H ), p -S rc p ro te in  leve ls were 
reduced to  levels s im ila r to  those seen w ith  incuba tion  w ith  fis h  o il a lone (6 .10  C -D ). 
F igure 6.10 O-P shows tha t incuba tion  o f  Tam R  ce lls  w ith  lp lm L ’ 1 fis h  o il 2 5p M  
PD98059 and 5 pM  LY294QQ2 gave the greatest knockdow n in  p-S rc p ro te in  
expression in  th is  ce ll line .
k
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Figure 6.10 I-P Immunocytochemical detection of phospho-Src in TamR cells. Cells were incubated with O.lplml'1 DMSO (I & J), lplml'1 fish oil (K & L), 25pM PD98059 
and 5pM LY294002 (M & N) or lplml'1 fish oil, 25pM PD98059 and 5pM LY294002 (O & P) for three hours Cell were grown to 70% confluency on TESPA coated glass 
coverslips and fixed using formal saline. Primary antibody was Cell Signal Technology phoshpo-Src rabbit primary antibody at 1/40 for 2 hours. Secondary antibody was 
DAKO Rabbit EnVision peroxidase labeled polymer antibody for 2 hours. I, K, M, x 10, O x 20 and J, L, N, P x 40. Passage numbers were 15, 19 and 30.
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This chapter was aimed at exploring the effect, if  any, o f fish oil and the oth 
actives o f the developed cocktail therapeutic on the migratory potential 
cultured human breast cancer cells. Three cell lines were chosen to repress 
an invasive (TamR and FasR) and non-invasive (MCF-7) phenotype.
Initially, the growth rates o f the three cell lines were examined. The hormo 
resistant cell lines (TamR and FasR) showed accelerated growth rai 
compared to the parental MCF-7 cell line, with the order in growth rate bei 
MCF-7<TamR<FasR. The elevation in growth rates seen in both tamoxif 
and faslodex (fulvestrant) resistance has been previously demonstrated and it 
accepted that growth factor signalling is responsible for this trend. Hiscox, 
and colleagues (2005) reported that TamR cells displayed enhanced grov 
rates along with an augmented invasive capacity. The increased growth n 
seen with TamR cells was observed previously, correlating to similar grov 
seen with E2 induced proliferation in MCF-7 cells.
Growth curves examined in chapter 5 were repeated to ensure the ce 
displayed the same phenotype and behaved in the same way when insulted wi
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fish oil, PD98059, LY294002 and 4-hydroxytamoxifen. Figure 6.2 and 6.3 
showed that both MCF-7 and TamR cells behaved very similarly when 
incubated with these compounds as in chapter 5. Interestingly, no significant 
difference in growth rates between control and treated MCF-7 and TamR cells 
were observed after 2 days. This indicated that the results of 2-day migration 
assays, performed in this chapter, were a consequence of altered migratory 
potential of the cells rather than an effect on cell number.
Investigations into the migratory potential of the three cell lines followed the 
same pattern as growth rates, as shown in figure 6.4, where the order of 
metastatic potential was MCF-7<TamR<FasR. This observation of a 
correlation existing between loss of hormone sensitivity, elevated growth rate 
and elevated invasive behaviour has been reported previously (Hiscox, S. et al 
2005, Sommer, A. et al 2003), with the switch to growth factor signalling 
suggested as being responsible for this phenomenon. EGFR signalling is 
involved in a wide array of processes in tumor biology and tumorogenesis, 
including invasion and metastasis (Baselga, J. 2002). Indeed, several studies 
using cells engineered to overexpress certain growth factors and their ligands 
have uncovered that growth factor signalling is sufficient to induce migration 
and invasion (Kruger, J.S. & Reddy, K.B. 2003, Wells, A. et al 2002). The 
elevated migratory potential of the cells is thought to arise form an altered cell- 
to-cell and cell-to-matrix adhesion (Hiscox, S. et al 2004)
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The involvement of COX-2 in tumorogenesis was first brought to light with the 
discovery that regular NSAID use was inversely correlated to colon cancer 
risk. Since then COX-2 expression has been correlated to higher tumor grade 
and metastatic potential of many solid cancers such as colon, lung, prostate and 
breast (Masferrer, J.L. et al 2000). In breast cancer, as with other cancers, the 
exact role of COX-2 in tumorogenisis remains vague, although many reports 
suggest a role for it in many processes involved in metastasis, including 
invasion, chemotaxis and angiogenesis as well as proliferation (Costa, C. et al 
2002).
The data in this chapter indicate that total COX-2 protein is expressed in both 
hormone sensitive MCF-7 and tamoxifen resistant TamR breast cancer cells, 
albeit at much lower levels in MCF-7 cells, as shown in both the western blot 
and ICC experiments. In breast cancer cell lines COX-2 expression has only 
been demonstrated previously in hormone insensitive cells with an increased 
invasive capacity, such as MDA-MB-231 cells (Larkins, T.L. et al 2006). 
Expression of COX-2 has previously been shown in MCF-7 cells by Lui, X-H. 
and Rose, D.P. (1996), however, this expression was only seen post 
tetradecanoyl phorbol acetate induction. Results in this chapter show 
constitutive basal COX-2 expression in MCF-7 cells. The expression of COX- 
2 in TamR cells has been previously demonstrated in house, which correlates 
with its expression in other highly motile cells such as MDA-MB-231 (Liu, X- 
H. & Rose, D.P. 1996).
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Overexpression of COX-2 has been linked to an increase in invasive and 
metastatic potential both in vitro and in vivo. Elevated COX-2 has been shown 
to enhance the levels of expression and secretion of vascular endothelial 
growth factor-C (VEGF-C), a potent mediator of lymphangiogenesis. It was 
further revealed that knockdown of VEGF-C expression reduced the migration 
of the highly migratory cell line MDA-MB-231 (Timoshenko, A.V. et al 
2005). Stasinopoulos and colleagues (2007) showed that silencing of COX-2 
in MDA-MB-231 showed a reduction in oncogenic markers such as MMP-1, 
interleukin 11 and chemokine receptor 4. The COX-2 knockdown also induced 
up-regulation of anti-metastatic markers such as thrombospondin-1 and 
Epstein-Barr-Induced 3. These cells also showed a decreased migratory and 
invasive capacity. Overexpression of COX-2, and so over production of PGE2, 
can also promote migration via cross-talk with the EGFR. PGE2 can induce 
shedding of active EGFR ligands from the PM, thus activating EGFR 
signalling pathways (Pai, R. et al 2002). PGE2 can also transactivate EGFR 
through Src stimulation (Buchanan, F.G. et al 2003).
Addition of PD98059 and LY294002 caused a slight reduction in COX-2 
protein in both MCF-7 and TamR cells. A study by Borsch-Haubold, A.G and 
co-workers in 1998 described how PD98059, previously thought to be a 
specific inhibitor of the p42/44 MAPK signalling pathway, inhibited the 
conversion of AA into thromboxanes (Tx) A2 . The authors showed that 
PD98059 was capable of preventing platelet aggregation induced by collagen 
and AA but not by thrombin. Further experiments revealed that this was a
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result of inhibition of cyclooxygenase 1 and 2 and not the inhibition of 
thromboxane synthase. This inhibition of cyclooxygenase by PD98059 may 
have been the reason for the additive knockdown in COX-2 protein in the 
western blot analysis of total COX-2 protein seen when TamR cells were 
simultaneously incubated with both fish oil and PD98059 plus LY294002 for 
two hours.
The migration assay displayed in figure 6.5 revealed that incubation with 1 pL 
mL"1 fish oil reduced the migratory potential of TamR cells significantly. 
Dietary fat has been the topic of much debate in its effect on tumorogenesis. 
Much work has concentrated on the type of fat intake and the different effects 
they have on both prostanoid/eicosanoid synthesis and on tumor growth, 
proliferation and apoptosis, however, their involvement in metastasis remains 
largely unknown and unexplored.
It has been previously shown that the n-3 PUFAs EPA and DHA, which are 
contained at high concentrations in fish oil, are capable of inhibiting cell 
growth in the highly invasive MDA-MB-231 breast cancer cell line (Rose, D.P. 
& Connolly, J.M. 1990), which correlated with results obtained in this chapter 
(figure 6.2 and 6.3). In the study conducted by Rose and Connolly, the use of 
selective COX or LOX inhibitors revealed that the inhibition of cell growth 
was as a result of LOX inhibition and reduction in leukotriene production 
rather than as a result of reduced prostaglandin production. Subsequent studies 
by the same group then explored the role of COX and LOX in metastasis of
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MDA-MB-231 cells in a nude mice model. This study showed that the growth 
of the tumors was lessened when the rats were fed with a diet rich in EPA and 
DHA, however the tumors of mice fed on a diet high in n- 6  PUFAs displayed 
increased growth rates. The occurrence and severity of lung metastasis in mice 
fed a diet rich in n-3 PUFAs was significantly less than control or mice fed a 
diet rich in n- 6  FAs. The authors also correlated this with the type of 
prostanoids produced in the tumor cells. The mice fed a diet rich in n-3 FAs 
showed high levels of series 3 prostaglandins and leukotrienes while mice fed a 
diet high in n- 6  FAs showed no series 3 PGs or LKs but showed high levels of 
AA metabolites such as PGE2 (Rose, D.P. et al 1995).
The most accepted mechanism for the chemopreventative actions of n-3 
PUFAs, such as EPA is the suppression of AA derived prostanoids, in 
particular, PGE2 (Horia, E. & Watkins, B.A. 2007). PGE2 is known to have a 
role in tumor progression through effects on proliferation and apoptosis. 
However the role for this prostanoid in metastasis is still vague. It has recently 
been observed that PGE2 can reverse the antiangiogenic effects of NSAIDs in 
CRC cells (Hernandez, G.L. et al 2001). N-3 PUFAs compete with AA for the 
cyclooxygenase enzyme and instead of forming series 2  prostanoids, which are 
highly inflammatory, series 3 prostanoids are produced. Series 3 prostanoids 
display a far weaker inflammatory action compared to series 2  prostanoid, 
which is believed to be the mechanism by which n-3 PUFAs give rise to anti­
inflammatory actions. The biological role of PGE3, derived from n-3 PUFAs 
has received scant attention. Human cells lack the ability to convert n- 6
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PUFAs into n-3 PUFAs due to the lack of the fat-1 gene. Kang, Z.B and 
colleagues in 2001 transfected A549 cells with the Caenorhabditis elegans fat- 
1 gene that encodes for an n-3 desaturase that converts n- 6  PUFAs to n-3 
PUFAs. They showed in this study that transfection efficiency was 90% and 
resulted in a rapid and remarkable modification of the n-6:n-3 ratio of fatty 
acids in the cell without need for dietary intervention. In fact a reversal in the 
ratio was seen whereby n-3 levels were twice as high as n- 6  levels. The same 
group later used this model to explore the role of high n-3 PUFA 
concentrations on the metastatic potential of A549 cells. This subsequent study 
again showed 90% transfection efficiency and highlighted several interesting 
observations. The authors showed that fat-1 gene expression led to an 
inhibition of adhesion and invasive potential of A549 cells, along with an 
elevation in apoptosis. They also used a low density array and RT-PCR to 
reveal and verify that MMP-1, ITG-a2 and NM23-H4, which are all involved 
in the metastatic process, were down regulated in A549 cells (Xia, S-H. et al
2005).
The addition of the two STIs also inhibited the migration of TamR cells. 
Dissection of Src signalling in migration and invasion of hormone resistant cell 
lines has exposed a role in this process for both the MAPK/ERK1/2 pathway 
and the PI3K pathway. The acquisition of endocrine resistance is paralleled 
with an elevation in the activity of Src kinase. Activated Src kinase has the 
ability to interact with many molecules such as growth factor receptors, steroid 
receptors, integrins and cell-cell adhesion receptors and thus is involved in
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many tumorogenic processes such as proliferation, differentiation, migration 
and invasion (Hiscox, S. et al 2004). Inhibition of Src kinase activity is known 
to decrease the motility and invasion of TamR cells by reducing the levels of 
activated FAK and paxillin and by elongating focal adhesions. Interestingly, 
concomitant incubation with the EGFR inhibitor Gefitinib augmented this 
decrease in motility and invasion suggesting a role for the EGFR signalling 
pathway and downstream mediators (Hiscox, S. et al 2006). The MAPK (or 
ERK 1/2) signalling pathway has been correlated to and proved to be necessary 
for the invasive capability of Dunning rat prostatic adenocarcinoma cell lines, 
furthermore, the addition of PD98059 significantly reduced the invasive 
capability of such cell lines. However, PD98059 inhibited cell motility 
independent of any effects on adherence to the ECM or the secretion of ECM 
degrading proteases such as MMP2 (Suthiphongchai, T. et al 2006). A more 
recent study, conducted by Mendes, O. and co-workers (2007) found 
contradictory results regarding MMP2. They confirmed the role of ERK 1/2 in 
breast cancer metastasis to the brain, however, blockade of this pathway with 
PD98059 suppressed the secretion of MMP2, which they suggest was the main 
mechanism by which ERK 1/2 increased metastatic potential due to MMP2 
being a pivotal candidate in cell motility.
PGE2 has been shown to change the morphology of colorectal cancer cells by 
inducing reorganisation of actin stress fibres and focal adhesion complexes 
(Sheng, H. et al 2001). These changes were later attributed to the binding of 
PGE2 to the EP4 receptor. This binding activated Akt through an EGFR/Src
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mediated mechanism and was reversed by the addition of LY294002 
(Buchanan, F.G. et al 2003). This data supports a role for PI3K/Akt in 
migration. The over expression of COX-2 in TamR cells in this study would 
give rise to elevated levels of PGE2 and thus elevated activation of Akt. This 
could explain the inhibition in migration of TamR cells, seen in this chapter, 
when incubated with PD98059 and LY294002 (figure 6.3). The 
overexpression of Akt2 has also been linked to an increased P integrin 
|  expression, which in turn led to increased invasion and metastasis of human
|  breast and ovarian cancer cells (Arboleda, M.J. et al 2003). This suggests that
the blockade of Akt with LY294002 would reverse this event. The Rho family 
of proteins belongs to the Rho-GTPases, which are responsible for the 
assembly of the contractile actomyosin machinery that is imperative for most 
types of cell motility. Overpression of the Aktl protein has been shown to 
phosphorylate and target the tumor suppressor TSC2 (tuberous sclerosis 2) for 
degradation. This led to reduced Rho-GTPase activity, which led to decreased 
actin stress fibres, focal adhesions and cell motility and invasion (Lui, H. et al 
2006).
MAPK signalling is also involved in migration and invasion. TGF-P is a 
potent mediator of immune response, inflammation, tumor growth and 
metastasis. Three mitogen activated protein kinase signalling pathways (Jun, 
ERK1/2 and p38 MAPK contribute to TGF-P induced increased tumor 
migration and invasion. Work by Safina, A.F and colleagues in 2006 showed 
that constitutive activation of TGF-P type 1 receptor gave rise to elevated
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migratory potential of MDA-MB-231 cells and that this could be reversed by 
blockade of MAPK signalling. It has recently been discovered that MAPK 
signalling contributes to metastasis of renal cell carcinoma. ERK 1/2 has been 
shown to be overexpressed in this malignancy and blockade of MAPK 
signalling reduced cell proliferation by the disruption of tumor vasculature 
(Huang, D. et al 2008).
The addition of fish oil reduced p-Src protein in both cell lines. PGE2 is known 
to stimulate Src, which in turn activates EGFR signalling leading to increased 
cell motility (Shao, J. et al 2003). The addition of fish oil may have reduced 
levels of PGE2 and thus decreased the stimulation of Src and so reduced the 
levels of phosphorylated Src in both cell lines.
6.5 Conclusion
The processes of invasion, migration and metastasis are complex and involve 
many signalling pathways. The literature suggests that cross-talk between 
several of these pathways is responsible for these events. Figure 6.11 is 
modified from (Meric, J.B. et al 2006) and highlights the cross talk between 
COX-2, PGE2, PI3K, ERK 1/2, Src and EGFR. This diagram represents only a 
fraction of the mediators involved in metastasis. It highlights the complexity 
that researchers face when trying to dissect the biology of this event.
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Figure 6.11 Schematic to show pathways involved in metastasis (a) Cyclooxygenase, (b) 
Cyclooxygenase (c) liberated EGF.
This short study has demonstrated the constituents o f the cockta il fo rm u la tion  
in h ib it both p-Src and C O X-2, both o f w h ich , a lthough the exact m echanism s 
rem ain uncertain, are m ediators o f m o tility  and invasion. They also decrease 
m igra tion  o f Tam R cells s ig n ifican tly . The results therefore suggest tha t the 
transcutaneous fo rm u la tion  developed in  previous chapters m ay dem onstrate 
anti-m etastatic properties in  tam oxifen  resistant and invasive  cells.
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7.1 Introduction
The plausibility of delivering a cocktail of anti-breast cancer agents: PD98059, 
LY294002 and 4-hydroxytamoxifen across skin was demonstrated in vitro in 
chapters 3 and 4. Furthermore, cell culture and growth assay studies also 
found that the levels of agent permeating skin were sufficient to significantly 
inhibit MCF-7 cell growth, shown in chapter 5. The current work is part one of 
two concerning the development of a composite transcutaneous model, with 
the aim of more closely reflecting in vivo situations. In this model, the target 
breast cancer cell line (MCF-7) were cultured directly into the receptor 
compartments of all-glass Franz diffusion cells (FDC), and the cell is then 
assembled with the inclusion of excised full thickness skin. When 
contemplating a model such as the one proposed here, where viable cells are to 
be cultured directly within receptor compartments, the issue of microbial 
contamination becomes paramount as this can have a profound affect on 
cultured cell viability and growth.
The use of porcine skin as a model for human skin is now widespread, with 
numerous studies suggesting parity in terms of histology, morphology and 
permeability compared to the human counterpart (Sekkat, N. et al 2002). It is 
accepted that in order to serve as a model for human skin, the tissue must not 
have been subjected to any of the disinfection processes that pigs undergo 
immediately post slaughter. The clean, pink butcher products familiar to many 
are far removed from the anim al within its farm environment and at the time of 
slaughter. To the skin scientist, the main problem is that the cleaning process
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is highly effective in liberating all traces of epidermis, rendering the material 
useless as a penetration model. Another, more insidious issue involves the 
lifestyle of the pig and the close and prolonged exposure to faecal and other 
materials that make pre-disinfected porcine skin a haven for the proliferation of 
microorganisms.
7.1.2 Microorganisms
Microorganisms are described as organisms too small to see with the naked 
eye, thus needing the aid of a microscope. Microorganisms include fungi, 
bacteria, protists, and archaea however this group of mainly single celled 
organisms does not include viruses and prions. Microorganisms have the 
capability of living almost anywhere and the skin has its own resident 
microorganisms that act beneficially to the health of the skin (Roth, R.R. & 
James, W.D. 1989).
7.1.2.1 Bacteria
Bacteria belong to a group of organisms termed Prokaryotes. This term is used 
to descibe organisms that lack a cell nuclues and other organelles. The have a 
genome made up of one single loop of DNA, however, they have the capability 
of harbouring small pieces of DNA called plasmids. They range in size 
between 0.5pm to 8 pm in diameter (Spellman, F.R. 1998).
The skin has its own resident bacteria in the form of skin microflora. This 
microflora normally consists of staphylococci, micrococci, corynebacteria, and
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propionibacteria (Ramero-Steiner, S. et al 1990). The variety of bacterial 
inhabitants differs with anatomical site, according to temperature, pH, 
availability of nutrients and humidity. Personal hygiene also contributes to the 
level of colonization. The axilla presents as the optimum body location for 
bacterial population (Leyden, J. et al 1981). A balance or relationship between 
species of bacteria found in the skin microflora has also been described. It is 
this relationship in species that maintains the symbiotic relationship of the 
bacteria and the skin (Marples, R.R. & Williamson, P. 1969). Upsetting this 
balance with antibacterial remedies can result in elimination of non-pathogenic 
bacteria, which then are replaced by more harmful species. It has been 
reported that persistent use of antibacterial soap on the foot suppressed gram- 
positive bacteria, which allowed enterobacteria to colonize this region of the 
skin. This in turn allowed Pseudomonas to inhabit this region which gave rise 
to lesion formation. These lesions allowed infection with Candida Albicans 
(Ehrenkrans, N.J. et al 1967).
7.1.2.2 Fungi
Fungi are also microorganisms; however they are eukaryotes, meaning they 
contain organelles such as a nucleus, golgi apparatus and mitochondria. Fungi 
were originally thought to be most similar to plants but are now thought to 
have more characteristics in common with animals. Fungi may be unicellular 
but most strains string their cells together, forming a mycelium that may be 
visible to the naked eye.
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There are five distinct characteristics that are used to classify fungi detailed 
below.
1. Fungi cells contain a nucleus and chromosomes.
2. They cannot photosynthesise.
3. They develop hyphae, which are long, tubular branching filaments used to 
absorb food.
4. Fungi absorb their food by osmosis.
5. They reproduce via spores, which develop on the fungi and are released by 
it
Little is known about the incidence of fungi on normal human skin (McBride, 
M.E. et al 1979). However it is now understood that Pityrosporum 
(Malassezia spp.) is commonly detected in normal, healthy skin (Eisner, P.
2006). Candida Albicans is a common pathogenic fungi found in skin 
(Ehrenkrans, N.J. et al 1967).
7.1.23 The 0.22pm cyclopore track etched membrane
The trademark registered cyclopore track etched membranes are filters that are 
manufactured by Cyclotron technology giving accurate pore size and uniform 
distribution compared to general filter pore creation.
The pore size of membrane used throughout these studies was 0.22pm in 
diameter. This size was used to prohibit the passage of microorganisms, such
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as bacteria and fungi. These microorganisms can be as small as 0.25 pm in 
diameter but should be retained cyclopore track etched membrane.
7.13 Aims
The aim of the work was to examine the microorganisms colonising freshly 
excised porcine ears. Secondly, the possibility of excluding such 
microorganism contamination from receptor phases was explored by the 
inclusion of a 0.22 pm Cyclopore track etched membrane between the skin and 
receptor compartment, as it is established and widely agreed by microbiologists 
that most, if not all, recognised fungal and bacterial organisms are above 0.25 
pm in diameter.
7.2 Materials and Methods
7.2.1 Materials
Most materials used in this chapter were discussed in chapter 2 (section 2.1). 
Tryptone soya agar (TSA) and sabouraud dextrose agar (SDA) were from 
Oxoid LTD, Basingstoke, Hampshire, England. Cyclopore track etched 
membrane (47mm diameter, 0.22pm) petri dishes and Dow Coming high 
vacuum grease were from Fisher Scientific, Loughborough, England. Crystal 
violet solution, Gram’s iodine solution and safranin were from Sigma-Aldrich 
Ltd, Poole, England.
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7.2.2 Methods
7.2.2.1 Preparation of the porcine ears
Porcine ears were collected from a local abattoir and kept on ice during 
transportation. The ears were then washed with cool water, patted dry and kept 
in the fridge until the following day.
73.2.2 Preparation of the agar
TSA is a broad range culture medium, used in the culture of microorganisms. 
It is not selective over aerobes or anaerobes. TSA media was made up by 
dissolving 40g thoroughly in 1L of deionised water and was then autoclaved. 
This was then left to cool at room temperature. It was then poured into sterile 
Petri dishes in a laminar flow cabinet and allowed to set overnight. SA was 
introduced by Sabouraud in 1910 as a selective medium for fungi and yeasts. 
Using this medium inhibits the growth of most bacteria due to its acidic pH of 
5.6. To achieve these properties 65g was dissolved thoroughly in 1L of 
deionised water, and autoclaved to sterilise the media according to the 
manufacturer’s guidelines.
7.2.23 Swabs of whole porcine ears
Swabs of the porcine ear were taken to show the extent of colonisation on the 
s k i n  surface. Swabs were taken from three different locations on the ear; swab 
A was taken from skin closest to the point of dissection, swab B was from the
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tip of the ear and swab C was taken from the middle of the ear. Individual 
sterile swabs were rubbed across the skin and the rotated 5  times in the 
described area. They were then rubbed across the agar in a similar manner to 
ensure all swabbed material was transferred to the agar plates.
Swabs a, b and c were transferred to TSA containing plates to detect bacterial 
growth and swab d was transferred to SDA containing plates to detect fungal 
growth. Plates containing swabs a, b and d were incubated at 37°C while the 
plates containing swab c were kept at 30°C. Plates were removed from the 
incubators after 48 hours and placed in the fridge until required.
Single colonies were isolated using a flame sterilised wire loop. The loop was 
rubbed across one place of the agar and then sterilised further. The wire was 
then used to spread out the swabbed colony onto the rest of the agar plate. The 
agar plates were then incubated according to the previous incubation. This was 
able to produce sufficient single colonies to perform gram staining. Colonies 
were photographed using an Olympus DP-12 digital camera (Olympus, 
Oxford, UK).
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7.2.2.4 Swabbing of receptor phase with and without cyclopore track 
etched membrane in place
Franz diffusion cells were cleaned and autoclaved and kept in a sterile 
environment until required. Prior to experimentation, ears were prepared as 
stated in chapter 2 ; however, the stratum comeum was swabbed with 70% 
ethanol made up with de-ionised water. Cells were set up as stated in table 7.1
Cell number CTEM Excised skin Fungizone and 
streptomycin
1-5 Present Present Present
6-10 Present Present Absent
11-15 Present Absent Present
16-20 Present Absent Absent
21-25 Absent Present Present
26-30 Absent Present Absent
Table 7.1 Table to show the diffusion cell set up to assess the ability o f the CTEM in 
preventing microbiological contamination o f the receptor solution. Cells were maintained in a 
sterile environment at 37 °C to provide a skin surface temperature of 32 °C. Receptor solution 
was wRPMI plus 5% SFCS. Fungizone and streptomycin were added as stated in the table.
Cells were set up with both the excised porcine skin membrane and the 
cyclopore track etched membrane in place; with the membrane filter being in 
contact with the receptor compartment and being greater in diameter than the 
s k i n  m e m b r a n e ,  so to prevent contamination of the receptor compartment. 
This methodology was to determine the capability of the CTEM to prevent
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bacterial and fungal passage from the skin surface to the receptor compartment. 
This was repeated in the presence and absence of antibacterial and anti fungal 
solutions to assess the importance of the presence of these compounds in the 
receptor phase. Cells were set up in the absence of the CTEM, to gauge the 
necessity of this filter being in place and to assess its ability to prevent 
contamination of the receptor phase. This was again done in the presence and 
absence of antibacterial and antifungal. Cells were also set up with just CTEM 
present. It was deemed essential to calculate the sterility of such membranes to 
ensue they themselves could not contaminate the receptor phase. Receptor 
phase in all diffusion cell set-ups was wRPMI with 5% SFCS.
7.2.2.5 Gram’s stain
Christian Gram developed the method followed in this thesis in 1884. The 
protocol relies on a fundamental difference in the structure of the bacterial cell 
wall. This cell wall is the outermost structure of bacteria and confers to its 
rigidity and mechanical strength. Gram-positive bacteria have up to 40 layers 
of peptidoglycan giving it high mechanical strength; however gram-negative 
bacteria only possess 1 or 2  layers of peptidoglycan and so are mechanically 
weak. It is this difference in cell wall thickness that allows the gram reaction 
to differentiate the two sub types of bacteria. The presence of multiple layers of 
pepidoglycan allows crystal violet-iodine complex stain to be retained in the 
bacteria, even after an ethanol/acetone wash. The absence of these 
pepidoglycan layers allows the crystal violet stain to be washed off by 
ethanol/acetone and the bacteria are susceptible to safranm counterstain. The
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method described by Lesher. J.L & Aly, R. (2000) was closely followed. 
Single colonies were isolated using a wire loop, emulsified in water and spread 
upon glass microscope slides. This slide was then heated over a Bunsen burner 
to attach the bacteria to the glass slide and allowed to cool.
The bacterial specimen was then flooded with crystal violet solution for 10 
seconds, which was subsequently washed off with tap water. The slides were 
then flooded with Gram’s iodine solution for 10 seconds, which was 
subsequently washed off with tap water. The slides were then washed with 
ethanol-acetone solution until the solvent ran clear. The bacterial specimens 
were the counterstained with saffanin for 10 seconds and washed carefully with 
tap water. The slides were then air dried and analysed using microscopy and 
images captured using an integrated Olympus DP-12 digital camera system 
(Olympus, Oxford, UK)..
73 Results 
73.1 Microbiological examination of porcine ear
73.1.1 Swabbing of whole porcine ear skin
The microbiological examination of the porcine ear swabs firstly revealed that 
3 m ain  types of colonies grew at both 37 °C and that anatomical site showed 
no difference. This was shown across all 3 ears swabbed also. Isolation 
revealed ano ther two strains. Table 7.2 describes bacterial colonies grown
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from each swab and results from the Gram’s stain, to ascertain the species of 
bacteria, are shown in figure 7.2.
Swab Incubation
temperature
Description of colony grown
A 37° C Small yellow  and small white colony, large white, 
colony
B 37° C Small yellow  and small white colony, large white, 
colony
C 30° C W hite diffused colony, diffused yellow  colony
D 37° C N o bacterial growth
Table 7.2 Descriptions o f bacterial colonies grown from swabs o f porcine skin, taken at 
different locations on the upper surface o f the ear skin after 48 hours. Swabs a-c were grown 
up on TSA, while swab d was grown up on SDA.
Repeated isolation and re-swabbing of colonies determined that 5 distinct 
bacterial colonies were present on the surface of porcine ear skin. 
Unsurprisingly, no bacterial colonies were detected on the SDA plates, as this 
agar in specifically for the growth of fungal colonies.
Figure 7.1 shows digital photos of the result of the Gram’s stain. 7.1 A shows 
that the small white colony, grown on TSA at 37° C, stained a violet colour, 
revealing that this was a Gram-positive bacterium.
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Figure 7.1 A-E Gram’s stain of bacterial colonies (x80). A = small white colony, B = diffused white colony, C = large white colony, D = smell yellow colony, E = diffused 
yellow colony photos of gram stain were taken using an Olympus BH-2 phase microscope and photographed using an integrated Olympus DP-12 digital camera system 
(Olympus, Oxford, UK).
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Figure 7.1 B shows that the diffused white colony, grown on TSA at both 30°C 
after 48 hours, stained violet indicating this too was a Gram-positive 
bacterium.
Figure 7.1 C the results of the Gram’s stain for the large white colony, grown 
on TSA incubated at 37°C. This indicates that this was also a gram-positive 
bacterium. Figure 7.1 D reveals that the small yellow colony, which grew on 
TSA incubated at 37°C after 48 hours stained pink/orange indicating this was a 
Gram-negative bacterium. Figure 7.1 E shows that the diffused yellow colony 
that grew on TSA incubated at 37°C after 48 hours stained pink/orange 
suggesting that this was a Gram-negative bacterium
The SD agar plate, incubated at 37°C, allowed the growth of a large diffused 
white fungal colony.
73.1.2 The effect of the cyclopore track etched membrane on the 
microbiological contamination of the receptor solution
Due to the heavy microbiological contamination of the porcine ears, it was 
necessary to assess the ability of the CTEM to prevent the ingress of 
microorganisms from the skin into the diffusion cell receptor compartment. 
This was vital to the success of the full model system, as any bacterial 
contamination of the receptor compartment would almost certainly kill cells 
grown on the bottom of this vessel.
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CTEM Skin AB and AF Growth after 6 hours Growth after 24 hours Growth after 48 hours
Present Present Present No growth No growth No growth
Present Present Absent No growth White diffused (30 °C) White diffused (30 °C)
Present Absent Present No growth No growth No growth
Present Absent Absent No growth No growth No growth
Absent Present Present Small white & yellow (37 °C) Small white & yellow (37 °C) Small white & yellow (37 °C)
Absent Present Absent Large white, small white, small 
yellow (37 °C) white diffused 
(30 °C)
Large white, small white, small 
yellow (37 °C) white diffused 
(30 °C)
Large white, small white, small 
yellow (37 °C) white diffused 
and yellow diffused (30 °C)
Table 7.3 Table to show the diffusion cell set up to assess the ability of the CTEM in preventing bacterial contamination of the receptor solution. Cells were maintained in a 
sterile environment at 37 °C to provide a skin surface temperature of 32 °C. Receptor solution was wRPMI plus 5% SFCS. Fungizone (AF) and streptomycin (AB) were 
added as stated in the table. Samples of the receptor solution were taken at 6,24 and 48 hours (n=5).
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The data displayed in table 7.3 shows that bacterial growth was not seen when 
diffusion cells were set up with CTEM membrane alone both with and without 
antibacterial and antifungal present and at all time points, suggesting that this 
membrane was reliably sterile. Bacterial growth was detected in diffusion cells 
set up with skin, without the CTEM present, both with and without 
antibacterial and antifungal present and at all time points. The diffusion cells 
with both porcine skin and CTEM showed no bacterial growth at each time 
point when the antibacterial and anti-fungal were present. However, in the 
absence of the antibacterial and antifungal bacterial contamination was seen in 
the 24 and 48 hour sample.
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CTEM Skin AB and AF Growth after 6 hours Growth after 24 hours Growth after 48 hours
Present Present Present No growth No growth No growth
Present Present Absent No growth No growth Large white diffused
Present Absent Present No growth No growth No growth
Present Absent Absent No growth No growth No growth
Absent Present Present Large white diffused Large white diffused Large white diffused
Absent Present Absent Large white diffused Large white diffused Large white diffused
Table 7.4 Table to show the diffusion cell set up to assess the ability of the CTEM in preventing fungal contamination of the receptor solution. Cells were maintained in a 
sterile environment at 37 °C to provide a skin surface temperature of 32 °C. Receptor solution was wRPMI plus 5% SFCS. Fungizone (AF) and streptomycin (AB) were 
added as stated in the table. Samples of the receptor solution were taken at 6,24 and 48 hours (n=5). Incubation of Petri dishes was at 37°C.
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The data displayed in table 7.4 shows that fungal contamination of the receptor 
phase was prevented when both the CTEM and antibiotic and antifungal were 
present. The presence of just the skin and CTEM, without antibiotic and 
antifungal present, delayed fungal contamination for 24 hours. Inclusion of the 
skin and the antibiotic and antifungal were present without the addition of the 
CTEM gave rise to contamination at the first sample point of 6 hours.
7.4 Discussion
This chapter has highlighted the extent of microbial contamination to which 
transdermal/transcutaneous permeation studies are subjected to, however, the 
normal cleansing routine post-slaughter would be a compromise but not an 
acceptable one for permeation studies due to the stripping of SC and epidermis. 
Microbial contamination of receptor phase is not normally considered a major 
pitfall in permeation studies, however, when developing such a composite 
transcutaneous model aimed at reflecting in vivo situations, this consideration 
becomes paramount.
This chapter has determined that 5 distinct bacterial colonies and 1 fungal 
colony exist on excised porcine ear skin. These were detected in three different 
ears on three separate occasions, suggesting that these microorganisms are 
commonly found on porcine ear skin.
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One species of fungi was also present on excised porcine ear skin, which if 
human and porcine skin share the same resident fungi, this could be 
Pityrosporum (Malassezia spp).
It is widely acknowledged by microbiologists that the sizes of bacteria and 
fungi are in excess of 0.22 pm, suggesting that this would provide a suitable 
filter to stop the ingress of these microorganisms from the skin to the receptor 
phase cyclopore track etched membrane.
Diffusion experiments with CTEM present beneath the skin membrane delayed 
bacterial contamination of the receptor phase, however complete inhibition of 
contamination was only seen when AB and AF were included into the receptor 
phase. This suggests that either species of bacteria exist that are smaller than 
0.22 pm in diameter and that are not widely documented in microbiology texts 
or that the pore sizes were not uniformly accurate at 0.22 pm in diameter. 
Another plausible explanation could be that the bacteria could pass around the 
edges of the CTEM and enter between the CTEM and receptor compartment 
flanges.
The amounts of bacteria entering the receptor phase in the presence of the 
CTEM was much reduced compared to that entering without the CTEM 
present as the AB present within the receptor phase was capable of killing 
these. Streptomycin and penicillin were added to die receptor phase and act on 
Gram-negative and Gram-positive bacteria respectively. Streptomycin is a
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bactericidal agent, capable of killing many species of bacteria (Donald, P.R. 
2002). Streptomycin delivers the bactericidal by binding to the 30S subunit of 
bacterial ribosomes, changing their shape. This leads to misreading of 
bacterial messenger RNA, thus inhibits bacterial protein synthesis (Rang, H.P. 
et al 2000). Penicillins are also bactericidal; however, they inhibit bacterial 
wall synthesis. Data in this chapter suggests that the inclusion of these Abs is 
crucial in maintaining a sterile receptor phase in which MCF-7 cells may later 
be cultured.
7.5 Conclusions
The 0.22 pm cyclopore track etched membrane proved sufficient in retarding 
the ingress of microorganisms. It is established that most, if not all, recognised 
fungal and bacterial organisms are above 0.5 pm in diameter (Spellman, F.R. 
1998) and therefore it is not surprising that the 0.22 pm pore size of the 
membrane was sufficient to prevent the passage of the microorganisms.
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8.1 Introduction
In chapters 3 and 4 the plausibility of delivering PD98059, LY294002 and 4- 
hydroxytamoxifen across excised porcine skin was demonstrated and 
discussed. Furthermore, chapter 5 revealed that concentrations permeated were 
enough to inhibit MCF-7 cell growth significantly.
Throughout the literature, there is scant evidence of any intermediate between 
in vitro transcutaneous delivery studies and in vivo animal studies. Little effort 
has been made to further develop the diffusion cell methodology to incorporate 
post skin targets.
This chapter examined the plausibility of a composite model, incorporating 
elements of both skin permeation and cell culture. The first part of the model 
consists of MCF-7 cells grown at the bottom of a glass Franz diffusion cell 
(FDC) receptor compartment. This, in itself, provides a major challenge as 
uncoated glass is not considered to be an effective substrate for the growth of 
this type of cell line. The second part of the model involves a full-thickness 
skin membrane, mounted between the greased flanges of the diffusion cell, 
shown in Figure 8.1. Drug solutions applied to the skin in the donor phase 
permeating the skin enter the receptor phase and diffuse to the cells, where 
their pharmacological activities would be exerted.
300
Chapter 8 Towards a Prana DMAulon Call Model Ibr the In vitro Asseument or Topleal Breast cancer Iherapeutlos it
Figure 8.1 An illustration to show the experimental set up of the “composite model”.
Cyclopore track 
etched > 
membrane
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The final part of the model surrounds the necessity to prevent microbial 
contamination of the receptor phase/cell growth medium. To this end a 0.22 
pm cyclopore track etched membrane was used- these are filters that contain 
highly accurate and uniform pore distribution compared to general filter pore 
creation. This was placed between the lower surface of the skin and receptor 
phase, chapter 7 validated the prevention of bacteria and fungal entry into the 
receptor phase when both AB and AF were present.
A successful composite system based on the above would mimic a topical drug 
delivery system scenario more closely than two disparate experiments. In this 
work, the individual elements of the proposed model were validated and 
ultimately used to determine the effects of the aforementioned drug 
combination on the cells cultured within the FDC receptor compartment. This 
composition of the separate methodologies has not been presented in the 
literature, and thus it can be presumed has not been attempted or been 
successful, therefore optimisation of all aspects had to be performed (described 
in chapter 7 and section 8.2.2).
8 .U  Aims
The aim of the work in this chapter was to probe a novel composite model for 
studying in vitro the activity of topically applied compounds against breast 
cancer cells (figure 8.1).
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8.2 Material & Methods
8.2.1 Materials
Most materials used in this chapter were introduced in chapter 2 (section 2.1) 
Cyclopore track etched membranes (CTEM), 47mm diameter, 0.22 pm and 
Dow Coming high vacuum grease were from Fisher Scientific, Loughborough, 
UK.
8.2.2 Methods
8.2.2.1 Cell culture in glass Franz diffusion cells
Franz diffusion cells were cleaned and autoclaved and stored in a sterile 
environment until required. MCF-7 cells were grown in plastic flasks, in 
RPMI plus 5% FCS until 70% confluent. At this point cells were passaged, 
using the protocol outlined in chapter 2 and 1 million cells per Franz diffusion 
cell were seeded into each diffusion cell in 1ml of wRPMI. The media was 
supplemented with 5% SFCS, lOUmL1 and 10 pg mL' 1 penicillin/streptomycin 
and 2.5 pg mL"1 fungizone. The diffusional area of the receptor compartment 
was sealed with a sterile cover slip, while the sampling arm was sealed with 
sterile tin foil. This time point was taken as day 0. On day 2 the media was 
removed and replenished with fresh media, on this instance the whole receptor 
compartment was filled. On day 4, media was replenished and on day 7 cells 
were counted, as outlined previously. Counts were corrected for the area of the 
receptor compartment.
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8.2.2.2 Permeation studies through 0.22 pm pore membrane filters
All studies were conducted in a laminar flow cabinet and under sterile 
conditions. A sterile cyclopore track etched membrane (CTEM) was necessary 
in the whole model as it has been previously demonstrated that this is sufficient 
to prevent the ingress of bacteria and fungus, described in chapter 7. It was 
hoped that the 0 .2 2 pm pores would be sufficiently small to prevent 
microorganisms from entering the receptor phase from the skin but large 
enough so as not to impede the permeation of the three compounds. This 
section was aimed at ensuring that the cyclopore track etched membrane was 
not a limiting factor in the permeation of the compounds.
Glass diffusion cells were washed, autoclaved and set up as described in 
chapter 3. However, a cyclopore track etched membrane was added in place of 
the skin membrane. The CTEM was soaked in receptor phase prior to 
incorporation into the diffusion cell apparatus to ensure that any drug 
penetration was not out-balanced by the upward movement of receptor phase 
into the CTEM. A donor compartment was clamped to the upper surface of the 
membrane with a stainless steel clamp. Both donor and receptor flanges were 
greased with high vacuum silicon grease to ensure no leakage of donor phase. 
Receptor phase was cetrimide (30 mg mL'1) and donor phase was 2.54 x 10*4  
M 4-hydroxytamoxifen, PD98059 and LY294002 in a fish oil vehicle. The 
donor compartment was occluded to mimic a patch application. Samples were
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taken at 1,2,3,4,5, 6  and 24 h (n=5 for both experiments). Samples were 
analysed for the three compounds and for EPA as described in chapter 2.
8.2.23 Permeation studies through both excised porcine skin and 0.22 pm 
cyclopore track etched membrane
Franz diffusion cells were set up as stated in 8.2.2.2, however, excised porcine 
skin was placed onto the uppermost surface of the membrane, stratum comeum 
upward. Again, a donor compartment was clamped into place. Donor phase 
was 2.54 x 1 0 ”4 M PD98059, LY294002 and 4-hydroxytamoxifen in a fish oil 
vehicle. Samples were taken at 3, 6 , 12, 24, 36 and 48 h and analysed as 
above.
8.2.2.4 Cell growth studies with trans-CTEM dosing of 4- 
hydroxytamoxifen, PD98059 and LY294002
Franz diffusion cells were cleaned and autoclaved prior to use and all 
experimentation was conducted in a laminar flow cabinet to maintain a sterile 
environment. Diffusion cells were set up as described in section 8.2.2.1. 
MCF-7 cells were seeded at a density of 1 x 106 cells per diffusion cells on day 
0. Flanges of the receptor compartment were greased to ensure no leakage and 
the receptor compartment was sealed with a sterile cover slip. On day 1 media 
was removed from the receptor compartment and replenished with fresh, on 
this occasion the whole receptor compartment was filled. The receptor the 
compartment was sealed in this circumstance with a 0.22 pm CTEM and a pre­
greased donor compartment was clamped into place. A donor phase of 2.54 x
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10-4 M 4-hydroxytamoxifen, PD98059 and LY294002 in a fish oil vehicle or 
fish oil alone (control) was applied to the surface of the track-etched 
membrane. On day 6  cells were trypsinized and counted using the method 
outlined previously.
8.2.2.5 Composite model
Experimental protocol described in the section 8.2.2.4 was repeated, however, 
a porcine skin membrane was placed above the CTEM, stratum comeum 
upward facing. It was ensured that the CTEM was greater in diameter than the 
porcine skin membrane to restrict passage of microorganisms under the CTEM.
8.23 Statistics
One-way ANOVA was used to assess the similarity in cell growth between 
FDCs. Cell counts were deemed statistically insignificantly different at P < 
0.05. Un-paired t-tests were used to compare the permeation of PD98059, 
LY294002, 4-hydroxytamoxifen and EPA through full thickness skin, the 
CTEM and both skin and CTEM. T-tests were also used to assess the effect of 
the cocktail formulation on MCF-7 cell growth when cultured in FDCs. P 
values less than 0.05 were deemed to represent statistically significant results
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8.3 Results
8.3.1 MCF-7 cell culture in glass Franz diffusion cells
Figure 8.2 shows ce ll counts a fte r 7 days o f cu lture  in  a ll glass Franz ce lls. S ix 
d iffu s io n  cells were investigated, w h ich  gave consistent ce ll counts between 
the 6 d iffe re n t d iffu s io n  ce lls and between the 5 repeats (P = 0.870). A  P value 
above 0.05 suggests that no s ig n ifican t d iffe rence was seen between ce ll 
counts.
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Figure 8.2 Histogram to show diffusion cell MCF-7 counts after 1 week incubation (n=5 ± 
SD). Passage numbers were 12, 13, 14, 19, 22.
Each d iffu s io n  ce ll a llow ed a ce ll count o f  between 40,000 and 50,000 ce lls, 
w ith  no s ign ifican t d ifference in  ce ll count between each d iffu s io n  ce ll. 
Reproducible ce ll counts meant tha t any effects on ce ll g row th  occurring  in
1 2 3 4 5
Diffusion cell number
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treated diffusion cells could confidently be attributed to the effects of the 
compounds.
83.2 Permeation of 4-hydroxytamoxifen, PD98059 and LY294002 through 
a 0.22 pm cyclopore track etched membrane
Figure 8.3 shows the permeation of all compounds through the CTEM. The 
CTEMs allowed 0.0167 ± 0.0026, 0.011 ± 0.001 and 0.016 ± 0.0025 mg cm"2 
of PD98059, LY294002 and 4-hydroxytamoxifen respectively, which was 
significantly greater than the mass permeating through M l thickness skin (P = 
0.03, 0.02, 0.04 respectively). Equilibrium was seen at just 3 h with steady 
state flux observed at 2-3 h. The steady state fluxes of the three compounds 
were significantly greater than through M l thickness skin (P = 0.013, 0.008, 
0.001 respectively for PD98059, LY294002 and 4-hydroxytamoxifen).
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Figure 8.3 Permeation profiles for 4-hydroxytamoxifen, PD98059 and LY294002 through a 
0.22pm cyclopore track etched membrane. Diffusion cells were kept in a water bath at 37°C to 
mimic normal diffusion experiments. Donor phase was 2.54 x 10"4 M 4-hydroxytamoxifen, 
PD98059 and LY294002 in fish oil (plus 0.05 v/v BHA, 2.5% DMSO/ethanol and 4% w/v cab- 
o-sil). Receptor phase was 30mgmr‘ cetrimide solution (n=5 ± SD).
These were 7.55 ±  1.72, 5.03 ±  1.4 and 9.225 ±  1.28 pg cm '2 h '1. Lag tim es 
were 1.53 ±  0.18, 1.7 ±  0.13 and 1.72 ±  0.01 hours respective ly fo r PD98059, 
LY294002 and 4-hydroxytam oxifen , these were also s ig n ifica n tly  less than 
those seen across fu ll thickness skin  (P =  0.01, 0.05, 0.05 respective ly).
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Figure 8.4 Permeation profile for EPA through a 0.22pm  cyclopore track etched membrane. 
Diffusion cells were kept in a water bath at 37°C to mimic normal diffusion experiments. 
Donor phase was 2.54 xlO-4 4-hydroxytamoxifen, PD98059 and LY294002 in fish oil (plus 
0.05 v/v BHA, 2.5% DMSO/ethanol and 4% w/v cab-o-sil). Receptor phase was SOmgmf1 
cetrimide solution (n=5 ± SD).
Figure 8.4 shows the perm eation o f  E PA  th rough  the C TE M . The C TE M  
allow ed 5543.494 ±  955.9 p gem '2 o f  E PA  to  perm eate a fte r 24 h, w h ich  was 
s ig n ifica n tly  greater than the mass perm eating through excised porcine skin 
after 24 h (P =  0.016). The steady state flu x  o f  EPA through the C T E M  was 
s ig n ifican tly  h igher also (P =  0.02). T h is was seen between 2-3 hours and was 
1878.75 ± 1 3 9 .1  pg cm ’2 h-1. The lag tim e  was 1.54 ±  0.02 hours under these 
conditions, w h ich  was m uch reduced com pared w ith  perm eation through skin  
membranes, how ever, th is  was not s ta tis tica lly  s ig n ifica n t (P =  0.08).
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Figure 8.5 Histogram to show the percentage o f  applied dose permeating after 24 hours, 
comparing the percentage permeating through skin and the cyclopore track etched membrane.
Figure 8.5 compares the percentage o f  applied dose permeated o f each active 
o f the fo rm u la tion . I t  also compares th is  against the percentage o f applied dose 
perm eating fu ll thickness porcine  skin . I t  dem onstrates very com prehensibly 
that perm eation through the C T E M  was greater than through the porcine skin 
membranes fo r each active constituen t o f the fo rm u la tion .
8 .3 .3  P e r m e a t i o n  s tu d ie s  t h r o u g h  b o th  e x c is e d  p o r c in e  s k in  a n d  0 .2 2 p m  
c y c lo p o r e  t r a c k  e tc h e d  m e m b r a n e
Figure 8.6 shows perm eation data fo r 4 -hydroxytam oxifen , PD98059 and 
LY294002 across both excised porcine sk in  membrane and the C TE M . The
40HTam
Compound 
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mass o f 4 -hydroxytam oxifen  that perm eated through both  sk in  and C TE M  a fte r 
48 hours was 6.22 ±  0.29 pg cm '2, no s ig n ifica n t d iffe rence  was seen in  
perm eation w ith  the inc lus ion  o f the C T E M  (P =  0.990). N o s ig n ifica n t 
d ifference in  the steady state flu x  o r lag  tim e  o f 4 0 H T a m  was detected w ith  the 
add ition  o f the C TE M  to  the d iffu s io n  ce ll set up (P =  0.096 and 0.169 
respectively). Steady-state flu x  was observed betw een 12 and 24 hours, flu x  
was 0.21 ±  0.021 pg cm '2 h '1 and lag tim e  was 6.03 ±  1.42 h. The perm eab ility  
coeffic ien t fo r 4 -hydroxtam oxifen  th rough  both  fu ll th ickness porcine skin  and 
the C TE M  was 1.74 x  10'3 ±  1.74 x  10-4 c m h '1 com pared to  2.27 x l0 '3±  1.65 x 
KT4 c m h '1.
6050403020100
Time (hours)
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Figure 8.6 Permeation profile for 4-Hydroxytamoxifen, PD98059 and LY294002 through both 
full thickness excised porcine skin and a 0.22pm cyclopore track etched membrane. Diffusion 
cells were kept in a water bath at 37°C. Donor phase was 2.54 xlO"1 4-hydroxytamoxifen, 
PD98059 and LY294002 in fish oil (plus 0.05 v/v BHA, 2.5% DMSO/ethanol and 4% w/v cab- 
o-sil). Receptor phase was SOmgml'1 cetrimide solution (n=5 ±  SD).
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The inclusion of the CTEM to the diffusion cell set up gave no significant 
effect (P = 0.996) on the mass of PD98059 permeating after 48 hours, this was 
5.06 ± 0.74 pg cm'2. The steady state flux of PD98059 was 0.23 ± 0.04 pgcm' 
2h_1 and was observed between 12 and 24 h. It was not significantly altered 
with the inclusion of the CTEM (P = 0.1115). The lag time of PD98059 was 
6.43 ± 1.1 h in the presence of the CTEM, which was not significantly different 
from the lag time seen when PD98059 was applied to skin only (P = 0.432). 
The permeability coefficient for PD98059 was 2.16 x 10 '3 ± 4.1 x 10"4  cmh'1.
The mass of LY294002 that permeated both skin and CTEM was 7.89 ± 0.68 
pg cm"2, which was not significantly different to the mass permeating full 
thickness skin without CTEM present (P = 0.316). The flux of LY294002 was 
slightly reduced with the insertion of the CTEM from 0.64 ± 0.07 pg cm'2 h’1 to 
0.55 ± 0.004 pg cm'2 h*1, however this was not a significant reduction (P = 
0.115). The lag time was 6.187 ± 0.987 h and was also not significantly 
changed with the inclusion of the CTEM (P = 0.161). The permeability 
coefficient of LY294002 was 4.2 x 10 '3 ± 4.56 x 10-4 cmh"1 with the addition of 
the CTEM.
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Figure 8.7 Permeation profile for EPA through both full thickness excised porcine skin and a 
0.22 pm cyclopore track etched membrane. Diffusion cells were kept in a water bath at 37 °C. 
Donor phase was 2.54 xl(T* 4-hydroxytamoxifen, PD98059 and LY294002 in fish oil. 
Receptor phase was 30mgmr* cetrimide solution (n=5 ± SD).
Figure 8.7 shows the perm eation o f  E PA  through both a skin  and cyclopore 
track etched membrane. I t  dem onstrates tha t the perm eation o f EPA was not 
s ig n ifica n tly  d iffe re n t w ith  the a dd itio n  o f the C TE M . The mass perm eating 
after 48 h was 1159 ±  168.9pgcm ’2, w h ich  was not a s ig n ifican t change from  
the mass perm eating through fu ll thickness skin  w ith o u t C TE M  present (P — 
0789). Steady-state flu x  o f  E PA  was seen between 3-12 h. The flu x  was 57.67 
±  10.26 pg cm ’2 h’1 and lag tim e  was 5.83 ±  1.042 hors, w ith  neither o f these 
results show ing a s ig n ifica n t d iffe rence  fro m  results obtained fo r perm eation o f
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EPA through just full thickness skin (P = 05 and 0162 respectively for flux and 
lag time results).
83.4 Cell growth studies with trans-CTEM dosing of 4-hydroxytamoxifen, 
PD98059 and LY294002
This small investigation was to determine whether the 3 compounds and EPA 
could penetrate the CTEM and exert their growth inhibitory effects on the 
MCF-7 cells seeded below. Figure 8 . 8  shows cell counts of MCF-7 cells after 
7  days, treated with either fish oil alone (control) or with the final formulation.
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Figure 8.8 Histogram to show the effect o f  CTEM dosed 4-hydroxytamoxifen, PD98059 and 
LY294002 on MCF-7 cells seeded in glass diffusion cells. Control formulation consisted o f  
fish oil (plus 2.5% v/v DMSO/ethanol, 0.05% v/v BHA, 4% w/v Cab-o-sil. Test formulation 
was the same however included 2.54 x 10-4 4-hydroxytamoxifen, PD98059 and LY294002. 
Receptor phase was wRPMl + 5% v/v SFCS +1%  antibacterial and antifungal. Diffusion cells 
were maintained in a Diffusion cells were maintained in a Sanyo MCO-17AIC incubator 
(Sanyo, E&E Europe BV, Loughborough, UK) at 37°C in a humidified atmosphere o f  5% C 0 2 
in air throughout the experiment (n=6 for control and 12 for test ± SD). Passage numbers were 
12, 17 and 27.
Figure 8.8 shows tha t the fo rm u la tion  permeated the C TE M  and reduced ce ll 
grow th s ig n ifica n tly  to  20.8 ± 5 . 1  %  o f con tro l ce ll g row th  (P =  0.01. This 
in h ib itio n  in  ce ll g row th  is less than seen when M C F-7 ce lls were treated 
d ire c tly  w ith  IC 50 concentrations o f the three com pounds, w h ich  reduced ce ll 
grow th to  2.6 ±  0.5 %  o f  contro l.
control
Treatmert
316
Chapter 8 Towards a Franz Diffusion Cell Model for the in vitro Assessment o f Topical Breast
Cancer Therapeutics II
8.3.5 E ffec t o f  PD 98059, LY 294002 4 -h y d ro x y ta m ix ife n  a n d  fish  oil on 
M C F -7  cells c u ltu re d  w ith in  F D C s, h a v in g  p e rm e a te d  th e  C T E M  a n d  full 
th ickness  p o rc in e  e a r  sk in
F in a lly  in  th is short study, the cu lm ina ting  experim ent was to  com bine a ll the 
p re lim ina ry investigations discussed above in to  the ‘ com posite m odel’ as 
detailed in  figure  8.1.
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Figure 8.9 Histogram to show the effect o f  porcine skin and CTEM dosed 4- 
hydroxytamoxifen, PD98059 and LY294002 on MCF-7 cells seeded in glass diffusion cells. 
Control formulation consisted o f fish oil (plus 2.5% v/v DMSO/ethanol, 0.05% v/v BHA, 4% 
w/v Cab-o-sil). Test formulation was the same however included 2.54 xlO^ 4- 
hydroxytamoxifen, PD98059 and LY294002. Receptor phase was wRPMI + 5% v/v SFCS + 
1% antibacterial and antifungal. Diffusion cells were maintained in a Sanyo MCO-17AIC 
incubator (Sanyo, E&E Europe BV, Loughborough, UK) at 37°C in a humidified atmosphere 
of 5% COz in air throughout the experiment (n=6 x 3 for control and 12 x 3 for test ±SD). 
Passage numbers were Passage numbers were 22, 30 and 35.
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Figure 8.9 showed that the test formulation was capable of permeating the skin 
and significantly inhibiting MCF-7 cell growth to 6 6 . 6 8  ± 13.41 % compared 
to control growth (P = 0.044). This was a significantly smaller inhibition in 
cell growth than that seen with IC50 concentrations of the three compounds (P = 
0.023).
8.4 Discussion
This investigation into the development and validation of a composite model, 
incorporating both permeation and growth elements uncovered several 
significant results. Firstly, it was encouraging to discover that MCF-7 cells 
adhered to glass diffusion cells extremely well. It has been widely 
acknowledged that treated plastic, eg Dow Coming tissue culture treated 
polystyrene, is the preferred substrate for the growth of cultured cells.
Previously, several investigations have shown that cultured cells do not grow 
well on glass cells and require a coating (often TESPA or components of the 
ECM such as lamanin or fibronectin) for adequate seeding and growth. Ability 
of cell to adhere to glass is also cell specific. Bovine aortic endothelial cells 
show good attachment to glass, enabling normal growth of this cell line; 
however, human umbilical vein epithelial cells attached and grew poorly when 
the same methodology was followed. These two cell lines both attached and 
proliferated on plastic surfaces equally well (Grabowski, E. F. & McDonnell, 
S.L. 1982). It has been suggested that the mechanism of cell attachment to
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glass is not a result of interactions between substrate and charged regions of the 
cell surface, but as a result of interactions with non-polar regions of the cell 
surface, however, in the presence of serum, electrostatic forces may be 
responsible for cellular attachment George, J.N et al 1970). .Another study 
suggested that red blood cell attachment to glass was a result of long-range 
electrostatic repulsive and electrodynamic attractive forces (Tommler, A. et al 
1985).
A possible explanation for the unexpected cell attachment could be due to the 
cleaning process with Decon 90, which may have made the inner surfaces of 
the FDC rough and uneven. It has previously been shown that grit blasted 
glass equates to better cell attachment than smooth glass surfaces (Banks, B. et 
al 2 0 0 1 ).
The flux of all 4 of the active constituents was not hindered by the presence of 
the CTEM. This was evident from comparing diffusion studies through CTEM 
alone, skin alone and composite CTEM and skin. The flux of the permeants 
through the CTEM was significantly greater than across the skin and there was 
virtually no lag time seen. This is most probably a result of the relative sizes of 
the drugs being in the nanometre range, while the pore sizes of the CTEM are 
0 .2 2 pm, suggesting that the pores would offer no resistance to the passage of 
the compounds and the CTEM was not rate limiting to the permeation of 
PD98059, LY294002,4,hydroxytamoxifen or EPA.
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Due to the presence of the MCF-7 cells at the bottom of the receptor 
compartment, the micro magnetic stirrer normally inserted into the receptor 
compartment to agitate the receptor solution could not be used in this work. 
Thus an additional barrier, in the form of a stagnant diffusion layer, would 
have existed at the membrane/receptor solution interface. The average area of 
the receptor compartment used was 3.2 mL, thus it would be necessary for the 
permeants to diffuse through this medium prior to interacting with the MCF-7 
cells. These stagnant diffusion layers, in some way mimics permeation 
through sub-skin tissues. Post skin targets would not be subjected to large 
concentration gradients as seen in standard diffusion experiments caused by the 
constant agitation of the receptor phase. Instead passive diffusion through the 
tissue would dominate the route of entry and passage through tissues. The lack 
of agitation of the receptor phase in these diffusion experiments would reduce 
the impact of the concentration gradient, especially at lower stagnant diffusion 
layers of the receptor phase, and so passage of compounds through this media 
would be by passive diffusion.
Finally, it is acknowledged that dermal clearance will remove some permeating 
drug, and some skin scientists argue that transcutaneous delivery of compounds 
is made impossible due to the extent of this phenomenon (Krestos, K. et al 
2007). This was mimicked, in this chapter, by replenishment of media on day 
4 and by daily agitation of the receptor compartment. In spite of this media 
removal and agitation, sufficient concentrations of compounds were capable of
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reaching the under-laying cells and inhibiting their growth significantly (P = 
0.044).
8.5 Conclusions
There are two major conclusions from this work. Firstly, MCF-7 breast cancer 
cells can be successfully cultured directly within glass Franz diffusion cells. 
Secondly, a composite diffusion cell/ cell culture model can be used to indicate 
the potential efficacy of topically delivered anti breast cancer therapeutic 
agents. The model may be considered as an intermediate between in vitro and 
in vivo experiments. By combining two separate and time consuming 
experiments, such a model could be used as a high throughput experiments 
screen in other transcutaneous drug delivery systems.
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Chapter 9
Delivery of PD98059, LY294002 and 4- 
hydroxytamoxifen via the mammary papilla
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9.1 Introduction
Previous chapters have considered the potential of delivering PD98059, 
LY294002, 4, hydroxytamoxifen and EPA across full thickness porcine skin, 
and their effects on breast cancer cells having diffused through the multiple 
layers of the skin. Thereafter, it has been hypothesised that the agents will 
diffuse further through and pervade the breast tissue providing therapeutic 
levels in situ. The fact that little control can be exerted over the ultimate 
localisation of the drugs could limit the efficacy of the system. However, an 
encouraging clinical study was recently published describing the effect of a 4- 
hydroxy tamoxifen gel on cyclical mastalgia in premenopausal women, where 
symptoms were found to diminish after 4 months of topical application to the 
breast (Mansel, R. et al 2007).
This chapter is concerned with a somewhat different approach for delivering 
the aforementioned compounds, involving permeation across the mammary 
papilla (nipple). To the best of our knowledge, the approach is novel.
The rationale for this study was centralised around the location in which breast 
cancers originate from. Most breast carcinomas and pre-cancers are believed 
to originate in the lining of the milk duct or in the lobule (figure 9.1), making 
such areas the major target for any topical delivery system.
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Figure 9.1 Upper: Normal (left) versus cancerous (right) mammography images (National 
Cancer Institute, http:// history.nih.gov/exhibits/genetics/sect2.htm) Lower: Anatomy o f the 
mammary papilla and breast. A-milk duct, B-lobule, C-dilated section o f duct to hold milk, D- 
nipple, E-fatty tissue, F-pectoralis major muscle, G-chest wall/ribs (www.breastcancer.org).
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Until recently direct access to this area has been by core biopsy or fine needle 
aspiration only (Shen, K.W. et al 2000), although the newer techniques of 
‘ductography’ and ‘fiberoptic ductoscopy’ have been explored and proposed 
for visualisation in the diagnosis of breast cancer and other diseases of the 
breast (Yamamoto, D. et al 2001).
Ductoscopy has also been investigated for delivering breast cancer treatment to 
the tumor directly. Although deemed ‘minimally invasive’ this procedure was 
painful to the extent that general anaesthesia was necessary.
Surprisingly, passive delivery via the mammary papilla to the lobules, via the 
ducts, has not received attention. The mammary papilla, or nipple, exists to 
concentrate the flow of milk from the breast lobules and facilitate transfer to 
the infant As a tissue, it is leaky and would in theory allow the transfer of 
liquids in forward or reverse directions in non-lactating subjects.
The passive diffusion of chemical dyes throughout the full ductal networks 
have been mapped previously, however, these were applied via intraductal 
injection (Murata, S. et al 2006). It is not stated in the literature whether 
passive entry of compounds into the nipple would be possible. However this 
offers the most direct route to the site of action and so is necessary to explore.
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9.1.1 Aims
The aim of the work in this chapter was to explore in vivo the potential of 
delivering the previously developed formulation via the mammary papilla. It 
was hypothesised that the applied drugs would be capable of passively 
migrating through the ducts of the breast and be detected by the use of regular 
Franz diffusion cells.
9.2 Materials and Methods
9.2.1 Materials
Most of the materials used within this chapter were detailed in section 2.1. 
Strips of porcine sow breasts were obtained from a local abattoir prior to 
cleansing procedure. These were transported to the lab on ice and maintained 
in HHBBSS.
9.2.2 Methods
9.2.2.1 Preparation of porcine mammary papilla
Freshly excised strips of porcine mammary papilla were washed in tepid water 
to remove surface dirt
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Figure 9.2 Diagram to illustrate the dissection o f mammary papilla and their set up in Franz 
diffusion cells.
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Mammary papilli, surrounded by 2 x 2 cm of belly skin, were excised by blunt 
dissection as illustrated in figure 9.2. Subcutaneous fatty tissue was also 
removed by blunt dissection and pieces were maintained in HHBBSS until set 
up in diffusion cells.
9.2.2.2 Trans-mammary papilla delivery of PD98059, LY24002, 4, 
hydroxytamoxifen and EPA
The diffusion cells were cleaned and autoclaved prior to use. Both receptor 
and donor flanges were greased and a 2  x 2  cm porcine breast membrane 
containing a mammary papilla at approximately the middle of the skin was 
inserted onto the receptor compartment, nipple upward facing (shown in figure 
9.2). The donor compartment was then fixed to the receptor chamber with a 
stainless steel clamp, thus holding the tissue in a fixed position and creating an 
air and liquid-tight seal. The receptor compartment was then filled with a 
30mgmT1 cetrimide solution (which had previously been degassed), to which, a 
micro-stirrer bar was then added. The diffusion cells were then placed onto a 
submersible stirrer plate in a water bath set at 37° C and allowed to equilibrate. 
After 30 minutes, equimolar concentrations of PD98059, LY294002 and 4, 
hydroxytamoxifen (2.54 x 10-4 mol) were simultaneously applied to the surface 
of the skin in 200pL fish oil (containing 0.05% v/v BHA 2.5% DMSO, 2.5% 
ethanol v/v and 4% Cabosil w/v) as developed in chapter 4. Samples of 
receptor phase were collected, over a 24 h period.
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9.2.23 Quantification of amounts of PD98059, LY24002, 4,
hydroxytamoxifen and EPA passing through the mammary papilla
HPLC analysis was performed as described in chapter 2.
9.23 Statistical analysis
Permeation through the nipple was compared to that through skin via the use of 
unpaired t-tests. These were conducted on Minitab for Windows. P values of 
less than 0.05 were deemed as statistically significant.
93 Results
93.1 Delivery of PD98059, LY24002 and 4-hydroxytamoxifen via the 
mammary papilla
Figure 9.3 shows the mass of PD98059, LY294002 and 4-hydroxytamoxifen 
reaching the receptor phase after application to the nipple. This figure shows 
that saturation was reaches very quickly compared to delivery across skin: after 
just 5 hours.
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Figure 9.3 Cumulative mass o f  PD98059, LY294002 and 4, hydroxytamoxifen traversing the 
mammary papilla and reaching the receptor phase over 24 hour period. Receptor phase was 
30mgml-l cetrimide solution, which was stirred with a micro-stirrer and maintained in a water 
bath set at 37°C to give a skin surface temperature o f  32°C. Donor phase was dosed with 2.54 
x lO^mol PD98059, LY294002 and 4, hydroxytamoxifen in 200pl fish oil with 0.05% BHA 
2.5% DMSO and ethanol and 4% Cabosil (n=5 ± SD).
A t 5 h, 24.69 ±  3.31, 17.87 ±  2.44, 20.13 ±  2.89 gg cm"2 PD98059, LY294002 
and 4 -hydroxytam oxifen  passed in to  the receptor phase respectively.
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Figure 9.4 Cumulative mass o f EPA traversing the mammary papilla and reaching the receptor 
phase after 24 hours. Receptor phase was 30mgml-l cetrimide solution, which was stirred 
with a micro-stirrer and maintained in a water bath set at 37°C to give a skin surface 
temperature o f 32°C. Donor phase was dosed with 2.54 x lO^mol PD98059, LY294002 and 4, 
hydroxytamoxifen in 200pl fish oil with 0.05% BHA 2.5% DMSO and ethanol and 4% Cabosil 
(n=5 ± SD).
Figure 9.4 shows the mass o f E PA  able to  reach the receptor phase also 
increased compared to d e live ry  across fu ll thickness skin. Saturation was 
reached at 10 h, when, w h ich  was a lm ost exactly h a lf the applied dose o f each 
compound. A fte r 10 h, 2611.4 ±  497.5 pg cm '2 EPA  passed in to  the receptor 
phase. A fte r the 24-hour investiga tion  3081 ±  252.7 pg cm '2 EPA passed in to  
the receptor phase.
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The mass of PD98059 reaching the receptor phase 24 hours post application to 
the nipple was significantly greater than that 24 hours post skin application (P 
= 0.039). This was same for LY294002, 4-hydroxytamoxifen and EPA (P = 
0.019, 0.011 and 0.001 respectively).
M ass perm eating  a fte r  2 4  hours (jliL  m L '1)
Full th ickness sk in N ipple
PD98059 5.06 ± 0 .93 25.1 ± 6 .8 9
LY294002 6.97 ± 0 .9 9 18.2 ± 2 .5 5
4 0 H T am 5.14 ± 0 .93 21.14 ± 2 .7 5
EPA 1121.6 ±  143 3081.2 ± 252 .7
Table 9.1 Comparison of the mass o f PD98059, LY294002, 4-hydroxytamoxifen and EPA 
reaching die receptor phase after 24 hours when applied to full thickness skin or to die 
mammary papilla (nipple). Donor phase was 2.54 x 10“*mol PD98059, LY294002, 4- 
hydroxytamoxifen in 200pl fish oil plus 0.05% BHA 2.5% v/v DMSO and ethanol with 4% 
w/v Cabosil. Receptor phase was SOmgrnl'1 cetrimide solution, previously degassed, agitated 
with a magnetic micro-stirrer and maintained to give a skin surface temperature of 32°C (n=5 ± 
SD).
Table 9.1 compares the mass of each active constituent of the cocktail reaching 
the receptor phase after 24 h when dosed onto full thickness skin and onto the 
nipple. It is obvious that trans-mammary papilla dosing was superior to 
transcutaneous dosing.
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Figure 9.5 Cumulative mass o f  PD98059, LY294002 and 4, hydroxytamoxifen traversing the 
mammary papilla and reaching the receptor phase after 24 hours. Receptor phase was 
30mgml-l cetrimide solution, which was stirred with a micro-stirrer and maintained in a water 
bath set at 37°C to give a skin surface temperature o f  32°C. Donor phase was dosed with 2.54 
x lO^mol PD98059, LY294002 and 4, hydroxytamoxifen in 200pl fish oil with 0.05% BHA 
2.5% DMSO and ethanol and 10% Cab-o-sil (n=5 ± SD).
Figure 9.5 shows the e ffec t o f  increasing the w e igh t in  volum e o f cabosil added 
to the form ula tion . A t 4%  cab-o-s il the fo rm u la tion  rem ained liq u id , w h ile  
increasing the percentage o f cab-o-s il to  10% gave a m ore viscous gel 
form u la tion , w h ich  rem ained at the p o in t o f  app lica tion  (on the top o f the 
n ipp le ) rather than co lle c ting  at the base o f the n ipp le . Th is increase o f cab-o- 
s il lengthened the tim e  taken to reach e q u ilib riu m  fo r PD98059, LY294002 or
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4 - h y d ro x y ta m o x if e n  f r o m  5 to  8  h  a n d  a ls o  in c r e a s e d  th e  m a s s  o f  a l l  3 
c o m p o u n d s  th a t  w a s  a b le  to  r e a c h  th e  r e c e p to r  p h a s e  a t  th e  p o in t  o f  e q u i l ib r iu m  
a n d  a t  2 4  h o u rs ,  s h o w n  in  ta b le  9 .2 . T h e  in c re a s e  f r o m  4  to  1 0 %  c a b - o - s i l  d id  
n o t  e le v a te  th e  m a s s  p e r m e a te d  a f te r  2 4  h  s ig n if ic a n t ly  f o r  a n y  c o m p o u n d  (P  =  
0 .1 0 4 , 0 .0 5 5 , 0 .1 5 7  a n d  0 .0 7  f o r  P D 9 8 0 5 9 ,  L Y 2 9 4 0 0 2 ,  4 - h y d r o x y ta m o x if e n  
a n d  E P A  re s p e c t iv e ly ) .
C om pound 4%  C abosil 10%  C abosil
PD989059 equilibrium 24.5 ±  3.47 34.96 ± 5 .0 2
24 h 25.01 ± 3 .9 6 36.49 ± 4 .95
LY294002 equilibrium 17.89 ±  1.79 28.71 ± 4 .5 9
24 h 18.5 ± 2 .1 31.42 ± 5 .01
4-
hydroxytamoxifen
equilibrium 20.2 ±  2.58 28.35 ± 7.6
24 h 20.86 ± 2 .5 8 32.4 ± 8 .28
EPA equilibrium 2611.4 ± 497 .6 3508 ±  747.2
24 h 3081.03 ± 252 .7 4794 ± 780.4
Table 9.2. The mass of PD98059, LY294002, 4-hydroxytamoxifen and EPA reaching the 
receptor phase at the point of equilibrium and after 24 hours when applied to the nipple with 
either 4 or 10 % Cab-o-sil. Donor phase was 2.54 x lO^mol PD98059, LY294002, 4- 
hydroxytamoxifen in 200pl fish oil plus 0.05% BHA 2.5% v/v DMSO and ethanol with either 
4 or 10% w/v Cab-o-sil. Receptor phase was SOmgml'1 cetrimide solution, previously 
degassed, agitated with a magnetic micro-stirrer and maintained to give a skin surface 
temperature of 32°C. (n=5 ± SD).
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Figure 9.6 shows the mass o f EPA  able to reach the receptor phase when 
applied to the mammary pap illa  when form ulated w ith  10 % cab-o-sil. Figures
9.4 and 9.6 show that the mass o f EPA able to  reach the receptor phase a fte r 24 
hours was increased when fish  o il was thickened w ith  10 %  w /v  cab-o-sil 
compared to w ith  4 %  w /v  C ab-o-sil, as h igh ligh ted  in  table 9.2.
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Figure 9.6 Cumulative mass o f  EPA traversing the mammary papilla and reaching the receptor 
phase after 24 hours. Receptor phase was 30mgml-l cetrimide solution, which was stirred 
with a micro-stirrer and maintained in a water bath set at 37°C to give a skin surface 
temperature o f  32°C. Donor phase was dosed with 2.54mol PD98059, LY294002 and 4, 
hydroxytamoxifen in 200pl fish oil with 2.5% DMSO and ethanol and 10% Cabosil (n=5 
±stdev).
E q u ilib riu m  o f EPA between donor and receptor phase may not have been 
reached in  the 24-hour investiga tion ; how ever, the d iffu s io n  o f EPA slows a fte r 
10 h.
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9.4 Discussion
T h is  s h o r t  s tu d y  h a s  d e m o n s tr a te d  th e  p o s s ib i l i ty  o f  p a s s iv e ly  d e l iv e r in g  a n t i -  
b r e a s t  c a n c e r  a g e n ts  v ia  th e  n ip p le .  A s  d is c u s s e d  in  p r e v io u s  c h a p te r s ,  b r e a s t  
c a n c e r  th e ra p ie s  a r e  p r e d o m in a n t ly  d e l iv e r e d  o r a l ly  o r  b y  i .v .  in je c t io n s .  T h is  
m e th o d  h a s  b e e n  r e l ie d  u p o n  f o r  m a n y  y e a r s  a n d  o n ly  re c e n t ly  h a s  th e  id e a  o f  
lo c a l is e d  d e l iv e ry  r e c e iv e d  a t te n t io n . S e v e ra l  s tu d ie s  h a v e  s h o w n  th a t  4 -  
h y d ro x y ta m o x if e n  c a n  b e  d e l iv e r e d  t r a n s c u ta n e o u s ly  to  b r e a s t  tu m o r s  a n d  is  
r e ta in e d  p re fe r e n t ia l ly  in  th e s e  t i s s u e s  w h e n  c o m p a r e d  to  a b d o m in a l  d e l iv e ry .
I t  is  e s t im a te d  th a t  9 5 %  o f  b r e a s t  c a n c e r s  o r ig in a te  in  th e  e p i th e l ia l  c e l l s  o f  th e  
d u c ts  o r  lo b u le s  o f  t h e  b re a s t .  A d d i t io n a l ly ,  c a r e f u l  a n d  p a in s ta k in g  d is s e c t io n s  
o f  8 2  m a s te c to m y  s a m p le s  r e v e a le d  th a t  in  a l l  b u t  o n e  th e ,  c a n c e r  o r ig in a te d  
a n d  r e m a in e d  a s  o n e  m u l t i f o c a l  l e s io n  in  o n e  d u c ta l  s y s te m  (H o lla n d , R  1 9 8 5 ) . 
A l th o u g h  th is  k n o w le d g e  is  w id e ly  a c c e p te d  a m o n g  c l in ic ia n s  a n d  p a th o lo g is ts ,  
d i r e c t  a p p l ic a t io n  o f  th e r a p e u t ic  a g e n ts  v i a  t h e  n ip p le  h a s  r e c e iv e d  s c a n t  
a t te n t io n  (K in g , B .L . &  L o v e , S .M . 2 0 0 6 ) .
H o w e v e r  th e  d e v e lo p m e n t  o f  d u c to s c o p y  a n d  in t r a d u c ta l  in je c t io n  b y  n ip p le  
b lo c k  a n d  c a n n u la t io n  h a v e  le a d  to  a  s u rg e  o f  in te r e s t  in  th is  a r e a  a n d  m o re  
re c e n t  s tu d ie s  h a v e  s o u g h t  to  e x p lo r e  th e  v a l id i ty  o f  d e l iv e r in g  a n t i -b re a s t  
c a n c e r  a g e n ts  d i r e c t ly  to  th e  s i te  o f  a c t io n  v ia  th e  m a m m a r y  p a p i l la  (n ip p le ) .  
T h e s e  s tu d ie s  in v o lv e d  in t r a d u c ta l  in je c t io n s ,  w h ic h  r e q u ir e d  h o s p i ta l  d a y  
v is i ts ,  h o w e v e r  p r o v e d  to  h a v e  f a v o u r a b le  e f f e c ts  to  i .v  o r  o r a l  t r e a tm e n ts .  
M u ra ta ,  S . a n d  c o l le a g u e s  (2 0 0 6 )  d e m o n s tr a te d  th a t  a n  in tr a d u c ta l  in je c t io n  o f
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c ry s ta l  v io le t  w a s  c a p a b le  o f  r e a c h in g  a l l  p a r ts  o f  th e  m a m m a r y  g la n d  in c lu d in g  
th e  t e r m in a l e n d  b u d s ,  in  w h ic h  th e  m a jo r i ty  o f  c a n c e r s  o r ig in a te .  T h e y  a ls o  
s h o w e d  th a t  in tr a d u c ta l  in je c t io n  o f  e i th e r  4 -h y d r o x y ta m o x if e n  o r  p e g y la te d  
l ip o s o m a l  d o x o ru b ic in  (P L D )  w a s  a s  e f f e c t iv e  a t  p r e v e n t in g  N - m e th y l - N ’- 
n i t r o s o u r e a  in d u c e d  m a m m a ry  tu m o r o g e n e s is  in  th e  r a t  a s  s y s te m ic a l ly  
a d m in is te r e d  ta m o x if e n . T h e y  a ls o  s h o w e d  th a t  in tr a d u c ta l  a d m in is t r a t io n  
r e s u l te d  in  lo w e r  c i r c u la t in g  le v e ls  o f  P L D  w h e n  c o m p a r e d  to  i.v . 
a d m in is t r a t io n  a n d  f u r th e rm o re ,  r e s u l te d  i n  n o  s y s te m ic  o r  m a m m a r y  g la n d  
to x ic i ty .
A n o th e r  s tu d y  e x p lo r e d  th e  p la u s ib i l i ty  o f  d e l iv e r in g  a d e n o v ir u s  v e c to r s  f o r  th e  
d e l iv e r y  o f  g e n e s  v ia  th e  n ip p le .  T h e  s tu d y  s h o w e d  th a t  in tr a d u c ta l  in je c t io n  o f  
th e  a d e n o v ir u s  v e c to r  g a v e  t r a n s d u c t io n  e f f ic ie n c y  in  e p i th e l ia l  c e l ls  o f  th e  d u c t  
th a t  v a r ie d  f r o m  7 -2 5 %  a n d  f a i le d  to  e v o k e  a n  in f la m m a to ry  re s p o n s e . 
A l th o u g h  th e  s tu d y  d id  n o t  e x p lo r e  g e n e  d e l iv e ry , i t  h ig h l ig h te d  th e  p o s s ib i l i ty  
o f  d e l iv e r in g  g e n e s  in  th i s  m a n n e r  (R u s s e l l ,  T .D . e t  a l  2 0 0 3 ) . T h e  t r e a tm e n t  o f  
D C IS  o r  L C IS  b y  in tr a d u c ta l  in je c t io n  h a s  o n e  m a jo r  f la w . T h e  n ip p le  p re s e n ts  
w i th ,  o n  a v e ra g e , 5 -9  d u c ta l  o r i f ic e s  (L o v e , S . &  B a r s k y , S .H . 2 0 0 4 ) .  B e fo re  
t r e a tm e n t  c a n  b e g in  th e  c o r r e c t  d u c ta l  o r i f ic e  m u s t  b e  fo u n d , w h ic h  d r a in s  th e  
a f f e c te d  d u c ta l  c a n a l .  T h is  m a y  b e  o b v io u s  in  a  m in o r i ty  o f  c a s e s  d u e  to  
s p o n ta n e o u s  d is c h a r g e  t h a t  lo c a l is e s  th e  a f f e c te d  d u c t  b u t  in  m o s t  c a s e s  i t  is  
im p o s s ib le  to  g u e s s  a n d  s o  d u c to s c o p y  m u s t  b e  p e r f o r m e d  b e fo re h a n d  (M u ra ta ,  
S . 2 0 0 6 ) .
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T h e  p a s s iv e  d e l iv e ry  o f  c o m p o u n d s  th r o u g h  th e  d u c ta l  c o m p o n e n ts  o f  th e  
b r e a s t  h a s  n o t  b e e n  e x p lo re d  w i th in  th e  l i te ra tu re .  I t  h a s  b e e n  a c c e p te d  th a t  
b e c a u s e  n ip p le  d is c h a rg e  a n d  m i lk  s e c re t io n  o c c u r s  in  th e  o p p o s i te  d ire c t io n , 
th e  p a s s iv e  in g re s s  o f  c o m p o u n d s  f r o m  th e  o u ts id e  d o w n  th e  d u c ts  t o  th e  
lo b u le s  w o u ld  n o t  b e  v ia b le  a n d  th e r e f o r e  th i s  ro u te  o f  a d m in is t r a t io n  h a s  b e e n  
d is m is s e d . T h is  s h o r t  s tu d y  h a s  i l lu s t r a te d  th a t  th i s  d is m is s a l  m a y  h a v e  b e e n  
to o  h a s ty ,  b u t  m a y  b e  r e s t r ic te d  to  n o n - la c ta t in g  in d iv id u a ls .
T h e  s tu d y  b y  R z q s a , A . in  2 0 0 5  s ta te d  th a t  th e  a n a to m y  o f  th e  p o r c in e  s o w  
m a m m a ry  g la n d  c o m p a r e s  a d e q u a te ly  to  th a t  o f  th e  h u m a n  m a m m a ry  g la n d  
(R z q s a , A . e t  a l  2 0 0 5 ) .  T h e  m a m m a r y  g la n d  o f  a  la c ta t in g  s o w  h a s  a  s h o r t  
d u c t u s  p a p i l a r e s  c a n a l  t h a t  e x te n d s  b e tw e e n  3 -4 m m . T h e re  a r e  9 -1 4  b ig  a n d  6 -
1 0  s m a l l  l a c t i f e r o u s  d u c ts  th a t  b r a n c h  f r o m  th is  c a n a l ,  w h ic h  in  t u r n  b r a n c h  in to  
n u m e r o u s  s m a l le r  d u c ts  a n d  te r m in a te  a s  in tr a - lo b u la r  d u c ts  (R z q sa , A . e t  a l  
2 0 0 5 ,  F r a n d s o n ,  R .D . e t  a l  2 0 0 3 ) .
T h e  c o c k ta i l  t r e a tm e n t  o f  P D 9 8 0 5 9 ,  L Y 2 9 4 0 0 2  a n d  4 - h y d ro x y ta m o x if e n  in  f is h
011 p lu s  2 .5  %  v /v  D M S O /e tO H  a n d  4  %  w /v  c a b -o - s i l  w a s  c a p a b le  o f  
d e l iv e r in g  6 .9 2  ±  0 .5 5 , 9 .1 7  ±  0 .7 7 ,  8 .2 5  ±  0 .3 6  a n d  1 4 2 0 .1 2  ± 1 1 9  n g  c m '2 
P D 9 8 0 5 9 , L Y 2 9 4 0 0 2 , 4 - h y d r o x y ta m o x if e n  a n d  E P A  r e s p e c t iv e ly  a c r o s s  fu ll 
th ic k n e s s  p o r c in e  s k in  a f te r  4 8  h o u r s ,  w h ic h  w a s  v a s t ly  le s s  th a n  w a s  d e l iv e re d  
a c ro s s  th e  n ip p le  in  a  f o r m u la t io n  c o n ta in in g  1 0 %  c a b -o - s i l  a f te r  2 4  h ,  a s  
s h o w n  in  ta b le  9 .1 .
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T h e  f o r m u la t io n  c o n ta in in g  1 0 %  c a b - o - s i l  d id  n o t  h in d e r  th e  d e l iv e ry  o f  E P A  
th r o u g h  th e  n ip p le .  H o w e v e r  a t  p e r c e n ta g e s  o v e r  4 %  h a d  a  r e ta r d in g  e f f e c t  o n  
th e  p e r m e a t io n  o f  E P A  a c ro s s  fu l l  th ic k n e s s  s k in  ( P h i lp o t ,  I. e t  a l  m a n u s c r ip t  in  
p r e p a ra t io n ) .  T h is  c o u ld  b e  e x p la in e d  b y  th e  l a c k  o f  b a r r ie r  p r o p e r t ie s  i n  th e  
n ip p le  c o m p a re d  to  th e  m a n y  b a r r ie r s  p r e s e n te d  in  th e  s k in . T h is  in  tu r n  
s u g g e s ts  w h o le  f o rm u la t io n ;  in c lu d in g  c a b -o - s i l  m ig r a te d  in to  th e  n ip p le .  T h e  
s a fe ty  o f  c a b -o - s i l  h a s  b e e n  d e te r m in e d  in  c h a p te r  4 , a n d  th e  f a c t  t h a t  i t  i s  u s e d  
to  th ic k e n  fo o d  s u c h  a s  to m a to  k e tc h u p  s u g g e s ts  t h a t  th e  in g re s s  o f  c a b -o - s i l  
in to  th e  n ip p le  w o u ld  r a is e  n o  a d v e r s e  to x ic o lo g ic a l  a c t io n , h o w e v e r  m u c h  
m o r e  e x te n s iv e  s a f e ty  s c r e e n in g  w o u ld  b e  re q u ir e d .
T h e  e a s e  o f  p e r m e a t io n  f r o m  th e  n ip p le  s u r fa c e  in to  th e  r e c e p to r  p h a s e  s u g g e s ts  
t h a t  t h i s  r o u te  o f  a d m in is t r a t io n  m a y  b e  s u p e r io r  to  c la s s ic a l  r o u te s ;  h o w e v e r ,  
s e v e r a l  i s s u e s  m u s t  b e  a s s e s s e d  b e fo re h a n d .
F ir s t ly ,  th e  fo r m u la t io n  w a s  c a p a b le  o f  p a s s in g  d o w n  th e  m a jo r  a n d  la r g e r  
d u c ts  r e la t iv e ly  w e l l ;  h o w e v e r  i t  w a s  im p o s s ib le ,  in  th is  s tu d y , to  m a p  th e  e x a c t  
r o u te  o f  th e  c o m p o u n d s  th r o u g h o u t  th e  b r e a s t .  F o r  a d e q u a te  t r e a tm e n t  a  
s u f f ic ie n t  d o s e  m u s t  r e a c h  th e  d e s i r e d  d u c t  o r  lo b u le ,  f o r  e x a m p le ,  th e  tu m o r  
m a y  r e s id e  in  a  m a jo r  d u c t  o r  m a y  b e  in  a  n a r r o w  d u c t  o r  lo b u le  to w a r d  th e  
b a s e  o f  th e  b r e a s t  a n d  s o  i t  w o u ld  b e  im p o r ta n t  to  m e a s u re  th e  le v e ls  o f  d ru g s  
a b le  to  r e a c h  th e s e  n a r r o w  d u c ts  t h a t  b r a n c h  f ro m  th e  m a in  d u c t.
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S e c o n d ly , th i s  s tu d y  h a s  s h o w n  a d e q u a te  p a s s a g e  o f  c o m p o u n d  f ro m  th e  n ip p le  
s u r f a c e ,  th r o u g h  to  th e  r e c e p to r  p h a s e .  H o w e v e r ,  th i s  s tu d y  u s e d  e x c is e d  
b re a s ts  th a t  w e re  d o s e d  f a c in g  u p w a rd s .  I n  th e  h u m a n , th e  n ip p le  i s  v e r t ic le , 
w h ic h  m a y  re d u c e  to  p a s s a g e  o f  c o m p o u n d s  th r o u g h  th e  b r e a s t  s tru c tu re . T h is  
m a y  m e a n  th a t  th e  p a t ie n t  w o u ld  n e e d  to  l ie  f la t  u p o n  a p p l ic a t io n  a n d  r e m a in  
th e r e  f o r  u p  to  5  h o u r s .
F u r th e r  w o r k  c o u ld  in v o lv e  d o s in g  th e  n ip p le  w i th  a  b io lo g ic a l  d y e  t o  m a p  its  
p a s s a g e  th r o u g h  th e  b r e a s t .  A ls o  th e  n ip p le  c o u ld  b e  d o s e d  w i th  c o m p o u n d s  
a n d  a f te r  s e t  t im e s ,  th e  b r e a s t  d is s e c te d  a n d  IC C  e m p lo y e d  to  d e te c t  p -M A P K , 
p -A k t ,  E R  a n d  C O X -2  th r o u g h o u t  th e  b r e a s t  s t ru c tu re .
P a s s iv e  p a s s a g e  th r o u g h o u t  th e  d u c ta l  n e tw o r k  w i th in  th e  b r e a s t  is  o n ly  p a r t  o f  
th e  p ic tu r e ,  a s  t h e  m a s s  o f  d r u g  a b le  to  p a r t i t io n  in to  th e  in n e r  e p i th e l ia l  l in in g  
o f  th e  d u c ts  w o u ld  n e e d  to  b e  c a lc u la te d .
9.5 Conclusions
T h is  s tu d y  c o n f irm e d  th a t  a l l  4  a c t iv e s  o f  th e  f o rm u la t io n  d e v e lo p e d  in  c h a p te r s  
3  a n d  4  c o u ld  b e  d e l iv e re d  s u c c e s s f u l ly  a n d  h ig h  c o n c e n tr a t io n s  b y  th is  ro u te  
a n d  o v e rc o m e  th e  n o r m a l  d i r e c t io n  o f  m i lk  s e c re t io n  a n d  d is c h a rg e . 
A d d it io n a l ly ,  th e  d e l iv e ry  v i a  th i s  r o u te  s u rp a s s e d  th e  c o n c e n tr a t io n s  o f  th e  4  
c o m p o u n d s  th a t  c o u ld  b e  d e l iv e r e d  t r a n s c u ta n e o u s ly .
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W o rk  in  c h a p te r  4  s h o w e d  th a t  E P A  w a s  n o t  r e le a s e d  f ro m  C a b -o -s i l  
f o rm u la t io n s  a b o v e  4 %  w /v . T h is  s tu d y  s h o w s  th a t  E P A  w a s  d e te c te d  in  th e  
re c e p to r  p h a s e  w h e n  f o rm u la te d  a t  1 0 %  C a b -o -s i l ,  s u g g e s t in g  th a t  th e  
fo rm u la t io n  p e n e tr a te d  th e  m a m m a ry  p a p i l la  a s  a  w h o le .
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10. General Discussion
10.1 Overview
B r e a s t  c a n c e r  is  th e  m o s t  c o m m o n  f e m a le  m a l ig n a n c y  in  th e  w e s te r n  w o r ld .  
E a c h  y e a r  in  th e  U K  in  e x c e s s  o f  4 4 ,  0 0 0  w o m e n  a n d  3 0 0  m e n  a r e  d ia g n o s e d  
w i th  b r e a s t  c a n c e r  (w w w . c a n c e r re s e a r c h u k )  a n d  in c id e n c e  r a te s  a r e  in c r e a s in g  
e a c h  y e a r . T a m o x if e n  r e m a in s  th e  th e r a p y  o f  c h o ic e  in  p a t ie n ts  w i th  E R +  
b re a s t  c a n c e r . H o w e v e r ,  n e w  in s ig h ts  in to  th e  b io lo g y  o f  E R +  b r e a s t  c a n c e r  
a n d  th e  lo n g - te rm  g e n e t ic  im p l ic a t io n s  o f  t a m o x i f e n  t r e a tm e n t  h a v e  h ig h l ig h te d  
k e y  c o n c e rn s  a m o n g  c a n c e r  a n d  e n d o c r in e  b io lo g is ts .
T h e  b io lo g y  o f  e n d o c r in e  r e s i s ta n c e  is  p o o r ly  u n d e r s to o d  a n d  c o m p le x  to  e v e n  
th e  c o m p e te n t  e n d o c r in o lo g is t .  M a n y  m e c h a n is m s  o f  a n t i - h o r m o n e  r e s is ta n c e  
h a v e  b e e n  p ro p o s e d  in c lu d in g  lo s s  o f  o r  m u ta t io n  o f  E R a ,  la c k  o f  p r o g e s te r o n e  
r e c e p to r  e x p re s s io n , in c r e a s e d  E R 0  a n d  e le v a te d  g r o w th  f a c to r  s ig n a l l in g .  T h e  
c l in ic a l  e x tr a p o la t io n  o f  s o m e  o f  th e s e  m e c h a n is m s  la c k s  e v id e n c e , h o w e v e r ,  
h ig h  h o m o lo g y  b e tw e e n  i n  v i t r o  m o d e ls  o f  e n d o c r in e  r e s is ta n c e  a n d  c l in ic a l  
o b s e rv a tio n s  e x is t  in  r e g a r d s  to  th e  in v o lv e m e n t  o f  g r o w th  f a c to r  s ig n a ll in g . 
T h e  in c re a s e  in  g r o w th  f a c to r  s ig n a l l in g  i s  th o u g h t  to  a r is e  f ro m  th e  e f f e c t  o f  
ta m o x if e n  o n  A F -1  m e d ia te d  g e n e  t r a n s c r ip t io n .
In a p p ro p r ia te  in v o lv e m e n t  o f  g r o w th  f a c to r  s ig n a l  t r a n s d u c t io n  p a th w a y s  h a v e  
n o w  b e e n  a c c e p te d  a s  m e c h a n is m s  o f  a c q u i r e d  a n t i - h o r m o n e  re s is ta n c e . T h e ir  
in c re a s e d  in v o lv e m e n t  c a n  o c c u r  v i a  a  n u m b e r  o f  m e th o d s ;  a c t iv a t io n  o f  ta r g e t  
re c e p to r s ,  a n  in c re a s e d  s u p p ly  o f  g r o w th  f a c to r  l ig a n d s  o r  a n  in c r e a s e d
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a c t iv a t io n  o f  d o w n s tr e a m  m e d ia to r s .  E p id e rm a l  g r o w th  f a c to r  r e c e p to r  
e x p re s s io n  i s  o f te n  in c re a s e d  in  e n d o c r in e  re s is ta n c e ,  w h ic h  is  p a r a l le le d  in  th e  
c l in ic a l  s e t t in g . H o w e v e r ,  th e  ta r g e te d  a n d  s p e c i f ic  in h ib i t io n  o f  E G F R  h a s  
s h o w n  d is a p p o in t in g  r e s u l ts  b o th  in  v i t r o  a n d  in  v iv o ,  w i th  r e s is ta n c e  to  a n t i -  
E G F R  a g e n ts  d e v e lo p in g  in  a  m a t te r  o f  m o n th s .  F u r th e rm o re ,  e x p r e s s io n  o f  
E G F R  d o e s  n o t  c o n f e r  to  th e r a p e u t ic  r e s p o n s e  to  a n t i - E G F R  c h a l le n g e . T h e s e  
d a ta  r e v e a le d  th a t  th e  c o m p le x i ty  o f  E G F R  s ig n a l l in g  w a s  g re a t ly  
u n d e re s t im a te d . O n ly  r e c e n t ly  h a s  i t  b e e n  d is c o v e r e d  th a t  c ro s s  t a lk  b e tw e e n  a  
d iv e r s e  a r ra y  o f  g r o w th  s ig n a l l in g  p a th w a y s  e x is t s  w h ic h  r e n d e r s  c a n c e r  c e l l  
e x tre m e ly  a d a p ta b le  in  r e g a r d s  t o  c e l l  g r o w th  a n d  s u rv iv a l .  U p o n  b lo c k a d e  o f  
o n e  g ro w th  p a th w a y , c a n c e r  c e l ls  p o s s e s s  t h e  in t r in s ic  a b i l i ty  to  s w i tc h  to  a n d  
u t i l is e  a l te rn a t iv e  p a th w a y s  in  o r d e r  t o  e v a d e  g r o w th  in h ib i t io n  ( J o n e s ,  H .E . e t  
a l  2 0 0 6 ) .
10.2 Aims of the thesis
T h e  a im s  o f  th is  th e s i s  w e r e  to  d e v e lo p  a  t r a n s c u ta n e o u s  b r e a s t  c a n c e r  
th e ra p e u t ic  a n d  e v a lu a te  i t s  e f f e c t s  o n  b r e a s t  c a n c e r  c e l ls .  T h is  f o rm u la t io n  
w a s  h o p e d  to  o v e rc o m e  h y p o th e s iz e d  a d v e r s e  e f f e c ts  o f  o r a l  a d m in is t r a t io n  a n d  
p re v e n t  o r  d e la y  re s is ta n c e ,  s e e n  b o th  c l in ic a l ly  a n d  i n  v i t r o ,  w i th  ta m o x if e n  
t re a tm e n t.
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T h e  f i r s t  is s u e  to  b e  a d d r e s s e d  w a s  th e  c o m p o u n d s  to  in c lu d e  in  th i s  c o c k ta i l  
th e ra p e u t ic .  T w o  d o w n s tr e a m  p a th w a y s  o f  E G F R  a n d  I G F R  s ig n a l l in g  w e re
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t a r g e te d  d u e  to  th e i r  r o le  in  r e s i s ta n t  g ro w th . T h e s e  w e r e  th e  P I 3 K  a n d  M A P K  
p a th w a y s . In h ib i to r s  o f  th e s e  p a th w a y s  w e r e  in v e s t ig a te d  f o r  th e i r  s k i n  
p e n e t r a t in g  c a p a b i l i t ie s .  L Y 2 9 4 0 0 2 , a  w id e ly  e x p lo r e d  P I 3 K  in h ib i to r  a n d  
P D 9 8 0 5 9 , a  M A P K  in h ib i to r  o f te n  u s e d  a s  a  s c ie n t i f ic  to o l  to  b lo c k  E R K 1 /2  
s ig n a l l in g  g a v e  s u p e r io r  s k in  p e r m e a t io n  p r o f i le s  c o m p a re d  to  o th e r  in h ib i to r s  
o f  th e s e  p a th w a y s  a n d  s o  w e re  t a k e n  f o r w a r d  to  d e v e lo p ,  a lo n g  w i th  ta m o x if e n ,  
in  to  a  t r a n s c u ta n e o u s  g e l  o r  p a tc h .
F o rm u la t io n  c h o ic e  i s  f u n d a m e n ta l  t o  b o th  m a x im is in g  p e n e t r a t io n  a n d  c l in ic a l  
s a fe ty  a n d  to x ic o lo g y . P r e l im in a r y  p e r m e a t io n  s tu d ie s  u s e d  D M S O  a s  v e h ic le ,  
w h ic h  h a s  r e c e iv e d  a  g r e a t  d e a l  o f  p r e s s  r e g a r d in g  i t s  p e r m e a t io n  e n h a n c e m e n t  
o f  a  w id e  a r r a y  o f  c o m p o u n d s .  A s  a  s k in  s c ie n t is t ,  th i s  i s  o n e , b u t  n o t  a l l  
c r i te r ia  o f  a  h ig h - q u a l i ty  t r a n s c u ta n e o u s  v e h ic le .  D e lv in g  d e e p e r  in to  th e  
e f fe c ts  o f  D M S O  le a d  to  c o n c e r n s  o n  th e  s u b je c t  o f  to x ic i ty ,  w h ic h  w e re  
v is u a l is e d  in  im m u n o h is to -  a n d  im m u n o c y to c h e m ic a l  a n a ly s is  o f  D M S O  
t r e a te d  p o rc in e  s k in . A t  c o n c e n t r a t io n s  e x c e e d in g  6 0 %  D M S O  is  p ro p o s e d  to  
g iv e  i r r e v e r s ib le  S C  a n d  k e r a t in o c y te  to x ic i ty  (W il l ia m s ,  A .C . 2 0 0 3 ) .  I t  
a d v o c a te s  th e s e  e v e n ts  b y  r e m o v in g  S C  l ip id s  a n d  k e r a t in o c y te  c e l l  m e m b ra n e  
l ip id . C o n c e n tr a t io n s  b e lo w  6 0 %  a r e  d e e m e d  ‘s a f e ’ a n d  p r o p o s e d  a s  r e v e r s ib le  
e f fe c ts ;  h o w e v e r ,  m o d u la t io n  o f  S C  f u n c t io n  a n d  k e r a t in o c y te  v ia b i l i ty  b y  s u c h  
a  s e v e re  m e c h a n is m  s u g g e s ts  t h a t  c l in ic a l ly  a c c e p ta b le  f o rm u la t io n s  w o u ld  n o t  
p e rm it  th e  in c lu s io n  o f  th i s  s o lv e n t  e v e n  a t  p e r c e n ta g e s  <  6 0 % .
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C h a p te r  4  in v e s t ig a te d  f i s h  o i l  a s  a  r e p la c e m e n t  v e h ic le  a n d  in i t ia l  IH C  a n d  
IC C  a n a ly s is  r e v e a le d  a  f a r  s u p e r io r  to x ic o lo g ic a l  p r o f i le  w i th  n o  S C  o r  
k e ra t in o c y te  d a m a g e  a n d  m a in te n a n c e  o f  v ia b i l i ty  u p  to  12 h o u rs .  T h is  c h a p te r  
a ls o  h ig h l ig h te d , a g a in ,  th a t  f o r m u la t io n  c h o ic e  r a d ic a l ly  e f f e c ts  e x te n t  o f  
p e rm e a t io n , lu c k i ly  th e  p e r m e a t io n  o f  a l l  4  c o m p o n e n ts  o f  th e  th e r a p e u t ic  w e re  
e n h a n c e d  to  th e  g re a te s t  e x te n t  b y  th e  a d d i t io n  o f  D M S O /e th a n o l .
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O n c e  a n  o p t im a l  f o r m u la t io n  w a s  f o u n d ,  i t  w a s  n e c e s s a r y  to  e v a lu a te  th e  p o s t  
s k in  e f fe c ts  o f  th e  f o rm u la t io n .  R e s u l ts  th r o u g h o u t  c h a p te r s  5 a n d  6  lo o k e d  a t  
th e  e f fe c ts  o f  P D 9 8 0 5 9 ,  L Y 2 9 4 0 0 2 ,  4 - h y d r o x y ta m o x i f e n  a n d  f is h  o i l  th e  
g ro w th  o f  h o rm o n e  s e n s i t iv e  ( M C F - 7 )  a n d  t a m o x i f e n  r e s is ta n t  ( T a m R )  c e lls .  
T h e  e x p re s s io n  o f  E R , p A k t ,  p E R K l / 2 ,  E G F R , C O X -2 , a n d  S rc  w a s  a ls o  
d e s c r ib e d . T h e  e f f e c t  o f  f i s h  o i l  a n d  f i s h  o i l  p lu s  P D 9 8 0 5 9  a n d  L Y 2 9 4 0 0 2  o n  
th e  m ig ra to ry  p o te n t ia l  o f  T a m R  c e l l s  w a s  a l s o  d e te rm in e d .
10.4.1 PI3K and MAPK signalling
P I3 K  a n d  M A P K  s ig n a l l in g  h a v e  b e e n  s h o w n  to  b e  im p o r ta n t  in  c e l l  
p ro lif e ra t io n , a v o id a n c e  o f  a p o p to s i s  a n d  in  m e ta s ta s is .  T h e  c o c k ta i l  
fo rm u la t io n  w a s  c a p a b le  o f  d e c r e a s in g  th e  e x p r e s s io n  o f  p A k t  a n d  p E R K l / 2  in  
b o th  M C F -7  a n d  T a m R  c e l l s ,  w h ic h  h a v e  p r e v io u s ly  b e e n  s h o w n  to  g iv e  r i s e  to  
a n t i - tu m o r  e f fe c ts . I t  w a s  a ls o  c a p a b le  o f  in h ib i t in g  M C F -7  a n d  T a m R  c e ll  
g ro w th  s ig n if ic a n tly .  T h e  c o c k ta i l  th e r a p e u t ic  a ls o  s h o w e d  a n t i -m e ta s ta t ic  
p o te n tia l .
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10.4.2 Cyclooxgenase signalling
C O X -2  o v e re x p re s s io n  i s  o f te n  s e e n  in  b r e a s t  c a n c e r ,  a n d  h a s  b e e n  l in k e d  to  
in c re a s e d  m e ta s ta t ic  p o te n t ia l .  C O X -2  e x p r e s s io n  h a s  a ls o  b e e n  s h o w n  to  b e  
s u f f ic ie n t  to  in d u c e  tu m o r o g e n e s is  i n  m ic e .  I t  i s  s u g g e s te d  th a t  i t  i s  th e  
a c c u m u la t io n  o f  P G E 2  th a t  g iv e s  r i s e  to  th e  tu m o r o g e n ic  a c t io n s  o f  C O X -2 , 
w i th  c ro s s ta lk  b e tw e e n  C O X - 2 /  P G E 2 /E G F R /S r c  g iv in g  r is e  t o  p r o - m e ta s ta t ic  
e f fe c ts .
10.5 Suggested future work
T h is  th e s is  h a s  g e n e r a te d  s e v e r a l  e x c i t in g  r e s u l t s ,  s e v e ra l  o f  w h ic h  c o u ld  b e  
e x p a n d e d  o n  a n d  d e v e lo p e d .
M a n y  ty ro s in e  k in a s e  in h ib i to r s ,  w h ic h  t a r g e t  g ro w th  f a c to r  s ig n a l l in g  
p a th w a y s , a r e  s m a ll  m o le c u le s  a n d  s o  m a y  a ls o  b e  c a n d id a te s  fo r  
tra n s c u ta n e o u s  d e l iv e ry . T h e s e  in c lu d e  G e f i t in ib  ( E G F R  in h ib i to r )  a n d  
A x it in ib  (V E G F R  in h ib i to r ) .  T h e s e  tw o  in h ib i to r s  a r e  a r o u n d  4 0 0 K D a , m a k in g  
th e m  s u ita b le  c a n d id a te s  f o r  to p ic a l  d r u g  d e l iv e ry .
O th e r  d o m in a n t  p a th w a y s  in v o lv e d  in  r e s i s ta n t  g r o w th  c e n tr a l is e  a r o u n d  s u c h  
m e d ia to r s  a s  N F k B  a n d  IG F - IR . I t  w o u ld  b e  e x t r e m e ly  in te r e s t in g  to  e x p lo re  
th e  p o te n t ia l  o f  d e l iv e r in g  in h ib i to r s  o f  th e s e ,  b o th  in d iv id u a l ly  a n d  
s im u lta n e o u s ly  w i th  v a r io u s  c o n s t i tu e n ts  o f  th e  c o c k ta i l  a l r e a d y  d e v e lo p e d .
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A lthough  porcine  sk in  show s good  hom ology  to  h u m an  skin, it is  n o t ideal to  
use  in vitro m odels  fo r perm eation  studies. I t  w o u ld  b e  advan tageous to  u se  in 
vivo m odels, e ither an im al o r hum an , to  exp lo re  th e  p o s t sk in  transport o f  the  
delivered  com pounds. A  study  m app ing  th e  tran sp o rt o f  rad io labe lled  4- 
hydroxy tam oxifen  has a lready  b een  conducted , w here  it  w as show ed  th a t the  
com pound had  a  sign ifican tly  g rea te r ha lf-life  in  b reast tissue , com pared  to  
w hen  dosed  to  the  abdom en  (M auv is-Jarv is, P . et a l 1986).
T he resu lts  ob tained  from  chap ters  7 and  8, d e ta iling  the  deve lopm en t o f  a  
com posite  m odel, h ig h ligh t an  in te resting  p o ssib ility  to  develop  a  h igh- 
throughput assay  fo r cand ida te  tran scu tan eo u s b rea s t cancer therapeu tics , and 
serves as a  p ro o f  o f  p rinc ip le  fo r  th is . It co u ld  p o ssib ly  save th e  researcher 
w eeks o f  investiga tion , w h ich  is  ex trem ely  va luab le  in  cancer therapeu tics  
research  and  developm ent.
F inally , m aybe th e  m o st ex c itin g  resu lts  cam e from  the  shortest study 
conducted. C hap ter 9 inv estig a ted  th e  cred ib ility  o f  de livering  the 
aforem entioned cock ta il th erap eu tic  v ia  th e  m am m ary  p ap illa  (nipple). 
A lthough the  gross ana tom y  o f  the  sow  m am m ary  g land  m ay  d ifferfrom  
hum an, th is  chap ter saw  up  to  a  7 -fo ld  increase  in  th e  pene tra tion  o f  th e  ac tives 
o f  the  fo rm ula tion  w hen  de livered  trans-m am m ary  p ap illa  ra th e r th an  across 
skin. Furtherm ore, the  com pounds w ou ld  b e  delivered  to  th e  site  o f  action , 
w ithou t need  o f  d iffusing  th ro u g h  severa l m illim etres o f  tissue. T hese  resu lts  
w arran t fu rther exam ination  o f  th is  de livery  rou te , w ith  particu la r em phasis  on
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delivery  th rough  hum an, ex-vivo, tissue. It w ou ld  a lso  b e  critical to  p in  p o in t 
th e  rou te  o f  d rug  passage th ro u g h  th e  com plex  ducta l netw ork , to  ensu re  
hom ogenous spread  o f  th e  com pound  is a ttainable.
I f  possib le , it  w ou ld  ideal to  analyse  a  coho rt o f  m astectom y tissue , w here  the 
cancerous lesion  cou ld  b e  sub jec ted  to  co re  b iopsy . T h is  cou ld  th en  b e  assayed  
fo r the  expression  o f  m ed ia to rs  such  as  pA k t, pE R K , E G F R , IG FR . T h is  tissue  
w ould  the  b e  sub jected  to  the  cock ta il therapeu tic  v ia  the  m am m ary  p ap illa  and  
subsequently  re-analysed  to  d e tec t an d  v isua lise  any  effec ts o n  the  expression  
o f  such  m ediato rs w ith in  the  duc ta l netw ork .
10.6 Conclusions
T his transcu taneous cock ta il an ti-b reast cancer therapeu tic  show s p rom ising  
sk in  perm eating  p roperties , w ith  pe rm eatin g  concen tra tions capab le  o f  
d iffusing  th rough  stagnan t d iffu s io n  layers an d  inh ib iting  under-lay ing  M C F-7 
cells. It serves as  a  p ro to type  to p ica l therapy  th a t m ay  b e  m od ified  or 
developed fu rther and  suggests  th a t a  p a tch  o r  gel fo rm ula tion  m ay  be  usefu l as 
an  ad juvant to  su rgery  o r  as a  chem opreven ta tive  device.
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A p p e n d ix  1 W e s te rn  b lo t  rec ip es  
L o a d in g  b u f fe r
A  stock so lu tio n  o f 4m l 10% SDS 2m l g lyce ro l, 2 .4m l 0 .5M  T ris  (pH  6.8), 
1 .6m l de-ion ised H 2O, lm g  brom ophenol b lue was prepared. Im m edia te ly 
before  experim enta tion  lS .S m g m f1 D T T  was added.
L y sis  B u ffe r
A  stock so lu tio n  o f 50m M  T rizm a HC1, 5nM  E G T A , 150m M  N aC l, 1% v /v  
tr ito n  X -100 . T h is so lu tion  was stored at 4 °C u n til required. Im m edia te ly 
p rio r to  experim enta tion , the fo llo w in g  were added to  the stock so lu tion : 2m M  
sodium  vanadate, 50m M  sodium  flu o rid e , Im M  phenylm ethyl su lphonyl 
F lu o rid e , 20m M  phenylarsine oxide, lO m M  sodium  m olybate, 10 pgm l"1 
leupeptin , 2 m g m l'1 ap ro tin in .
R u n n in g  b u ffe r
A  x  10 stock so lu tion  o f runn ing  b u ffe r was made, w h ich  was d ilu ted  1:10 in  
de-ion ised H 2O p rio r to  SDS-PAG E.
The x  10 stock so lu tion  included; 0 .23M  T rizm a Base, 1.92M  g lyc ine , 0.1%  
SDS
Separating Gel
1. 7.5 %  gel (p ro te in  ra n g e  70-200 k D a)
2.5m l 30%  A cylam ide , 4 .8m l de-ionised H 2O, 1.5M  (2 .5m l) tris  HC1 (pH  8.8), 
0 .1m l 10% SDS, 0 .1m l 10% APS, lO p l temed.
2 .1 0 %  gel (p ro te in  ra n g e  20-100 kD a)
3.3m l 30%  acrylam ide, 4m l de-ionised H 2O, 1.5M  (2 .5m l) tris  HC1 (pH  8.8), 
0 .1m l 10% SDS, 0 .1m l 10% APS, lO p l temed.
S ta c k in g  gel
1.7m l 30%  A cry lam ide , 5 .8m l de-ionised H 2O, 2 .5m l 1.5M  tris  HC1 (pH  6.8), 
0 .1m l 10% SDS, 0 .1m l 10% APS, lO p l temed.
T ra n s fe r  b u ffe r
A  x  10 stock so lu tion  was made, w h ich  was d ilu ted  1:10 w ith  de-ion ised H 2O 
p rio r to  transfer.
The x  10 so lu tion  com prised o f; 0 .25M  T rizm a Base, 1.92M  g lyc ine , 20%  
m ethanol.
T B S -T W E E N
A  x  10 stock so lu tion  was made, w h ich  was d ilu ted  1:10 w ith  de-ion ised H 2O 
p rio r to  use. The x  10 stock so lu tion  was made using; 12. lg  T rizm a  Base 58g 
N aC l, 5m l Tween 20, 15m l 5M  HC1.
A p p e n d ix  2. IC C  rec ip es  
E R -IC A  fix a tio n
C overslips were placed in to  a m etal rack and fix e d  in  3.7%  form aldehyde fo r 
15 m inutes at room  tem perature. They were then bathed in  PBS fo r 5 m inutes 
at room  tem perature. C overslips were then subjected to  m ethanol between -10 
and -30°C, acetone at the same tem perature fo r 3 m inutes and fin a lly  PBS at 
room  tem perature fo r 5 m inutes. C overslips were then stored in  sucrose 
storage m edia (SSM ) at -20°C u n til required.
F o rm a l S a line
Form al saline was made o f 4.5g N aC l, 450m l o f tap w ater and 50m l o f 37%  
form aldehyde so lu tion . The so lu tion  was a llow ed to  d isso lve tho rou gh ly  and 
stored at room  tem perature u n til required.
F o rm a l S a line  f ix a tio n
Tissue cu lture  m edia was rem oved by asp ira tion  and coverslips w ere incubated 
w ith  1m l fo rm a l saline so lu tion  fo r 10 m inutes. They were then incubated w ith  
1 m l ethanol fo r 5 m inutes, fo llo w e d  by  a q u ick  rinse in  ethanol. E thanol was 
rem oved and coverslips subsequently incubated w ith  1m l PBS fo r 5 m inutes, 
fo llo w ed  by a q u ick  rinse in  PBS. They were then stored in  SSM  at -20°C  u n til 
required.
P h e n o l  F o r m a l  S a l in e
The preparation o f phenol fo rm a l saline was conducted under a fum e hood, 
w h ils t w earing fu ll p ro tective  c lo th ing . A  2.5%  w /v  so lu tion  o f phenol fo rm a l 
saline was prepared fo rm a l saline p re v iou s ly  prepared.
P h e n o l  F o r m a l  S a l in e  f ix a t io n
Tissue cu ltu re  m edia was rem oved by asp ira tion . C overslips were incubated 
w ith  2m l phenol fo rm a l saline so lu tion  fo r 5 m inutes. T h is was the rem oved 
and replaced w ith  1 m l o f ethanol fo r 5m inutes fo llo w e d  by a q u ick  rinse in  
ethanol. E thanol was then rem oved b y  asp ira tion  and coverslips incubated 
w ith  1 m l PBS fo r 5 m inutes, fo llo w e d  by a q u ick  rinse in  PBS. C overslips 
were then stored in  SSM at -20°C u n til required.
A p p e n d ix  3 .T issue  C u ltu re  rec ip es
C h a rc o a l  S tr ip p in g
The pH  o f 100m l FCS was adjusted to  4.2 and le ft to  equ ilib ra te  fo r 30 m inutes 
at 4°C. M eanw h ile , an 11% activated charcoal/0.06%  dextran C so lu tion  was 
made in  10 m l d is tille d  w ater. Th is was agitated v ig o ro u s ly  fo r 1 hour and 5m l 
was then added to  100m l FCS. Th is was the incubated at 4°C, w ith  gentle 
ag ita tion , fo r 16 hours. Charcoal was then rem oved b y  ce n trifu ga tion  at 
12000g fo r 40 m inutes. The rem ain ing so lu tion  was filte re d  several tim es 
using a W hatm an N o 4 filte r  paper and subsequently adjusted to  pH  7.2. 
F in a lly , the so lu tion  was s terilised  using a 0.22pm  mem brane filte r.
Iso to n  S o lu tion
Iso ton  I I  azide-free balanced e lectro lyte  so lu tion , cou lte r counter so lu tion , 
7 .9g l-1 N aC l, 1.9gl_1 d isodium  hydrogen orthophosphate, 0 .4 g l_1 E D T A  
d isodium  salt, 0 .2g l_1 orthophosphate and 0.3gls"j odium  flu o rid e .
S u cro se  S to ra g e  M e d ia  (SSM )
SSM  was made using 0.33g N aC l, 42 .8g sucrose in  250m l PBS. A fte r 
su ffic ie n t s tirrin g  250m l g lyce ro l was added. SSM  was stored at -20°C  u n til 
required.
